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Increasingly chronic liver disease is being acknowledged as a complication of type 2 
diabetes, in particular non-alcoholic fatty liver and non-alcoholic fatty liver disease. 
Rates of non-alcoholic fatty liver are higher in people with type 2 diabetes than in the 
general population, with prevalence rates believed to be between 40-70%. Given the 
aging Scottish population and the obesity driven diabetes epidemic, the problem of 
chronic liver disease is likely to increase. 
Despite this there has been little investigation into the natural history of non-
alcoholic fatty liver disease and the risks of clinically significant chronic liver 
disease in community based cohorts because diagnosis has been heavily reliant on 
liver biopsy. The use of liver biopsy is limited in both research and clinical practice 
due to its associated high mortality (1/1000) and morbidity and also due to practical 
limitations (sampling variability, semi-quantitative scoring systems). As a result the 
use of non-invasive markers of liver injury (non-specific liver injury, steatosis, 
steatohepatitis, liver fibrosis and surrogates of advanced portal hypertension) are 
rising, in the diagnosis of chronic liver disease, however, their utility in both 
community cohorts and patients with type 2 diabetes has not been widely studied. 
The aims of the studies presented in the thesis, using the Edinburgh Type 2 Diabetes 
Study, were: (i) to describe the distributions of a range of non-invasive markers of 
steatohepatitis and liver fibrosis in older people with type 2 diabetes, their 
relationship with metabolic and liver disease risk factors, and to compare the 
agreement of different non-invasive markers of hepatic fibrosis; (ii) to determine the 
frequency (prevalence and incidence) of and risk factors for clinically significant 
chronic liver disease in people with type 2 diabetes; and (iii) to determine the 
importance of chronic liver disease as a risk factor (or risk marker) for cardiovascular 
mortality or morbidity in type 2 diabetes. 
Prior to undertaking this work I undertook a detailed systematic review of the 
literature relating to the use of non-invasive markers of hepatic fibrosis to inform the 
choice of markers used in the study.  
iii 
Examination of a wide range of potential markers of steatohepatitis and liver fibrosis 
found varied relationships with diabetes history. Most commonly, elevated markers 
of steatohepatitis and liver fibrosis were associated with older age and higher body 
fat measures.  However, most of these relationships between liver markers and body 
fat measures lost statistical significance when limiting the population to only those 
with hepatic steatosis and/or non-alcoholic fatty liver disease.   
There were marked differences in the associations between different liver fibrosis 
markers and potential diabetes and metabolic risk factors, suggesting that these 
markers are not actually measuring the same underlying “fibrosis” condition. There 
was poor correlation between the five markers of liver fibrosis studied.  Using the top 
vigintile (5%) of each marker resulted in excellent agreement on the absence of 
advanced liver disease but poor agreement on the presence of advanced liver disease. 
The prevalence of clinically significant CLD (defined as cirrhosis, HCC or gastro-
oesophageal varices) was 2.2% - 0.9% diagnosed prior to enrolment with an 
additional 1.4% identified by study investigations.  Over nearly 6 years of follow-up, 
only 1.4% of the cohort developed incident clinically significant CLD. 
Higher levels of systemic inflammation, steatohepatitis and hepatic fibrosis markers 
were associated with both unknown prevalent and incident clinically significant 
chronic liver disease.  Less than half of participants developing incident significant 
disease were identified as high risk by the study investigations.  Abnormal liver 
enzymes were statistically significantly associated with incident cases, however the 
presence of hepatic steatosis was not.   
There were 372/1033 (36.0%) patients with prevalent CVD and 319 (30.9%) with 
prevalent CAD at baseline.   After mean follow-up of 4.4 years there were 44/663 
incident CVD events, including 27 CAD events.  There were 30/82 CVD related 
deaths.  
However, risk of dying from or developing CVD was no higher in subjects with 
steatosis than in those without.  There was also no statistically significant 
relationship between CVD and steatohepatitis or liver fibrosis. The only statistically 
iv 
significant relationship between CVD and any liver markers was with GGT 
(prevalent CVD, OR 1.28, p=0.007; incident CAD, OR 2.35, p=0.042), suggesting 
that in our study population, CLD may have little effect on the development of, or 
mortality from, CVD.   
In conclusion, the potential for using non-invasive biomarkers to diagnose clinically 
significant chronic liver disease in type 2 diabetes remains limited, however chronic 
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CHAPTER 1  
1.1 Type 2 diabetes mellitus 
Diabetes mellitus encompasses a number of metabolic disorders all resulting in 
hyperglycaemia due to defects in insulin secretion, insulin action, or both.  In turn, 
this chronic hyperglycaemia is associated with long-term damage, dysfunction, and 
failure of multiple organs.  Diabetes can be classified (Appendix A) dependant on the 
underlying cause e.g. type 1 diabetes – insulin deficiency.  This thesis will focus on 
type 2 diabetes only. 
1.1.1 Aetiology 
Type 2 diabetes is characterised by impaired pancreatic β-cell function and insulin 
resistance.  Insulin is a hormone released from the β-cells of the pancreas to help 
control glucose metabolism.  Failure to respond to insulin leads to increased levels of 
circulating glucose.  In response the β-cells increase insulin production, however, 
this ultimately becomes insufficient and a chronic hyperglycaemic state (diabetes) is 
reached. 
Whilst type 2 diabetes has traditionally been seen as driven by insulin resistance, 
however genome wide association studies (and meta-analyses) have identified a 
number of loci associated with reduced β-cell function and a number where the effect 




Exact causes of type 2 diabetes are unclear.  One concept is the ectopic fat theory 




1.1.2 The ectopic fat theory 
The ‘normal’ place for fatty acid storage is in adipocytes as triglyceride. Ectopic fat 
refers to the accumulation of excess intracellular lipid outside of these typical fat 
2 
stores.  Lipid oversupply leads first to deposition in subcutaneous adipose tissue, 
visceral adipose tissue and then into viscera such as the liver and skeletal muscle.  
The causes of ectopic fat deposition of three-fold: adipose tissue dysfunction, fat 
oxidation dysfunction and inflammation. Adipocyte dysfunction occurs when 
adipocyte tissue mass increases
5
, but not adipocyte number. The pattern of adipokine 
secretion then changes: leptin secretion increases, adiponectin secretion decreases, 
and chemokine secretion increases to recruit macrophages into the tissue leading to 
adipose tissue inflammation
6
. These large fat cells are unable to sequester the excess 
energy as triglyceride which leads to insulin resistance and type 2 diabetes
7,8
. Ideally 
the increased supply of lipid from dysfunctional adipose tissue is sequested as 
triglyceride through mitochondrial oxidation of lipid. However, there is evidence of 
mitochondrial dysfunction and reduced mitochondrial volume in skeletal muscle in 
type 2 diabetes
9
, associated with increasing insulin resistance. 
The consequences of this ectopic deposition include insulin resistance, pancreatic β-
cell failure and increased very-low density lipoprotein cholesterol production. It has 
been shown that skeletal muscle fat deposition (intramyocellular lipid) is directly 
correlated with insulin sensitivity, with increased insulin resistance related to 
increased ectopic intramyocellular lipid
10
. In the case of people with type 2 diabetes 
this is due to decreased oxidative capacity. The β-cell is also susceptible to the 
effects of increased lipid supply. Lipotoxicity leads to β-cell apoptosis and failure of 
insulin production
11,12
.  Hepatic lipid accumulation is associated with increased very-
low density lipoprotein production; hepatic insulin resistance
13,14
 and non-alcoholic 
steatohepatitis (NASH) and NASH-cirrhosis. Not all visceral ectopic fat is ‘bad’. 
Cross-sectional data suggest that gluteal adipose tissue is protective and not 




The most recent figures from the diabetes Managed Clinical Networks in Scotland
16
 
report 236,605 patients with type 2 diabetes in Scotland at the end of 2013, 88% of 
all diabetes cases.  In the Lothian region there were 31,833 (crude prevalence 3.8%).  
There has been a year-on-year increase in the crude prevalence over at least the last 
3 
seven years, most likely due to: increased surveillance for and diagnosis of type 2 
diabetes; improved data linkage and recording of known cases; and a true increase in 
the underlying prevalence.   
Type 2 diabetes typically affects older people with more than 70% occurring in 
people aged 60 years or over in Scotland.  The current overall incidence of type 2 
diabetes in Scotland is 3.4/1000 population/year, rising in those aged 60-69 years to 
8.3/1000 population/year and to 7.6/1000 population/year in those aged 70 years and 





Type 2 diabetes has a number of well acknowledged micro- and macrovascular 
complications.  More recently it has been linked with non-alcoholic fatty liver 
disease (NAFL) and non-alcoholic fatty liver disease (NAFLD)
17
. 
1.2 Chronic liver disease  
1.2.1 Aetiology 
There are a wide range of causes of chronic liver disease (CLD) (Table 1-1).   
1.2.2 Prevalence 
It is difficult to determine the prevalence of CLD as there is no agreed definition of 
CLD for collecting data.  The recent Lancet Commission – Addressing liver disease 
in the UK – reported that unlike other chronic diseases the standardised mortality rate 
for liver disease has increased 400% since 1970 and hospital admissions have 
increased 62% in just 10 years, and that this rise is in contrast to many other 
European countries where rates are falling
18
.   
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Table 1-1 Causes of chronic liver disease 
Long term alcohol consumption 
Viral hepatitis (B and C) 
Use of certain drugs e.g.  amiodarone, methotrexate, glucocorticoids 
Chemical exposure e.g.  carbon tetrachloride, N,N-Dimethylformamide 
Bile duct obstruction 
Autoimmune diseases e.g.  autoimmune hepatitis, primary biliary cirrhosis 
Obstruction of outflow of blood from the liver (for example, Budd-Chiari syndrome) 
Heart and blood vessel disturbances e.g.  congestive cardiac failure,  
Alpha1-antitrypsin deficiency 
High blood galactose levels 
High blood tyrosine levels at birth 
Glycogen storage disease 
Cystic fibrosis 
Diabetes/obesity/non-alcoholic fatty liver +/- disease 
Malnutrition 
Wilson’s disease (hereditary copper accumulation) 
Haemochromatosis (hereditary iron accumulation) 
 
The Scottish Public Health Observatory data collection has defined CLD as 
International Classification of Diseases (ICD) codes: ICD-9 571.0-571.6, ICD-10 
K70 (alcoholic liver disease, ALD), K73 (chronic hepatitis not classified elsewhere), 
and K74 (fibrosis and cirrhosis of liver)
19
.  It does not include chronic viral hepatitis 
(ICD-10 B18 codes), fatty liver (K76.0), haemochromatosis (E83.1), or 
complications such as hepatocellular carcinoma (HCC, C22.0). 
CLD is mainly treated in the community or through hospital out-patient clinics with 
much disease being asymptomatic until the later stages.  Whilst only the tip of the 
ice-berg in terms of disease burden, admissions to hospital in Scotland coded through 
hospital statistics as CLD have been rising in both men and women over the past 20 
years.  Interestingly associated mortality rose and has since began to fall again 
(Figure 1-1, Figure 1-2 and Figure 1-3).   
5 
Figure 1-1 Chronic liver disease hospital discharge rates in Scotland 1982-2013 
 
EASR European Age Standardised Rate 
Data from Information Services Division, NHS National Services Scotland
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Figure 1-2 Chronic liver disease mortality rates in Scotland 1982-2012 
 
EASR European Age Standardised Rate 
Data from Information Services Division, NHS National Services Scotland
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Figure 1-3 Cancer of the liver and intrahepatic bile ducts: Incidence and mortality rates in Scotland, 
1988-2012 
 
EASR European Age Standardised Rate 




1.2.3 Pathogenesis of fibrosis and cirrhosis 
Following any chronic injury to the liver there is a stereotypical cellular response 
resulting in by the accumulation of excessive amounts of extracellular matrix.  If the 
injury is short-lived then the extracellular matrix can remodel and normal liver 
architecture is restored, however, if the insult becomes chronic then accumulation of 




The liver parenchyma is made up of: hepatocytes and cholangiocytes (epithelial 
cells), sinusoidal endothelial cells and other non-parenchymal cells including hepatic 
stellate cells and Kupffer cells.  Figure 1-4a illustrates the structure of normal liver 
with the endothelial lining separated from the hepatocytes by the subendothelial 
space of Disse, where the hepatic stellate cells can be found.  The space of Disse 
contains low-density matrix that is both porous enough to allow metabolic exchange 
between the bloodstream and hepatocytes but dense enough to maintain the different 
structural areas.   
Progressive deposition of extracellular matrix in the space of Disse as a result of 
chronic liver injury reduces the endothelial porosity (‘capillarisation’ of the 
sinusoids) and impairs hepatic function (Figure 1-4b).  Different underlying CLD 
aetiologies result in differing patterns of liver fibrosis (Figure 1-5).  For example 
chronic viral hepatitis typically cause portal-central bridging fibrosis and ALD and 
NAFLD are characterised by peri-cellular fibrosis, having a characteristic chicken-
wire pattern.   
As fibrosis progresses to cirrhosis the scar tissue results in distortion of both the liver 
vasculature and parenchyma.  Nodules of regenerating liver tissue can be seen 
enclosed within fibrotic septae.  These events result in significant impairment of liver 
function with porto-systemic shunting and venous occlusion often occurring and 
leading to portal hypertension (Figure 1-6). 
 
7 
Figure 1-4 Liver structure 
 





There is increasing evidence (experimental models and human studies) that liver 
fibrosis is reversible and even cirrhosis can regress, although heavily cross-linked 






Figure 1-5 Patterns of liver fibrosis by aetiology 
 




Figure 1-6 The natural history of chronic liver disease 
 





1.2.4 Complications of chronic liver disease – hepatic decompensation 
Compensated cirrhosis means that the scarred and damaged liver is still able to 
undertake most of its functions.  Patients may be asymptomatic.  Ultimately the liver 
loses its ability to maintain normal function when the damage becomes too extensive 
or when further challenged (e.g during a period of infection, dehydration, 
constipation) – termed hepatic decompensation.   
Portal hypertension, hypersplenism and gastro-oesophageal varices 
Portal hypertension is an increase in the blood pressure within the portal venous 
system.  Portal hypertension can be classified according to the anatomic site of 
increased resistance to portal blood flow: pre-hepatic, intrahepatic and post-hepatic.  
In cirrhosis, architectural (structural) changes in the chronically injured liver are 
responsible for 60-70% of the increase in intra-hepatic vascular resistance that 
initiates portal hypertension
25
.  Contraction of peri-sinusoidal myofibroblasts (mostly 
derived from activated hepatic stellate cells) contributes to 30-40% of the increase in 
intra-hepatic vascular resistance, and is mainly due to a deficiency in hepatic nitric 
oxide levels.  In addition, splanchnic arteriolar vasodilation and a hyper-dynamic 
circulation increase portal blood flow and aggravate portal hypertension
26
.  Clinically 
significant portal hypertension is defined as a hepatic venous pressure gradient ≥10 
mmHg.  The consequences of portal hypertension include hypersplenism, 
development of gastro-oesophageal varices and ascites.  Variceal bleeding is the last 
step in a chain of events initiated by an increase in portal pressure, followed by the 
development and progressive dilation of varices until these finally rupture and bleed.  
It has been estimated that varices are present in about 30–40% of compensated 




Thrombocytopenia and coagulopathies 
Splenic enlargement occurs as a result of portal hypertension.  Thrombocytopaenia 
(platelet count <150x10
9
/L) may be present in as many as in 76% of patients with 
cirrhosis
30
 – occurring partly due to the increased pooling of platelets in the enlarged 
spleen, and also due to suppressed bone marrow production.  Furthermore, 
immunosuppressive medication and anti-viral therapy can also induce 
10 
thrombocytopaenia.  In addition, patients with cirrhosis develop coagulopathy due to 
loss of synthetic function.  This is evidenced as a reduction in the production of:  
clotting factors (I (fibrinogen), II (prothrombin), V, VII, IX, X, XI, protein C, and 
anti-thrombin) and increased bleeding risk
31
.   
Hepatorenal syndrome 
The initial change in renal function is the reduced capacity to excrete sodium, 
resulting in the accumulation of sodium and water in the abdominal cavity (ascites).  
The reabsorption of sodium is driven by i) the up-regulation of the renin-angiotensin-
aldosterone system, and ii) over-activity of the sympathetic nervous system.  In 
addition, free water excretion by the kidney is reduced.  The final change in renal 
function is renal vasoconstriction leading to reduced renal blood flow and a fall in 
glomerular filtration rate
32
.  The diagnostic criteria for hepatorenal syndrome include 
a number of major and minor criteria.  Major criteria: portal hypertension; renal 
failure; the absence of shock; infection; recent treatment with nephrotoxic 
medications and fluid losses; the absence of sustained improvement in renal function 
despite treatment with 1.5 litres of intravenous normal saline; the absence of 
proteinuria; and, the absence of renal disease or obstruction of renal outflow as seen 
on ultrasound.  Minor criteria: a low urine volume (less than 500 mL per day), low 
urinary sodium concentration, urine osmolality > blood osmolality, the absence of 





Hepatopulmonary syndrome involves the formation of arteriovenous dilations in the 
intrapulmonary vasculature, leading to over-perfusion relative to ventilation, and 
hypoxaemia.  The severity of hepatopulmonary syndrome is based on the 
oxygenation deficit rated from mild, with an alveolar–arterial oxygen gradient ≥15 
mmHg and a partial pressure of oxygen ≥80 mmHg, through moderate and severe, to 







Cirrhosis also causes changes in the systemic circulation.  A hyper-dynamic 
circulation results from reduced systemic vascular resistance and arterial 
vasodilation.  In addition, pooling of the blood in the splanchnic circulation results in 
effective central hypovolaemia, which is followed by baroreceptor-induced 
activation of renin-angiotensin-aldosterone-system and the sympathetic nervous 
system.  In response there is an attempt at increasing and maintaining cardiac 
output
36-38
.  There is a further suggestion that cirrhosis itself may have an influence 
on the heart – although this is unclear.  The result of these events is a cardiac 
condition characterized by a reduced contractility, diastolic dysfunction and 
electromechanical abnormalities, in the absence of any other cardiac disease
39,40
.  
These cardiac changes have been reported to occur in up to 40–50% of patients with 
cirrhosis
41,42
.   
Hepatocellular carcinoma 
It is thought that approximately a third of patients with cirrhosis will develop HCC at 
some point and that 90% of patients with HCC have cirrhosis
43
.  Screening for HCC 
is recommended for patients with: cirrhosis and Child-Pugh stage A or B; cirrhosis 
and Child-Pugh stage C awaiting liver transplant; non-cirrhotic hepatitis B virus 
carriers with active hepatitis or family history of HCC; and non-cirrhotic chronic 




Hepatic encephalopathy encompasses a range of reversible neuropsychiatric 
abnormalities as a result of the livers inability to remove toxins (e.g.  nitrogenous 
substances derived from the gut) from the portal blood
45-47
.  In the brain these 
substances alter neurotransmission affecting conscious level and behaviour.  hepatic 
encepalopathy is graded as: Grade 1 - trivial lack of awareness, euphoria or anxiety, 
shortened attention span, impaired performance of addition; Grade 2 - lethargy or 
apathy, minimal disorientation for time or place, subtle personality change, 
inappropriate behaviour, impaired performance of subtraction; Grade 3 - somnolence 
to semi-stupor, but responsive to verbal stimuli, confusion, gross disorientation; and 
Grade 4 - coma (unresponsive to verbal or noxious stimuli)
48




 defines hepatic encepalopathy as: hepatic encepalopathy associated 
with acute liver failure; hepatic encepalopathy associated with porto-systemic bypass 
without intrinsic hepatocellular disease; and hepatic encepalopathy associated with 
cirrhosis and/or portal hypertension.  This third group can be further subdivided into 
episodic, persistent and minimal.  Treatment of hepatic encepalopathy is centred on 
supportive care, identification and removal of precipitants (e.g.  infection, 
dehydration, renal failure, constipation, gastro-oesophageal haemorrhage), reduction 
of the nitrogenous load from the gut, and assessment of the need for long term risk 
reduction therapy (e.g.  non-absorbable antibiotics)
50
.   
Malnutrition 
The prevalence of malnutrition in cirrhosis is as high as 65%–90%
51,52
.  A variety of 
processes contribute to malnutrition in cirrhotic patients: poor dietary intake, 
malabsorption, increased intestinal protein loses, reduced protein synthetic function, 
disturbances in substrate use, and a hypermetabolic state
53
. 
1.3 Non-alcoholic fatty liver and non-alcoholic fatty liver disease 
1.3.1 Terminology 
The terminology used to describe non-alcoholic fatty liver (NAFL) and non-
alcoholic fatty liver disease (NAFLD) can be confusing. Until relatively recently the 
term NAFLD was used to include all stages of the disease process and this frequently 
remains the case. In 2012, The American Association for the Study of Liver Diseases 
published an updated practice guideline separating the spectrum of changes within 
the liver into two parts: 1) benign non-alcoholic fatty liver with hepatosteatosis only 
– NAFL, and 2) bringing necro-inflammatory non-alcoholic steatohepatitis (NASH), 
liver fibrosis and cirrhosis together to form the ‘disease’ element of the spectrum – 




Figure 1-7 The natural history of non-alcoholic fatty liver disease 
 
As such, throughout this thesis the following terms will be used: 
 NAFL, non-alcoholic fatty liver – the presence of hepatic steatosis only 
 NAFLD, non-alcoholic fatty liver disease – the presence of NASH, hepatic 
fibrosis or cirrhosis 
 NAFL/D, the full spectrum of liver disorder – NAFL and NAFLD combined. 
1.3.2 Prevalence 
The unadjusted prevalence of NAFL/D in the general population is estimated to be 
between 9-46%
54-58
 with the wide variation in reported results being due to the 
population studied and diagnostic criteria used.  This wide range is due to NAFL/D 
being diagnosed using elevated liver enzymes, USS or liver biopsy. The most 
plausible estimates come from USS and other imaging studies as whilst not having 
the diagnostic accuracy of liver biopsy, USS is non-invasive and can be used widely 
in general populations unlike liver biopsy which is typically restricted to patients 
with a high suspicion of disease. It is generally accepted that the prevalence is rising 
(although there are no definitive confirmation of this) and that the driving factors 
behind this are diabetes and obesity.   
One of the most plausible estimates for the prevalence of NAFL/D include those 
provided by the Dallas Heart Study (a multi-ethnic population-based sample)
59
 which 
used high resolution magnetic resonance spectroscopy to measure hepatic TG. With 
NAFL/D defined as hepatic steatosis (hepatic TG content >5.5%) in the presence of 
no alcohol consumption the prevalence was29.3% (670/2287)
60
.   










fatty liver (NAFL) 
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What is more difficult to determine is the prevalence of NASH and related fibrosis.  
Studies are limited by the need for liver biopsy (the current controversial gold 
standard) with understandably few undertaken in the general population who are 
typically asymptomatic. 
The overall prevalence of NAFL/D is quoted as up to 70%
61
, however the studies 
providing these estimates are frequently restricted to selected populations.  For 
example, a recent study of a largely military population in the USA found a NAFL/D 




The initial pathological hypotheses, the ‘double hit’ hypothesis
62
 proposed by Day et 
al in 1998 was highly influential in the understanding the pathogenesis of NAFL/D.  
It has since been superseded by the ‘multiple parallel hits’ hypothesis
63
 however, 
they have a number of elements in common, and both surmise that the development 
of NAFL/D is a multifactorial disease, both genetic and environmental in origin, with 
both perpetuating and restorative events repeatedly occurring over time (Figure 1-8). 






Restorative mechanisms      Perpetuating mechanisms 
Phenotype 
Progression < healing   Progression = healing   Progression > healing 
DISEASE RESOLUTION  NON-PROGRESSIVE/BENIGN PROGRESSIVE DISEASE 
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Non-alcoholic fatty liver 
The first stage of the development of NAFL/D is the accumulation of adipose tissue 
within the liver parenchyma (steatosis), known as NAFL.  Figure 1-9 shows the 
pathophysiological process of NAFL/D. 
There are three key drivers of this process: i) increased free fatty acid influx into the 
liver; ii) de novo lipogenesis within the liver; and iii) reduced export of fat from the 
liver.   
The core underlying premise is that a series of events occurs in response to insulin 
resistance and resultant hyperinsulinaemia.  Ectopic hepatic steatosis is thought to 
occur due to an increase in hepatic free fatty acids driven by insulin resistance 
through: the hydrolysis of triglycerides (TG) in peripheral adipocytes, hydrolysis of 
dietary TG, and also endogenous free fatty acid synthesis
64,65
. 
Insulin triggers hepatic lipogenesis through sterol regulatory element-binding 




In addition, hyperinsulinaemia results in higher circulating levels of TG in the form 
of very low density lipoproteins due to increased delivery of free fatty acids to the 
liver though impaired inhibition of hormone-sensitive lipase, and reduced hepatic TG 
secretion through impaired mitochondrial β-oxidation
67,68
.   
NAFL is thought to be a largely benign condition that is in itself it doesn’t appear to 











The progression of NAFL to inflammation (NASH) and fibrosis/cirrhosis is believed 
to be a response to i) oxidative stress within the liver and ii) cytokine production.   
Usually there is a balance between antioxidants and reactive oxygen species.  In 
normal circumstances, some degree of lipid oxidation occurs to prevent excess lipid 
being deposited in the liver.  In progressive NAFLD, excessive lipid oxidation occurs 
causing oxidative stress and reduced levels of antioxidants. 
Mitochondria play a key role in the inflammatory process.  There are a number of 
mitochondrial abnormalities present in NASH, namely mega-mitochondria, loss of 
cristae and the presence of paracrystalline inclusions.  These structural abnormalities 
result in abnormal electron transport chain activity and ultimately the development of 
reactive oxygen species, which perpetuates a vicious cycle of events.  The ineffective 
electron transport chain activity also leads to increased expression of tumour necrosis 
factor-α (TNF-α) which also further stimulates lipid peroxidation
63,66
. 
Lipid peroxidation produces aldehydes, 4-hydroxynonenal and malondialdehyde, 
which activate hepatic stellate cells.  These collagen producing cells lead to the 
formation of Mallory bodies and neutrophil chemotaxis.  Malondialdehyde may also 
stimulate nuclear factor kappa-light-chain-enhancer of activated B cells which 
controls expression of further proinflammatory mediators including TNF-α, 
interleukin-8, intercellular adhesion molecule 1 and E-selectin
63,69
. 
Liver fibrosis and cirrhosis 
The development of fibrosis is a response to chronic liver damage.  Quiescent 
hepatic stellate cells become ‘activated’ in response to persistent injury and undergo 
a transition to matrix-producing myofibroblast-like cells.  They also influence 
inflammatory cell activity and cytokine production that perpetuate the fibrotic 
response.  The severity of underlying insulin resistance is independently associated 




NAFL/D is largely a diagnosis of exclusion.  The formal definition provided by the 
American Association for the Study of Liver Diseases is: 
“[T]here is evidence of hepatic steatosis, either by imaging or by histology and there 
are no causes for secondary hepatic fat accumulation such as significant alcohol 
consumption, use of steatogenic medication or hereditary disorders61.” 
Table 1-2 outlines typical causes of hepatosteatosis that need to be excluded for 
clause (b) of the definition above, however there is no definitive agreed criteria for 
these, such that different studies apply for example differing alcohol cut-offs or 
include different drugs on their list of medications causing hepatic fat accumulation. 
Table 1-2 Causes of hepatic steatosis 






Disorders of lipid 
metabolism 
Abetalipoproteinaemia, hypobetalipoproteinemia, Anderson’s disease, 
Weber-Christian syndrome, acute fatty liver of pregnancy, Wolman’s 
disease, Wilson’s disease, Reyes syndrome, Dorfman Chanarin 
syndrome 
Nutritional 
Total parenteral nutrition, severe weight loss (jejunoileal bypass, 
gastric bypass, severe starvation), refeeding syndrome, protein calorie 
malnutrition, coeliac disease, inflammatory bowel disease 
Drugs 
Amiodarone, diltiazem, nifedipine, verapamil, synthetic oestrogens, 
corticosteroids, highly active antiretroviral therapy, tetracycline,  
methotrexate, sodium valproate, aspirin 
Hepatotoxins 
Phosphorus, petrochemicals, toxic mushrooms (Amanita phalloides, 
Lepiota), organic solvents, Bacillus cereus toxin 
Infections 
Human immunodeficiency virus, hepatitis C virus, small bowel 







Diagnosis of steatosis 
There are a number of methodologies allowing the diagnosis of hepatic steatosis.  
The validity of each is considered to vary.   
The simplest and most commonly used method is abdominal ultrasound scan (USS).  
Detection of hepatic fat is based on well-established characteristics including a 
hyperechogenic parenchyma (especially in relation to the right kidney), posterior 
attenuation (posterior darkness and loss of definition of the diaphragm) of the 
ultrasound beam as it passes through the liver, and areas of focal fatty sparing 
71-74
.  
However there is no definitive consensus on diagnostic criteria
75
.   
USS is frequently cited as having poor diagnostic accuracy in the identification of 
hepatic steatosis.  A 2011 meta-analysis determined the sensitivity of ultrasound in 
diagnosis of any degree of hepatic steatosis was 73.3% and corresponding specificity 
was 84.4%
76
.  However, the diagnostic accuracy of included studies varied with 
sensitivity as low as 53% and specificity as low as 77%.  Some of this variation may 
be explained by the varied populations under study and by variation in diagnostic 
criteria used. 
The non-invasive gold-standard for the detection of hepatic steatosis is magnetic 
resonance spectroscopy.  Different “normal” values for hepatic fat fraction on 
magnetic resonance imaging have been reported but typically are attributed to ≤5% 
fat
60,77,78
.  A recent meta-analysis found magnetic resonance spectroscopy to be 
superior to both computed tomography and USS for the diagnosis of hepatic steatosis 
with sensitivity and specificity of 89% and 92% respectively for a fat fraction of up 
to 5% steatosis, and of 73% and 96% respectively for a fat fraction above 25%
77
. 
Diagnosis of non-alcoholic steatohepatitis and liver fibrosis 
Currently the only universally accepted method (and gold standard) for the diagnosis 
of the inflammatory and fibrotic stages of NAFLD is liver biopsy to allow 
histological assessment.  Numerous non-invasive methods have been introduced over 
recent years.  Suggested markers of NASH include cytokeratin-18 (CK18), adipocyte 
fatty acid binding protein, fibroblast growth factor 21 and NASHTest
79-81
.  CK18 has 
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been most extensively investigated.  Across 6 studies involving a total of 561 
participants (range 44-139) the diagnostic accuracy of CK18 (vs liver biopsy) as 
determined by the area under received operating characteristic (AUROC) to be 0.71-
0.93.  The associated sensitivities and specificities for the optimal cut off to 
determine NASH in each study were 62-86% and 81-100% respectively.  It should 
be noted that all of the studies used secondary/tertiary care based populations with a 
high prevalence of NASH
82-87
. 
Non-invasive markers of liver fibrosis are reviewed in detail in Chapter 2. 
1.3.5 Risk factors 
Age 
NAFL/D is found in all age groups including children, however there is an increasing 
prevalence with increasing age
60
.  For example, a general population post mortem 
study found the prevalence of fatty liver in the was 1% in people below 20 years, 




Differing ethnicities bring differing risk profiles for NAFL/D.   
Browning et al found that African Americans have significantly less magnetic 
resonance spectrospcopy measured hepatic TG (median 3.2%) and hepatic steatosis 
(24%) than non-Hispanic whites (3.6% and 33%) or Hispanics (4.6% and 45%) even 
after adjusting for obesity and diabetes
60
. 
Asian populations have a higher prevalence of type 2 diabetes and insulin resistance 





A number of different studies have suggested that there is a heritable component to 










A number of genetic associations have been observed.  The first genome wide 
association study by Romeo et al in 2008
97
 identified a single highly significant 
association with increased hepatic TG levels for the PNPLA3 gene.  A gene dose 
effect for the index SNP (rs738409) was observed.  Following this PNPLA3 remains 




Reports are very mixed on the distribution of NAFL/D between men and women.  
Initial reports suggested NAFL/D was more common in females, with a shift now to 
a more even distribution or possibility of an increased prevalence in males.  NAFL/D 
is more common is post-menopausal women than pre-menopausal
104
, and hormone 
replacement therapy appears protective
105
.  Sex-related fat distribution differences 
mean that females tend to have less visceral fat and this may explain a reduced 




Obesity is a recognised risk factor for NAFL/D, even after adjustment for insulin 
resistance.  As a response to excess calorific intake the adipocytes hypertrophy 
followed by hyperplasia (fat cell replication).  As described in section 1.3.3, in an 
attempt to avoid excess hepatic TG accumulation the adipocytes activate a number of 
inflammatory pathways potentially leading to NASH. 
Type 2 diabetes 
The relationship between type 2 diabetes and NAFL/D is discussed in section 1.5. 
1.3.6 Disease progression 
Given that hepatic steatosis is considered to be a benign condition for the majority of 
patients, of more interest is (a) the rate of progression to NASH and to liver fibrosis 
and cirrhosis, and (b) any evidence of reversal from the later stages back to simple 
steatosis.  The recent Lancet Commission – Addressing liver disease in the UK – 
suggested that a third of obese UK individuals have NAFL/D, and in almost one in 
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 of ten studies (221 subjects) of NAFL/D progression found 
37% progressed to a higher fibrosis category (Metavir F1+ disease 0.41 stages/year, 
overall 0.03 Metavir stages/year) and 21% improved their fibrosis classification 
during a median follow-op period of 3.7 years (range 1.0-21.3 years).  Further 
analysis found that age (younger) and the presence of inflammation on the diagnostic 
biopsy were independent predictors of this progression.  Expected risk factors (e.g. 
diabetes and obesity) were not statistically significant.  Table 1-3 summarises the 
data on histological changes in NAFL/D from each of the studies contributing to the 
fore-mentioned meta-analysis and the additional studies identified.  Caution is 
required in the interpretation and comparison of these studies for a number of 
reasons: (a) there was a different baseline prevalence of NASH stages and fibrosis 
scores in each study, thus the %change does not reflect the baseline number able to 
change (ie a study with predominantly F0 and F1 subjects at baseline will by 
definition have a low proportion regressing); (b) some of the studies were appended 
to intervention studies; and (c) all of the studies were based on biopsy data therefore 
have been performed in selected populations. 
Of note, most of the studies were small (max n=103) with short follow-up periods 
(50% <5 years).  Six studies either reported overall fibrosis change rates or provided 
sufficient data to allow their calculation.  Only one study
108
 found the average rate of 
change to be in the direction of regression.  The others had progression rates between 
0.03 and 0.11 Metavir fibrosis stages/year.  This would translate that a subject with 






Table 1-3 Progression and regression of pathological changes in non-alcoholic fatty liver /disease 
Study Year
a



































































 1980/2003 USA 103 45.0 (11.5) 37 3.2 (3.0) - - 36.9 29.1 0.09 
Argo
108
 1997/ USA 5 - - 4.4 (1.9) - - 60.0 20.0 -0.07 
Ekstedt
113
 1988/2003 Sweden 70 51.0 (12.9) 67 13.8 (1.2) - - 41.4 15.7 - 
Evans
114
 1985/1999 UK 7 57.5 (9.1) 43 8.2 (2.6) 0 42.9 57.1 0 0.09 
Fassio
115
 1986/2002 Argentina 22 44.7 (12.7) 41 4.3 (3.0-14.3) - - 31.8 18.2 0.06 
Hamaguchi
112
 1997/2008 Japan 39 47 (20-79) 56 2.4 (1.0-8.5) 23.1 17.9 28.2 30.7 - 
Harrison
116
 1985/2001 USA 22 50.6 59 5.7 18.2 45.5 31.8 18.2 - 
Hui
117
 1996/2004 Hong Kong  17 41.8 (2.6) 65 6.1 (3.8-8.0) 11.8 23.5 52.9 0 0.11 
Chan
118
  2014 Kuala Lumpar 35 47.5 (10.9) 40 6.4 (0.8) 37.1 37.1 51.4 0  
Pais
111
 1998/2009 France 70 52 (10.5) - 3.7 (2.1) 41.4 31.4 28.6 28.6 - 
Ratziu
119
 1988/1999 France 14 - - 5.2 (3.9) - - 14.3 - - 
Wong
110
 2006/2009 Hong Kong 52 44 (9) 65 3 38.5 19.2 26.9 25.0 0.03 
a
year recruitment commenced/year follow-up finished or year of publication; 
b
mean (sd) or median (range) 
NASH non-alcoholic steatohepatitis. 
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In addition, whilst many of the studies found univariate associations between 
potential risk factor for and fibrosis change, few reported independent associations 
after adjustment in multivariable analysis.  Those that did reported progression of 
fibrosis associated with increasing baseline body mass index (BMI, p=0.008)
109
, 
presence of baseline obesity (p=0.005)
109
, increase in waist circumference between 
biopsies (p=0.002)
110
, increased baseline low-density lipoprotein (LDL) cholesterol 
(p=0.019)
110
 and increased quantitative steatosis measurement on baseline biopsy 
(p=0.001)
111
.  Regression of liver fibrosis was independently associated with >1% 
improvement in HbA1c between biopsies (p=0.01)
112





At present there is no pharmacological therapy licenced for the treatment of 
NAFL/D.  Research into treatments is focusing on two main effects (i) early disease: 
regression/halting the progression of steatosis and/or NASH, and (ii) later disease: 
anti-fibrotic therapies.  Clinical trials are limited by the lack of a non-invasive 
marker that aligns with the histological grade of disease to allow monitoring of 
disease progression/regression.  There is also no universally agreed 
endpoint/outcome for trials.  Currently, histological changes seen on liver biopsy are 
the suggested end-point for trials of 12-24 month duration, including reduction in 
NAFLD Activity Score combined with either improvement or lack of progression in 
fibrosis score (see section 1.4.2).   
Insulin resistance is probably the main driver in NAFL/D, however, targeting the 
steatosis element of NAFL/D is unlikely to be sufficient to treat NASH and fibrosis.  
In the early stages of NAFL treatment options include lifestyle modification and 
weight loss, alongside lipid lowering agents.  Newer antifibrotic targets include: 
obeticholic acid (a semi-synthetic derivative of the primary human bile acid 
chenodeoxycholic acid involved in the regulation of  glucose and lipid metabolism); 
dual peroxisome proliferator-activated receptor  α/δ Agonist (regulation of metabolic 
homeostasis, inflammation, cellular growth and differentiation); anti-LOXL2 
monoclonal antibody (an enzyme that promotes cross-linking of fibrillar collagen I); 
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modulating the gut-liver axis; adiponectin agonists (anti-inflammatory cytokines);  
glucagon-like peptide 1 analogues (reduces pancreatic insulin secretion following 
feeding); galectin inhibitors; and C-C chemokine receptor 2 and 5 antagonists.  It 
may be that combined approaches, targeting both inflammatory and fibrogenic 
pathways, will be need to treat NASH and fibrosis. 
Thoma
120
 recently undertook a systematic review of lifestyle modification on 
intrahepatic TG concentration, liver enzymes, and/or insulin sensitivity in adults 
(⩾19years) with NAFL or NASH.  They concluded that lifestyle modifications are 
effective in reducing intrahepatic TG and circulating liver enzymes, and improving 
measures of glucose control and/or insulin sensitivity in patients with NAFL/D.  
They noted that these improvements were driven by weight reduction with weight 
reductions of 4–14% resulting in statistically significant relative reductions in 
intrahepatic triacyglycerol of 35–81% but that physical activity could result in (not 
statistically significant) reductions in intrahepatic TG without a reduction in weight. 
Musso
121
 performed a meta-analysis examining pharmacological agents for the 
treatment of NAFL/D.  Overall they concluded that most of the 49 included trials 
were small (median 50 subjects, range 16-247) with a duration of less than one year.  
Weight loss, thiazolidinediones and antioxidants constituted the majority of trials 
(10, 8 and 12 respectively).  Weight loss had no significant reported side effects and 
a dose-dependent response was seen with improvement in NASH.  However, in 
excess of 50% of subjects failed to achieve their target weight loss.  
Thiazolidinediones improved steatosis and inflammation but were not well tolerated 
(up to 18% drop-outs) due to associated weight gain of 2-5kg in 66-75% of subjects 
and peripheral oedema in 4-10%.  Randomised controlled trials of antioxidant 
therapies have reported mixed results for improvement in steatopsis, histological 
NASH and transaminases, and no effect on fibrosis.  Improvement in NASH 
histology in at least one randomised controlled trial was seen with pentoxifylline, 
telmisartan and L-carnitine.  Finally, polyunsaturated fatty acids improved 




Diabetes therapy and non-alcoholic fatty liver 
Several common diabetes treatments have been considered in the treatment of 
NAFL, due to the shared aetiology (ectopic fat). 
Metformin improves hepatic insulin action without affecting hepatic or muscle lipid. 
Thiazolidinediones (TZDs) have been shown to modulate ectopic fat (despite often 
increasing total body fat
122
) through the formation of new adipocytes, storage of 
lipids in adipose tissue
123,124
, increased adiponectin secretion
125
, decreased ectopic 
liver fat
125
 and improved insulin sensitivity
125
. 
Whilst not a diabetes treatment, the majority of patients with type 2 diabetes will be 
receiving a statin (3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase 
inhibitors) as advised in national guidelines
126
. Statins act on hepatocytes to inhibit 
HMG-CoA reductase, reducing the production of cholesterol precursors.  The most 
common hepatic adverse event involves asymptomatic increases in liver 
transaminases. This dose-dependent reaction usually occurs within the first year of 
therapy, but may present at any time
127,128
. To date, there is no convincing evidence 
that lipid-lowering agents, including statins, are beneficial for patients with NAFL. 
1.3.8 Extrahepatic complications 
Type 2 diabetes 
The relationship between type 2 diabetes and NAFL/D is discussed in section 1.5. 
Cardiovascular disease 
The relationship between cardiovascular disease (CVD) and NAFL/D is discussed in 
section 1.6. 
Renal disease 
Several studies have suggested NAFL/D as an independent risk factor for chronic 
kidney disease (CKD) with studies finding a prevalence of 21-54% compared to 3.7-
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24.2% in non-NAFLD patients
129-132
.  Even after adjusting for traditional risk factors 
for CKD (including age, sex, hypertension, diabetes, BMI, dyslipidaemia) NAFL/D 
on imaging has been found to confer an increased risk with OR 1.87-6.14
129-132
.  
Although this has not been a universal finding
133
.  The risk of developing CKD 
following a diagnosis of NAFLD is also elevated, HR 1.49-4.38 (after adjustment)
134-
137
, however, these studies use differing diagnoses of NAFL/D (USS or elevated 
gammaglutamyl transferase, GGT) and had variable follow-up time.   
Colorectal cancer 
There is increasing interest in the relationship between NAFL/D and colorectal 
cancer.  Three retrospective studies have found an association between NAFL/D and 
colorectal adenomas after adjustment (NAFL/D OR 1.45-1.47
138,139
, NASH OR 
4.89
140




NAFL/D has been associated with growth hormone deficiency, hypogonadism, 
hypopituitarism, polycystic ovarian syndrome, hypercortisolaemia and 
hypothyroidism
142
 although the evidence is currently limited.   
Obstructive sleep apnoea syndrome  
There is an increased prevalence of NAFL/D in people with obstructive sleep apnoea 
independent of age, sex and BMI.  In a recent meta-analysis
143
 of 18 studies (2183 
subjects) Musso et al  found pooled OR in obstructive sleep apnoea syndrome for the 
presence of NAFL/D, as defined by histology, radiology, or transaminase  elevation, 
2.53 (95%CI 1.93-3.31).  Pooled ORs in obstructive sleep apnoea syndrome with 
severity of NAFL/D liver histology were similar at 2.37 (95%CI 1.59-3.51), 2.16 
(95%CI 1.45-3.20) and 2.30 (95%CI 1.21-4.38), for NASH, fibrosis-any stage, or 
advanced fibrosis respectively.   
Osteoporosis 
Three studies in adults have found a relationship between the presence of NAFL/D 
and osteoporosis (bone mineral density measure or fracture assumed to be 
osteoporotic) after adjustment for known risk factors (including age, sex, BMI, 
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smoking, alcohol, metabolic syndrome)
144-146
.  This risk is appears to be present in 
both males and females (prevalence of osteoporotic fracture 2.3% in men and 2.9% 
in women)
145
, and also in both adults and children
146
. 
1.4 Liver biopsy  
1.4.1 Procedure 
Liver biopsy involves the physical sampling of a small portion of the liver for 
histological examination.  The most common method is percutaneous biopsy where a 
biopsy needle is advanced through the skin to obtain the sample within a few 
seconds.  The use of USS guidance to facilitate the procedure is now recommended 
due to its reduced complication rates 
147
 compared to a ‘blind’ procedure and 
resultant reduced costs 
148,149
.  An alternative approach (when percutaneous is not 
possible) is via the transjugular route and occasionally laparoscopically. 
Complications 
Liver biopsy is associated with a small but significant morbidity and mortality with a 
suggested directly attributable mortality rate of  between 1 in 1000 
150
 and 1 in 10000 
151
 for the percutaneous procedures.  The most frequently cited UK figure for the rate 




Reliability of liver biopsy in non-alcoholic fatty liver disease 
There are justified concerns about the reliability of liver biopsy in NAFL/D.  It 
samples only 1/50,000th of the liver, which is particularly problematic in NAFL/D 
and NASH because they are often patchy disorders throughout the liver.  A recent 
study by Ratzui looking at reproducibility of biopsy results in patients with NAFL/D 
found that on 40% of occasions there was a staging difference between the 2 








Beyond liver biopsy there is increasing interest in the use of non-invasive diagnostic 
markers.  Chapter 2 reports the findings of a systematic search of non-invasive 
markers of liver fibrosis.   
1.4.2 Histological grading and staging in non-alcoholic fatty liver /disease 
The histological determination of NAFL/D is based on three components: i) 
steatosis, ii) hepatocellurlar injury and inflammation, and iii) fibrosis.  ‘Grading’ is 
typically used in reference to measures of ongoing disease activity 
(necroinflammation).  ‘Staging’ refers to the longer term disease progression 




By definition steatosis must be present for a diagnosis of NAFL/D.  On histological 
examination a minimum of 5% of hepatocytes containing fat droplets must be 
present to meet the diagnosis. 
Non-alcoholic steatohepatitis 
The NAFLD Activity Score score
154
 was developed by the Pathology Subcommittee 
of the NASH Clinical Research Network.  It is the un-weighted sum of scores 
assigned to steatosis, ballooning and lobular inflammation and was originally 
developed to examine treatment response histologically (Table 1-4).  Whilst it can be 
used to monitor NASH, it is neither linear nor designed as a diagnostic tool.  In 
practice the sum score is often interpreted as: 0-2 unlikely NASH, 3-4 indeterminate, 
and ≥5 NASH likely. 
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Table 1-4 NAFLD Activity Score: histological criteria 












<2 foci per 200x field 
2-4 foci per 200x field 







Few balloon cells 




NAFLD non-alcoholic fatty liver disease 
 
Liver fibrosis 







, see Appendix B) for chronic liver disease, which were 
primarily designed for the staging of hepatitis C induced fibrosis and cirrhosis.  
These are largely interchangeable with similar criteria, however more recently there 
has been a tendency towards the Kleiner criteria
154
 developed specifically in NAFLD 
from the Brunt criteria
158
, see Table 1-5.   
Table 1-5 Kleiner (modified Brunt) non-alcoholic fatty liver disease histological fibrosis staging 
criteria 
Stage Fibrosis features 
0 None 
1 Perisinusoidal or periportal 
1A Mild, zone 3, perisinusoidal 
1B Moderate, zone 3, perisinusoidal 
1C Portal/periportal 
2 Perisinusoidal and portal/periportal 




1.5 Non-alcoholic fatty liver disease and type 2 diabetes 
1.5.1 Prevalence  
The prevalence of NAFL/D amongst people with type 2 diabetes is reported to be 
higher than in the general population. 
Extensive searching identified 10 studies (published prior to 31
st
 March 2012) 
reporting the prevalence of NAFL amongst people with type 2 diabetes (Table 
1-6)
57,159-167
.  All of them based the diagnosis of NAFL on USS (with four 
supplemented with liver biopsy providing NASH and fibrosis prevalence), however, 
nearly all (8/10) were based on subjects drawn from secondary care diabetes 
outpatients clinics and are therefore not representative of all patients with type 2 
diabetes.  In addition there was wide heterogeneity in the age and sex of subjects 
studied. 
Estimates of the prevalence on NAFL ranged from 35-70%.  Of note there were two 
large European studies:  the first including nearly 1000 UK community-based 
subjects (the Edinburgh Type 2 Diabetes Study) with a NAFL prevalence of 43%
165
, 
and the second including nearly 3000 Italian hospital out-patient subjects with a 
higher NAFL prevalence of 70%
162
. 
The four biopsy studies all used hospital out-patient populations (three in India, one 
in Brazil).  They were relatively consistent in their NASH findings, prevalence 26-
36%, but there was a larger discrepancy in their fibrosis findings, prevalence 7-
33%
159,161,163,164
.   
Overall, the estimates based on hospital out-patients (and therefore subject to 
selection bias) tended to have higher point estimates than the three general 
population studies (Figure 1-10). Given the aforementioned issues it is likely that the 




Figure 1-10 Prevalence of non-alcoholic fatty liver (+/- disease) in people with type 2 diabetes. 
Values are % and 95%CI.  
 
NAFL/D non-alcoholic fatty liver +/- disease 

























Table 1-6 Prevalence of non-alcoholic fatty liver /disease in people with type 2 diabetes 















 2006 Italy Out-patient 2839 40-86 - USS 69.5% - - 
Williamson
165
 2008 UK General 939 61-76 - USS 42.6% - - 
Leite
163
  2007 Brazil Out-patient 244 <65 30.0% USS + liver biopsy 51.2% 31.3% 33.0% 
Prashanth
161
 2005 India Out-patient 204 20-70 - USS + liver biopsy 62.3% 25.5% 15.2% 
Mohan
166
 2009 India General 132 50.4 56.1% USS 54.5% - - 
Agarwal
167
 2011 India Out-patient 124 >35 59.7% USS 57.2% - - 
Akbar
160
 2003 Saudi Out-patient 116 54 27.0% USS 55.2% - - 
Jimba
57
 2003 Japan General 111 49 69.0% USS 55.9% - - 
Gupte
159
 2002 India Out-patient 100 - - USS + liver biopsy 49.0% 28.0% 7.0% 
Banerjee
164
 2008 India Out-patient 47 - - USS + liver biopsy 66.0% 36.2% 31.9% 
NAFL non-alcoholic fatty liver; NAFL/D non-alcoholic fatty liver disease; NASH non-alcoholic steatohepatitis; USS ultrasound scan
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1.5.2 Complications  
Diabetes is also associated with an increased risk of hepatic complications.  In the 
Verona Diabetes Study chronic liver disease had an SMR of 2.52
168
.  A Danish study 
examined the incidence of HCC amongst hospitalised patients and found it to be 
higher amongst people with diabetes (SMR 4.0 men and 2.1  women) 
169
.  Hassan et 
al investigated the diagnosis of diabetes in patients with HCC and found an adjusted 
OR of 4.3(1.9-9.9) for diabetes in HCC compared with other primary cancers 
170
. 
1.6 Non-alcoholic fatty liver /disease and cardiovascular disease 
Patients with CLD, and in particular NAFL/D, are reported to have both higher all-
cause mortality
171,172
 and cardiovascular (CV) mortality rates than the general 
population
113,173
.   
Two questions are currently not fully answered:  
(i) Is the relationship between NAFL/D and CVD driven by their shared risk 
factors, or does NAFL/D ‘cause’ CVD independently?  
(ii) Is the increased risk of CVD in people with NAFL/D present in those with 
simple NAFL or is more advanced NAFLD required? 
1.6.1 The atherogenic liver hypothesis 
Many of the likely causal explanations for both fatty liver and atherosclerosis are 
shared (e.g.  insulin resistance, dyslipidaemia, systemic inflammation, see Table 
1-7).  However, the concept  of the liver-vessel axis hypothesis
174
 could  explain the 
biological mechanisms linking the liver directly to  the accelerated atherosclerosis 
proposed in NAFL/D.   
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Table 1-7 Possible pathophysiological associations between NAFL/D and CVD 
Factor Atherosclerosis NAFLD 
Atherogenic 
hyperlipidaemia 
Associated with high low and 
very-low density lipoprotein and 
with low high density lipoprotein 
Prevalence increased in mixed 
hyperlipidaemia 
Arterial hypertension 
Associated and partially reversible 
with a decrease in hypertension 
Prevalence higher in people with 
hypertension 
Hyperhomocycteinaemia Associated 
Evidence from animal and human 
studies, including HCV steatosis 
Type 2 diabetes Strongly associated 
Prevalence increased and a risk 
factor for the development and 
progression of NAFLD 
Abdominal obesity Strongly associated 
Associated and a predictor of liver 
fibrosis 
Prothrombotic state 
Association with fibrinogen, PAI-1, 
Factor VII, Factor VIII, platelet 
reactivity and others 
Associated with fibrinogen, PAI-1, 




Associated with CRP and other 
acute-phase proteins 
Postulated major determinant for 
the development of NAFLD 
Metabolic syndrome and 
insulin resistance 
Strongly associated 
Prevalence higher in metabolic 
syndrome and a risk factor for the 
progression of NAFLD 
Sex Men < (premenopausal)  women Findings not conclusive 
High-fat diet Strong association with lifestyle 
Reported in NAFLD and impaired 
postprandial lipid metabolism 
Cigarette smoking 
Strongly associated and reversible 
by stopping 
Findings not conclusive 
Antioxidants Findings not conclusive Findings not conclusive 
Sedentariness 
Independent association Associated with NAFLD; exercise 
is recommended as a treatment 
Adapted from Loria et al
174
 
CRP C-reactive protein; CVD cardiovascular disease; HCV hepatitis C virus; NAFL/D non-alcoholic 
fatty liver +/- disease; PAI-1 plasminogen activator inhibitor-1 
 
Although links between liver disease and CVD have frequently been attributed to the 
inter-relationships between NAFL/D, obesity and the metabolic syndrome, it is 
emerging that there is an increased risk of CV events in subjects with NAFLD, 





There is increasing evidence that the consequences of NASH include atherosclerosis 
via further insulin resistance leading to atherogenic hyperlipidaemia (low high 
density lipoprotein (HDL) with high TG and LDL levels) and systemic inflammation 
through pro-inflammatory and pro-atherogenic factors (e.g.  interleukin-6 (IL6), 
TNFα, NF-κB)
179,180
 and this is supported by the observation that cardiovascular risk 





Several large cross-sectional studies have shown a higher prevalence of CVD in 
people with NAFL/D, beyond any risk conferred by the coexistence of type 2 
diabetes other traditional CV risk factors.  In the NHANES II cohort study over 2000 
individuals were identified as having NAFLD by USS, with an OR 1.23 for prevalent 
CVD compared to people without NAFL/D
184
.  In a large study of type 2 diabetes 
out-patients (n=2839), all components of CVD were more common in people with 
USS diagnosed NAFL/D than in those without: coronary artery disease (CAD) 27 vs 
18%, cerebrovascular disease 20 vs 13% and peripheral vascular disease 15 vs 10%.  
This association remained independent after adjustment for multiple CV risk 
factors
162
.  A prospective study of patients undergoing coronary angiography found 
that CAD was present in significantly more patients with NAFL/D (USS diagnosed) 
than in those without NAFL/D, 85 vs 64% and that after adjustment the association 
persisted with OR 2.31
185
.  All of these studies used USS to diagnose NAFL/D not 
liver biopsy, the gold standard, however this allowed the authors to investigate 
community/general populations. 
1.6.3 Gamma-glutamyl trasnferase and cardiovascular disease 
To date, the most commonly cited hepatic marker of incident CVD and CV mortality 
is plasma gamma-glutamyl transferase (GGT).  However, reports are conflicting, and 
it is unclear if any relationship relates to a specific hepatic influence on CVD or 
whether GGT is a surrogate marker for systemic inflammation.   
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Systematic searching for all publications identified 8 papers reporting the association 
between GGT with incident CVD (Table 1-8) and 15 with CVD mortality (Table 
1-9). 
Gamma-glutamyl transferase and incident cardiovascular disease 
Of the eight studies investigating incident CVD, five found a statistically significant 
relationship
186-190
 with GGT and three found no relationship
162,191,192
.   
The two largest studies (cohorts in excess of n=10,000) both found a statistically 
significant relationship between increased GGT and the incidence of CVD.  For any 
CAD event (fatal and non-fatal) Lee et al found an incident rate of 6.3 events /1000 
person-years in the highest GGT quartile compared to 4.2 events /1000 person-years 
in the lowest.  Similarly there were significant multivariable adjusted (cardiovascular 
risk factors) hazard ratios for both men and women  (men HR 1.27 (95%CI 1.02-
1.59) , women HR 1.32 (95%CI 0.96-1.80) in the top quartile of GGT compared to 
the lowest quartile
186
.  The study by Jousilahti
187
 was limited to incident stroke only, 
however, still found a significant association between log10GGT and all types of 
incident stroke after extensive adjustment for CV risk factors (male HR 1.24 (95%CI 
1.03–1.50), female HR 1.33 (95%CI 1.06–1.65)
187
. 
Two studies were limited to patients with diabetes
162,189,192
 with neither finding an 
association between GGT and incident CVD.  Note that whilst Targher found an 
association in the 2005 publication
189
, when the same cohort was followed up for a 
longer time period the association was no longer statistically significant
162
. 
Gamma-glutamyl transferase and cardiovascular mortality 
Of the 15 studies investigating CVD related mortality seven found a statistically 
significant association with GGT
188,190,193-197
, four had mixed results
186,198-200
 and 
four found no relationship
173,192,201,202
.  Of the four with mixed relationships three 
found an association for males but not females
198,199,203
 and the fourth found a 





 followed nearly 300,000 subjects attending hospital for the first 
time (in- or outpatient) in Vienna, Austria for >2,000,000 person-years.  They found 
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increasing mortality increasing with increasing GGT for all types of CVD (vascular 
HR 1,7 (1,6-1,8), ischaemic heart disease HR 1,7 (1,6-1,9), cerebrovascular disease 
HR 1,4 (1,1-1,6) for elevated GGT (>56 U/L) vs normal levels in men, similar results 
for females).  Despite the impressive size of this study it should be interpreted with 
knowledge of the ascertainment bias of hospital patients receiving GGT 
measurement and that there was limited adjustment of results for existing CV risk 





 investigated patients with type 2 diabetes without 
prevalent CVD at baseline and found no association between GGT and CVD 
mortality over modest follow-up periods.  Both studies adjusted extensively for 







Table 1-8 Gamma-glutamyl transferase and incident cardiovascular disease 












 2006 Finland General 28,838 47.9 25-64 11.9 Incident CVD: 5.1% 
GGT and all CVD– significant relationship for both 
males and females (p<0.001) 
GGT and nonfatal MI – significant relationship for 
males (p=0.04) but not females 
Jousilahti
187
 2000 Finland General 14,874 48.2 25-64  Incident stroke: male 3.6%, female 2.7% 
GGT and stroke - significant relationship for both 
males and females 
Lee
188




3,451 48.1 44 19.1 Incident CVD: males 21.8%, females 9.7% 
GGT and all CVD - significant relationship (p≤0.01) 
Monami
191
 2008 Italy General, excluded existing 
diabetes and CVD 
2,617 46.4 40-75 3.3 Incident CVD (fatal + nonfatal): 0.8% 
GGT and all CVD - significant relationship (p<0.001) 
Targher
162




 63 60 6.5 Incident CVD: fatal + nonfatal 18.3%, nonfatal 10.4% 
GGT and all CVD – no association after controlling for 
the metabolic syndrome 
Targher
189
 2005 Italy Type 2 diabetes out-patient 
clinic, excluded existing CVD 
2,103
b
 - - 5 Incident CVD:  fatal + nonfatal 11.8%, nonfatal 8.1% 
GGT and all CVD – no association after controlling 
the metabolic syndrome 
Sluik
192
 2012 Germany 
Netherlands 
Type 2 diabetes out-patient 
clinic, excluded existing CVD 
1,280 - 58 8.2 Incident CVD (fatal + nonfatal) 11.1% 
GGT and all CVD – no association 
Emdin
190
















GGT and all CVD - significant relationship (p=0.036) 
a
values are mean, median or range; 
b
same cohort of patients followed for 2 differing time periods. 






Table 1-9 Gamma-glutamyl transferase and cardiovascular mortality 












 2007 Austria Hospital attenders 283,438 45.4 50 7.6 CVD mortality 6.1% 




 2005 Austria General 163,944 45.6 42 males 11.1 
females 12.0 
CVD mortality male 2.1%, female 1.6% 
GGT and all CVD– significant relationship 
for both male and female (p<0.001) 
Strasak
198
 2008 Austria General 76,113 42.5 42 males 9.8 
females 10.6 
CVD mortality male 3.0% female 2.2% 
GGT and all CVD/CHD/stroke – significant 




 2006 Finland General 28,838 47.9 25-64 11.9 CVD mortality 2.1% 
GGT and all CVD– significant relationship 
for males (p<0.01) but not female 
Ruhl
201
 2009 USA General 11,630 47 >2months 8.8 CVD mortality 4.1% 
GGT and all CVD – no association 
Wannamethee
195
 1995 UK British Regional Heart 
Study - General 
7,613 100 40-59 11.5 
[Excl.  deaths 
in first 5 
years] 
CVD mortality 5.9% 
GGT and ischaemic heart disease– 
significant relationship after adjustment for 
pre-existing ischaemic heart disease 
Hozawa
196
 2007 Japan General 6,846 39.8 >30  CVD mortality male 3.0%, female 1.2% 
GGT and all CVD– significant relationship 


















 2009 Germany General 4,160 49.1 50.6 7.2 GGT and all CVD– significant relationship 
for male (p<0.001) but not female 
Lee
188




3,451 48.1 44 19.1 CVD mortality male 13.9%, female 7.3% 




 2011 Italy General 2,011 44.0 57 15 GGT and all CVD – no association 
Monami
202
 2007 Italy Type 2 diabetes out-
patient clinic, excluded 
existing CVD 
1,952 51.6 65.6 6.4 CVD mortality 7.8% 




 2012 Germany 
Netherlands 
Type 2 diabetes out-
patient clinic, excluded 
existing CVD 
1,280 - - 8.2 CVD mortality 2.7% 




 2009 Italy Cardiac catheterisation 
patients 
474 80.4 64 1.5 CVD mortality 5.5% 
GGT and all CVD– significant relationship 
Emdin
190
 2001 Italy Ischaemic heart disease 
patients 
469 85.3 59 2.7 CVD mortality 6.0% 




 2009 USA Minnesota Heart Survey - 
General 
386 56.5 68 10-12 GGT and all CVD– significant relationship 
for age<70yrs (p=0.02) but not >70yrs 
a





This systematic review will follow the format of a Cochrane Review of diagnostic 
test accuracy (http://srdta.cochrane.org/handbook-dta-reviews). The protocol, study 
selection and data extraction forms are available in Appendices C and D. The 
original intention had been to have two reviewers, as is standard for systematic 
reviewing and as described in the protocol, however due to unforeseen circumstances 
the second reviewer was unable to complete the review. A summary PRISMA 
statement checklist is included in Appendix E. 
2.1 Background 
2.1.1 Role of non-invasive markers of liver fibrosis 
NAFL/D involves a wide spectrum of disease with histological findings ranging from 
fat deposition only, through inflammatory changes to fibrosis and cirrhosis
204
.  
Clinical difficulties arise as most patients with NAFL/D have no clinical signs or 
symptoms until the disease has progressed to significant fibrosis, with a proportion 
progressing to end-stage liver disease
205,206
. 
Confirmation of liver fibrosis in NAFLD is currently only definitive using liver 
biopsy
158
.  This is an invasive investigation requiring a 6 hour inpatient observation 
period post procedure.  Common minor complications include pain, nausea, and 
vomiting.  Potential significant complications include haemorrhage, biliary leakage 
and transient jaundice, with a small but acknowledged mortality rate of <0.5%
150,207
.  
It is therefore not feasible to use liver biopsy recurrently for follow-up investigation 
of patients or in large population based research studies given its unfavourable 
nature.   
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As a result, over recent years, alternative non-invasive tools for the diagnosis of liver 
fibrosis have been developed.  In addition, to the problems noted above, sometimes 
the staging system cannot provide a dynamic picture of the changes that have already 
taken place in the liver.  Therefore, alternative biological parameters may be 
considered to be more accurate than liver biopsy in reflecting the fibrogenesis in 
hepatocytes.  It is unclear if any of these non-invasive tools have any advantage over 
others, in terms of diagnostic test accuracy and practicality of application.   
2.1.2 Selected liver fibrosis markers 
Many liver fibrosis markers have been investigated, some more so than others.  This 
section will provide an overview of some of the most commonly studied/used 
fibrosis markers in NAFLD. 
Because liver fibrosis is characterised by excess collagen deposition, decreased 
extracellular matrix degradation and activation of hepatic stellate cells most serum 
markers of hepatic fibrosis are related to this common pathway.  A number of 
individual markers have been investigated, before later being combined into 
supposedly more accurate panel markers.  Imaging modalities focus on the 
architectural changes present in fibrotic liver. 
In general these markers were first investigated in chronic viral hepatitis e.g.  
aspartate aminotransferase (AST) -to-platelet ratio index (APRI)
208
, the Forns test
209
, 
FibroTest (Biopredictive SAS, Paris, France)
210-216
  and  transient ultrasound 





CK18 is a marker of hepatocyte apoptosis, a process occurring in the presence of 
hepatocyte damage and therefore as part of the fibrotic pathway.  As part of the 
apoptotic process within the liver effector caspases (which act on a number of 
different substrates inside the cell) are activated.  As a result of this one of the 
 
45 
substances generated is CK18
218,219
.  More frequently CK18 has been described as a 
marker of NASH
82,84,220,221
 than for the diagnosis of liver fibrosis. 
Extracellular matrix proteins and formation of fibrosis  
Type IV collagen (COL-IV), hyaluronic acid (HA) and laminin are all extra-cellular 
matrix proteins
222,223
.  All are produced by connective  tissue cells and are 
maintained by the balance of production, with degradation by liver sinusoidal 
endothelial cells
224,225
.  It is understandably hypothesised that extracellular-matrix 
proteins could be used as a markers of liver function and fibrosis, with reduced 
hepatic function being associated with increased levels of such markers.   
Metalloproteinases are a group of peptidases involved in degradation of 
the extracellular matrix and therefore tissue inhibitor metalloproteinase-1 (TIMP-1) 
levels are thought to be related to hepatic fibrosis levels.  In addition, TIMP-1 
promotes cell proliferation in a number of cell types including the liver. 
YKL-40 is an inflammatory glycoprotein mainly produced by macrophages, 
neutrophils, and vascular smooth muscle cells
226
 and involved in endothelial 
dysfunction by promoting chemotaxis, cell attachment and migration, reorganization, 
and remodelling of the extracellular matrix as a response to endothelial damage.  
YKL-40 has roles in cell proliferation and differentiation, angiogenesis, 
inflammation, remodelling of the extracellular matrix, and the innate immune 
response
227
.   
Panel markers 
Aspartate aminotransferase to platelet ratio index 
APRI was developed in a cohort of 192 patients with hepatitis C virus
208
.  The 
original study determined a cut-off of 1.5 for significant fibrosis (Ishak stages 3-6) 
and 2 for cirrhosis (Ishak stages 5-6).   
APRI = [(AST (U/L) / ULN (U/L)) / platelet (x10
9
/L)]*100 
A recent study 145 patients with biopsy proven NAFLD using a cut-off of 1 for 
advanced fibrosis had an unimpressive AUROC of 0.67 (0.54-0.8) with an associated 
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sensitivity of 27% and specificity of 89% at the most accurate cut-off
228
.  A further 
small study of 30 NAFLD patients had similar findings with significant fibrosis 
AUROC 0.56 (0.35-0.78) and cirrhosis AUROC 0.57 (0.19-0.95)
229
. 
Aspartate aminotransferase to alanine aminotransferase ratio 
The aspartate aminotransferase (AST) to alanine aminotransferase (ALT) ratio is a 
simply calculated marker using two commonly measured liver enzymes.  Originally 
an elevated AST and AST:ALT ratio was thought to be related to a high alcohol 
intake prior to the realisation that some heavy drinkers did not have any elevation 
and that the elevation related to the resulting liver damage
230,231
. 
The difficulty with the interpretation of the AST:ALT ratio lies with differing liver 
disease aetiologies.  Typically ALD leads to an elevated ration (often >2) with 
NAFLD and hepatitis C virus having a ratio ≤1.  This is further complicated by the 
co-existence of the metabolic syndrome and alcohol excess in many patients.  A 
recent biopsy based study of 140 participants with NASH or ALD found mean ratios 
of 0.9 and 2.6 respectively
232
.  As the stage of NASH fibrosis increased, so did the 
AST:ALT ratio with the mean ratio in NASH cirrhosis being 1.4, although there 
were only five patients in this group.   
BAAT 
BAAT is a system based on BMI, age, ALT and TG.   
It is scored as follows: BMI ≥28 score 1, age ≥50 score 1, 
ALT ≥2x upper normal limit score 1, and TG ≥1.7mmol/l 
score 1, with total score being 0-4. 
Ratziu and colleagues
119
 developed this simple scoring system in a cohort of 93 
obese patients (30% with fibrosis) in an attempt to derive a simple approach to the 
diagnosis of NASH fibrosis without the need for biopsy in an increasingly obese 
population.  It is good for predicting those that do not have severe fibrosis (negative 
predictive value, NPV), but only 45% of those with a positive test (positive 
predictive value, PPV) actually have severe fibrosis (using a cut-off of 1) so further 
investigation would be required
119




BARD is a system based on BMI, AST:ALT ratio and a diagnosis of diabetes.   
Scoring is as follows: BMI ≥28 score 1, ALT:AST ratio ≥0.8 
score 2, and diagnosis of diabetes score 1.   
Again the NPV appears much better than  PPV for severe fibrosis, with only 27-43% 
of those with a positive test actually having severe fibrosis, thus not completely 
averting the need for biopsy
233
.  It was also trialled in a Japanese cohort where it was 
found to be less effective 
234
. 
Enhanced Liver Fibrosis panel 
The Enhanced Liver Fibrosis (ELF) panel includes: TIMP 1, HA, and aminoterminal 
peptide of pro-collagen III (P3NP).  These are combined into the following formula: 
ELF =  -7.412 + (ln(HA)*0.681) + (ln(P3NP)*0.775) + 
(ln(TIMP1)*0.494) 
Prior to a NAFLD specific validation study, the formula was derived using a cohort 
of 921 patients attending for liver biopsy in an international multi-centre study and 
evaluated for the ability to discriminate between biopsy stages using a wide range of 
potential markers 
235
.  The results for the ELF formula resulted in the maximum 
separation of the biopsy groups over the full range of fibrosis stages.  It did however 
note variety in the performance of the test for different aetiologies of CLD with a 
wide range represented in the study (majority chronic hepatitis C virus (n=496),  
ALD, fatty liver, hepatitis C virus, primary biliary cirrhosis, autoimmune hepatitis, 
haemochromatosis, cryptogenic cirrhosis and granulomatous disease).  Since then a 
further validation study in NAFLD has been performed comparing ELF with the 
NAFLD Fibrosis Score (NFS) and the NFS in combination with ELF.  In this well 
conducted study of nearly 200 individuals with biopsy confirmed NAFLD they found 
ELF to be superior to the simple clinical model (modified NFS), with the combined 







Using 270 consecutive patients with treatment naïve hepatitis C virus Wai and 
colleagues
208
 developed a marker (Fibrosis-4 Index, FIB4) using two regularly 
measured laboratory parameters.   
FIB4 = (age[years] * AST[U/L]) / (platelets[x10
9
/L] *  
√ALT [U/L]) 
A large number of measures were investigated with platelet count, AST and alkaline 
phosphatase being the variables in the best models for prediction of significant 
fibrosis.  However, models with only platelet count and AST level were deemed 
more simple and had accuracies comparable with those with three or more variables 
(AUROC platelets, AST and alkaline phosphatase 0.82 (0.76-0.88) and AUROC 
APRI 0.80 (0.74-0.87)). 
Fibrometer 
Fibrometer NAFLD includes: glucose, AST, ferritin, platelet, ALT, body weight and 
age. 
Fibrometer NAFLD = 0.4184 *glucose (mmol/l) + 
0.0701*AST (UI/l) + 0.0008 *ferritin (lg/l) - 0.0102* platelet 
(G/l) -  0.0260*ALT (UI/l) + 0.0459*body weight (kg) + 
0.0842*age (yr) + 11.6226. 
The exact formula varies by underlying CLD aetiology and was first developed for 
viral hepatitis and ALD
237
.  For use in NAFLD it was developed in a group of 235 
patients with NAFLD 
238
 with less than three months between biopsy and blood 
sampling and had an overall accuracy (compared to liver biopsy) of 91.1% (95% CI 
87.4-94.7%).   
FibroTest 
FibroTest includes: α2-macroglobulin, apolipoprotein A1, haptoglobin, γ-glutamyl 
transpeptidase and total bilirubin.  The score ranges from 0 (reflecting to no fibrosis) 
to 1 (reflecting cirrhosis)
239









 searching Feb 2001 to June 2008 identified 2 studies for 
FibroTest in NAFLD
241
.  For both groups the lower cut-off value yielded high 
sensitivity and moderate specificity i.e. those scoring above the threshold probably 
do have advanced fibrosis or cirrhosis, but a negative result is not so reassuring.  For 
the higher cut-off there were low sensitivities and high specificities, i.e. those with 
negative results can be reassured but those with positive results may need further 
investigation. 
FibroTest produced non-interpretable results in about 5% of cases.  Causes of failure 
included false negative results due to high haptoglobin measures in cases of acute 
inflammation or sepsis, and false positives with low haptoglobin measures in cases 
with haemolysis and high bilirubin in cases with haemolysis or Gilbert disease
239
.  It 
has also been trialled specifically in patients with diabetes
242
.   
NAFLD fibrosis score  
The NFS uses: AST:ALT ratio, platelet, albumin, impaired fasting glucose/diabetes, 
age, and BMI. 
NFS = -1.675 + 0.037[age(yrs)] + 0.094[BMI(kg/m
2
)] + 
1.13[IFG/diabetes(yes=1, no=0)] + 0.99[AST/ALT ratio] – 
0.013[platelet(x10
9
/l)] – 0.66[albumin(g/dl)] 
Developed in a cohort of over 700 biopsy confirmed cases of NAFLD the laboratory 
measures were collected on the same day as the liver biopsy.  The agreement 
between the validation and estimation cohorts was evident but limited (AUROC 
95%CI’s 0.85-0.92 and 0.76-0.88 respectively).  Two cut-off values were identified 
in order to confidently diagnose the presence or absence of severe fibrosis with high 
PPV and NPV’s respectively and varying the prevalence of severe fibrosis 
maintained satisfactory discriminatory ability.  However, approximately 25% of 
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patients fall between the 2 cut-offs and be termed ‘indeterminate’ and requiring liver 
biopsy
243
.   
The discriminatory ability of the NFS fell when examined in a morbidly obese 
cohort
244
.  The number of ‘indeterminate’ patients rose to 47% of patients.  This may 
well be due to influence of BMI and diabetes status in the formula.  However, the 
accuracy for the diagnosis of fibrosis above the higher cut-off was still 88% and 
below the cut-off fibrosis excluded with 98% certainty.   
Imaging 
Elastography 
Elastography allows the measurement of stiffness of human tissues by measuring the 
velocity of wave propagation.  The theory behind elastogaphy measures is that 
scarred and fibrotic tissue is stiffer than normal hepatic tissue and that this can be 
detected.  Elastography is currently available in two forms: TUE which is 1-
dimensional, and magnetic resonance elastography (MRE) that can be 2- or 3-





.In addition to being non-invasive, a key benefit of elastography over 
liver biopsy is the ability to image/sample a larger proportion of the liver: liver 
biopsy samples 1/50000 of the liver, TUE 1/10000 and MRE potentially the whole 
liver.   
One dimensional TUE involves the use of an ultrasound transducer at the end of a 
vibrating piston.  The piston produces a low amplitude and frequency vibration that 
generates a sheer wave that passes through the liver.  The ultrasound then detects the 
sheer wave through the liver and measures its velocity.  The liver stiffness measure 
(LSM) is expressed in kilopascals.  The harder the tissue the faster the sheer wave 
travels.  TUE measures a cylinder 1cm wide by 4cm long, between 2.5cm and 6.5cm 
below the skin surface. 
The standard ‘M’ probe is placed in the intercostal space overlying the liver with the 
patient in the supine position.  Using ultrasound to guide the positioning a portion of 
the liver that is at least 6cm thick and free from large vessels is used for the 
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investigation.  Use of TUE is therefore contraindicated in people with known 
structural liver abnormalities or masses (tumours or cysts).  In addition, for reasons 
that are unclear its use is contraindicated in people with a pacemaker. 
Ten LSM are recorded by the machine (taking approximately 3-10 minutes).and the 
median calculated.  In order to be considered valid at least 60% of the LSM need to 
be successful, and the inter-quartile range <30% of the final (median) result.   




 have been reported for patients 
with NAFLD.  The main factor influencing the acquisition of valid readings is 
obesity with the failure rate in obese patients (BMI >30) 25.5% vs 2.2% in those 
with lower BMI
246
 .  In order to try and address this issue the manufacturers of 
Fibroscan have developed a newer probe (the ‘XL’ probe) for use in larger patients.  
Preliminary published data for the XL probe using patients with BMI >30 has found 
a 60% increase in the success rate compared with the standard M probe (76.9% vs 
45.5%)
248
.  Probe details are given in Table 2-1. 
Table 2-1 Fibroscan probe details 
 ‘M’ probe ‘XL’ probe 
Central ultrasound frequency 5 MHz 3.5 MHz 
Ultrasound transducer focal length 35 mm 50 mm 
Probe tip external diameter 9 mm 12 mm 
Vibration amplitude 2 mm 3 mm 
Measurement depth 25-65 mm 35-75 mm 
 
In studies of reproducibility of TUE in people with CLD inter-observer agreement 
was 0.98 (95% CI 0.977, 0.987)
249
.  Gender, age, aetiology and liver disease severity 
did not affect inter-observer variability.  High BMI, increased steatosis on USS and 
histology, and low stage fibrosis were associated with reduced inter-observer 
agreement.  In the same study the intra-observer agreement was 0.98.  Over time and 
with practice, reproducibility of results improved (month 1 0.97, month 2 0.99, 





MRE can be implemented on conventional magnetic resonance imaging (MRI) 
equipment.  In addition a sheer wave source and specialised software are required.  
Sheer waves are generated by an external device at frequencies between 40 and 
200Hz.  Sheer waves can be generated by electromechanical voice coils, passive 
rigid rod drivers and most commonly passive pneumatic drum drivers.  The passive 
pneumatic driver has several advantages over the others.  It can be easily placed 
against the body and can be manoeuvred into any orientation.   
The software required for MRE includes a specialised phase-contrast magnetic 
resonance pulse sequence to image the waves and an inversion algorithm to process 
them 
Benefits of MRE over TUE include
250
: a freely orientated field of view; no acoustic 
window requirement; operator independence; insensitivity to body habitus; potential 
assessment of the entire liver parenchyma; ability to obtain conventional magnetic 
resonance imaging at the same time 
Obesity currently limits the use of TUE, despite the newer ‘XL’ probe.  Yin et al
251
 
found that the physical application of the external sheer wave generator to larger 
patients was not problematic and that steatosis did not affect liver stiffness 
measurements using MRE. 
The main limitations of MRE are: cost, body habitus limiting access through the 
scanner and scan acquisition time.  The two main methods of image generation are 
spin-echo ad echo-planar.  One of the difficulties with 3-dimensional spin-echo 
imaging is the long acquisition time.  Single shot echo-planar sequencing is much 
faster.  Huwart et al
252
 compared the two methods and found that echo-planar 
imaging substantially reduced the examination time from 20 down to 4 minutes 
without reducing image quality or diagnostic ability. 
A number of studies have measured MRE of the liver in healthy volunteers and 
patients.  The patients include a wide range of aetiologies of liver disease, but the 
majority are hepatitis B virus and hepatitis C virus.  Average “normal” readings 
amongst healthy controls range from 2.0 to 3.1.  Reporting of values for different 
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stages of fibrosis varied between papers, with some reporting average values and 
other diagnostic cut-offs.  Reliability of MRE was examined in 5 healthy volunteers 
and the coefficient of variation for elasticity was only 9%
253
.  The reproducibility of 
MRE in fibrotic liver has not been reported. 
2.2 Aim 
To systematically identify all published original research studies examining the use 
of non-invasive methods for the diagnosis of liver fibrosis in patients with NAFLD 
2.2.1 Review question (PICO format) 
For adults with NAFL/D, are non-invasive methods as accurate (ie with equal or 
better sensitivity and specificity) as liver biopsy, the current gold standard, for 
diagnosing liver fibrosis? 
2.3 Methods 
2.3.1 Search strategy 
Search sources: 
 An electronic database search was conducted from inception to 31st March 2012; 
MEDLINE, EMBASE.  Global Health, Web of Science, SCIRUS and Cochrane.   
 Additional studies were identified via manual review of the reference lists of 
identified studies, review articles and citation searching using Web of Science 
Citation Index.   
 From relevant websites: American Association for the Study of the Liver, 
European Association for the Study of the Liver.   




Table 2-2 Medline search strategy 
1.  *Hyperlipidemia/ or *Hypertriglyceridemia/ or *Metabolic Syndrome X/ or *Obesity/ or *Insulin 
Resistance/ or *Diabetes Mellitus, Type 2/ or metabolic syndrome.mp.   
2.  fatty liver.mp.  or exp Fatty Liver/ 
3.  NAFLD.mp. 
4.  NASH.mp. 
5.  steatohepatitis.mp. 
6.  steatosis.mp. 
7.  non-alcoholic.mp. 
8.  1 or 2 or 3 or 4 or 5 or 6 or 7 
9.  fibrosis.mp. 
10.  cirrhosis.mp. 
11.  $hepatitis.mp. 
12.  steatosis.mp.  [mp=title, original title, abstract, name of substance word, subject heading word] 
13.  inflammation.mp. 
14.  9 or 10 or 11 or 12 or 13 
15.  serum markers.mp.  or exp Biological Markers/ 
16.  diagnosis/ or "diagnostic techniques and procedures"/ or "laboratory techniques and 
procedures"/ 
17.  $invasive.mp. 
18.  exp Liver Function Tests/ 
19.  exp DIAGNOSTIC IMAGING/ 
20.  ELASTOGRAPHY.MP 
21.  predict$.mp. 
22.  marker$.mp. 
23.  surrogate.mp. 
24.  15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 OR 23 
25.  8 and 14 and 24 
26.  limit 25 to (humans and english language) 





2.3.2 Criteria for inclusion 
Types of study  
There was no restriction on study design.  Primary studies were sort where available 
from identified systematic reviews and meta-analyses.  Studies were required to be 
written in English as translation was not available for this literature review.  Studies 
reporting AUROC analysis were included.   
Subjects 
All study populations allowing data on patients with NAFLD to be extracted were 
included.  Studies were required to have ≥30 adult (age ≥18 years) subjects. 
Definition of NAFLD 
NAFLD was required to be defined as a biopsy diagnosis with a statement regarding 
the attempt to exclude other causes of liver disease (e.g.  alcoholic liver disease, viral 
hepatitis, autoimmune disorders, metabolic disorders).  Studies of obese populations 
without mention of NAFLD, in whom there had been a clear attempt to exclude other 
causes of liver disease as above, were included. 
Non-invasive methods of diagnosing liver fibrosis 
 Individual serum markers; or 
 Marker panels (≥2 components); or 
 Any imaging modality 
 Any other diagnostic modality 
Individual physiological markers were excluded (e.g.  age, sex). 
Target condition 
Liver fibrosis as defined using any recognised histological classification. Fibrosis 
was then further sub-divided into any Metavir F1-4, moderate Metavir F2-4 and 
significant Metavir F3-4.  Cirrhosis (Metavir F4) only was excluded. 
Reference standard 
Liver biopsy (any method) was the reference standard 
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2.3.3 Data collection and analysis 
Selection of studies 
One researcher (JRM) undertook all searching.  Following electronic searching 
results from multiple databases were combined before duplicate entries were 
removed.  Titles were then screened for relevance and where necessary abstracts 
reviewed.  Full papers were then reviewed to confirm studies meeting the inclusion 
criteria.  Reference lists were then scrutinised and addition studies identified from 
citation searching.  Where a conference abstract was identified later publication of a 
full original article was sought. 
Data extraction and management 
Data extraction was undertaken by one reviewer (JRM). 
The following data was extracted where available: i) study characteristics - year of 
study/publication, number of subjects, mean/median age, % male, % diabetes, study 
population and selection, NAFLD criteria, histological classification, and ii) 
diagnostic test characteristics – marker name, marker components/formula, AUROC, 
prevalence of fibrosis, marker cut-off and associated sensitivity, specificity.   
Where more than one cut-off and associated sensitivity and specificity were provided 
the preferential figure for inclusion in this review was a) a cut-off analysed to be the 
most accurate, then b) a cut-off consistent with other studies/a generally accepted 
cut-off, and then c) cut-offs associated with a 90% sensitivity and specificity. 
Methodological quality 
Methodological quality assessment of the identified studies was undertaken using the 
risk of bias component of the Quality Assessment of Diagnostic Accuracy Studies II 
tool
254-256
.  The Quality Assessment of Diagnostic Accuracy Studies II tool examines 
four domains with potential for risk of bias: i) Could the selection of patients have 
introduced bias?; ii) Could the conduct or interpretation of the index test have 
introduced bias?; iii) Could the reference standard, its conduct, or its interpretation 
have introduced bias?; and iv) Could the patient flow have introduced bias?   
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The studies identified with a definite or unclear risk of bias were not excluded from 
the review, but the risk taken into consideration in the interpretation of results.   
Statistical analysis and data synthesis 
A narrative description of the findings was compiled. 
To allow across test comparisons to be made, where a sensitivity and specificity were 
available 2x2 tables were constructed to calculate the PPV and NPV for a 
hypothetical population of 1000 individuals with a) a fibrosis prevalence of 5%, and 
b) a fibrosis prevalence of 30%.  These figures were chosen to mirror the potential 
fibrosis prevalence in a general population. 
2.4 Results 
2.4.1 Search results 
Searching identified 73 potential studies for inclusion.  After examination of the full 
text 16 studies were excluded 
244,248,257-270
 and are detailed in Appendix C with 57 
studies included.   
From the 57 included studies 49 different diagnostic tests were found, totalling 215 
assessments of a diagnostic test (Figure 2-1) as a number of studies examined a 
number of different tests at each different fibrosis level.  There were 10 different 
single markers (29 assessments), 36 panel markers (146 assessments), 3 imaging 
modalities (40 assessments) and 1 other marker (1 assessment) identified. 
Table 2-3 shows the range of markers included.   
Table 2-4 summarises the characteristics of included studies.   






















AUROC area under the receiver operating curve; NAFLD non-alcoholic fatty liver disease.














Following abstract screening 
n=71 
Following full paper screening 
n=55 
Rejected following abstract review n=131 
No original data presented, 81 
n<30, 16 
Not NAFLD, 14 
Not liver biopsy as gold standard, 6 
Can’t separate NAFLD data, 5 
Duplicate publication, 3 
 
Included following citation searches and 
reference list scrutiny n=2 
Rejected following full paper review n=16 
AUROC not presented, 10  
N<30, 1  
Not NAFLD, 1  
Biopsy only in a subset, 1  
Can’t separate NAFLD data, 1  
Duplicate publication, 1  
 
Total different markers n=51 
Total included test assessments 
n=212 
(vs. F1+=38, F2+=59, F3+=115) 







Table 2-3 Number of studies for each diagnostic test for liver fibrosis in NAFLD 
Single markers    Panel markers   Imaging + other  
 F1 F2 F3 Total   F1 F2 F3    F1 F2 F3 Total   F1 F2 F3 Total 
ALT 1   1  APRI 2 7 11 20  HAIR  2 2 4  ARFI   2 2 
AST 2 1  3  AST:ALT ratio 1 2 9 12  Hepascore  1 1 2  MRE  1  1 
CK18 1  1 2  AP ratio   2 2  Mansousou-1  2  2  TUE 5 15 16 36 
HA 4 1 6 11  BAAT  2 2 4  Mansousou-2  1  1  C-caffeine breath test  1  1 
Laminin 2   2  BARD  2 9 11  NAFIC  1 1 2       
SPEA 1   1  CDS  1 2 3  NFS 2 5 17 24       
TGF-B -  1 1  dosSantos-1 1   1  N-score  1 2 3       
TIMP-1 1  1 2  dosSantos-2 1   1  OELF 1  2 3       
COL-IV 1  3 4  dosSantos-3 1   1  P2/MS   1 1       
YKL 40 1  1 2  ELF 3 2 3 8  PAF   1 1       
      ELF+NFS 1 1 1 3  Susuki-1   1 1       
      FibroMeter  1 1 2  Susuki-2   1 1       
      FIBROspect II  1  1  Tetri-1 1  1 2       
      FibroTest  4 4 8  Tetri-2 1  1 2       
      FIB4  1 5 6  Tetri-3 1  1 2       
      FM8  1 1 2  Tetri-4 1  1 2       
      Gholam 1 1 1 3  Younossi-1 1   1       
      GUCI  1 2 3  Younossi-2   1 1       






APRI aspartate to platelet ratio index; ALT alanine aminotransferase; ARFI acoustic radiation force impulse; AST aspartate aminotransferase; CDS cirrhosis 
discriminant score; CK18 cytokeratin-18; COL-IV Type IV collagen; ELF Enhanced Liver Fibrosis panel; FIB4 Fibrosis-4 Index; GUCI Goteburg University Cirrhosis Index; 
HA hyaluronic acid; MRE magnetic resonance elastography; NAFLD non-alcoholic fatty liver disease; NAS NAFLD Activity Score; NFS NAFLD Fibrosis Score; N-score 
Nippon-score;  OELF Original European Fibrosis panel; PAF Probability of Advanced Fibrosis; SPEA serum prolidase enzyme activity; TIMP-1 metallopeptidase 







Table 2-4 Included studies 




















































Secondary care.  Two 
centres.  Elevated liver 
enzymes or USS steatosis and 
at least one component of 
MS.   
51.1 74.5 24.1 Metavir A None 
TUE de Ledinghen
273
  France, HK 2009
3
 208 
Secondary care.  Multicentre.  
Routine biopsy attendees. 




AST, HA, Laminin, 







Secondary care.  BMI>25, 
USS steatosis and elevated 
liver enzymes. 
44.9 60.0 23.3 Brunt 









Secondary care.  Routine 
biopsy attendees. 






Secondary care.  Routine 
biopsy attendees. 







Secondary care.  Routine 
biopsy attendees. 






Secondary care.  BMI ≥40 
kg/m
2
 undergoing bariatric 
surgery. 



























Secondary care.  BMI ≥40 
kg/m
2
 undergoing bariatric 
surgery.  Retrospective. 









Secondary care.  Two 
centres.  Routine biopsy 
attendees. 
48.7 64.1 - Kleiner 









Secondary care.  Two 
centres.  Routine biopsy 
attendees.  Military. 
49 49.0 35.0 
Brunt 
Kleiner 
A B C D Unclear 





Secondary care.  Obese 
patients undergoing bariatric 
surgery. 
- - - Kleiner - Risk 








Secondary care.  Single 
centre.  Routine biopsy 
attendees. 
52.0 52.7 27.7 Brunt 
A B C D 
E 
Unclear 







Secondary care.  Single 
centre. 
- 27.5 - Brunt A B C E Unclear 










Secondary care.  Three 
centres. 
53.5 - 24.8 Brunt A B C  Risk 







Secondary care.  Three 
centres. 







Secondary care.  BMI ≥40 
kg/m
2
 undergoing bariatric 
surgery. 



































Secondary care.  Routine 
biopsy attendees.  BMI >25  












Secondary care.  Single 
centre.  Routine biopsy 
attendees.  Prospective. 
48.5 61.1 27.4 Kleiner 









search of liver biopsies with 
the keywords ‘steatosis’ 
and/or ‘steatohepatitis’.  
Normal thyroid function and 
not on thyroxine. 
52.6 64.0 57.7 Kleiner 
A B C D 
E 
Unclear 
AST:ALT ratio, APRI, 







Secondary care.  ‘Fatty liver’ 
clinic. 
51 60.7 50.3 Kleiner A F Risk 







Secondary care.  Morbidly 
obese.   






















Secondary care.  Consecutive 
patients 







Secondary care.  Routine 
biopsy attendees. 
























Secondary care.  Routine 














NASH CRN database and 
adult PIVENS trial, without 
cirrhosis 
49 39% 31% Kleiner 
A B C D 
E 
Unclear 







Secondary care.  Routine 
biopsy attendees.  
Retrospective review over 1 
year.  Military. 
50.8 52.5 21.3 Brunt 


















Secondary care.  Two 
centres.  Study biopsies. 







Secondary care.  Routine 
biopsy attendees. 
44.1 71.2 13.7 Kleiner 









Secondary care.  Elevated 










Secondary care.  Elevated 
liver function tests. 

























(1) Secondary care.  Routine 
biopsy attendees. 
(2) Secondary care.  Elevated 















Secondary care.  BMI ≥40 
kg/m
2
 undergoing bariatric 
surgery.  >5% steatosis on 
biopsy. 
40.6 - - Kleiner 








Secondary care.  Routine 
biopsy attendees. 









Secondary care.  Routine 
biopsy attendees. 






Secondary care.  Single 
centre.  Consecutive routine 
biopsy attendees. 







Secondary care.  Multicentre.  
Routine biopsy attendees. 
56.3 32.1 30.4 Brunt 
A B C D 
E 
Unclear 
APRI, AST:ALT ratio, 
AST:Plt ratio, BARD, 






NASH CRN database and 
adult PIVENS trial. 










Secondary care.  Eight 
centres.  Routine biopsy 
attendees. 
- 53.2 41.0 Kleiner 

























Secondary care.  Single 
centre.  Elevated liver 
function tests.  Routine 
biopsy attendees.   






Secondary care.  Routine 
biopsy attendees.  Obese. 





 397 - 49.9  - Metavir - Unclear 
TUE Wong
308$
 HK 2008* 66 
Secondary care.  Consecutive 
routine biopsy attendees. 
49 51.5 - Kleiner - Unclear 








Secondary care.  Elevated 
liver function tests and either 
obesity or T2DM.  Routine 
biopsy attendees. 
46 59.3 71.0~ Brunt 
A B C D 
E 
Risk 
APRI, AST:ALT ratio, 








Secondary care.  Routine 
biopsy attendees. 
51 54.9 36.2 Kleiner 







 140 - 48.1 55.0 - Kleiner 









Secondary care.  Single 
centre.  Routine biopsy 
attendees. 
52.6 - - Brunt A B C D Risk 
ARFI, TUE Yoneda
270
 Japan 2008 54 
Secondary care.  Single 
centre.  Routine biopsy 
attendees. 























Secondary care.  Two 
centres.  Routine biopsy 
attendees.  NASH. 












NAFLD (EPI-NAFLD) database 
42 32.8 24.4 - A B C D Unclear 
APRI, AST:ALT ratio, 
AST:plt ratio, BARD, 








Secondary care.  Consecutive 
routine biopsy attendees. 
- 53.2 13.2 Metavir A B C D Risk 
APRI aspartate to platelet ratio index; ALT alanine aminotransferase; ARFI acoustic radiation force impulse; AST aspartate aminotransferase; BMI body mass index; 
CDS cirrhosis discriminant score; CK18 cytokeratin-18; COL-IV Type IV collagen; CRN clinical  research network; ELF Enhanced Liver Fibrosis panel; FIB4 Fibrosis-4 
Index; GUCI Goteburg University Cirrhosis Index; HA hyaluronic acid; MRE magnetic resonance elastography; MS metabolic syndrome; NAFLD non-alcoholic fatty 
liver disease; NAS NAFLD Activity Score; NASH non-alcoholic steatohepatitis; NFS NAFLD Fibrosis Score; N-score Nippon-score;  OELF Original European Fibrosis 
panel; PAF Probability of Advanced Fibrosis; PIVENS Pioglitazone versus Vitamin E versus Placebo for the Treatment of Nondiabetic Patients with NASH trial; SPEA 
serum prolidase enzyme activity; TIMP-1 metallopeptidase inhibitor 1; TGF-β transforming growth factor beta; TUE transient ultrasound elastography (Fibroscan); 
T2DM type 2 diabetes mellitus; USS ultrasound scan. 
1 
NAFLD defined as: A – alcohol statement; B- viral hepatitis statement; C – autoimmune statement; D – metabolic statement; E – hepatosteatotic drug statement; F 




date of publication; 
$
Abstract only, no full paper identifiable; 
#











Table 2-5 Components of panel markers of liver fibrosis 
Aspartate to platelet ratio index 





Age score: <30 = 0; 30–39 = 1; 40–49 = 2; 50–59 = 3;60–69 = 4; ≥70 = 5 
Platelet count score: ≥225 (x10
9
) = 0; 200–224 (x10
9
) = 1; 175–199 (x10
9
) = 2; 150–174 (x10
9
) = 3; 125–149 (x10
9
) = 4; >125 (x10
9
) =5  
(Possible value 0–10) 
AST:ALT ratio 
AST (U/L) / ALT (U/L) 
BAAT 
Sum of: BMI ≥28 score 1, age ≥50 score 1, ALT ≥2x upper normal limit score 1, and triglycerides ≥1.7mmol/l score 1, with total score being 0-4. 
BARD 
Sum of: BMI ≥28 score 1, ALT/AST ratio ≥0.8 score 2, and diagnosis of diabetes score 1 
Cirrhosis discriminant score 
Sum of:  
Platelet count score:: ≥340 (x10
9
/L) =0; 280–339 (x10
9
/L)  =1; 220–279 (x10
9
/L) =2; 160–219 (x10
9
/L) =3; 100–159 (x10
9
/L) =4; 40–99 (x10
9
/L) =5; <40 (x10
9
/L) =6  
AST/ALT ratio score: 1.7 = 0; 1.2–1.7 = 1; 0.6–1.19 = 2; <0.6 = 3  
INR score: <1.1 = 0; 1.1–1.4 = 1; >1.4 = 2  
(Possible value 0–11). 
dosSantos-1 







Laminin + type IV colagen 
dosSantos-3 
Laminin + AST 
Enhanced Liver Fibrosis panel 
-7.412 + (ln(HA)*0.681) + (ln(P3NP)*0.775) + (ln(TIMP1)*0.494) 
Enhanced Liver Fibrosis panel + modified NAFLD Fibrosis Score 
-2.722 + 1.482*ELF + 0.062*BMI (kg/m2) + 1.241*diabetes/IFG (yes=1, no=0) - 0.590*AST/ALT ratio - 0.002*platelets (x10
9
/L) - 0.043*alb (g/L) 
FibroMeter NAFLD 
11.623 + 0.418*glucose (mmol/l) + 0.070*AST (UI/l) + 0.001*ferritin (lg/l) - 0.010*platelet(G/l) - 0.026*ALT (UI/l) + 0.046*weight (kg) + 0.084*age (yr) 
FIBROspect II 











Cholesterol, triglyceride, AST, ALT, GGT, gammaglobulins, age and weight (formula not published) 
Gholam 
5 + 2.45*ln ALT (U/L) - 38.55* (1/HbA1C) 
Goteburg University Cirrhosis Index  













Ferritin ≥240 ng/ml and BMI ≥28.2kg/m2 = positive score 
Manousou(2) 
Ferritin ≥240 ng/ml and BMI ≥28.2kg/m2 and type 2 diabetes = positive score 
NAFIC 
Sum of: Ferritin ≥200 ng/ml (female) or ≥300 ng/ml (male)=1, immunoreative insulin ≥10 microU/ml=1 and COL-IV ≥5,0 ng/ml=2 
NAFLD Fibrosis Score 
-1.675 + 0.037*age (years) + 0.094*BMI (kg/m2) + 1.13*IFG/diabetes (yes=1, no=0) + 0.99*AST/ALT ratio - 0.013*platelet (x10
9
/l) - 0.66*albumin (g/dl) 
Modified NFS: 
6.375 + 0.062*BMI (kg/m2) + 1.745*diabetes/IFG (yes=1, no=0) - 1.103*AST/ALT ratio - 0.037*age (years) - 0.005*platelets (x10
9





=1, type 2 diabetes=1, systolic blood pressure>130mmHg or diastolic blood pressure>85mmHg=1 (total score range 0-4) 
Original European Liver Fibrosis panel 










Probability of Advanced Fibrosis 
Sex, diabetes, ALT, AST (formula not published) 
Susuki-1 
Age, obesity, AST:ALT ratio >1 and diabetes (formula not published) 
Susuki-2 
Age, obesity, AST:ALT ratio >1, diabetes and HA (formula not published) 
Tetri-1 
AST, ALT, AST:ALT ratio (formula not published) 
Tetri-2 
AST, ALT, AST:ALT ratio, age, race, gender, ethnicity (formula not published) 
Tetri-3 
AST, ALT, AST:ALT ratio, age, race, gender, ethnicity, hypertension, Type 2 diabetes, body mass index, waist circumference, waist/hip ratio, acanthosis nigricans 
(formula not published) 
Tetri-4 
AST, ALT, AST:ALT ratio, age, race, gender, ethnicity, hypertension, Type 2 diabetes, body mass index, waist circumference, waist/hip ratio, acanthosis nigricans, ALP, 
GGT, globulin, albumin, total and direct bilirubin, international normalized ratio, hematocrit, white blood cells, platelet count, total cholesterol, triglyercides, HDL 
cholesterol, LDL cholesterol, HbA1c, HOMA-IR, fasting serum glucose, fasting serum insulin, autoimmune markers (ANA, AMA, ASMA), metabolic syndrome, ferritin 
(formula not published) 
Younossi-1 
Type 2 diabetes, sex, BMI, triglycerides, CK18 (formula not published) 
Younossi-2 
Type 2 diabetes, AST, triglycerides, TIMP1 (formula not published) 
ALT alanine aminotransferase; AST aspartate aminotransferase; BMI body mass index; CK18 cytokeratin-18; ELF Enhanced Liver Fibrosis panel; GGT gammaglutamyl 
transferase; HA hyaluronic acid; INR international normalised ratio; P3NP procollagen type III N-terminal peptide; TIMP1 tissue inhibitor of metalloproteinase-1. 
 
72 
2.4.2 Methodological quality 
The overall rating using the Quality Assessment of Diagnostic Accuracy Studies II 
approach found 8 studies to have no risk of bias, 23 studies to have a definite risk of 
bias and 26 studies where the risk of bias was unclear.  Full details are included in 
Appendix G. 
For the studies with a definite risk of bias 16/23 were due to concerns over the 
patients group selected (e.g.  gastric bypass participants, NASH patients, specific 
ethnic group) and 9/23 were due to a time interval >3 months between the index and 
reference test (2 studies had both risks). 
For studies where the risk of bias was unclear 15/26 were because of incomplete 
description of the study population and 22/26 were due to failure to disclose the 




Table 2-6 summarises the characteristics of included studies of any fibrosis. 
The prevalence of underlying fibrosis ranged from 26 to 81%. 
For any fibrosis (F0 vs F1-4) there were 25 different markers trialled in 38 
assessments.  For mild fibrosis 18/25 (72%) markers were only considered once.  
The highest numbers of different studies was for TUE (5), HA (4) and ELF (3).  In 
general, when a marker was assessed in more than one different study the resulting 
AUROC statistics were similar with the exception of HA and TUE which are 
discussed below. 
For TUE the five assessments totalled 414 participants.  The AUROC statistics 
ranged from 0.88-0.93 in four studies and a fifth study found a lower score of 0.78.  
All five studies optimised similar cut-offs (5.3-5.9 kPa) which in a low fibrosis (5%) 
 
73 
prevalence cohort gave a low PPV of 9-42%, and an excellent NPV of 98-100%.  
When the fibrosis prevalence was increased (30%) the PPV improved to 45-76% and 
NPV fell to 89-96%. 
The four HA studies contained in total 254 participants with wide ranging AUROC 
varying from 0.67-0.98.  Only three reported optimal cut-off values and these varied 
from 25 -149 ng/ml.  In taking the higher cut-off Lydatakis
286
 was able to produce a 
sensitivity and specificity both of 96%, however the lower cut-off from dos Santos
274
 
had values of 82% and 68% respectively. 
The three ELF studies total 375 participants with consistent AUROC of 0.76-0.82.  
Guha and colleagues
236
 improved this to 0.84 by combining ELF with the NFS.  
Again reported cut-offs and their corresponding sensitivity and specificity were 
varied.  Despite different cut-offs (-0.21 vs 0.18) Rosenberg
300
  and Guha
236
 found 
similar sensitivity and specificity of 61-69% and 80-82% respectively. 
Of the remaining markers the best AUROC statistics were for complex formulas 




 (all >0.80) and the lowest were for 
individual markers (TIMP-1 0.57 and YKL-40 0.62). 
Overall there was a clear improvement in AUROC for panel markers and TUE over 
individual markers.  In a low fibrosis prevalence (5%) hypothetical cohort the PPV 
values were very poor for all markers (often <20%).  This improved with a higher 






Table 2-6 Non-invasive markers of ANY (F0 vs F1-4) liver fibrosis  










Individual markers     
ALT Kayadibi
281
 0.76 26.4% 26 U/L 68 60  10 97  42 81 
AST Dos Santos
274
 0.73 36.7% 44 U/L 64 79  13 97  56 83 
AST Kayadibi
281
 0.73 26.4% 25 U/L 67 68  9 97  48 83 
CK18 Malik
86
 0.67 (0.63,0.71) 69.5% - - -  - -  - - 
HA Lydatakis
286
 0.98 (0.93,1.01) 46.0% 149 ng/mL 96 96  56 100  91 99 
HA Malik
86
 0.73 (0.68,0.78) 69.5% 45 ng/ml - -  - -  - - 
HA Dos Santos
274
 0.73 36.7% 24.6 ng/ml 82 68  12 98  53 91 
HA Suzuki
305
 0.67 (0.55,0.80) 74.7% - - -  - -  - - 
Laminin Dos Santos
274
 0.87 36.7% 282 ng/mL 82 89  29 99  76 95 
Laminin Lydatakis
286
 0.79 (0.66,0.92) 46.0% 293 ng/ml 74 74  14 99  55 87 
SPEA Kayadibi
281
 0.84 (0.73,0.94) 26.4% 1134 84 82  19 99  66 92 
TIMP-1 Malik
86
 0.59 (0.53,0.65) 69.5% - - -  - -  - - 
COL-IV Dos santos
274
 0.80 36.7% 145 ng/mL 64 89  69 98  70 85 
YKL-40 Malik
86
 0.62 (0.55,0.69) 69.5% - - -  - -  - - 
Panel markers       
APRI Younossi
313




































 0.67 26.4% 1.09 63 60  7 97  40 79 
dosSantos-1 Dos santos
274
 0.87 36.7% - 73 95  44 99  88 89 
dosSantos-2 Dos santos
274
 0.87 36.7% - 64 100  100 98  100 86 
dosSantos-3 Dos santos
274
 0.80 36.7% - 55 95  38 98  85 84 
ELF Rosenberg
300






















 0.76 (0.69,0.83) 58.9% -0.207 61 80  14 97  56 82 
ELF+NFS* Guha
236


















 0.90  6.60 83 82  19 99  66 92 
Tetri-1 Tetri
293
 0.72 (0.67,0.76) 73.1% - - -  - -  - - 
Tetri-2 Tetri
293
 0.74 (0.70,0.78) 73.1% - - -  - -  - - 
Tetri-3 Tetri
293
 0.78 (0.74,0.82) 73.1% - - -  - -  - - 
Tetri-4 Tetri
293
 0.84 (0.80,0.87) 73.1% - - -  - -  - - 
NFS* Guha
236





















































































Imaging            
TUE Yoneda
247
 0.93 81.4% 5.9 kPa 86 89  29 99  76 94 
TUE Yoneda
312
 0.88 77.6% 5.6 kPa 83 81  18 99  66 92 
TUE Lupsor
285





 67.4% 5.6 kPa 82 81  18 99  66 92 
TUE Gaia
276
 0.78 (0.67,0.88) 68.1% 5.5 kPa 84 57  9 98  45 89 
ALT alanine aminotransferase; APRI aspartate to platelet ratio index; AST aspartate aminotransferase; AUROC area under the receiver operator curve; CK18 
cytokeratin-18; COL-IV Type IV collagen; ELF Enhanced Liver Fibrosis panel; HA hyaluronic acid; NAFLD non-alcoholic fatty liver disease; NFS NAFLD Fibrosis Score; 
NPV negative predictive value; OELF Original ELF panel; PPV positive predictive value; SPEA serum prolidase enzyme activity; TIMP-1 metallopeptidase inhibitor 1; 




Table 2-7 summarises the characteristics of included studies of moderate fibrosis. 
The prevalence of underlying fibrosis ranged from 9 to 53%. 
For moderate fibrosis (F1 vs F2-4) there were 34 different markers trialled in 59 
assessments.  For moderate fibrosis 16/34 (47%) markers were only considered once.  
The highest numbers of different studies was for NFS (17) and TUE (15).  Unlike for 
any fibrosis, when a marker was assessed n more than one different study the 
resulting AUROC statistics were in poor agreement with the exception of TUE.  For 
example, from seven assessments of APRI the AUROC spread from 0.56-0.87.   
The 17 assessments of the NFS totalled 1275 participants.  The AUROC ranged from 
0.79-0.94.  The underlying fibrosis prevalence of the investigated cohorts ranged 
from 25-53%.  The cut-offs suggested varied but in general corresponded to a 
sensitivity of 70-90% and a specificity of 60-80%.  Seven studies had a cut-off 
between 6.5-7.5 kPa corresponding to sensitivities 67-89% and specificities 70-91%.  
In the low fibrosis prevalence group the PPV was <31% (except one assessment) and 
the specificities >96%.  For the higher fibrosis prevalence group the PPV rose to 
above 50% with an NPV >80%. 














.  The only assessment of the C-caffeine breath test was 
for moderate fibrosis with an AUROC of 0.74. 
Notable poor AUROC occurred for AST (0.60)
278








Table 2-7 Non-invasive markers of MODERATE (F0-1 vs F2-4) liver fibrosis 










Individual markers            
AST Guajardo-Salinas
278
 0.60 (0.37,0.83) 8.7% - - -  - -  - - 
HA Suzuki
305
 0.87 (0.80,0.95) 32.9% - - -  - -  - - 
Panel markers             
APRI  Cales
272
 0.87 27.6% - 66 91  25 97  77 86 
APRI Tropet
307
 0.79 32.5% - - -  - -  - - 
APRI Adams
271
 0.73 (0.64,0.82) 42.0% - 72 70  13 99  51 86 
APRI Kelleher
282
 0.73 (0.61,0.84) 49.6% - - -  - -  - - 
APRI Shah
303
 0.70 (0.67,0.74) 44.7% - - -  - -  - - 
APRI Wong
309
 0.62 (0.51,0.72) 25.3% - - -  - -  - - 
APRI Loaeza
229
 0.56 - - - -  - -  - - 
AST:ALT ratio Kelleher
282
 0.67 (0.58,0.77) 49.6% - - -  - -  - - 
AST:ALT ratio Wong
309
 0.63 (0.53,0.73) 25.3% - - -  - -  - - 
BAAT Ratziu
119
































 0.59 24.6% - - -  - -  - - 
BARD Sumida
304
 0.69 24.6% - - -  - -  - - 
BARD Shah
303


















 0.63 (0.59,0.67) 44.7% - - -  - -  - - 
ELF Rosenberg
300
 0.91 (0.85,0.969) 31.7% 0.24 88 79  17 91  63 93 
ELF Guha
236
 0.82 (0.75,0.88) 40.1% -0.107 70 80  17 99  60 86 
ELF+NFS* Guha
236




















 0.94  27.6% - 79 96  50 99  88 91 
FIBROspect II Guajardo-Salinas
278
 0.78 (0.62,0.94) 8.7% 20 100 42  100 96  100 74 
FibroTest Ratziu
241




















 0.82 (0.67,0.90) 6.9% 0.48 5 100  - 95  100 71 
FibroTest Ratziu
241




















 0.72 (0.62,0.81) 42.0% - 73 60       
FIB4 Shah
303
 0.75 44.7% - 80 56  9 98  44 87 
FM8 Tropet
307
 0.87 - - - -  - -  - - 
Gholam-1 Sumida
304
 0.79 24.6% - - -  - -  - - 
GUCI Shah
303
 0.71 (0.63,0.74) 44.7% - - -  - -  - - 
HAIR Sumida
304
 0.59 - - - -  - -  - - 
HAIR Wong
309
 0.51 (0.41,0.61) 25.3% - - -  - -  - - 
Hepascore Adams
271
 0.75 (0.66,0.84) 42.0% - 56 94  33 98  81 84 
Manousou-1 Manousou
287


















 0.87 (0.80,0.93) 32.4% +ve 82 79  17 99  63 92 
Manousou-2 Manousou
287
 0.85 (0.78,0.93) 24.2% +ve 90 72  14 99  57 94 
N-Score Sumida
304
 0.72 24.6% - - -  - -  - - 
NAFIC Sumida
304
 0.83 24.6% 3 84 74  14 99  58 91 
NFS Cales
272
 0.88 27.6% - 61 96  43 98  86 85 
NFS* Guha
236








































 0.69 (0.65,0.73) 44.7% - - -  - -  - - 
NFS Wong
309


















Imaging            
MRE Talwalkar
306
 0.90 48.1% 4.2 kPa 78 94  40 99  85 90 
TUE De Ledinghen
273
 0.94 (0.91,0.97) 38.0% 7.0 kPa 77 77  54 99  59 89 
TUE Yoneda
312
 0.88 49.3% 6.65 kPa 82 91  31 99  81 93 
TUE Yoneda
247





 - 6.65 kPa 81 91  31 99  80 91 
TUE Kelleher
282




























 0.84 (0.73,0.95) 34.0% 7.7 kPa 94 61  12 100  51 96 
TUE Wong
246


































 - - - -  - -  - - 
TUE Gaia
276





 - - - -  - -  - - 
TUE Lupsor
285
 0.79 (0.67,0.88) 25.0% 6.8 kPa 67 84  17 98  65 86 
TUE Petta
297
 0.79 46.6% 7.25 kPa 69 70  10 97  50 84 
‘Other’ markers             
13
C-caffiene breath test Park
296
 0.74 (0.60,0.88) 47.9% - - -  - -  - - 
APRI aspartate to platelet ratio index; ALT alanine aminotransferase; AST aspartate aminotransferase; BMI body mass index; CDS cirrhosis discriminant score; ELF 
Enhanced Liver Fibrosis panel; FIB4 Fibrosis-4 Index; GUCI Goteburg University Cirrhosis Index; HA hyaluronic acid; MRE magnetic resonance elastography; NAFLD 
non-alcoholic fatty liver disease; NFS NAFLD Fibrosis Score; NPV negative predictive value; N-score Nippon-score;  OELF Original European Fibrosis panel; PPV 





Table 2-8 summarises the results of included studies of significant fibrosis. 
The prevalence of underlying fibrosis ranged from 3 to 43%. 
For significant fibrosis (F0-2 vs F3-4) there were 37 different markers trialled in 118 
assessments.  For moderate fibrosis 16/34 (47%) markers were only considered once.  
The most frequently assessed markers were: NFS (17), TUE (16), APRI (10), 
AST:ALT ratio (9), and BARD (9).   
Again, when a marker was assessed i n more than one different study the resulting 
AUROC statistics were widely varied.  For example, 17 assessments of NFS 
(including 4480 participants) produced AUROC spread from 0.59-0.96.   
Five assessment of HA had similar cut-offs (33-50 ng/ml) with corresponding 
sensitivities 69-100% and specificities 66-89%.  For a low fibrosis prevalence cohort 
this gave a PPV general of <20% and an NPV >97%.  By increasing the fibrosis 
prevalence the PPV rose to <66%. 
Overall the AUROC for the AST:ALT ratio was average to good (0.59-0.83).  Three 
assessments used a cut-off of 1.0 with sensitivities 21-52% and specificities 78-90%.  
Four assessments used a cut-off of 0.8 with marginally improved sensitivities of 40-
74% and specificities of 62-90%. 
Four assessments of BARD reported for a cut-off of 2 (AUROC 0.65-0.81).  The 
sensitivities were 51-89% and specificities 34-77%.   
FIB4 was assessed five times (AUROC 0.75-0.96).  as cut-offs increased from 1.3 to 
2.67 and 3.25 the sensitivities fell (65-85%, 21-33% and 26-71% respectively) and 
specificities improved (65-80%, 96-80% and 96-80% respectively). 
FibroTest had consistently very good AUROC from four studies (0.81-94).  For a 




69-73%.  For a higher cut-off of 0.70 (two studies) the sensitivity was 25% and 
specificity 97-99%. 
From the 17 NFS studies there were seven reporting a low cut-off of -1.455.  These 
had a sensitivity of 39-100% and a specificity of 31-99%.  Nine studies used a higher 
cut-off of 0.676 with sensitivity 0-62% (majority <50%) and specificity 31-99% 
(mainly >90%). 
For TUE nine assessments used a lower cut-off of 7.9-8.7 kPa with sensitivity 46-
91% and specificity 75-92%.  Four assessments used a cut-off of 9.8-10.4 kPa with 
similar results: sensitivity 46-91% and specificity 75-92%. 
Markers with notable high AUROC were ARFI (0.90-0.97), P2/MS (0.94) and FM8 
(0.94).  The markers with consistently low AUROC were HAIR (0.50-0.57) and 
BAAT (0.53-0.57).   
Overall 
For all levels of fibrosis across all of the cut-offs assessed and all of the varying 
sensitivity and specificity there was consistently poor PPV and excellent NPV, 
meaning that many people with a positive test result would be falsely diagnosed with 
liver fibrosis but that a negative test would be highly reassuring for the absence of 
fibrosis.  The PPV improved with increased fibrosis prevalence.  As the fibrosis stage 






Table 2-8 Non-invasive markers of SIGNIFICANT (F0-2 vs F3-4) liver fibrosis 
 










Single markers            
CK18 Malik
86
 0.71 (0.68,0.74) 26.3% - - -  - -  - - 
HA Kaneda
280
 0.97 27.0% 42 ng/mL 100 89  33 100  79 100 
HA Suzuki
305
 0.89 (0.81,0.97) 25.3% 46.1 ng/mL 85 80  17 99  65 93 
HA Palekar
294
 0.89 (0.76,1.00) 17.5% 45.3 micrg/L 86 80  17 99  65 93 
HA Sakugawa
302
 0.80 (0.65,0.85) 42.9% 50 ng/mL 69 83  16 98  64 87 
HA Malik
86
 0.77 (0.73,0.81) 26.3% - - -  - -  - - 
HA Yoneda
311
 0.75 25.0% 32.5 ng/dL 78 66  11 98  49 87 
TGR-B Palekar
294
 0.67 (0.50,0.84) 17.5% - - -  - -  - - 
TIMP-1 Malik
86
 0.60 (0.56,0.64) 26.3% - - -  - -  - - 
COL-IV Kaneda
280
 0.87 27.0% - - -  - -  - - 
COL-IV Sakugawa
302
 0.82 (0.74,0.90) 42.9% 5.0 ng/mL 81 71  13 99  55 89 
COL-IV Yoneda
311
 0.77 25.0% 4.3 ng/dL 89 60  10 98  49 93 
YKL-40 Malik
86
 0.64 (0.59,0.69) 26.3% - - -  - -  - - 
Panel markers            
APRI Cales
272
 0.86 18.7% - - -  - -  - - 
APRI Kruger
283
 0.85 17.1% 0.98 75 86  24 99  70 90 
APRI Tropet
307
 0.83 - - - -  - -  - - 
APRI Yu
314
 0.83 (0.74,0.91) 3.0% - - -       
APRI Adams
271







































 0.73 23.1% - - -  - -  - - 
APRI Wong
309
 0.70 (0.55,0.84) 11.1% - - -  - -  - - 
APRI Younossi
313




















 0.67 (0.54,0.80) 18.6% 1 27 89  9 96  50 74 
APRI Loaeza
229























 0.79 (0.69,0.89) 3.0% - - -  - -  - - 
AST:ALT ratio Palekar
294
 0.74 (0.61,0.88) 17.5% 0.79 71 70  13 99  50 84 
AST:ALT ratio Shah
303
 0.74 (0.69,0.79) 23.1% - - -  - -  - - 
AST:ALT ratio Miao
288
 0.66 3.1% - - -  - -  - - 
AST:ALT ratio Wong
246




















 0.61 17.1% 0.8 58 62  8 97  39 77 
AST:ALT ratio Kallwitz
279
 0.59 - 1 41 78  9 96  40 74 
AST:ALT ratio Wong
309
 0.58 (0.44,0.71) 11.1% - - -  - -  - - 
AST:Plt ratio Yu
314
 0.83 (0.74,0.91) 3.0% - - -  - -  - - 
AST:Plt ratio Shah
303



















 0.57 27.0% - - -  - -  - - 
BAAT Sumida
304





  22.0% 2 - -  - -  - - 
BARD McPherson
228
 0.77 18.6% 2 89 44  7 98  41 91 
BARD Fujii
234
 0.73  37.7% - - -  - -  - - 
BARD Sumida
304
 0.73 10.8% - - -  - -  - - 
BARD Shah
303
 0.70 (0.64,0.75) 23.1% - - -  - -  - - 
BARD Wong
246
 0.69 (0.61,0.77) 22.8% 2 62 66  9 97  43 79 
BARD Yu
314
 0.69 (0.54,0.84) 3.0% - - -  - -  - - 
BARD Ruffillo
301
 0.67 26.8% 2 51 77  12 97  48 78 
BARD Kallwitz
279
 0.65 - 2 82 34  6 97  35 83 
CDS Yu
314
 0.94 (0.86,1.00) 3.0% - - -  - -  - - 
CDS Shah
303
 0.67 (0.61,0.72) 23.1% - - -  - -  - - 
ELF Rosenberg
300
 0.93 (0.87,0.98) 24.0% 0.62 83 90  31 99  78 93 
ELF Guha
236
 0.90 (0.84,0.96) 22.9% 0.358 80 90  31 99  70 91 
ELF Younossi
313
 0.65 (0.53,0.75) 20.3% 0.358 44 73  7 96  41 75 
ELF+NFS Guha
236
















































































































FIB4 Miao 0.75 
3.1% - - -  - -  - - 
FibroMeter Cales
272
 0.94 (0.91,0.98) 18.7% - - -  - -  - - 
FibroTest Ratziu
298








































 0.82 (0.73,0.92) 24.4% - - -  - -  - - 
FibroTest Ratziu
241




















 0.94 32.5% - - -  - -  - - 
Gholam-1 Sumida
304
 0.73 10.8% - - -  - -  - - 
GUCI Yu
314
 0.86 (0.78,0.94) 3.0% - - -  - -  - - 
GUCI Shah
303
 0.74 (0.70,0.79) 23.1% - - -  - -  - - 
HAIR Sumida
304



















 0.50 (0.36,0.65) 11.1% - - -  - -  - - 
Hepascore Adams
271
 0.82 (0.72,0.93) 24.4% 0.50 56 94  33 98  81 84 
NAFIC Sumida
304
 0.87 10.8% 3 84 82  19 99  66 92 
NAS Malik
86
 0.79 (0.75,0.83) 26.3% - - -  - -  - - 
NFS Yu
314




















 0.93 18.7% - - -  - -  - - 
NFS Guha
236




















 0.88 (0.85,0.92) 26.0%
e























 0.84 37.7% - - -  - -  - - 
NFS Angulo
243
 0.82 (0.76,0.88) 28.9%
v























 0.79 3.1% - - -  - -  - - 
NFS Shah
303
 0.77 (0.72,0.82) 23.1% - - -  - -  - - 
NFS Kruger
283
 0.77 17.1% -1.31 76 69  12 99  51 87 
NFS Wong
246











































































































































 0.70 10.8% - - -  - -  - - 
OELF Rosenberg
235




























































 0.84 3.1% - - -  - -  - - 
Susuki-1 Suzuki
305



















 0.92 (0.85,0.98) 25.3% - - -  - -  - - 
Tetri-1 Tetri
293
 0.73 (0.68,0.78) 24.6% - - -  - -  - - 
Tetri-2 Tetri
293
 0.75 (0.70,0.79) 24.6% - - -  - -  - - 
Tetri-3 Tetri
293
 0.77 (0.73,0.81) 24.6% - - -  - -  - - 
Tetri-4 Tetri
293
 0.85 (0.82,0.89) 24.6% - - -  - -  - - 
Younossi-2 Younossi
313


















Imaging             
ARFI Yoneda
270
 0.97 (0.93,1.02) 18.5% 1.77 m/sec 100 91  36 100  83 100 
ARFI Palmeri
295
 0.90 29.6% 4.24 kPa 90 90  33 99  79 95 
TUE Yoneda
247
 0.99 (0.97,1.01) 18.5% 9.9 kPA 100 93  42 100  86 100 
TUE Lupsor
285
 0.98 (0.91,1.00) 6.9% 10.4 kPa 100 97  63 100  94 100 
TUE De Ledinghen
248
 0.95 (0.91,0.99) 21.2% 8.7 kPa 84 87  25 98  74 92 
TUE Wong
246
































  8 kPa 87 84  21 99  70 94 
TUE Yoneda
247





 - - - -  - -  - - 
TUE Wong
308





























 - - - -  - -  - - 
TUE Myers
291
 0.82 (0.67,0.97) 20.0% 10.3 kPa 70 76  13 98  55 85 
TUE Gaia
276










 28.3% 8.7 kPa 46 91  18 97  70 80 
APRI aspartate to platelet ratio index; ALT alanine aminotransferase; ARFI acoustic radiation force impulse; AST aspartate aminotransferase; BMI body mass index; 
CDS cirrhosis discriminant score; CK18 cytokeratin-18; COL-IV Type IV collagen; ELF Enhanced Liver Fibrosis panel; FIB4 Fibrosis-4 Index; GUCI Goteburg University 
Cirrhosis Index; HA hyaluronic acid; NAFLD non-alcoholic fatty liver disease; NAS NAFLD Activity Score; NFS NAFLD Fibrosis Score; N-score Nippon-score;  OELF 




2.5.1 Summary of main findings 
There have been a large number of studies investigating the diagnostic test accuracy 
of non-invasive markers for hepatic fibrosis against the reference standard of liver 
biopsy.  Numerous authors have developed differing formulas, largely based on the 
same components.  Very few studies used a development and a validation cohort –
the majority have not been replicated in any way.   
The studies used were frequently small (26/57 46% with n<100 and 13/57 23% with 
n>200).  Also methodological quality in terms of risk of bias and applicability was 
often unclear or had definite risks meaning the results needed to be interpreted with 
caution.   
Across all of the markers assessed the AUROCs were widely varied both within and 
across the markers.  Despite this, many assessments did produce an AUROC >0.80 
(any fibrosis 15/38 39%, moderate 31/58 53%, significant 58/118 49%) and the 
proportion above 0.90 improved with fibrosis stage (any fibrosis 3/38 8%, moderate 
5/58 8%, significant 23/118 19%).  Interpretation with caution is needed.  Many did 
not report confidence intervals around the AUROC, and given the small size of 
studies and those that were reported, the confidence intervals are wide, often 
stretching as low as 0.6. 
The need to use liver biopsy as the reference standard has limited the generalizability 
of studies.  Populations studied were typically limited to those with a clinical need 
for biopsy i.e. those with a high level of suspicion of advanced CLD and therefore a 
high prevalence of liver fibrosis.  In some studies the populations were restricted to 
the severely obese undergoing surgery, a select group who may have different 
‘normal/abnormal’ values of the markers.  However, in many general secondary care 
populations many of the subjects with NAFLD are obese. 
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Overall, the sensitivity of the markers for diagnosing liver fibrosis of all levels was 
moderate to poor with a much better specificity.  The specificity improved with 
increasing level of liver fibrosis i.e.  the ability to correctly rule out liver fibrosis was 
good, especially for significant liver fibrosis.  However, the PPV was generally poor 
across all of the markers. 
2.5.2 Strengths and weaknesses of the review 
In order to facilitate the capture of all reports of non-invasive markers in NAFLD a 
very wide search strategy and inclusion criteria were successfully employed.  A 
consequential limitation is that the selection of studies and extraction of data of this 
large number of reports (>11000) was by a single reviewer.  The possibility of 
erroneously discarding a valid report would have been reduced with the use of a 
second reviewer
118
.  Whilst the same criteria were applied to identifying each study 
the use of a single reviewer risks bias in the study selection through the influence of 
any existing preferences or opinions
317
.  Despite this I have a high level of 
confidence in the selection of studies given the multiple sources of cross-referencing 
in study identification including the use of reference and citation searches of 
included studies. 
There is a risk of reporting bias due to the nature of the topic.  Only studies finding 
good or better diagnostic test accuracy tend to be published.  It is reassuring that 
there were some markers with lower AUROCs (5% <0.60) published suggesting that 
this bias is not as great as it could be.  Few markers were replicated and it is unclear 
if this was attempted and any failure to replicate their findings went un-published.  
This publication bias is also influenced by the commercial value in identifying a non-
invasive marker of liver fibrosis. 
Whilst every attempt was made to avoid duplicate publishing of results there is a 
small possibility of this having occurred.  Frequently study results were published as 
conference abstracts and then later as full research papers.  In addition it is small 
field and the same researchers go on to publish additional data or combine individual 
markers to form panels and it can be difficult to tease out where the data may relate 
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to the same patients
318
.  To try and avoid this problem this review has clearly marked 
which reports reflect abstracts and carefully checked author lists to look specifically 
for the possibility of dual publication. 
Another bias is that of language.  This review excluded all papers that were not 
available in the English language, however this proved not to be a problem as the 
few foreign language papers provided English language abstracts containing 
sufficient information. 
Due to the small numbers in many of the reports is may have been beneficial to 
undertake a meta-analysis.  However, this was not performed because the benefits 
were unlikely to outweigh the difficulties: time and statistical knowledge, 
heterogeneity between studies, and many markers had only one or two studies 
reported. 
2.5.3 Agreement/disagreement with other studies 
There have been a number of reviews published previously
319-322
.  This review is 
larger, finding more studies for inclusion, than previous systematic reviews and 
focusses only on liver fibrosis, as opposed to the full NAFLD spectrum.  However, 
despite this the main findings have remained much the same: non-invasive markers 
have a poor PPV and have improved diagnostic accuracy at higher fibrosis stages.  
For example, Guha et al
319
 and Dowman et al
321
 describe 9 different fibrosis markers 
(vs 49 in this review).   
2.5.4 Implications for future research 
There are increasing numbers of diagnostic test accuracy studies of non-invasive 
fibrosis markers continuing to be published, but they are currently adding little to the 
existing body of evidence.  The focus needs to shift to defining and studying the 
populations of most clinical interest, rather than developing ‘more’ potential markers 
in the same select hospital populations.  Community-based settings are neglected in 
the current studies due to the ethical difficulties of performing large scale liver 
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biopsy.  This could be achieved if a non-invasive gold standard could be agreed - for 
example an imaging modality such as MRE.   
2.5.5 Implications for thesis 
There are a wide variety of markers that could be considered for use in this thesis for 
investigating hepatic fibrosis.  It is unlikely that any one marker can be used to 
diagnose hepatic fibrosis given the difficulties discussed above.   
The choice of markers to investigate with therefore is affected by several 
considerations: a) choice of fibrosis stage of interest; b) those markers with a large 
number of high studies suggestive of good utility; c) those markers which can be 
utilised easily and acceptably to the study participants, d) efficiency within the 
studies existing samples and resources, and affordable; e) variety of biological  
plausibility’s of interest; and e) taking into consideration any biases the participants 
investigated in this thesis may bring to the use of the markers. 
Due to the improvement in diagnostic accuracy with increasing liver fibrosis stage 
and because of the clinical significance for patients this thesis will focus on 
significant fibrosis/cirrhosis (F3-4).  For this stage of fibrosis, APRI, AST:ALT ratio, 
ELF, NFS and TUE are the most well validated, and will therefore form the focus for 
the thesis investigations. 
Markers such as MRE are both time consuming and expensive and therefore will not 
be available for use in this thesis. 
Many of the pane markers use the same components in their formulas e.g.  AST and 
platelets.  For specific analyses the use of similar markers will be limited to reduce 
the amount of unnecessary statistical testing.  Further to this a range of markers 
based on differing biological plausibility will be investigated e.g.  simple non-
specific markers, extra-cellular matrix based markers, portal hypertension based 
markers and imaging. 
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Some panel markers use and age and the presence of diabetes in their models (e.g.  
NFS) and as such have the potential to produce repeated high scores in the study 
given its focus on older people with type 2 diabetes.  Markers of this nature will not 
be used to attempt to diagnose fibrosis in the thesis but will be considered as 
potential risk factors for other outcomes. 
2.6 Conclusions 
There is no clear ‘best’ non-invasive marker of liver fibrosis in patients with 
NAFLD.  At present, the evidence suggests, markers can only be reliably used to 
exclude the presence of liver fibrosis (high NPV).  In addition, markers are better at 
excluding the presence of advanced fibrosis (Metavir F3-4) than moderate or low 
grade fibrosis.  Given the evidence collected it appears that serum markers will be 
unlikely to be able to be used to diagnose the presence of liver fibrosis given their 
low PPV, particularly in low prevalence settings.    
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CHAPTER 3  
People with type 2 diabetes are reported to be at greater risk of CLD than the general 
population.  However, little is known of the true burden of CLD in this population in 
terms of its prevalence and incidence and associated risk factors. 
The overall aim of this thesis was to investigate the epidemiology of CLD in older 
people with type 2 diabetes.   
In order to do this, data from the three Edinburgh Type 2 Diabetes Study (ET2DS) 
data collection phases (baseline, year 1 liver study and year 4 follow-up) was used 
with a focus on the use of non-invasive markers of liver injury. Non-invasive liver 
markers were grouped as follows: non-specific liver injury - ALT, AST and GGT; 
hepatic steatosis - steatosis on USS; steatohepatitis (inflammation/apoptosis) - CK18; 
liver fibrosis - APRI, AST:ALT ratio, ELF, FIB4 HA, NFS and LSM; and surrogate 
markers of advanced portal hypertension - platelet count and spleen diameter. 
3.1 Research questions 
Given the shared mechanisms for both the development of type diabetes and 
NAFL/D it is believed that NAFL/D is more prevalent amongst those with type 2 
diabetes compared to those without, however, it has been difficult to confirm this 
because of the lack of non-invasive diagnostic techniques. Given the rise in the 
number of non-invasive markers of NAFLD made available in the past ten years (see 
Chapter 2) we are now in a possible to start addressing these issues. If the ectopic fat 
hypothesis is to hold true then it may be expected that patients with more ‘severe’ 
type 2 diabetes (a poorer metabolic profile) would have both a higher prevalence of 
NAFL/D and higher non-markers of NAFL/D. 
1. How do the distributions of non-invasive markers of NAFLD (NASH and 
liver fibrosis) in a community sample of older people with type 2 diabetes 
compare with a) those in hospital samples of people with type 2 diabetes, and 
b) those in the general population? 
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2. Are levels of NASH and NASH-fibrosis (as determined by higher levels of 
non-invasive markers) higher in patients with a poorer metabolic profile? 
3. Are established risk factors for CLD associated with associated with higher 
levels of non-invasive markers of NAFLD? 
If non-invasive markers of hepatic fibrosis are to be useful in the diagnosis of 
subclinical CLD for further research (and/or clinical practice) clear guidance in their 
use, with validated cut-offs and diagnostic criteria determined.  
4. Do non-invasive markers of hepatic fibrosis agree with each other? 
In order determine the clinical need and to inform further research strategies the true 
burden of CLD in people with type 2 diabetes needs to be determined. In addition 
prognostic models for the early identification of subclinical CLD and incident CLD 
are needed. Given the shared aetiology of type 2 diabetes and NAFL/D, it could be 
hypothesised that risk factors attributable to a poorer metabolic and diabetes profile 
may be useful in the identification of CLD. 
5. What is the prevalence and incidence of advanced clinically significant liver 
outcomes in older people with type 2 diabetes? 
6. Are there any non-invasive markers of CLD or measures of metabolic disease 
that are associated with prevalent and/or incident clinically significant CLD 
in older people with type 2 diabetes, that may be useful for prognostic 
modelling? 
It is currently not possible to determine if the relationship between NAFL/D and 
CVD driven by their shared risk factors, or if NAFL/D ‘causes’ CVD independently. 
Investigation of markers related to liver disease, but not known to be related to CVD 
could help in determining which of these pathways is more likely and aid in the 
identification of individuals at risk of CVD. 
7. Are there any non-invasive markers of CLD associated with prevalent and/or 




3.2 Aims and objectives 
The detailed aims and objectives of this thesis were: 
I. To explore the epidemiology of non-invasive markers of NAFLD as potential 
measures of subclinical CLD in people with type 2 diabetes 
(i) To determine the distribution of non-invasive markers of NAFLD in older 
people with type 2 diabetes.   
Non-invasive markers will include: 
(i) CK18 (marker of steatohepatitis). 
(ii) APRI, AST:ALT ratio, ELF, FIB4, HA, TE and NFS (markers of 
liver fibrosis). 
(ii) To investigate the relationship of non-invasive markers of advanced 
NAFLD with metabolic and CLD risk factors. 
Risk factors will include: 
(i) patient demographics, 
(ii) diabetes history and glycaemic control, 
(iii) metabolic factors, 
(iv) hepatic steatosis, and 
(v) established risk factors for CLD, such as, alcohol, hepatotoxic 
medication and positive autoantibodies. 
(iii) To determine the level of agreement between five non-invasive markers of 
liver fibrosis (APRI, AST:ALT ratio, ELF, FIB4 and LSM) in older people 
with type 2 diabetes.   
(i) Using validated cut-offs to exclude advanced fibrosis; and  
(ii) In the same highest percentile across all marker panels. 
II. To determine the frequency of and risk factors for clinically significant CLD in 
people with type 2 diabetes. 
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(i) To describe the prevalence (known and unknown) and incidence of CLD 
amongst older people with type 2 diabetes. 
(ii) To determine the association of metabolic and CLD related risk factors with 
prevalent and incident clinically significant CLD in type 2 diabetes.   
Risk factors will include:   
(i) patient demographics, 
(i) diabetes history and glycaemic control,  
(ii) metabolic factors 
(iii) established risk factors for CLD, 
(iv) markers of liver injury, and 
(v) markers of systemic inflammation 
III. To determine the importance of CLD as a risk factor (or risk marker) for CV 
mortality or morbidity in type 2 diabetes. 
(i) To determine the association of a range of markers with prevalent and 
incident CV events and mortality.   
Markers will include: 
(i) ALT, AST and GGT (markers of non-specific liver injury), 
(ii) steatosis on USS, 
(iii) CK18 (marker of steatohepatitis) 
(iv) AST:ALT ratio and ELF (markers of liver fibrosis), and 
(v) platelet count (surrogate marker of portal hypertension). 
3.3 Thesis outline 
The methods chapter in this thesis describes in detail the methodology of the ET2DS 
and the data collection and analysis used to investigate liver disease in the ET2DS 
cohort (Chapter 4). 
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The subsequent three chapters (Chapters 5, 6 and 7) describe and discuss the results 
relating to each of the three major aims outlined above.   
The thesis concludes with an overall discussion and conclusions (Chapter 8) 
summarising the main findings of the work, discussing the strengths and limitations 
of the thesis and outlining future opportunities for research in this area.  
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CHAPTER 4  
4.1 The ET2DS 
The ET2DS is a prospective population based cohort study which commenced 
recruitment in 2006.  Core funded by the Medical Research Council it was conceived 
primarily to investigate the association between cognitive decline and potentially 
modifiable risk factors in people with type 2 diabetes.  It was later extended to 
investigate the prevalence of NAFL/D and risk factors associated with its 
development and progression.  In addition, the ET2DS seeks to identify circulating 
markers and other risk factors which predict the development and progression of 
symptomatic and asymptomatic micro- and macrovascular disease.  It also provides a 
well phenotyped population sample of subjects for future research. 
4.2 The study population 
4.2.1 Sampling frame: The Lothian Diabetes Register 
The target population was all older people with type 2 diabetes in Lothian, Scotland, 
and as such the sampling frame used was the Lothian Diabetes Register (LDR).  The 
LDR was fully established in 2001 and records the clinical details of all patients with 
diabetes in Lothian.  Patients are added to the register once a diagnosis of diabetes 
(WHO criteria) has been confirmed and medical staff can then assign any further 
classification.  Analysis by the Lothian Diabetes Services Advisory Group has found 
the register contains almost everyone diagnosed with diabetes in Lothian (Prof Sarah 
H Wild, personal communication). 
4.2.2 Definition: type 2 diabetes 
For the purpose of the ET2DS, type 2 diabetes was defined as: a diagnosis of type 2 
diabetes on the LDR and i) the use of oral antidiabetic agents and/or insulin, or ii) 
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any subject treated with dietary modification alone whose HbA1c was > 6.5% at the 
research clinic.  All subjects treated with dietary modification alone and with an 
HbA1c ≤ 6.5% had their medical records reviewed by a consultant Diabetologist to 
ensure that the diagnosis of diabetes was robust.   
The clinical records of individuals who either: (i) started on insulin within one year 
of diagnosis of diabetes, (ii) reported evidence of pancreatic surgery/disease at the 
research clinic or (iii) were treated with insulin and were aged < 35 years at diagnosis 
were also reviewed.  Such individuals were considered to be at the greatest risk of 
misclassification.  Any subject in whom it was not possible to confirm a clinical 
diagnosis of type 2 diabetes by review of hospital and/or general practitioner (GP) 
records was excluded. 
Exclusion criteria included: i) not confirmed type 2 diabetes, ii) non-English 
speakers (to allow completion of all assessment elements), iii) corrected visual acuity 
worse than 6/36 for distance vision or unable to read large print text (to allow 
completion of all assessment elements), iv) unwilling or unable to give consent, and 
v) physically unable to complete all assessment elements. 
4.2.3 Sampling methodology: statistical power and recruitment 
Sampling was undertaken with the aim of recruiting 1000 subjects.  This would 
allow 90% power at the two-sided 5% significance level to detect a Pearson 
correlation coefficient of ≥0.10 between continuous outcomes and independent 




 July 2006 there were 9646 patients identified on the LDR aged between 
60 and 74 years on 1st August 2006.  A total of 5454 potential subjects were 
randomly selected by sex and 5-year age bands and invited by written invitation to 
participate by the custodians of the LDR on behalf of the ET2DS. 
The detailed recruitment process is shown in Figure 4-1.  In brief, 3286 (60.2%) of 
invitees responded and 1252 (23.0%) expressed an interest in participation.  All 
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subjects expressing interest were invited to the baseline research clinic with 1077 
(19.7%) attending.  The final study sample consisted of 1066 individuals after a 
further 11 were excluded due to failure to meet the study inclusion criteria.   
To address non-responders to the initial invitation to participate in the study a 
representativeness analysis was undertaken using data from the LDR to compare 
those participating with non-responders. 
4.3 Data collection 
4.3.1 Study phases 
To date the ET2DS has had three phases of data collection in dedicated research 
clinics.  The baseline visits (2006/2007) and initial (year 1) liver sub-study visits 
(2007/2008) were undertaken prior to my full involvement with the study.  I was 
integrally involved with all aspects of the year 4 follow-up research clinics 
(2010/2011): design, invitation, data collection, data entry and quality control, and 
data management.  A summary of the data collection at each study phase is shown in 
Table 4-1. 
4.3.2 Research clinics 
Research clinics were held at the Wellcome Trust Clinical Research Facility, 
Western General Hospital, Edinburgh, UK at baseline, year 1 liver sub-study and at 
follow-up
323,324
.  Clinics were run by specially trained research nurses and there were 
study specific standard operating procedures for each aspect of data collection to 
ensure accuracy and consistency. 
Data were collected on a wide range of variables and only those relevant to this 






Figure 4-1 Edinburgh Type 2 Diabetes Study recruitment and participation flowchart 
 




Randomly selected for invitation 
n=5561 
Sampling frame 
All patients on the LDR ages 60-






Final ET2DS cohort 
n=1066 




No longer on LDR n=107 
Returned by post office n=64 
No response n=2104 
Declined participation n=2034 
Unable to contact n=56 
Unable to attend n=111 
Did not attend n=5 
Died n=3 
Excluded: 
Not type 2 diabetes n=7 
Could not complete assessment n=4 
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In brief, at baseline and/or initial liver sub-study clinics attendees underwent fasting 
venous blood sampling, physical examination including (blood pressure 
measurement and a 12-lead ECG which was subsequently coded using the Minnesota 
criteria
325
 (http://www.sph.umn.edu/epi/ecg/manual/)), and imaging (abdominal USS 
and TUE).  Detailed self-administered questionnaires included standard questions on 
current medications, alcohol consumption, history of liver disease and CVD and the 
Edinburgh Claudication and WHO Chest Pain Questionnaires
326,327
.   
At each research clinic visit patients were asked detailed questions on their diabetes, 
vascular health and liver disease.  In addition, at the LS, patients were asked 
specifically about joint disease.  Patients were also asked to provide a list of current 
medications and if this was absent subjects were advised that they would be 
telephoned within the forthcoming week to obtain this information.  Medication was 
subsequently coded using British National Formulary sections.  For liver sub-study 
data, self-reported information on potential hepatotoxic medication use within the 
previous 6 months was collected and confirmed by review of medical records.   
All questionnaires were reviewed with the subject by a research nurse to ensure 
accurate and complete completion. 
Copies of the questionnaires administered at each research clinic are included in 
Appendix H. 
4.3.3 Data linkage 
Data linkage was undertaken via the NHS National Services Scotland, Information 
Services Division, to SMR01 general and acute inpatient discharge records using 
ICD version 10 and related ICD-9 codes and to Office for Population Censuses and 
Surveys version 4 codes for CV interventions.  Linkage was undertaken following 




Table 4-1 Summary of data collection in the Edinburgh Type 2 Diabetes Study 
Baseline 





   
General questionnaire: current medications, past medical 
history, alcohol consumption, smoking 
   
Liver questionnaire: liver disease history, joint disease 
history, hepatotoxic medication use 
   
Cardiovascular questionnaire: chest pain and claudication 
scales 
   Physical examination 
   Fasting venous blood sample 
   Liver USS 
   TUE 
   ECG 
   Data linkage 
ECG electrocardiogram; USS ultrasound scan; TUE transient ultrasound elestography (Fibroscan ) 
 
The major acute hospitals included in our analyses (Edinburgh Royal Infirmary, 
Western General Hospital Edinburgh, and St John’s Livingstone) all performed 
above the Scottish average for coding of the main condition causing admission to 
hospital (www.isdscotland.org/Products-and-Services/Data-Quality/). 
4.4 Variable measurement and definitions 
For clarity, variables (both risk factor and disease variables) were grouped into 
categories: 
 Demographics: age, sex, socio-economic deprivation. 
 Diabetes history: fasting serum glucose, HbA1c, duration of diabetes, treatment 
type. 
 Metabolic factors: BMI, waist circumference, blood pressure, lipids. 
 Inflammatory markers: IL6, C-reactive protein (CRP), TNFa. 
 Lifestyle risk factors:  alcohol and smoking. 
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 Non-invasive liver markers: non-specific liver injury, inflammation and 
apoptosis, liver fibrosis, surrogates of portal hypertension 
 NAFL/D and CLD outcomes. 
 CV events. 
4.4.1 Demographics 
Date of birth (for age) and sex of subjects was obtained from the self-report 
questionnaire and assessed against information on the LDR, with discrepancies being 
resolved by referring to clinic records.   
Socio-economic status was measured using the Scottish Index of Multiple 
Deprivation (SIMD) 2006 converted from patient home postcodes at baseline (see 
http://openscotland.gov.uk/Topics/Statistics/SIMD/FAQs#lookups) and defined as 
quintiles. 
4.4.2 Diabetes history 
Duration of diabetes was calculated from the date of diagnosis provided by the 
subject on the self-report questionnaire.  This was also defined as a binary 
categorical variable: <5 years and ≥5 years. 
Diabetes treatment type was revised following each research clinic attendance from 
the self-report questionnaire and medication lists.  Data from both diabetes specific 
questions and the general medication question was used to define treatment type as: 
i) diet controlled, ii) oral anti-hyperglycaemic agent (OAHA) only, and iii) insulin 
+/- OAHA.  Additionally OAHA were sub-categorised into i) metformin, ii) 
sulphonylureas, and iii) thiazolidinediones. 
Serum fasting glucose and HbA1c were measured on the fasting venous blood 
samples and analysed using a Vitros Fusion chemistry system (Ortho Clinical 
Diagnostics, Bucks, UK) at the Western General Hospital (Edinburgh, UK). 
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4.4.3 Metabolic factors 
Height was measured using a wall-mounted vertical rule standing height was 
measured to the nearest mm, standing without shoes.  Weight was measured using 
SECA 761 electronic weighing scales to the nearest 0.1 kg without outdoor clothing 
or shoes.  BMI was subsequently calculated height (in m)/weight (in kg)
2
. 
Waist circumference was measured using a non-expandable tape measure twice and 
the average of two readings taken to the nearest 0.5 cm was taken as the final 
measurement.  Measurements were made at the level midway between the lower rib 
margin and the iliac crest, with the subject standing with their feet 30 cm apart and 
with their hands by their sides, during exhalation.   
Systolic and diastolic blood pressures were measured using a standard stethoscope 
and an aneroid, 6 inch dial, desk standing sphygmomanometer (Acceson™, AC 
Cossor & Son (Surgical) Ltd, Harlow, UK) in the supine position in the right arm to 
the nearest 2 mmHg.   
Lipids (total cholesterol, HDL-cholesterol and TG) were measured using the fasting 
venous blood sample and analysed using a Vitros Fusion chemistry system (Ortho 
Clinical Diagnostics, Bucks, UK) at the Western General Hospital (Edinburgh, UK). 
4.4.4 Inflammatory markers 
CRP was measured using an immunonephelometric assay, and IL-6 and TNF-α were 
measured using the ELISA system (R&D Systems, Oxon, UK), all at the Glasgow 
Royal Infirmary, UK.   
4.4.5 Lifestyle risk factors 
Average alcohol intake per week over the previous year and history of alcohol excess 
were determined from two questions in the self-completion questionnaire, adapted 
from the AUDIT-C screening tool
328
: “How often did you have a drink containing 
alcohol in the past year?”(a drink was considered to be one and a half alcohol units); 
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and “How many drinks did you have on a typical day when you were drinking in the 
last year?”.   
Average alcohol units during a drinking opportunity = 1.5 * “How many drinks did 
you have on a typical day when you were drinking in the last year?  
Average alcohol units per week = average units during a drinking opportunity * 
average number of drinking days per week (from “How often did you have a drink 
containing alcohol in the past year?”).  Creating a continuous variable. 
Alcohol excess was defined according to established criteria as alcohol intake >14 
units/week (female) or >21 units/week (male)
70
, or subject self-report of 
current/previous alcohol excess.  Resulting in a binary yes/no variable. 
Patients were asked if they were a current smoker, had ever been a regular smoker 
and questions about how much and what they smoked.   
Smoking was then defined categorically as current, ever or never. 
4.4.6 Non-invasive liver markers 
Non-specific liver injury 
Plasma liver enzymes (ALT, AST and GGT) were measured using the fasting venous 
blood sample and analysed using a Vitros Fusion chemistry system (Ortho Clinical 
Diagnostics, Bucks, UK) at the Western General Hospital (Edinburgh, UK). 
Abnormal liver enzymes were defined as: i) abnormal - greater than the upper limit 
of normal (ULN) – ALT >50U/L, AST >45 U/L, GGT >55U/L; ii) highly abnormal - 
greater than twice the ULN for ALT, AST, GGT; and iii) greater than recently 
proposed sex specific cut-offs for ALT – males >30U/L, females >19U/L
329
.   
Hepatic steatosis 
Presence of liver fat (hepatic steatosis) was determined by abdominal USS using a 
Sonoline Elegra Ultrasound Imaging System (Siemens Medical Systems Inc, 
Washington, USA), software version 6, with a 3.5 MHz transducer.  The same 
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sonographer, blinded to the subjects’ clinical history, undertook all scanning and 
grading.  The liver was graded for markers of hepatic steatosis using established 
criteria
165
.  Subjects were given an overall hepatic steatosis grade based on a 
subjective measurement of the severity of steatosis: normal, mild, moderate or 
severe.  In a subset, steatosis was validated using magnetic resonance spectroscopy
330
 
following which grades were condensed to: “normal” or “significant steatosis”.  
Radiological signs of cirrhosis were also noted and spleen size was measured in cm. 
Non-alcoholic steatohepatitis (inflammation and apoptosis) 
CK18 was measured on samples collected at the research clinic and stored at -80
o
c 
and analysed using the M30-Apoptosense® ELISA (PEVIVA AB, Stockholm, 
Sweden) at the Biomedical Research Unit laboratory (University of Nottingham, 
UK). 
Liver fibrosis 
A wide range of markers of fibrosis were measured (APRI, AST:ALT ratio, ELF, 
FIB4, NFS and TUE). 





AST:ALT ratio calculated as AST(U/L)/ALT(U/L). 
ELF calculated as 2.588 + (ln(HA)*(ln(P3NP)*0.775) + (ln(TIMP1)*0.494)
236
. 





NFS calculated as -1.675+0.037*age(years)+0.094*BMI(kg/m
2
)+1.13*IFG/diabetes 






ELF was measured on samples collected at the research clinic and stored at -80
o
c and 
analysed using the ADVIA Centaur immunoassay system (Siemens Healthcare 
Diagnostics Inc, New York, USA) at the iQur laboratory (London, UK).   
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One dimensional TUE was performed using a FibroScan  (Echosens, Paris, France) 
machine.  A single operator was formally trained by Echosens personnel prior to 
commencement of the study.  Initial ultrasound assessment allowed measurement of 
the skin-capsule distance.  For skin-capsule distances <2.5cm the M probe was used, 
for ≥2.5cm the XL probe was used in accordance with recommended standard 
Fibroscan operating procedures.   
The TUE probe was placed in an intercostal space overlying the liver with the patient 
in the supine position.  Using ultrasound to guide positioning, an area of the liver that 
was at least 6cm deep and free from large vessels was selected for investigation.  The 
area measured was between 25mm-65mm below the surface of the skin for the M 
probe and 35mm-75mm for the XL probe.  The operator aimed to obtain ten valid 
LSMs.  All scans were undertaken in the fasting state.  Every six months the probes 
were serviced and calibrated. 
Surrogates of portal hypertension 
Platelets were measured as part of the full blood count.  This was also defined as a 
binary categorical variable: <150 x10
9
/L and ≥150 x10
9
/L. 
Spleen diameter was measured during the abdominal USS.  This was also defined as 
a binary categorical variable: >13cm and ≤13 cm. 
4.4.7 Non-alcoholic fatty liver /disease and chronic liver disease outcomes 
NAFL/D was defined as the presence of hepatic steatosis on USS without alcohol 
excess or use of hepatotoxic medication and a negative liver screen
61
.   
Alcohol excess was as defined above (Section 4.4.5).  Hepatotoxic medication use 
was defined as the use of non-topical glucocorticoids for >2 weeks, isoniazid, 
methotrexate, amiodarone, or tamoxifen within the 6 months prior to USS.  A 
positive liver screening included any of positive autoantibodies (any of anti-nuclear 
antibody (ANA), anti-smooth muscle antibody (ASMA), anti-mitochondrial antibody 
(AMA)), ferritin >1000 ng/mL, alpha-feto protein >6 ng/mL, or positive hepatitis B 
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or C serology).  Clinically significant positive immunology titres were defined as 
ASmA titre >1:160 or AMA titre >1:40
332
. 
‘Clinical’ CLD and clinically significant CLD (prevalent and incident) were 
identified from multiple sources.  CLD was defined as a clinician diagnosis of any 
aetiology and stage of CLD.  Definite clinically significant CLD was a composite 
outcome defined as a diagnosis of cirrhosis, HCC (with confirmatory radiology) or 
gastro-oesophageal varices (with confirmatory endoscopy) recorded in the patients’ 
medical records.   
Research study referral criteria were designed in conjunction with an experienced 
consultant Hepatologist for incident abnormalities found during the year 1 clinic 
which suggested that a patient may be at high risk of clinically significant CLD.  The 
referral criteria were any of: routine liver enzyme tests above the laboratory ULN 
(ALT >50 U/L, AST >45 U/L, GGT >55 U/L, ALP >125 U/L); AST:ALT ratio >1; a 
positive liver screen (described above), hyaluronic acid >100 microg/L (in the 
absence of known joint disease),spleen >13cm (in the absence of known 
haematological cause), platelets <150 x10
9
/L (in the absence of known 
haematological cause) or suspected cirrhosis on USS.   
In addition to clinical examination, prevalent and incident clinically significant CLD 
was identified using a two-stage process across multiple sources.  Stage one: possible 
cases were identified from year 1 liver sub-study and year 4 follow-up clinic patient 
self-reported questionnaires; data linkage to ICD-9/10 and Office for Population 
Censuses and Surveys coding within SMR01 general and acute inpatient discharge 
records (at NHS National Services Scotland, Information Services Division) in July 
2008 and July 2011; non-attenders at the year 4 follow-up clinic were sent a postal 
questionnaire and if no response was received a modified questionnaire was sent to 
the GP.  Stage two: definite cases were confirmed through the review of all patients’ 
electronic secondary care medical records (TrakCare, InterSystems Corp., 
Cambridge, USA) until 31 December 2013 in order to verify all possible diagnoses 
and to identify any additional CLD.  No patient had an ICD-10 code (cirrhosis 
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K70.3, K74.3, K74.4, K74.5, K74.6; HCC C22.0; gastro-oesophageal varices I98.2) 
without confirmation in their medical records. 
4.4.8 Cardiovascular events 
Information on CV events at baseline and at follow-up clinics was collected from 
multiple sources, including patient and/or GP completed questionnaires, 12-lead 
ECG, and linkage to hospital discharge and death certification data.  A fatal or non-
fatal CV event was recorded if pre-determined criteria based on the multiple data 
sources were met.   
Myocardial Infarction: (1) ICD-10 code for myocardial infarction on discharge/death 
record, plus either subject report of a doctor diagnosis of myocardial infarction, 
positive WHO chest pain questionnaire for myocardial infarction, report of 
myocardial infarction on GP questionnaire or new ECG codes for myocardial 
infarction or (2) clinical criteria for myocardial infarction met following scrutiny of 
hospital and/or GP notes.  Angina: (1) ICD-10 code for angina as primary diagnosis 
on discharge record, or (2) at least 2 of (a) subject report of a doctor diagnosis (self-
report) of angina or of starting angina medication, (b) ECG codes for ischaemia, and 
(c) positive WHO chest pain questionnaire, or (3) clinical diagnosis of angina on 
scrutiny of hospital notes.  Stroke: (1) ICD-10 code for stroke as discharge/death 
record, or (2) clinical criteria for stroke met on scrutiny of clinical notes in subjects 
with either self-report of stroke or with non-primary ICD-10 hospital discharge/death 
code for stroke.  Transient ischaemic attack: (1) ICD-10 code for transient ischaemic 
attack on discharge record, or (2) clinical criteria for transient ischaemic attack met 
on scrutiny of clinical notes in subjects with either self-report of stroke or with non-
primary ICD-10 hospital discharge code for stroke or transient ischaemic attack.  
Coronary intervention: (1) Office for Population Censuses and Surveys -4 code for 
coronary intervention on discharge record.  Intermittent claudication: (1) ICD-10 
code for intermittent claudication on discharge record, or (2) clinical criteria for 
intermittent claudication met on scrutiny of clinical notes in subjects with either self-
report of intermittent claudication, or (3) positive Edinburgh Claudication 
Questionnaire.  Peripheral vascular intervention: (1) Office for Population Censuses 
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and Surveys -4 code for peripheral intervention on discharge record.  Carotid 
endarterectomy: (1) Office for Population Censuses and Surveys -4 code for carotid 
endarterectomy on discharge record. 
Coronary artery disease (CAD) was defined as any of myocardial infarction, angina 
or coronary intervention and CVD as any CAD event or any of peripheral vascular 
intervention, stroke, transient ischaemic attack, and carotid endarterectomy.   
4.5 Ethical approval 
Initial ethical approval for the ET2DS was granted by the Lothian Medical Research 
Ethics Committee, both for the baseline study and then the liver sub-study.  I applied 
for an amendment to existing approvals for the follow-up study and this was 
subsequently granted. 
Permission to access the LDR was given by the Lothian Diabetes Services Advisory 
Group and the Caldicott Guardian for NHS Lothian. 
Written informed consent was obtained from all subjects on attendance at each phase 
of the study. 
4.6 Data management 
4.6.1 Data security 
Data were inputted into a master database (Microsoft Access 2003/2010, Microsoft 
Corporation, Washington, USA) and was held and backed up securely on a dedicated 
university server requiring both electronic permission to access the storage drive and 
password access to the database.  Paper records were stored in secured filing cabinets 
within a locked office with only authorised access allowed.   
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4.6.2 Quality assurance 
All paper records were manually entered into the database.  At baseline clinic records 
were double entered onto the database and checked for accuracy.  Discrepancies 
were settled by discussion.  At follow-up 10% (n=80) randomly selected records 
were double entered and checked for accuracy.  An overall error rate of 0.017 was 
calculated, reduced to 0.010 for important errors (i.e. deemed to have potential to 
affect onward analysis).   
Laboratory data was either manually entered from paper reports or electronically 
entered from files provided by participating laboratories.   
4.7 Data cleaning and analysis 
Data were analysed using SPSS v19.0 (SPSS Inc., Illinois, USA) and/or R. 
4.7.1 Data cleaning 
Following data entry, descriptive analyses were run on all measurement data.  These 
distributions were examined for outliers (any result felt to be erroneous based on 
medical knowledge and accepted laboratory limits) and for missing values.  For each 
outlier the original paper records were consulted and corrections made as 
appropriate.  For any persisting outliers those felt to be implausible were deleted and 
treated as missing.  Plausible but outlying data was allowed to remain and its use 
decided upon dependant on the individual research question.  For the results reported 
in Chapters 5, 6 and 7 plausible outliers were retained as they were felt to be relevant 
to the research aims and objectives. 
4.7.2 Missing data 
Both the ET2DS as a whole and variables included in the dataset used for this thesis 
were subject to missing data.  A number of study participants chose not to attend 
research clinics for the initial liver sub-study and/or follow-up, for some aspects of 
data collection subjects were unable to complete assessments at a given research 
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clinic due to physical inability, and for some specific variables, measurements on a 
patients biological sample were not obtained (e.g. due to limited sample being 
available).  The degree of missing data by individual variable is described in section 
5.1.2 in this thesis.  The general approach to missing data throughout the thesis is 
described here. 
There are a number of ways of addressing missingness due to non-attendance at a 
phase of a study and item missingness due to failure to complete a single component 
of the study.  A common way to address missingness is to restrict the analysis to 
subjects with no missing values in the specific analysis variables (available-case 
analysis) and in the case of multiple analyses exclude cases with any of the necessary 
data missing (complete-case or list-wise analysis).  If the missing data is missing 
completely at random this may be a valid approach, however there may be a 
systematic reason why data elements are missing resulting in a biased effect 
estimate
333
.  Also the combined exclusions from such an approach can lead to a 
substantial loss of the original sample and reduce the original power and precision 
intended.  For the purpose of this thesis, where there were small amounts of missing 
data (<5%) assumed to be missing completely at random available–case analysis was 
used.   
It is not possible to determine from observed data alone whether data are missing at 
random (systematic difference between the missing values and the observed values 
can be explained by differences in observed data) and missing not at random (even 
after the observed data are taken into account, systematic differences remain between 
the missing values and the observed values)
334
.  In order to assess the potential for 
missing not at random where variables had a large quantity of missing data (>5%) a) 
the method of obtaining the data was considered for the introduction of bias and b) 
systematic differences in the populations with and without the variable of interest 
was explored.   
The most common approaches to dealing with large quantities of missing completely 
at random data involve including individuals with incomplete data to maintain 
statistical power.  Options include: including partially available variables (random 
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effects models in longitudinal analysis), weighting the analysis to allow for the 
missing data
335,336
, and modelling the reasons for missing data and the associations of 
interest (maximum likelihood estimation)
337
, or through the creating of multiple 




Based on the statistical practicalities and types of analyses planned, where there were 
large quantities of missing completely at random or missing at random data in this 
thesis, the usefulness of multiple imputation was trialled and compared with 
available-case analysis (sensitivity analysis) in an attempt to minimise the effects of 
the missing data on the study’s power (i.e.  maximise the inferential validity, not to 
recover missing values). 
Multiple imputation involves the creation of multiple plausible (complete) datasets.  
The purpose of multiple datasets is to reflect the uncertainty due to imputation.  Each 
dataset is then analysed separately and the point estimates and the estimated standard 
errors combined. 
It should be noted that multiple imputation is not without its own limitations and a 
number of practical problems.  Either multiple datasets including all dependant and 
independent variables under consideration in the study need to be created or separate 
imputed datasets are required for each research question.  If all of the variables of 
interest both dependant and independent are not included the dataset is biased and the 
strength of any associations will be weakened
339
.  Non-normally distributed variables 
require to be transformed and then the imputed dataset transformed back to insure 
that a skewed variable does not develop implausible or impossible values (although 
in some techniques this can be addressed by putting limits on the imputed values).  In 
order to maintain the missing completely at random assumption all variables in the 
planned analysis must be included and all variables associated with the missing 
variable and all variables influencing the process causing the missing data, even if 
they are not of interest in the substantive analysis
340
.  Multiple imputation can be 
labour intensive for both the operator and the computer.  There are a wide range of 
different imputational methodologies and the suggested number of imputed datasets 
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varies widely.  For variables with large quantities of data missing completely at 
random multiple imputation by chained equations
341
 was undertaken to allow 
sensitivity analyses of analyses with the missing data to be performed. 
4.7.3 Statistical analysis 
Distributions of liver markers 
Hypothesis: Type 2 diabetes and NAFL/D share an underlying pathological 
mechanism (the ectopic fat hypothesis) therefore it may be expected that patients 
with more ‘severe’ type 2 diabetes (a poorer metabolic profile) would have both a 
higher non-markers of NAFL/D.  
To explore the distribution of markers of sub-clinical liver disease, data from the 
year 1 liver sub-study was used, with the exception of LSM which was only 
measured at the follow-up clinic. 
The associations of each of the markers of steatohepatitis (CK18) and liver fibrosis 
(APRI, AST:ALT ratio, ELF, FIB4, HA, NFS and LSM) with the following were 
examined, (i) duration of diabetes and diabetes treatment, (ii) metabolic variables 
(total cholesterol, triglycerides, fasting glucose, HbA1c, BMI and waist 
circumference), (iii) steatosis on USS and, (iv) established risk factors for CLD 
(alcohol excess, hepatotoxic medication, positive immunology).  Analyses were 
undertaken on (i) all subjects, (ii) subjects with steatosis (defined as the presence of 
steatosis on USS) and, (iii) subjects with NAFL (defined as the presence of steatosis 
on ultrasound without alcohol excess, use of hepatotoxic medication or raised 
autoantibodies).  The influence of CKD (defined as estimated glomerular filtration 
rate ,eGFR <60) and arthritis (patient reported history of osteoarthritis, rheumatoid 
arthritis, scleroderma or any other joint disease) on circulating biomarker level was 
also assessed by analysing the prevalence of these conditions in the highest and 
lowest quintiles of each biomarker.   
Univariate analysis on the association between liver markers and potential risk 
factors was undertaken using Pearson’s correlation and ANOVA adjusting for age 
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and sex.  Multivariable analysis was undertaken using linear regression both 
unadjusted and fully adjusted for age, sex, and established hepatic risk factors.  All 
continuous variables were assessed for approximation to the normal distribution.  
Where necessary, to address skewed data, CK18, APRI and HA were transformed on 
the logarithmic scale for analysis.  The maximum number available was used for 
each analysis.  A sensitivity analysis addressing missing CK18 and ELF data was 
performed using multiple imputation by chained equations
341
.  Data were considered 
to be missing completely at random as they were missing due to technical problems 
or insufficient stored sample.  Analysis was undertaken on both the whole population 
without pre-diagnosed liver disease and additionally in those with NAFL/D (defined 
as the presence of hepatic steatosis on USS without alcohol excess, use of 
hepatotoxic medication or abnormal liver screen).   
Liver fibrosis marker agreement 
Hypothesis: Hepatic fibrosis is a histologically advanced stage of CLD liver disease. 
Validated non-invasive measures of hepatic fibrosis would be expected to agree with 
each other as they are all measuring the same underlying pathological stage. 
The agreement between different markers of liver fibrosis was assessed - the five 
markers compared were APRI, AST:ALT ratio, ELF, FIB4 and LSM, all measured  
at year 4 follow-up.  These markers where chosen to include a range of different test 
rationales/measures (AST:ALT ratio – hepatocyte damage, APRI – hepatocyte 
damage and portal hypertension, ELF- extracellular matrix composition, FIB4 - 
hepatocyte damage and portal hypertension, and LSM - imaging) whilst avoiding 
bias from within the study population (e.g.  through the inclusion of age or BMI). 
Validated cut-offs to reliably exclude advanced fibrosis (≥ Metavir F3) in NAFLD 
were determined from the literature aiming to achieve negative predictive values 
(NPVs) 90-95%:  
i) APRI=1.0, specificity (spec.) 89%, NPV 84%208,228;  
ii) AST/ALT=1.0, spec.  90%, NPV 89%228;  
iii) ELF=10.358, spec.  94%, NPV 90%236;  
 
121 
iv) FIB4=1.30, spec.  65%, NPV 95%228,331; and  
v) LSM=8.7, spec.  83.2%, NPV 94.6%246.   
Since these threshold levels described above cannot reliably be extrapolated from the 
predominantly secondary care settings in which they were validated to a general 
population setting, I also assessed agreement between markers using the same 
highest percentile across all marker panels.  Prior studies suggest that the prevalence 
of advanced fibrosis in type 2 diabetes patients attending outpatient clinics is at least 
2-6% in all patients and 7-12% in those with NAFL/D
159,161,163
.  As a result I 
estimated that the underlying prevalence of significant liver fibrosis in the whole 
ET2DS cohort might be in the region of 5% and around 10% in those with NAFL/D.  
I therefore compared the top 5% (and 10%) of scores for each marker for agreement 
in the entire cohort (and in those with NAFL/D respectively).   
Correlation between markers was analysed after standardisation to Z-scores, and 
adjusted for age and sex.  Cronbach’s alpha was used to examine the inter marker 
agreement (using standardised Z-scores).  Student’s t-test or the Mann-Whitney U 
test were used to compare means and Chi-squared test to compare proportions.   
Individual 2x2 tables were calculated for the absence/presence of probable fibrosis 
(based on percentiles) for each pair of markers.  Due to the difficulties interpreting 
markers of total agreement
342
 (e.g.  kappa statistics), I calculated positive agreement 
(agreement on the presence of fibrosis by both markers) and negative agreement 
(agreement on the absence of fibrosis by both markers)
343








Figure 4-2 Agreement 
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Frequency of and risk factors for clinically significant chronic liver disease 
Hypothesis: Given the shared aetiology of type 2 diabetes and NAFL/D, it would be 
expected that the prevalence and incidence of clinically relevant CLD would be 
higher in those with type 2 diabetes than in the general population and that risk 
factors attributable to a poorer metabolic and diabetes profile may be useful in the 
identification of CLD.  
In order to measure clinically significant CLD, the outcomes of the research clinic 
investigations and specialist Hepatology referral process were reported for all 
subjects without known prevalent clinically significant CLD.  In addition, for all 
subjects without prevalent clinically significant CLD following the year 1 
investigations, rates of incident clinically significant CLD (/1000 person-years) 
during the follow-up period were calculated for those referred to Hepatology clinic, 
those seen in Hepatology clinic, those with abnormal liver enzymes, and for those 
with hepatic steatosis.  Negative binomial regression was used to calculate incidence 
rate ratios (IRR). 
Known prevalent clinically significant CLD was defined as: the number of patients 
with known clinically significant CLD at the liver sub-study research clinic visit 




Unknown prevalent clinically significant CLD was defined as: the number of patients 
with clinically significant CLD identified within 12 months as a direct result of the 
liver sub-study research clinic visit (numerator) divided by the number of all patients 
without clinically significant CLD after the liver sub-study (denominator). 
Incident clinically significant CLD was defined as: the number of patients with 
clinically significant CLD identified subsequent to the liver sub-study research clinic 
visit, excluding cases identified as unknown prevalent (numerator) divided by the 
number of person-years without the development of clinically significant CLD (ie 
total time for all subjects without clinically significant CLD from attendance to the 
first of development of clinically significant CLD, death, or 31 December 2013).  
Incidence was presented as a rate per 1000 person-years. 
Exploratory analysis of potential risk factors and markers associated with the 
development of clinically significant CLD was under taken using : (i) patient 
characteristics (age, sex and SIMD quintile ), ii) diabetes history (duration of 
diabetes categorised as < or ≥ 5 years; diabetes treatment categorised as diet-
controlled, OAHA, insulin, or insulin +/- OAHA; fasting glucose; HbA1c), (iii) 
metabolic variables (total cholesterol, triglycerides, BMI calculated as weight 
(kg)/height (m)
2
 and systolic blood pressure), (iv) established risk factors for CLD 
(alcohol excess, hepatotoxic medication, positive autoantibodies), (v) markers of 
liver injury, including those measuring non-specific liver injury (plasma liver 
enzymes), steatosis (USS), steatohepatitis (CK18), surrogates of advanced portal 
hypertension (platelet count, spleen size), and liver fibrosis (APRI, AST:ALT ratio, 
ELF, FIB-4, HA, NFS), and (vi) markers of systemic inflammation (CRP, IL-6 and 
TNF-α) 
For continuous variables mean (sd) or median (IQR) were calculated and for 
categorical variables % (n) reported for those patients with/out unknown prevalent 
and incident clinically significant CLD.  Cox proportional hazards regression was 
used to determine the risk (HR) of each risk factor associated with the development 
of incident clinically significant CLD. 
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Association of liver markers with cardiovascular disease 
Hypothesis:  If NAFL/D ‘causes’ CVD through the atherogenic liver hypothesis, as 
opposed to the relationship between NAFL/D and CVD being driven by their shared 
risk factors, it would be expected that markers of the full spectrum of NAFL/D 
would be related to the development of CVD.  
In order to maximise the follow-up time available for CV events to occur the markers 
collected at the baseline clinic were used where available.  The association of 
markers of non-specific liver injury (ALT, AST, GGT measured at baseline), hepatic 
steatosis (steatosis on USS measured at year 1), steaohepatitis (CK18 measured at 
year 1), liver fibrosis (APRI, AST:ALT ratio, FIB4 and NFS measured at baseline, 
and ELF measured at year 1), and portal hypertension (platelets measured at 
baseline) with prevalent and incident CV events and mortality were investigated. 
Individual cardiovascular events were determined from multiple sources as described 
in section 4.4.8.   
The primary outcome measures were all prevalent CV events and all incident CV 
events.  The secondary outcome measures were prevalent and incident CAD events.  
Fatal and non-fatal events were combined for analysis.  Prevalent CAD and CVD 
were taken as any event prior to the baseline/liver sub-study research clinic 
attendance.  Incident CAD and CVD were taken as defined as any new event 
occurring between baseline/liver sub-study research clinic attendance and the end of 
August 2011, for both non-fatal and fatal events.   
The follow-up time for each individual for incident disease was from the date of the 
baseline/liver sub-study research clinic attendance until the first of: CV event, death 
or end of August 2011. 
Analysis was undertaken using a listwise approach for three scenarios – 
measurements taken at baseline (ALT, APRI, AST, AST:ALT ratio, FIB4, GGT, 
NFS and platelets), measurements taken at the initial liver sub-study clinic (CK18 
and steatosis on USS) and ELF.   
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Univariate analysis with normal continuous variables was analysed using Student’s t-
test (ALT, AST, AST:ALT ratio, ELF FIB4, NFS and platelets), non-normal 
continuous variables (APRI, CK18 and GGT) using the Mann-Whitney U test and 
categorical variables (steatosis) using the ChiSq test was examined for both the 
presence of prevalent and incident CVD and CAD.   
Logistic regression for the association with prevalent CVD and CAD and Cox 
proportional hazards regression for the association with incident CVD and CAD was 
undertaken for all markers of liver injury.  Both were performed unadjusted, adjusted 
for age and sex and additionally adjusted for age, sex, duration of diabetes, treatment 
of diabetes, lipid lowering drugs, blood pressure lowering drugs, deprivation 
(Scottish Index of Multiple Deprivation quintile), smoking status, excess alcohol 
consumption, BMI, systolic blood pressure (sBP), diastolic blood pressure (dBP), 
HbA1c, HDL cholesterol, total cholesterol and eGFR.  Analysis of incident disease 
was also adjusted for baseline/year 1 history of prevalent CVD/CAD. 
A sensitivity analysis of the incident CV events was undertaken by excluding all 
subjects with prevalent CVD at baseline and the Cox regression then repeated. 
4.7.4 Cut point for statistical significance 
Conventional statistical cut-offs of p<0.05, p<0.01 and p<0.001 are highlighted 
within the results with respect to rejecting the null hypothesis, ie a <5%, <1% and 
<0.1% chance (respectively) that the null hypothesis is rejected when is in in fact true 
(type I error).   
This risk of obtaining a statistically significant result increases as the number of 
statistical tests performed increases e.g.  1 test  5% chance, 10 tests = 40% chance (1-
[1-0.5]
10
), 50 tests = 93% chance (1-[1-0.5]
50
). 
Some would argue the necessity adjust analyses to take this into account.  Most 
commonly the Bonferroni correction is applied whereby the significance level at 
which the null hypothesis is rejected is adjusted to reflect the increased risk from 
multiple testing – the original significance level is divided by the number of 
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individual tests e.g.  1 test = 0.05 (0.05/1), 10 tests = 0.005 (0.05/10), 50 tests = 
0.001 (0.05/50).  There are several problems with this approach
344
.  Firstly, the 
Bonferroni correction increases the risk of failing to reject a false null hypothesis 
(type II error).  Secondly, is the decision as to how to count the number of analyses 
to which to apply the correction.  In thesis would it be all the tests pertaining to a 
single research question, to a section, to a chapter, across the whole thesis, to the 
authors total involvement in the ET2DS? In addition, some of the analyses and 
decisions in this thesis are based on the results of earlier analyses (dependant) so it is 
not possible to exactly define the number of tests a priori. 
In order to attempt to address these issues whilst conventional statistical cut-offs of 
are highlighted within the results (and when text refers to non/significant results it a 
0.05 cut off), where possible exact p values and 95% confidence intervals are 
reported to allow the reader to make a context specific judgement.  Given that much 
of the work within this thesis is exploratory and hypothesis generating the number of 
tests performed will inevitably be large, however, informative results can then be 







Given the potential burden caused by both asymptomatic and symptomatic clinically 
significant CLD in the general diabetic population, there is a need to identify non-
invasive methods of detecting asymptomatic stages of the condition in adults with 
diabetes, as indeed is the case for other high risk sub-groups within the general 
population.   
In order to investigate a number of potentially useful non-invasive of liver disease in 
a diabetic population, in this chapter I have:  
(i) described the study population used in this thesis (numbers, 
representativeness, patient characteristics), 
(ii) described the variables included in subsequent analyses (in terms of 
missingness and statistical distributions), 
(iii)determined the distribution (by gender, steatosis and NAFL/D), and factors 
associated with altered levels of, a range of potential non-invasive markers of 
steatohepatitis (CK18) and liver fibrosis (APRI, AST:ALT ratio, ELF, HA, 
FIB4, NFS and LSM), 
(iv) determined the level of agreement between five potential markers of liver 
fibrosis (APRI, AST:ALT ratio, ELF, FIB4 and LSM): 
a. using validated cut-offs to exclude advanced fibrosis; and  
b. in the same highest percentile across all marker panels. 
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5.1 Study population 
The ET2DS baseline cohort comprised of 1066 individuals.  All patients still alive 
were invited to the liver sub-study at 1-year, with 939 subjects attending.  Again all 
surviving subjects were invited to the 4-year follow-up, with 831 subjects attending.  
By follow-up 88 subjects were deceased.  Full details of non-attendance at the 
research clinics for each phase of the study are shown in Figure 5-1 and Figure 5-2.   
5.1.1 Representativeness 
At baseline the ET2DS research team undertook a representativeness analysis
321
 of 
those recruited into the study (n=1066) versus those invited from the LDR but not 
participating (n=4388).  I repeated a similar analysis for subjects attending the liver 
sub-study one year after baseline (versus ET2DS participants not attending the liver 
sub-study) and again for subjects attending the follow-up clinic four years after 
baseline (versus participants not attending the follow-up clinic.  It should be noted 
that participants not attending the liver sub-study or follow-up research clinics were 
not lost to the study for all outcomes as they were still able to complete a 
questionnaire (or their GP on their behalf) and they remained subject to record 
linkage. 
Table 5-1 compares the characteristics of responders with non-responders at baseline 
and the baseline characteristics of research clinic attenders with non-attenders at each 
subsequent phase of the study.   
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Liver study cohort 
n=939 
Deceased n=2 
Declined future contact n=5 
Deemed unsuitable for contact by study 
team n=3 
Withdrew after attending BL n=2 
Deceased n=13 
Unable to contact n=19 
Declined participation: 
Due to health n=23 
Other n=38 
Cancelled/DNA n=21 
Could not complete assessment n=1 






Returned no data n=38 
Invited to year 4 follow-







Deemed unsuitable by 
study team n=26 




Participants in the ET2DS (n=1066) were found to be similar in age and 
socioeconomic-status distribution compared with those who did not participate.  The 
proportion of men was higher in the recruited cohort (51% vs 42%, p<0.001), which 
reflected the sampling method of the ET2DS which required similar numbers of men 
and women in each age range.  With regards to diabetes history, the two groups had 
similar durations of diabetes, use of insulin therapy (17% vs 16%, p>0.05) and mean 
plasma HbA1c levels.  Two small but statistically significant differences were found 
between ET2DS participants and non-responders: the ET2DS cohort had a lower 
mean sBP (133.3mmHg, sd 16.4 vs 137.2mmHg, sd 18.2, p<0.001) and a higher 
mean total cholesterol (4.3mmol/L, sd 0.9 vs 4.2mmol/L, sd 1.0, p<0.01). 
There were some differences between those subjects that attended the liver sub-study 
and those that did not - attenders were more likely to be male, have a shorter duration 
of diabetes and not to use insulin, but these differences were generally quite small 
and did not reach statistical significance. 
Statistically significant differences at follow-up study found attenders were slightly 
younger, had a lower BP and were of a higher SES.  In addition, non-significant 
differences in attenders were again being male, having a shorter duration of diabetes 
and not use insulin. 
5.1.2 Missing data 
The amount of missing data was assessed for each phase of the study (Table 5-2), in 
subjects attending each of the relevant research clinics. 
There was very little missing data at baseline and the liver sub-study (<4.0%) with 
the exception of CK18 (8.4%), ELF (27.3%) and HA (25.8%) at the liver sub-study.  
All three variables were measured on stored samples and data were missing due to 
inadequate sample volumes.  In the case of HA, data were already available from 
baseline, but large amounts of CK18 and ELF missing data were addressed further 
by imputation, especially as these were key variables for future analysis. 
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Data imputation was performed using multiple imputation using chained equations as 
data were considered to be MCAR.  This was felt to be appropriate since data were 
missing due to technical problems or insufficient stored samples and, compared with 
subjects in whom it was missing, the populations with ELF and CK18 data available 
had similar clinical and metabolic characteristics (see Table 5-3).  Although subjects 
with CK18 data available were significantly more likely to be male than those in 
whom it was missing (54% vs 33%), there was no sensible explanation for this 
finding other than for it to have occurred by chance.  The underlying premise for the 
potential for successful imputation was the correlation between baseline HA and ELF 
measured at the liver sub-study (r=0.594, p<0.001).  Initial analyses (sections 5.1 to 
5.6 and 5.8) were done on the original (un-imputed dataset), following which a 
sensitivity analysis was run on the imputed dataset (section 5.7). 
CK18 data were missing due to random insufficient stored samples.  As expected 
subjects with and without CK18 measures at follow-up were similar for the variables 
assessed (Table 5.4).  LSM measures were missing due to a) inability to obtain 
readings (105, 70.9%), b) LSM contraindicated (16, 10.9%), and c) missing no 
reason (27, 18.2%).  Subjects who had LSM missing were more likely to be female 
(63 vs 45%, p<0.001), be treated with insulin (30 vs 20%, p=0.007), have a larger 
body habitus (mean BMI 35 vs 31 kg/m2, p<0.001, mean waist circumference 111 vs 
104cm, p<0.001), were less likely to have hepatic steatosis (41 vs 52%, p=0.020), 
and had higher non-specific markers of liver injury (mean AST 32 vs 30 U/L, 
p=0.024, median GGT 20 vs 16 U/L, p=0.001)(Table 5-4).  Given that this measure 
was not missing completely at random, and LSM was a key variable required in the 







Table 5-1 Baseline characteristics of Edinburgh Type 2 Diabetes Study subjects attending each phase of the study compared with non-responders at baseline and 
non-attenders at the liver sub-study and follow-up clinics.  Values are mean (sd) or % (n). 





















            
Age, years 67.9 (4.20) 67.9 (4.35) -  67.9 (4.2) 67.8 (4.3) 0.857  67.7 (4.2) 68.7 (4.3) 0.001 
Sex, % male 51.3 (547) 41.9 (1839) <0.001  52.0 (488) 46.5 (59) 0.257  51.7 (430) 49.8 (117) 0.606 
Duration of diabetes, 





















HbA1c, % 7.4 (1.1) 7.4 (1.4) -  7.4 (1.1) 7.5 (1.1) 0.136  7.4 (1.1) 7.4 (1.1) 0.872 
Insulin therapy, %  17.4 (185) 16.1 (704) -  16.5 (151) 21.3 (27) 0.146  16.9 (137) 18.9 (41) 0.299 
Systolic BP, mmHg 133.3 (16.4) 137.2 (18.2) <0.001  133.2 (16.4) 133.8 (16.8) 0.712  132.5 (15.9) 136.1 (18.1) 0.006 
Total cholesterol, 
mmol/L 
4.3 (0.9) 4.2 (1.0) <0.001  4.3 (0.9) 4.3 (1.0) 1.000  4.3 (0.9) 4.2 (0.9) 0.100 
SIMD quintile, % 
   1 
   2 
   3 
   4 










































 Two invitees had data missing on the Lothian Diabetes Register; 
b
 p values >0.05 unless stated otherwise (provided by R Marioni) 
BP blood pressure; HbA1c glycosylated haemoglobin; SIMD Scottish Index of Multiple Deprivation. 
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5.2 Data distributions 
This section focuses on the statistical distributions of continuous variables prior to 
their use in subsequent analyses.  Wherever possible variables measured at the liver 
sub-study were used in subsequent analyses.  For a minority of variables, which had 
only been measured at baseline, baseline levels were used (BMI, CRP, IL6, platelets, 
TNFα, and waist circumference).  It was assumed that these variables were unlikely 
to alter greatly over the period of one year and were therefore unlikely to affect the 
results of analyses.  The statistical distribution of each variable was assessed and 
checked for normality ahead of analyses.  Distribution histograms are presented in 
Appendix J and a summary of the findings (mean (sd) or median (IQR)) are show in 
Table 5-5.  Continuous variables collected at the follow-up clinic and used in 
analyses had the same distributions as those at baseline/liver sub-study.   
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Table 5-2 Missing data in the Edinburgh Type 2 Diabetes Study at baseline and the liver study.  










Demographics      
   Age 0  0  0 
   Sex 0  0  0 
   SIMD 0  0  0 
Diabetes history      
   Duration of diabetes 1.2% (13)  0.9% (8)  0.8% (7) 
   Fasting glucose 1.5% (17)  1.6% (15)  1.6% (14) 
   HbA1c 3.6% (38)  1.3% (12)  1.9% (16) 
   Treatment type 0.1% (1)   0  0.5% (4) 
Cardio-metabolic variables      
   BMI 0.1% (1)  -  1.4% (12) 
   Diastolic BP 0..2% (2)  0.6% (6)  0.4% (3) 
   eGFR 1.2% (13)  -  - 
   HDL-cholesterol 0.8% (9)  1.3% (12)  1.4% (12) 
   Systolic BP 0.2% (2)  0.6% (6)  0.4% (3) 
   Takes BP lowering meds 0.7% (7)  0  - 
   Takes lipid lowering meds 0.2% (2)  0  - 
   Total cholesterol 0.8% (9)  1.3% (12)  1.4% (12) 
   Triglycerides -  1.3% (12)  1.4% (12) 
   Waist circumference 0.5% (5)  -  1.0% (8) 
Lifestyle risk factors      
   Alcohol excess 1.4% (15)  0.2% (2)  0 
   Smoking 0  -  0 
Liver markers      
   ALT 0.8% (9)  0.3% (3)  1.8% (15) 
   APRI 2.9% (31)  2.7% (25)  2.9% (24) 
   AST 1.1% (12)  0.7% (7)  1.4% (12) 
   AST/ALT ratio 1.1% (12)  0.7% (7)  1.8% (15) 
   CK18 -  8.4% (79)  29.4 (244) 
   ELF -  27.3% (256)  3.1% (26) 
   FIB4 2.9% (31)  2.7% (25)  4.2% (35) 
   GGT 1.0% (11)  0.6% (6)  2.0% (17) 
   HA 0.8% (9)  25.8% (242)  3.1% (26) 












   NFS 3.0% (32)  3.1% (29)  5.2% (43) 
   Platelets 2.0% (21)  -  2.5% (21) 
   Spleen size -  0.3% (3)  1.2% (10) 
   Steatosis (USS) -  0  1.2% (10) 
   USS cirrhosis -  0  1.2% (10) 
Other liver related      
   Liver screen -  6.7% (63)  6.3% (52) 
   Secondary causes for NAFLD -  0.2% (2)   
ALT alanine aminotransferase; APRI aspartate to platelet ratio index; AST aspartate 
aminotransferase; BMI body mass index; BP blood pressure; eGFR estimated glomerular filtration 
rate; ELF Enhanced Liver Fibrosis panel; FIB4 Fibrosis-4 Score; GGT gamma-glutamyl transferase; HA 
hyaluronic acid; HDL high density lipoprotein; NAFLD non-alcoholic fatty liver disease; NFS NAFLD 




Table 5-3 Patient characteristics for variables with high proportions of missing data (liver sub-












Age, years 68.9 (4.2) 69.6 (4.0) 0.142  68.8 (4.2) 69.3 (4.2) 0.103 
Sex, % male 53.7 (462) 32.9 (26) <0.001  52.6 (359) 50.4 (129) 0.558 
        
Duration of diabetes, % < 
5 years 
26.2 (223) 22.8 (18) 0.592  26.6 (180) 23.9 (61) 0.450 
HbA1c, % 7.19 (1.0) 7.18 (1.3) 0.919  7.23 (1.0) 7.11 (1.1) 0.131 
Fasting glucose, mmol/l 6.91 (2.3) 6.48 (2.4) 0.142  6.92 (2.3) 6.75 (2.2) 0.310 
Diet controlled, % yes 19.4 (167) 19.0 (15) 1.000  19.2 (131) 19.9 (51) 0.782 
OAHA use, % yes 65.3 (562) 59.5 (47) 0.325  66.2 (452) 61.3 (157) 0.168 
Insulin therapy, % yes 15.2 (131) 21.5 (17) 0.147  14.6 (100) 18.8 (48) 0.132 
        
BMI, kg/m
2
 31.2 (5.6) 32.4 (5.6) 0.072  31.2 (5.7) 31.6 (5.6) 0.298 









Total cholesterol, mmol/L 4.2 (0.8) 4.1 (0.8) 0.538  4.2 (0.8) 4.1 (0.8) 0.627 









        
Alcohol excess, % yes 13.6 (117) 16.5 (13) 0.496  14.4 (98) 12.5 (32) 0.525 
Ever smoked, % yes 60.2 (518) 62.0 (49) 0.655  60.5 (413) 61.1 (156) 0.882 
        
Steatosis, % yes 56.6 (487) 60.8 (48) 0.553  55.8 (381) 60.2 (154) 0.237 









AST, U/L 30.6 (10.7) 31.0 (9.2) 0.786  
30.4 
(10.8) 
31.3 (9.9) 0.243 
GGT, U/L 16 (10-29) 19 (10-36) 0.282  16 (10-29) 17 (10-31) 0.316 
ALT alanine aminotransferase; AST aspartate aminotransferase; BMI body mass index; BP blood 





Table 5-4 Patient characteristics for variables with high proportions of missing data (follow-up 












Age, years 71.4 (4.2) 71.4 (4.1) 0.920  71.4 (4.1) 71.2 (4.3) 0.582 
Sex, % male 52.3 (307) 50.4 (123) 0.648  54.9 (375) 37.2 (55) <0.001 
        
Duration of diabetes, % < 
5 years 
37.3 (217) 36.6 (89) 0.875  38.6 (261) 30.6 (45) 0.074 
HbA1c, % 7.38 (1.2) 7.29 (1.2) 0.343  7.31 (1.2) 7.53 (1.3) 0.069 
Fasting glucose, mmol/l 7.79 (2.9) 7.58 (2.9) 0.337  7.68 (2.8) 7.98 (3.2) 0.298 
Diet controlled, % yes 13.8 (81) 14.0 (34) 1.000  14.5 (99) 11.0 (16) 0.293 
OAHA use, % yes 77.8 (455) 78.5 (190) 0.854  78.4 (534) 76.0 (111) 0.511 
Insulin therapy, % yes 22.7 (133) 18.6 (45) 0.194  19.7 (134) 30.1 (44) 0.007 
        
BMI, kg/m
2
 31.5 (5.8) 31.2 (5.7) 0.462  30.7 (5.0) 35.0 (7.4) <0.001 









Total cholesterol, mmol/L 4.4 (3.0) 4.2 (0.9) 0.360  4.3 (0.9) 4.7 (5.8) 0.332 
        
Ever smoked, % yes 59.8 (350) 62.8 (152) 0.435  61.1 (416) 58.9 (86) 0.641 
        
Steatosis, % yes 52.2 (302) 46.5 (113) 0.146  52.4 (358) 41.3 (57) 0.020 















GGT, U/L 17 (10-30) 15 (9-28) 0.150  16 (9-27) 20 (12-51) 0.001 
ALT alanine aminotransferase; AST aspartate aminotransferase; BMI body mass index; BP blood 





Table 5-5 Summary data for distributions of continuous variables 
 
Mean (sd), median 
(IQR) or %(n) 
Min. Max. Distribution 
Diabetes duration, years 7.0 (4.0-12.0) 1.0 44.0 Negative skew 
Fasting glucose, mmol/L 6.87 (2.31) 2.0 20.6 Approx.  normal 
HbA1c, % 7.19 (1.07) 4.3 12.0 Approx.  normal 
BMI, kg/m
2
 31.3 (5.7) 18.4 55.4 Approx.  normal 
Diastolic BP, mmHg 73.9 (9.6) 34.0 115.0 Approx.  normal 
eGFR 64.2 (14.6) 8.0 90.0 Approx.  normal 
HDL-cholesterol 1.23 (0.34) 0.42 2.85 Approx.  normal 
Systolic BP, mmHg 138.5 (18.3) 89.0 250.0 Approx.  normal 
Total cholesterol 4.15 (0.80) 2.20 7.70 Approx.  normal 
Triglycerides 1.66 (0.90) 0.13 9.10 Approx.  normal 
Waist circumference, cm 106.8 (12.7) 73.0 159.0 Approx.  normal 
Alcohol, units/week 1.3 (0.0-10.1) 0.0 90.0 Negative skew 
     
AST, U/L 30.7 (10.6) 13.0 94.0 Approx.  normal 
ALT, U/L 33.6 (13.1) 3.0 135 Approx.  normal 
GGT, U/L 16.0 (10.0-30.0) 4.0 521.0 Negative skew 
CK18, U/L 104.6 (77.7-140.2) 24.4 1000.0 Negative skew 
APRI 0.25 (0.20-0.34) 0.07 2.56 Negative skew 
AST:ALT ratio 0.96 (0.31) 0.39 6.67 Approx.  normal 
ELF 8.96 (0.86) 6.89 17.40 Approx.  normal 
FIB4 1.60 (0.71) 0.47 10.81 Approx.  normal 
HA,  52.0 (35.74-85.1) 7.7 580.3 Negative skew 
NFS -26.4 (2.4) -35.2 -16.9 Approx.  normal 
Platelet count, x10
9
 257.7 (68.9) 52.0 606.0 Approx.  normal 
Spleen size 10.3 (1.6) 6.1 21.3 Approx.  normal 
ALT alanine aminotransferase; APRI aspartate to platelet ratio index; AST aspartate 
aminotransferase; BMI body mass index; BP blood pressure; eGFR estimated glomerular filtration 
rate; ELF Enhanced Liver Fibrosis panel; FIB4 Fibrosis-4 Score; GGT gamma-glutamyl transferase; HA 
hyaluronic acid; HbA1c glycosylated haemoglobin; NAFLD non-alcoholic fatty liver disease; NFS 




5.3 Difference in levels of steatohepatitis and liver fibrosis markers 
by gender, steatosis and non-alcoholic fatty liver /disease 
Of the 939 ET2DS subjects who underwent liver USS at the liver sub-study research 
clinic and further physical and liver assessment, 888 did not have pre-diagnosed liver 
disease or clinically significant CLD on screening (see Figure 5-3).  These subjects 
were considered for inclusion in the current analysis (sections 5.3 to 5.7) which 
aimed to determine the distribution of steatohepatitis and liver fibrosis markers by 
gender, steatosis and NAFL/D, as well as factors associated with altered levels of the 
markers, in a population free of clinical CLD.  Details of the data available on the 
final analysis population are presented in Figure 5-3, and the characteristics of this 
population are given in Table 5-6. 
The presence of steatosis was defined as definite steatosis on USS. NAFL/D was 
defined as the presence of steatosis on USS in the absence of an alternative cause 
(i.e. no known CLD, alcohol excess, hepatotoxic medication use or strongly positive 
autoantibodies. Of the 888 patients included in these analyses 499 (56.2%) had 
steatosis and 413 (46.5%) had NAFL/D.  In determining NAFL/D, of those 
participants with steatosis, 65 (13.0%) had alcohol excess, 21 (4.2%) hepatotoxic 
medication use and 2 (0.4%) strongly positive autoantibodies (with 2 participants 
having more than one of these). 
Difference in levels of markers of steatohepatitis and liver fibrosis) according to 
gender, steatosis and NAFL/D are shown in Table 5-6. 
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Figure 5-3 Study population and markers available 
 
ALT alanine aminotransferase; APRI aspartate to platelet ratio index; AST aspartate 
aminotransferase; CK18 cytokeratin-18; CLD chronic liver disease; ELF Enhanced Liver Fibrosis panel; 
FIB4 Fibrosis-4 Index; follow-up follow-up; HA hyaluronic acid; liver sub-study liver study; NFS NAFLD 
Fibrosis Score; LSM liver stiffness measurement. 
 
Attended liver sub-
study clinic n=939 
No known CLD 
n=888 
Known prevalent CLD, 16 
Unknown prevalent clinically 
significant CLD, 13 































Table 5-6 Distribution of markers of steatohepatitis and liver fibrosis by sex, presence of hepatic steatosis and presence of non-alcoholic fatty liver /disease.  
Values are mean (sd) or median (IQR). 
 All  Hepatic steatosis  NAFL/D 
 Male Female p  Steatosis No steatosis p  NAFL/D No NAFL/D p 

































































































































ALT alanine aminotransferase; APRI aspartate to platelet ratio index; AST aspartate aminotransferase; CK18 cytokeratin-18; ELF Enhanced Liver Fibrosis panel; FIB4 
Fibrosis-4 Index; HA hyaluronic acid; LSM liver stiffness measurement; NAFL/D non-alcoholic fatty liver /disease; NFS NAFLD Fibrosis Score;.
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5.3.1 Steatohepatitis marker 
CK18 values ranged from 29.4 to 993.1 U/L (median 101.2, IQR 76.7-135.0 U/L).   
The distribution of CK18 was similarly distributed between men and women 
(p=0.449), however levels were significantly higher in both those with hepatic 
steatosis and in those with NAFL/D (p<0.001) compared to those without.  CK18 
decreased with age (r=-0.10 p=0.003) 
5.3.2 Liver fibrosis markers 
In the full cohort, APRI ranged from 0.07-1.25 (median 0.25, IQR 0.19-0.33), 
AST:ALT ranged from 0.39-2.47 (mean 0.95, sd 0.23), ELF scores ranged from 6.89 
to 11.60 (mean 8.88, sd 0.73), FIB4 ranged from 0.41-5.58 (mean 1.51, sd 0.57), HA 
ranged from 7.7-580.3 microg/L (median 50.5 microg/L, IQR 35.0-82.3), NFS 
ranged from -5.45-4.61 (mean -0.39, sd 1.08) and LSM ranged from 0.37-33.30 kPa 
(mean 5.07 kPa, sd 2.27).   
Males had on average significantly worse (indicating fibrosis) APRI, AST/ALT 
ratio, FIB4 and NFS.  AST:ALT, ELF, FIB4, HA and NFS all increased with age 
(r=0.22, r=0.28, r=0.26, r=0.29 and r=0.18 respectively, all p<0.001). 
LSM was significantly higher in subjects with steatoisis compared with those without 
steatosis (means 5.46 vs 4.50 kPa, p<0.001).  The difference lessened but persisted 
with the presence of NAFLD.  Conversely, HA and AST:ALT ratio were 
significantly lower in those with steatosis (means 48.8 vs 52.3 microg/L, and 0.92 vs 
0.99 respectively, both p<0.001).  The same pattern was seen for AST:ALT ratio in 
the presence of NAFLD, but not for HA.  In addition, in NAFL/D, the NFS was 
significantly lower compared to those without NAFL/D (means -0.42 vs -0.36, 
p<0.001).  Levels were similar for both groups for the remaining fibrosis markers. 
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5.4 Association of steatohepatitis and liver fibrosis markers with 
metabolic risk factors and with established hepatotoxic causes 
5.4.1 Steatohepatitis marker 
Associations of CK18 with metabolic variables and established hepatotoxic causes 
(excess alcohol intake, positive immunology titres and hepatotoxic medication use) 
are shown in Table 5-7) for all subjects (n=825) and for those with steatosis (n=460).  
Higher CK18 levels were significantly associated with hyperglycaemia, increased 
body fat (higher BMI and waist circumference) and with higher serum triglyceride 
levels.  Levels were notably lower in patients on TZD therapy and in those solely 
diet controlled. Only the association with waist circumference remained statistically 
significant when analyses were restricted to subjects with NAFL/D.  
CK18 was significantly higher in subjects reporting excess alcohol intake and in 
those reporting any established hepatotoxic cause.   
5.4.2 Liver fibrosis markers 
The associations of the liver fibrosis markers with metabolic risk factors and with 
established hepatotoxic causes are shown in Table 5-7 for all subjects and for those 
with steatosis.   
AST:ALT ratio (Table 5-8), ELF (Table 5-9), FIB4 (Table 5-10) and LSM (Table 
5-11)  were associated with aspects of hyperglycaemia, measures of body fat and 
lipids.  The NFS (Table 5-12) was not associated with glycaemia, only body fat and 
lipids. 
ELF and HA (Table 5-13) were significantly associated with the duration of diabetes. 
In terms of diabetes therapy, there were few statistically significant associations. For 
ELF, NFS and HA, TZD use compared to non-use was associated with higher 
(worse) measures. compared with subjects who were treated with diet alone, mean 
ELF was significantly higher in subjects using OAHA alone and in those using 
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insulin.  For APRI (Table 5-14), FIB4, NFS when compared to diet alone, mean 
levels were significantly lower in subjects using OAHA and/or insulin.   
The associations of ELF, NFS and LSM with metabolic markers remained largely 
unchanged when restricted to subjects with steatosis or NAFL/D.  There was loss of 
statistical significance for metabolic markers with APRI, AST:ALT ratio and FIB4.   
APRI, FIB4 and LSM were significantly higher in those with established hepatotoxic 
risk factors.  ELF, HA and NFS were significantly lower in subjects with established 
risk factors for liver dysfunction.  A significant difference in AST:ALT ratio was 
only evident in those patients with hepatic steatosis. 
Of note, whilst statistically significant all of the correlations were weak with 
correlation coefficients between 0.07 and 0.24 (with the exception of the stronger 







Table 5-7 Association of CK18 with metabolic and established hepatic risk factors.  Values are age and sex adjusted correlation coefficients or mean (SEM) 
 All N=814 p Steatosis N=455 p NAFL/D N=261 p 
Duration of diabetes
a
 0.00 0.949 0.03 0.460 0.03 0.570 
Fasting glucose 0.09 0.012 0.11 0.021 0.06 0.249 
HbA1c 0.06 0.070 0.07 0.165 0.05 0.353 




































BMI 0.12 0.001 0.03 0.561 0.08 0.125 
Waist circumference 0.14 <0.001 0.08 0.096 0.14 0.009 
Total cholesterol -0.04 0.391 -0.04 0.516 -0.06 0.296 
Triglycerides 0.13 0.002 0.05 0.382 0.08 0.185 






























Analyses on a log10 scale; 
b
 Defined as alcohol excess, positive autoantibodies (ASmA titer >1:160 or AMA titer >1:40) or use of hepatotoxic medication (non-
topicalglucocorticoids for >1 week, isoniazid, methotrexate, amiodarone or tamoxifen within the 6 months prior to the year 1 clinic); 
c
 Defined as females >14 
units/week, males >21 unis/week or patient disclosed history of a current or prior alcohol problem.   








Table 5-8 Association of AST:ALT ratio with metabolic and established hepatic risk factors.  Values are age and sex adjusted correlation coefficients or mean 
(SEM) 
 All N=883 p Steatosis N=496 p NAFL/D N=286 p 
Duration of diabetes
a
 0.06 0.067 0.09 0.044 0.08 0.109 
Fasting glucose -0.14 <0.001 -0.11 0.011 -0.07 0.137 
HbA1c -0.16 <0.001 -0.13 0.004 -0.12 0.018 




































BMI -0.08 0.021 0.04 0.369 0.09 0.075 
Waist circumference -0.13 <0.001 0.00 0.967 0.02 0.698 
Total cholesterol 0.11 0.007 0.11 0.040 0.08 0.189 
Triglycerides -0.05 0.233 0.01 0.906 0.03 0.571 





























Analyses on a log10 scale; 
b
 Defined as alcohol excess, positive autoantibodies (ASmA titer >1:160 or AMA titer >1:40) or use of hepatotoxic medication (non-topical 
glucocorticoids for >1 week, isoniazid, methotrexate, amiodarone or tamoxifen within the 6 months prior to the year 1 clinic); 
c
 Defined as females >14 units/week, 
males >21 unis/week or patient disclosed history of a current or prior alcohol problem.   
ALT alanine aminotransferase; AST aspartate aminotransferase; BMI body mass index; NAFL/D non-alcoholic fatty liver /disease; OAHA oral anti-hyperglycaemic 







Table 5-9 Association of ELF with metabolic and established hepatic risk factors.  Values are age and sex adjusted correlation coefficients or mean (SEM) 
 All N=560 p Steatosis N=315 p NAFL/D N=176 p 
Duration of diabetes
a
 0.13 0.002 0.19 0.001 0.17 0.006 
Fasting glucose 0.01 0.860 0.00 0.965 -0.03 0.682 





































BMI 0.11 0.011 0.17 0.003 0.18 0.004 
Waist circumference 0.08 0.075 0.12 0.034 0.15 0.015 
Total cholesterol 0.01 0.783 -0.03 0.675 -0.03 0.722 
Triglycerides -0.06 0.228 -0.11 0.103 -0.12 0.137 





























Analyses on a log10 scale; 
b
 Defined as alcohol excess, positive autoantibodies (ASmA titer >1:160 or AMA titer >1:40) or use of hepatotoxic medication (non-topical 
glucocorticoids for >1 week, isoniazid, methotrexate, amiodarone or tamoxifen within the 6 months prior to the year 1 clinic); 
c
 Defined as females >14 units/week, 
males >21 unis/week or patient disclosed history of a current or prior alcohol problem.   
BMI body mass index; ELF Enhanced Liver Fibrosis panel; NAFL/D non-alcoholic fatty liver /disease; OAHA oral anti-hyperglycaemic agents; Sulph. sulphonylurea; 







Table 5-10 Association of FIB4 with metabolic and established hepatic risk factors.  Values are age and sex adjusted correlation coefficients or mean (SEM) 
 All N=866 p  Steatosis N=484 p  NAFL/D N=282 p 
Duration of diabetes
a
 -0.03 0.323  0.00 0.968  -0.05 0.308 
Fasting glucose 0.04 0.297  0.02 0.622  -0.01 0.772 
HbA1c -0.11 0.001  -0.10 0.033  -0.10 0.042 






































BMI -0.07 0.047  0.01 0.774  0.05 0.290 
Waist circumference -0.04 0.266  0.06 0.164  0.08 0.106 
Total cholesterol -0.05 0.252  -0.07 0.210  -0.12 0.047 
Triglycerides -0.03 0.527  0.02 0.690  0.04 0.541 







































Analyses on a log10 scale; 
b
 Defined as alcohol excess, positive autoantibodies (ASmA titer >1:160 or AMA titer >1:40) or use of hepatotoxic medication (non-topical 
glucocorticoids for >1 week, isoniazid, methotrexate, amiodarone or tamoxifen within the 6 months prior to the year 1 clinic); 
c
 Defined as females >14 units/week, 
males >21 unis/week or patient disclosed history of a current or prior alcohol problem.   









Table 5-11 Association of LSM with metabolic and established hepatic risk factors.  Values are age and sex adjusted correlation coefficients or mean (SEM) 
 All N=631 p  Steatosis N=371 p  NAFL/D N=186 p 
Duration of diabetes
a
 0.02 0.608  0.07 0.197  0.08 0.186 
Fasting glucose 0.09 0.024  0.07 0.160  0.08 0.190 







































BMI 0.24 <0.001  0.17 0.001  0.22 <0.001 
Waist circumference 0.23 <0.001  0.15 0.004  0.16 0.005 
Total cholesterol -0.08 0.106  -0.11 0.065  -0.14 0.032 
Triglycerides 0.06 0.204  -0.02 0.695  -0.03 0.675 







































Analyses on a log10 scale; 
b
 Defined as alcohol excess, positive autoantibodies (ASmA titer >1:160 or AMA titer >1:40) or use of hepatotoxic medication (non-topical 
glucocorticoids for >1 week, isoniazid, methotrexate, amiodarone or tamoxifen within the 6 months prior to the year 1 clinic); 
c
 Defined as females >14 units/week, 
males >21 unis/week or patient disclosed history of a current or prior alcohol problem.   









Table 5-12 Association of NFS with metabolic and established hepatic risk factors.  Values are age and sex adjusted correlation coefficients or mean (SEM) 
 All N=862 p  Steatosis N=481 p  NAFL/D N=282 p 
Duration of diabetes
a
 0.05 0.182  -0.01 0.756  -0.06 0.216 
Fasting glucose 0.05 0.170  0.05 0.283  0.02 0.622 







































BMI 0.44 <0.001  0.49 <0.001  0.51 <0.001 
Waist circumference 0.41 <0.001  0.47 <0.001  0.48 <0.001 
Cholesterol -0.15 <0.001  -0.20 <0.001  -0.21 <0.001 
Triglycerides 0.00 0.953  0.03 0.578  0.03 0.553 







































Analyses on a log10 scale; 
b
 Defined as alcohol excess, positive autoantibodies (ASmA titer >1:160 or AMA titer >1:40) or use of hepatotoxic medication (non-topical 
glucocorticoids for >1 week, isoniazid, methotrexate, amiodarone or tamoxifen within the 6 months prior to the year 1 clinic); 
c
 Defined as females >14 units/week, 
males >21 unis/week or patient disclosed history of a current or prior alcohol problem.   









Table 5-13 Association of HA with metabolic and established hepatic risk factors.  Values are age and sex adjusted correlation coefficients or mean (SEM) 
 All N=674 p  Hepatic steatosis N=374 p  NAFL/D N=219 p 
Duration of diabetes
a
 0.09 0.027  0.13 0.014  0.13 0.030 
Fasting glucose -0.05 0.218  -0.09 0.094  -0.09 0.107 







































BMI 0.03 0.450  0.11 0.039  0.11 0.057 
Waist circumference 0.02 0.689  0.08 0.102  0.09 0.121 
Total cholesterol -0.03 0.469  -0.05 0.396  -0.04 0.584 
Triglycerides -0.10 0.028  -0.11 0.070  -0.09 0.183 







































Analyses on a log10 scale; 
b
 Defined as alcohol excess, positive autoantibodies (ASmA titer >1:160 or AMA titer >1:40) or use of hepatotoxic medication (non-topical 
glucocorticoids for >1 week, isoniazid, methotrexate, amiodarone or tamoxifen within the 6 months prior to the year 1 clinic); 
c
 Defined as females >14 units/week, 
males >21 unis/week or patient disclosed history of a current or prior alcohol problem.   









Table 5-14 Association of APRI with metabolic and established hepatic risk factors.  Values are age and sex adjusted correlation coefficients or mean (SEM) 
 All N=866 p Steatosis N=484 p NAFL/D N=282 p 
Duration of diabetes
a
 -0.07 0.039 -0.06 0.201 -0.10 0.056 
Fasting glucose 0.07 0.051 0.04 0.328 -0.02 0.661 





































BMI -0.02 0.479 0.02 0.588 0.06 0.206 
Waist circumference 0.01 0.779 0.07 0.109 0.10 0.054 
Total cholesterol -0.06 0.140 -0.07 0.192 -0.11 0.058 
Triglycerides 0.02 0.606 0.03 0.582 0.04 0.462 





























Analyses on a log10 scale; 
b
 Defined as alcohol excess, positive autoantibodies (ASmA titer >1:160 or AMA titer >1:40) or use of hepatotoxic medication (non-topical 
glucocorticoids for >1 week, isoniazid, methotrexate, amiodarone or tamoxifen within the 6 months prior to the year 1 clinic); 
c
 Defined as females >14 units/week, 
males >21 unis/week or patient disclosed history of a current or prior alcohol problem.   




5.5 Characteristics of subjects in highest steatohepatitis and liver 
fibrosis marker quintiles 
Since particularly high levels of CK18 and ELF may be diagnostic of clinically 
important liver inflammation and fibrosis respectively, we determined the clinical 
characteristics of subjects in the top marker quintiles (Table 5-15 through Table 
5-22).   
5.5.1 Steatohepatitis marker 
Data for CK18 is shown in Table 5-15 
Compared with subjects in the bottom four quintiles, subjects in the highest CK18 
quintile were significantly older and had significantly higher indices of 
hyperglycaemia, higher triglyceride levels and increased body fat.  In addition, more 
were on intensive diabetes treatment (including insulin) and more reported drinking 
excess alcohol.  There was a significantly higer proportion of patients with hepatic 
steatosis in the highest quintile (49 vs 84%).   
When the analyses were restricted to subjects with hepatic steatosis only only 
measures of poorer diabetes control and alcohol excess remained significant.  When 
analyses were restricted to subjects with NAFL/D, no statistically significant 
differences were found.   
5.5.2 Liver fibrosis markers 
Associations between the highest marker quintiles and potential risk factors were 
varied according to the specific marker.  Full data is shown in Table 5-16 through 
Table 5-22. 
In general, subjects in the highest quintiles were older (for AST:ALT ratio, ELF, 
FIB4, HA and NFS).  Only APRI was associated with poorer glucose control.  Both 
HA and NFS had shorter diabetes durations in the top quintile.  In general (although 
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not always reaching statistical significance) there were larger proportions of patients 
using TZD therapy in the higher marker quintiles compared to the lower four (ELF, 
HA, NFS and LSM).  Measures of body fat were significantly higher for the top 
quintiles of NFS and LSM.  A higher proportion of alcohol excess was associated 
with APRI, FIB4 and LSM.  Conversely, the highest ELF and HA quintiles were 
associated with a lower alcohol intake.   
It should be noted that the highest quintile of AST:ALT ratio was generally 
associated with the opposite findings to all of the other markers: being female, better 
diabetes control, lower body fat measures and less hepatic steatosis (Table 5-17).   
When subjects were restricted to those with steatosis or NAFL/D the majority of 







Table 5-15 Risk factors in highest versus lower quintiles of CK18.  Values are mean (sd) or proportion (n) 
  All  Steatosis  NAFL/D 
  Q1-Q4 N=652 Q5 N=162 p  Q1-Q4 N=368 Q5 N=92 p  Q1-Q4 N=303 Q5 N=75 p 
Age  69.0 (4.1) 68.1 (4.5) 0.017  68.5 (3.9) 68.0 (4.5) 0.404  68.5 (4.0) 67.9 (4.3) 0.221 
Sex, % male  54.6 (356) 52.5 (85) 0.660  50.5 (186) 55.4 (51) 0.417  48.2 (146) 50.7 (38) 0.797 
Duration of diabetes, % ≤5years  38.6 (250) 34.8 (55) 0.419  40.1 (146) 37.8 (34) 0.719  59.8 (180) 60.8 (45) 0.895 






















































Fasting glucose, mmol/L  6.80 (2.24) 7.33 (2.32) 0.010  6.99 (2.3) 7.79 (2.5) 0.004  6.98 (2.4) 7.48 (2.1) 0.104 
HbA1c, %  7.14 (1.03) 7.36 (1.08) 0.020  7.26 (1.1) 7.54 (1.1) 0.027  7.27 (1.1) 7.47 (1.0) 0.160 
Body mass index, kg/m
2
  31.0 (5.6) 32.1 (5.7) 0.020  32.3 (5.5) 32.5 (5.4) 0.698  32.3 (5.6) 33.0 (5.6) 0.303 
Waist circumference, cm  106.1 (12.7) 108.8 (12.6) 0.016  108.6 (12.1) 109.9 (11.1) 0.351  108.1 (12.0) 110.0 (11.7) 0.240 
Total cholesterol, mmol/L  4.15 (0.79) 4.16 (0.75) 0.917  4.22 (0.8) 4.20 (0.8) 0.828  4.23 (0.8) 4.11 (0.8) 0.364 
Triglycerides
a
, mmol/L  1.61 (0.91) 1.92 (1.11) 0.009  0.23 (0.2) 0.27 (0.2) 0.190  0.23 (0.2) 0.29 (0.2) 0.083 
Steatosis, % ‘fatty’   48.9 (319) 84.0 (136) <0.001  - - -  - - - 
Excess alcohol intake
b
              10.3 (67) 17.9 (29) 0.010  11.4 (42) 20.7 (19) 0.025  - - - 
Established hepatotoxic cause
c
  21.3 (139) 24.1 (39) 0.458  15.8 (58) 26.1 (24) 0.032  - - - 
a 
Analysed on the Log10 scale; 
b
 Defined as females >14 units/week, males >21 unis/week or patient disclosed history of a current or prior alcohol problem; 
c 
Defined 
as alcohol excess or ASmA titer >1:160 or AMA titer >1:40; 
d 
Defined as the use of (non-topical) glucocorticoids for >1 week, isoniazid, methotrexate, amiodarone or 
tamoxifen within the 6 months prior to the year 1 clinic 







Table 5-16 Risk factors in highest versus lower quintiles of APRI.  Values are mean (sd) or proportion (n) 
  All  Steatosis  NAFL/D 
  Q1-Q4 N=693 Q5 N=173 p  Q1-Q4 N=393 Q5 N=98 p  Q1-Q4 N=323 Q5 N=80 p 
Age, years  68.8 (4.2) 69.1 (4.2) 0.489  68.6 (4.0) 68.0 (4.2) 0.197  68.5 (4.0) 68.1 (0.5) 0.373 
Sex, % male  50.2 (348) 59.5 (103) 0.033  49.4 (194) 51.0 (50) 0.822  45.2 (146) 50.0 (40) 0.455 
Duration of diabetes, % ≤5years  38.6 (265) 32.6 (56) 0.159  39.4 (153) 41.2 (40) 0.817  39.7 (127) 42.5 (34) 0.703 






















































Fasting glucose, mmol/L  6.74 (2.2) 7.19 (2.3) 0.017  6.95 (2.3) 7.47 (2.4) 0.051  6.93 (2.4) 7.12 (2.2) 0.557 
HbA1c, %  7.16 (1.0) 7.17 (1.0) 0.888  7.27 (1.1) 7.36 (1.0) 0.454  7.28 (1.1) 7.31 (0.98) 0.810 
Body mass index, kg/m
2
  31.2 (5.5) 31.3 (5.9) 0.867  32.2 (5.2) 33.2 (6.4) 0.103  32.2 (5.2) 33.7 (6.9) 0.076 
Waist circumference, cm  106.4 (12.7) 107.6 (13.4) 0.272  108.4 (11.4) 111.0 (13.8) 0.057  107.8 (11.4) 111.0 (14.2) 0.034 
Total cholesterol, mmol/L  4.17 (0.8) 4.04 (0.77) 0.077  4.23 (0.8) 4.07 (0.8) 0.119  4.23 (0.8) 0.40 (0.9) 0.058 
Triglycerides
a
, mmol/L  0.16 (0.2) 0.18 (0.2) 0.305  0.23 (0.2) 0.24 (0.2) 0.575  0.23 (0.2) 0.27 (0.2) 0.167 
Steatosis, % ‘fatty’   53.8 (373) 64.2 (111) 0.016  - - -  - - - 
Excess alcohol intake
b
              10.1 (70) 19.1 (33) 0.002  10.9 (43) 24.5 (24) 0.001  - - - 
Established hepatotoxic cause
c
  20.8 (144) 23.7 (41) 0.408  15.0 (59) 29.6 (29) 0.002  - - - 
a 
Analysed on the Log10 scale; 
b
 Defined as females >14 units/week, males >21 unis/week or patient disclosed history of a current or prior alcohol problem; 
c 
Defined 
as alcohol excess or ASmA titer >1:160 or AMA titer >1:40; 
d 
Defined as the use of (non-topical) glucocorticoids for >1 week, isoniazid, methotrexate, amiodarone or 
tamoxifen within the 6 months prior to the year 1 clinic 







Table 5-17 Risk factors in highest versus lower quintiles of AST:ALT ratio.  Values are mean (sd) or proportion (n) 
  All  Steatosis  NAFL/D 
  Q1-Q4 N=706 Q5 N=177 p  Q1-Q4 N=402 Q5 N=100 p  Q1-Q4 N=331 Q5 N=82 p 
Age  68.5 (4.1) 70.3 (4.2) <0.001  68.2 (3.4) 69.6 (4.2) 0.002  68.2 (4.0) 69.4 (4.2) 0.015 
Sex, % male  54.4 (384) 43.5 (77) 0.011  52.5 (211) 38.0 (38) 0.010  49.8 (165) 30.5 (25) 0.002 
Duration of diabetes, % ≤5years  37.4 (262) 36.6 (64) 0.862  40.2 (159) 37.0 (37) 0.647  39.9 (131) 39.0 (32) 0.900 






















































Fasting glucose, mmol/L  6.98 (2.3) 6.42 (2.3) 0.004  7.19 (2.3) 6.75 (2.5) 0.096  7.09 (2.2) 6.81 (2.9) 0.335 
HbA1c, %  7.25 (1.1) 6.91 (0.9) <0.001  7.36 (1.1) 7.15 (0.9) 0.055  7.34 (1.1) 7.21 (1.0) 0.337 
Body mass index, kg/m
2
  31.6 (5.6) 30.1 (5.8) 0.002  32.4 (5.3) 32.4 (6.1) 0.997  32.4 (5.5) 32.8 (6.2) 0.573 
Waist circumference, cm  107.6 (12.4 ) 103.1 (13.9) <0.001  109.0 (11.6) 108.6 (13.3) 0.755  108.6 (11.8) 108.1 (13.3) 0.710 
Total cholesterol, mmol/L  4.12 (0.8) 4.24 (0.7) 0.098  4.18 (0.8) 4.28 (0.8) 0.340  4.16 (0.8) 4.31 (0.8) 0.174 
Triglycerides
a
, mmol/L  0.18 (0.2) 0.13 (0.2) 0.033  0.23 (0.2) 0.24 (0.2) 0.507  0.23 (0.2) 0.26 (0.2) 0.276 
Steatosis, % ‘fatty’   60.2 (425) 40.1 (71) <0.001  - - -  - - - 
Excess alcohol intake
b
              11.3 (80) 13.6 (24) 0.433  12.2 (49) 19.0 (19) 0.101  - - - 
Established hepatotoxic cause
c
  20.3 (143) 24.9 (44) 0.182  15.7 (63) 26.0 (26) 0.019  - - - 
a 
Analysed on the Log10 scale; 
b
 Defined as females >14 units/week, males >21 unis/week or patient disclosed history of a current or prior alcohol problem; 
c 
Defined 
as alcohol excess or ASmA titer >1:160 or AMA titer >1:40; 
d 
Defined as the use of (non-topical) glucocorticoids for >1 week, isoniazid, methotrexate, amiodarone or 
tamoxifen within the 6 months prior to the year 1 clinic 







Table 5-18 Risk factors in highest versus lower quintiles of ELF.  Values are mean (sd) or proportion (n) 
  All  Steatosis  NAFL/D 
  Q1-Q4 N=448 Q5 N=112 p  Q1-Q4 N=255 Q5 N=64 p  Q1-Q4 N=207 Q5 N=52 p 
Age  68.3 (4.1) 70.5 (3.8) <0.001  67.9 (3.9) 69.7 (4.0) 0.002  67.8 (3.9) 69.4 (4.0) 0.017 
Sex, % male  51.3 (230) 46.4 (52) 0.398  49.0 (125) 46.9 (30) 0.781  43.0 (89) 48.1 (25) 0.535 
Duration of diabetes
, 
% ≤5years  40.8 (181) 32.7 (36) 0.128  41.8 (105) 36.5 (23) 0.476  42..0 (86) 33.3 (17) 0.338 






















































Fasting glucose, mmol/L  6.88 (2.2) 6.97 (2.5) 0.722  7.13 (2.3) 6.99 (2.7) 0.697  7.07 (2.3) 6.87 (2.5) 0.583 
HbA1c, %  7.19 (1.0) 7.25 (1.1) 0.596  7.35 (1.1) 7.23 (1.1) 0.435  7.35 (1.1) 7.30 (1.2) 0.764 
Body mass index, kg/m
2
  30.9 (5.5) 31.9 (6.1) 0.096  31.9 (5.2) 33.4 (6.5) 0.040  32.1 (5.6) 33.5 (6.5) 0.129 
Waist circumference, cm  105.8 (12.2) 108.1 (13.5) 0.082  107.7 (11.4) 110.5 (13.4) 0.091  107.2 (11.8) 1110.6 (13.6) 0.176 
Total cholesterol, mmol/L  4.17 (0.8) 4.13 (0.8) 0.670  4.27 (0.8) 4.07 (0.8) 0.135  4.28 (0.8) 4.03 (0.7) 0.094 
Triglycerides
a
, mmol/L  0.16 (0.2) 0.19 (0.2) 0.358  0.24 (0.2) 0.22 (0.2) 0.497  0.25 (0.2) 0.22 (0.2) 0.357 
Steatosis, % ‘fatty’   57.1 (256) 52.7 (59) 0.397  - - -  - - - 
Excess alcohol intake
b
              13.2 (59) 9.0 (10) 0.262  157 (40) 7.8 (5) 0.158  - - - 
Established hepatotoxic cause
c
  23.7 (106) 19.63 (22) 0.450  20.8 (53) 10.9 (7) 0.076  - - - 
a 
Analysed on the Log10 scale; 
b
 Defined as females >14 units/week, males >21 unis/week or patient disclosed history of a current or prior alcohol problem; 
c 
Defined 
as alcohol excess or ASmA titer >1:160 or AMA titer >1:40; 
d 
Defined as the use of (non-topical) glucocorticoids for >1 week, isoniazid, methotrexate, amiodarone or 
tamoxifen within the 6 months prior to the year 1 clinic 







Table 5-19 Risk factors in highest versus lower quintiles of FIB4.  Values are mean (sd) or proportion (n) 
  All  Steatosis  NAFL/D 
  Q1-Q4 N=693 Q5 N=173 p  Q1-Q4 N=393 Q5 N=98 p  Q1-Q4 N=323 Q5 N=80 p 
Age  68.6 (4.2) 70.0 (3.9) <0.001  68.3 (4.0) 69.2 (4.1) 0.046  68.3 (4.1) 69.1 (4.0) 0.086 
Sex, % male  50.8 (352) 57.2 (99) 0.148  49.1 (193) 52.0 (51) 0.652  44.9 (145) 51.2 (41) 0.319 
Duration of diabetes
, 
% ≤5years  38.0 (261) 34.9 (60) 0.481  59.0 (229) 64.9 (63) 0.299  40.0 (128) 41.3 (33) 0.899 






















































Fasting glucose, mmol/L  6.77 (2.2) 7.08 (2.4) 0.102  6.95 (2.3) 7.47 (2.5) 0.049  6.91 (2.3) 7.21 (2.6) 0.307 
HbA1c, %  7.19 (1.0) 7.06 (1.0) 0.168  7.29 (1.1) 7.28 (1.0) 0.937  7.28 (1.1) 7.30 (1.0) 0.873 
Body mass index, kg/m
2
  31.4 (5.5) 30.8 (6.2) 0.214  32.3 (5.2) 32.8 (6.5) 0.406  32.2 (5.2) 33.7 (6.8) 0.072 
Waist circumference, cm  106.8 (12.5) 105.6 (14.0) 0.279  108.4 (11.5) 110.7 (13.4) 0.087  107.8 (11.5) 111.3 (13.8) 0.018 
Total cholesterol, mmol/L  4.16 (0.8) 4.08 (0.8) 0.285  4.23 (0.8) 4.08 (0.8) 0.142  4.24 (0.8) 4.01 (0.8) 0.053 
Triglycerides
a
, mmol/L  0.17 (0.2) 0.15 (0.2) 0.218  0.23 (0.2) 0.23 (0.2) 0.856  0.23 (0.2) 0.24 (0.2) 0.867 
Steatosis, % ‘fatty’   57.3 (397) 50.3 (87) 0.104  - - -  - - - 
Excess alcohol intake
b
              10.3 (71) 18.6 (32) 0.004  10.7 (42) 25.5 (25) <0.001  - - - 
Established hepatotoxic cause
c
  20.8 (144) 23.7 (41) 0.408  15.3 (60) 28.6 (28) 0.003  - - - 
a 
Analysed on the Log10 scale; 
b
 Defined as females >14 units/week, males >21 unis/week or patient disclosed history of a current or prior alcohol problem; 
c 
Defined 
as alcohol excess or ASmA titer >1:160 or AMA titer >1:40; 
d 
Defined as the use of (non-topical) glucocorticoids for >1 week, isoniazid, methotrexate, amiodarone or 
tamoxifen within the 6 months prior to the year 1 clinic 







Table 5-20 Risk factors in highest versus lower quintiles of HA.  Values are mean (sd) or proportion (n) 
  All  Steatosis  NAFL/D 
  Q1-Q4 N=540 Q5 N=134 p  Q1-Q4 N=304 Q5 N=76 p  Q1-Q4 N=245 Q5 N=61 p 
Age  68.3 (4.0) 70.7 (3.9) <0.001  68.0 (3.9) 69.5 (4.2) 0.003  68.0 (3.9) 69.1 (4.1) 0.052 
Sex, % male  53.0 (286) 54.5 (73) 0.772  50.0 (152) 51.3 (39) 0.898  45.7 (112) 45.9 (28) 1.000 
Duration of diabetes
, 
% ≤5years  41.1 (220) 30.3 (40) 0.022  41.5 (124) 34.7 (26) 0.295  41.6 (101) 33.3 (20) 0.333 






















































Fasting glucose, mmol/L  7.02 (2.2) 6.65 (2.4) 0.095  7.30 (2.3) 6.58 (2.5) 0.017  7.23 (2.3) 6.51 (2.32) 0.030 
HbA1c, %  7.22 (1.1) 7.22 (1.0) 0.978  7.40 (1.1) 7.23 (1.1) 0.250  7.40 (1.1) 7.24 (1.1) 0.308 
Body mass index, kg/m
2
  31.2 (5.8) 31.0 (5.2) 0.646  32.2 (5.6) 32.6 (5.4) 0.520  32.2 (5.3) 32.4 (5.3) 0.890 
Waist circumference, cm  106.5 (12.8) 106.3 (12.4) 0.846  108.5 (12.0) 108.9 (11.7) 0.755  108.1 (12.5) 107.5 (10.7) 0.752 
Total cholesterol, mmol/L  4.18 (0.8) 4.06 (0.8) 0.185  4.26 (0.8) 4.09 (0.9) 0.175  4.48 (0.8) 4.05 (0.9) 0.107 
Triglycerides
a
, mmol/L  0.17 (0.2) 0.15 (0.2) 0.372  0.25 (0.2) 0.21 (0.2) 0.226  0.25 (0.2) 0.21 (0.2) 0.192 
Steatosis, % ‘fatty’   57.2 (309) 48.5 (65) 0.080  - - -  - - - 
Excess alcohol intake
b
              13.5 (73) 9.8 (13) 0.310  15.5 (47) 11.8 (9) 0.475  - - - 
Established hepatotoxic cause
c
  23.5 (127) 19.4 (26) 0.357  20.7 (63) 14.5 (11) 0.259  - - - 
a 
Analysed on the Log10 scale; 
b
 Defined as females >14 units/week, males >21 unis/week or patient disclosed history of a current or prior alcohol problem; 
c 
Defined 
as alcohol excess or ASmA titer >1:160 or AMA titer >1:40; 
d 
Defined as the use of (non-topical) glucocorticoids for >1 week, isoniazid, methotrexate, amiodarone or 
tamoxifen within the 6 months prior to the year 1 clinic 






Table 5-21 Risk factors in highest versus lower quintiles of NFS.  Values are mean (sd) or proportion (n) 
  All  Steatosis  NAFL/D 
  Q1-Q4 N=690 Q5 N=172 p  Q1-Q4 N=391 Q5 N=97 p  Q1-Q4 N=321 Q5 N=80 p 
             
Age  68.7 (4.1) 69.6 (4.2) 0.013  68.3 (4.0) 68.8 (4.4) 0.396  68.4 (4.0) 68.6 (4.4) 0.611 
Sex, % male  51.4 (355) 54.7 (94) 0.495  49.4 (193) 51.5 (50) 0.734  46.7 (150) 45.0 (36) 0.803 
Duration of diabetes, % ≤5years  39.4 (269) 30.2 (52) 0.028  40.5 (156) 38.1 (37) 0.728  39.9 (127) 42.5 (34) 0.703 






















































Fasting glucose, mmol/L  6.83 (2.2) 6.85 (2.4) 0.922  7.05 (2.3) 7.15 (2.6) 0.708  7.00 (2.3) 6.88 (2.4) 0.664 
HbA1c, %  7.18 (1.1) 7.07 (1.0) 0.198  7.30 (1.1) 7.23 (1.0) 0.583  7.29 (1.1) 7.24 (0.9) 0.725 
Body mass index, kg/m
2
  30.1 (4.8) 36.0 (6.2) <0.001  31.1 (4.5) 37.5 (6.0) <0.001  31.1 (4.6) 37.9 (6.1) <0.001 
Waist circumference, cm  104.1 (11.4) 116.8 (13.3) <0.001  106.2 (10.6) 119.5 (11.4) <0.001  105.8 (10.8) 119.0 (11.3) <0.001 
Total cholesterol, mmol/L  4.19 (0.8) 3.95 (0.7) 0.003  4.25 (0.8) 4.00 (0.7) 0.026  4.25 (0.8) 4.0 (0.8) 0.021 
Triglycerides
a
, mmol/L  0.16 (0.2) 0.18 (0.2) 0.602  0.23 (0.2) 0.22 (0.2) 0.822  0.24 (0.2) 0.22 (0.2) 0.541 
Steatosis, % ‘fatty’   56.2 (388) 54.1 (93) 0.608  - - -  - - - 
Excess alcohol intake
b
              11.2 (77) 14.6 (25) 0.234  12.5 (49) 18.6 (18) 0.138  - - - 
Established hepatotoxic cause
c
  21.0 (145) 22.1 (38) 0.755  16.9 (66) 21.6 (21) 0.300  - - - 
a 
Analysed on the Log10 scale; 
b
 Defined as females >14 units/week, males >21 unis/week or patient disclosed history of a current or prior alcohol problem; 
c 
Defined 
as alcohol excess or ASmA titer >1:160 or AMA titer >1:40; 
d 
Defined as the use of (non-topical) glucocorticoids for >1 week, isoniazid, methotrexate, amiodarone or 
tamoxifen within the 6 months prior to the year 1 clinic 







Table 5-22 Risk factors in highest versus lower quintiles of LSM.  Values are mean (sd) or proportion (n) 
  All  Steatosis  NAFL/D 
  Q1-Q4 N=514 Q5 N=117 p  Q1-Q4 N=297 Q5 N=75 p  Q1-Q4 N=244 Q5 N=62 p 
Age  68.9 (4.1) 68.0 (4.4) 0.045  68.4 (3.9) 67.5 (4.3) 0.100  68.4 (4.0) 67.8 (4.2) 0.185 
Sex, % male  54.9 (282) 55.6 (65) 0.918  53.2 (152) 48.0 (36) 0.440  50.8 (124) 40.3 (25) 0.156 
Duration of diabetes, % ≤5years  40.5 (206) 31.9 (37) 0.092  42.0 (123) 27.0 (20) 0.023  42.0 (102) 27.9 (17) 0.056 






















































Fasting glucose, mmol/L  6.88 (2.1) 7.10 (2.6) 0.386  7.18 (2.2) 7.46 (2.8) 0.360  7.11 (2.2) 7.40 (2.9) 0.398 
HbA1c, %  7.15 (1.0) 7.37 (1.3) 0.077  7.29 (1.0) 7.56 (1.2) 0.075  7.28 (1.0) 7.56 (1.3) 0.128 
Body mass index, kg/m
2
  30.1 (4.6) 33.1 (6.0) <0.001  31.0 (4.4) 33.8 (6.5) 0.001  31.0 (4.4) 34.2 (6.8) 0.001 
Waist circumference, cm  104.0 (10.8) 110.6 (12.1) <0.001  106.0 (10.3) 111.2 (12.6) 0.001  105.7 (10.4) 110.7 (13.3) 0.007 
Total cholesterol, mmol/L  4.18 (0.8) 3.97 (0.6) 0.032  4.28 (0.8) 4.00 (0.6) 0.005  4.28 (0.9) 3.97 (0.6) 0.007 
Triglycerides
a
, mmol/L  0.16 (0.2) 0.19 (0.2) 0.361  0.23 (0.2) 0.25 (0.2) 0.535  0.24 (0.2) 0.25 (0.2) 0.855 
Steatosis, % ‘fatty’   44.6 (229) 26.5 (31) <0.001  - - -  - - - 
Excess alcohol intake
b
              11.1 (57) 20.5 (24) 0.009  11.4 (34) 22.7 (17) 0.023  - - - 
Established hepatotoxic cause
c
  20.8 (107) 27.4 (32) 0.138  15.8 (47) 25.3 (19) 0.063  - - - 
a 
Analysed on the Log10 scale; 
b
 Defined as females >14 units/week, males >21 unis/week or patient disclosed history of a current or prior alcohol problem; 
c 
Defined 
as alcohol excess or ASmA titer >1:160 or AMA titer >1:40; 
d 
Defined as the use of (non-topical) glucocorticoids for >1 week, isoniazid, methotrexate, amiodarone or 
tamoxifen within the 6 months prior to the year 1 clinic 
HbA1c glycosylated haemoglobin; LSM liver stiffness measurement; Sulph. sulphonylurea; TZD thiozolidinedione
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5.5.3 Surrogate markers of portal hypertension 
In order to provide some validation of the highest quintiles of steatohepatitis and 
liver fibrosis markers containing the participants with the most advanced CLD 
associations with surrogate markers of portal hypertension were examined.   
The top quintiles of each of the markers generally had significantly higher surrogate 
measures of portal hypertension than the lower four quintiles (Table 5-23). 
Table 5-23 Surrogate markers of portal hypertension for quintiles.  Values are mean (sd). 
  Spleen size, cm  Platelet count, x10
9
/L 
  Q1-4 Q5 P  Q1-4 Q5 p 
CK18  10.1 (1.5) 10.6 (1.8) <0.001  260 (69) 259 (64) 0.887 
APRI  10.0 (1.4) 10.8 (1.8) <0.001  275 (64) 200 (45) <0.001 
AST:ALT ratio  10.3 (1.4) 9.9 (1.8) 0.019  259 (67) 261 (71) 0.808 
ELF  10.1 (1.5) 10.5 (2.0) 0.037  267 (70) 250 (60) 0.022 
FIB4  10.1 (1.4) 10.6 (1.7) <0.001  277 (62) 190 (42) <0.001 
HA  10.2 (1.5) 10.2 (1.9) 0.867  266 (69) 251 (69) 0.031 
NFS  10.0 (1.4) 10.9 (1.6) <0.001  275 (63) 197 (45) <0.001 
LSM  10.1 (1.5) 10.7 (1.6) <0.001  262 (67) 252 (61) 0.149 
 
5.5.4 Influence of chronic kidney disease and arthritis on liver markers 
Liver markers were not significantly associated with other conditions known to affect 
circulating levels.  With the exception of a significantly higher proportion of patients 
with chronic kidney disease in the highest NFS quintile (Table 5-24).   
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Table 5-24 Influence of chronic kidney disease and arthritis on markers.  Values are % (n). 
  Chronic kidney disease, %  Arthritis, % 
  Q1-4 Q5 P  Q1-4 Q5 p 
CK18  18.1 (118) 19.8 (32) 0.651  35.0 (228) 41.4 (67) 0.144 
APRI  20.1 (139) 17.3 (30) 0.454  37.8 (262) 32.9 (57) 0.253 
AST:ALT ratio  18.4 (130) 23.2 (41) 0.167  37.4 (264) 35.6 (63) 0.728 
ELF  15.8 (71) 24.1 (27) 0.051  37.3 (167) 45.5 (51) 0.129 
FIB4  19.6 (136) 19.1 (33) 0.915  38.2 (265) 31.2 (54) 0.094 
HA  17.4 (94) 19.4 (26) 0.614  36.7 (198) 37.3 (50) 0.920 
NFS  16.8 (116) 29.1 (50) <0.001  35.9 (248) 40.7 (70) 0.252 
LSM  18.1 (93) 14.5 (17) 0.419  34.2 (176) 34.2 (40) 1.000 
ALT alanine aminotransferase; APRI aspartate aminotransferase to platelet ratio index; AST 
aspartate aminotransferase; CK18 cytokeratin-18; ELF Enhanced Liver Fibrosis panel; FIB4 Fibrosis-4 
Index; HA hyaluronic acid; NAFLD non-alcoholic fatty liver disease; NFS NAFLD Fibrosis Score; LSM 
liver stiffness measure. 
5.6 Multivariable analysis 
In order to investigate the association between steatohepatitis and liver fibrosis 
marker with potential risk factors after adjusting for confounders, I undertook 
multivariable analysis of each of the markers by each of the potential diabetes history 
and metabolic risk factors, adjusted for age, sex and established causes of liver 
disease.   
The results of these analyses are shown in Table 5-25 to Table 5-32, both unadjusted 
(model 1) and adjusted for age, sex and established hepatotoxic causes (model 2).  
Each table is ordered by the risk factors explaining the greatest degree of variation 
after adjustment. 
Risk factors maintaining statistical significance after adjustment varied for each 
marker.  Most commonly, variables related to body fat (BMI and waist 
circumference) maintained statistical significance, for example with CK18, ELF, HA 
NFS and LSM. 
Diabetes history related risk factors were not consistently related.  In terms of 
diabetes treatment, higher CK18 and ELF levels were statistically significantly 
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associated with not being diet controlled (ie on a more intensive therapy), whereas 
higher APRI and FIB4 scores were significantly associated with having diet 
controlled diabetes.  CK18 was the only marker significantly associated with OAHA 
use, with APRI, FIB4 and NFS being significantly associated with not using 
OAHA’s.  There were very few statistically significant associations after adjustment 
with fasting glucose, HbA1c and duration of diabetes, with the exception of the 
AST:ALT ratio which was statistically associated with better glucose control and a 
shorter duration of diabetes.   
In general, the amount of variation in each of markers of steatohepatitis and liver 
fibrosis studied was poorly explained by any of the risk factors (R
2
<15%).  The only 
higher value was for the association between NFS and BMI (R
2
 28%), however, it 
should be noted that BMI is part of the NFS formula. 
Also of note, markers with similar compositions (APRI and FIB4) had similar 








Table 5-25 Multivariable association of risk factors with CK18.  Values are standardised beta coefficients (95% CI) 
  Model 1 p R
2
  Model 2 p R
2
 
Hepatic steatosis  0.308 (0.241,0.377) <0.001 0.095  0.299 (0.231,0.367) <0.001 0.110 
Triglycerides
a
, mmol/L  0.149 (0.064,0.223) <0.002 0.021  0.151 (0.066,0.226) <0.001 0.054 
Waist circumference, cm  0.135 (0.064,0.208) <0.001 0.018  0.118 (0.047,0.193) 0.001 0.036 
Body mass index, kg/m
2
  0.095 (0.024,0.167) 0.009 0.009  0.090 (0.016,0.164) 0.017 0.030 
Diet controlled  -0.082 (-0.150,-0.010) 0.024 0.007  -0.086 (-0.153,-0.014) 0.019 0.030 
Any OAHA use  0.079 (0.008,0.149) 0.030 0.006  0.085 (0.014,0.155) 0.019 0.030 
Fasting glucose, mmol/L  0.091 (0.019,0.160) 0.013 0.008  0.083 (0.012,0.152) 0.022 0.030 
HbA1c, % or mmol/mol  0.077 (0.006,0.146) 0.034 0.006  0.069 (-0.003,0.139) 0.060 0.028 
Total cholesterol, mmol/L  -0.038 (-0.121,0.044) 0.363 0.001  -0.043 (-0.127,0.042) 0.324 0.031 
Insulin therapy  0.026 (-0.046,0.099) 0.476 0.001  0.022 (-0.050,0.095) 0.546 0.023 
Duration of diabetes
a
, years  -0.001 (-0.073,0.070) 0.935 -  0.005 (-0.067,0.076) 0.897 0.023 
a
 Analysed on the Log10 scale 
Model 1 - Unadjusted model, individual variables with no adjustment 
Model 2 - Individual variables adjusted for age, sex, alcohol excess, hepatotoxic medication use and strongly positive autoantibodies 








Table 5-26 Multivariable association of risk factors with APRI.  Values are standardised beta coefficients (95% CI) 
 Model 1 p R
2
  Model 2 p R
2
  
OAHA -0.183 (-0.251,-0.115) <0.001 0.034  -0.173 (-0.240,-0.107) <0.001 0.080  
Diet controlled 0.154 (0.086,0.221) <0.001 0.024  0.141 (0.073,0.206) <0.001 0.069  
Duration of diabetes -0.064 (-0.135,0.005) 0.069 0.004  -0.065 (-0.134,0.003) 0.061 0.055  
Steatosis 0.053 (-0.016,0.124) 0.130 0.003  0.053 (-0.015,0.123) 0.122 0.053  
HbA1c -0.065 (-0.137,2.703) 0.156 0.004  -0.049 (-0.119,0.019) 0.156 0.055  
Trig 0.026 (-0.053,0.106) 0.513 0.001  0.045 (-0.033,0.124) 0.257 0.054  
Glucose 0.053 (-0.017,0.126) 0.134 0.003  0.044 (-0.025,0.115) 0.209 0.053  
Cholesterol -0.064 (-0.142,0.015) 0.115 0.004  -0.035 (-0.114,0.044) 0.388 0.053  
Waist 0.003 (-0.067,0.073) 0.936 -  -0.013 (-0.083,0.057) 0.718 0.053  
BMI -0.034 (-0.105,0.036) 0.338 0.001  0.009 (-0.062,0.081) 0.794 0.052  
Insulin -0.009 (-0.080,0.061) 0.797 -  0.003 (-0.066,0.072) 0.935 0.050  
a
 Analysed on the Log10 scale 
Model 1 - Unadjusted model, individual variables with no adjustment 
Model 2 - Individual variables adjusted for age, sex, alcohol excess, hepatotoxic medication use and strongly positive autoantibodies 








Table 5-27 Multivariable association of risk factors with AST:ALT ratio.  Values are standardised beta coefficients (95% CI) 
  Model 1 p R
2
  Model 2 p R
2
 
Steatosis  -0.171 (-0.242,-0.105) <0.001 0.029  -0.157 (-0.225,-0.092) <0.001 0.104 
HbA1c  -0.157 (-0.221,-0.088) <0.001 0.025  -0.128 (-0.191,-0.061) <0.001 0.096 
Glucose  -0.140 (-0.203,-0.070) <0.001 0.020  -0.124 (-0.185,-0.056) <0.001 0.095 
Duration of diabetes  0.085 (0.016,0.154) 0.015 0.007  0.088 (0.022,0.155) 0.009 0.090 
Cholesterol  0.108 (0.029,0.180) 0.007 0.012  0.083 (0.005,0.155) 0.037 0.076 
Waist  -0.122 (-0.192,-0.054) <0.001 0.015  -0.074 (-0.143,-0.007) 0.032 0.084 
BMI  -0.069 (-0.140,-0.001) 0.046 0.005  -0.056 (-0.126,0.012) 0.108 0.083 
Triglycerides  -0.073 (-0.148,0.006) 0.071 0.005  -0.052 (-0.126,0.024) 0.185 0.072 
OAHA  -0.043 (-0.111,0.025) 0.218 0.002  -0.030 (-0.096,0.036) 0.370 0.080 
Insulin  0.014 (-0.056,0.084) 0.691 -  0.026 (-0.041,0.094) 0.442 0.080 
Diet  0.016 (-0.052,0.084) 0.646 -  0.000 (-0.066,0.065) 0.989 0.079 
a
 Analysed on the Log10 scale 
Model 1 - Unadjusted model, individual variables with no adjustment 
Model 2 - Individual variables adjusted for age, sex, alcohol excess, hepatotoxic medication use and strongly positive autoantibodies 









Table 5-28 Multivariable association of risk factors with ELF.  Values are standardised beta coefficients (95% CI) 
  Model 1 p R
2
  Model 2 p R
2
 
Body mass index, kg/m
2
  0.135 (0.048,0.214) 0.002 0.018  0.171 (0.084,0.247) <0.001 0.132 
Insulin therapy  0.147 (0.060,0.228) 0.001 0.022  0.158 (0.075,0.234) <0.001 0.130 
Waist circumference, cm  0.085 (-0.002,0.169) 0.055 0.007  0.142 (0.058,0.222) 0.001 0.124 
Duration of diabetes
a
, years  0.149 (0.059,0.222) 0.001 0.022  0.124 (0.040,0.197) 0.003 0.120 
Diet controlled  -0.109 (-0.186,-0.021) 0.014 0.012  -0.114 (-0.187,-0.030) 0.007 0.118 
HbA1c, % or mmol/mol  0.047 (-0.037,0.128) 0.284 0.002  0.077 (-0.006,0.152) 0.070 0.112 
Any OAHA use  0.065 (-0.021,0.148) 0.141 0.004  0.067 (-0.015,0.147) 0.110 0.109 
Fasting glucose, mmol/L  0.000 (-0.083,0.82) 0.992 -  0.016 (-0.064,0.094) 0.711 0.106 
Total cholesterol, mmol/L  0.019 (-0.081,0.117) 0.719 -  -0.012 (-0.111,0.088) 0.823 0.092 
Hepatic steatosis  -0.030 (-0.113,0.054) 0.491 0.001  0.011 (-0.070,0.091) 0.802 0.105 
Triglycerides
a
, mmol/L  -0.026 (-0.120,0.072) 0.622 0.001  0.003 (-0.091,0.097) 0.947 0.090 
a
 Analysed on the Log10 scale 
Model 1 - Unadjusted model, individual variables with no adjustment 
Model 2 - Individual variables adjusted for age, sex, alcohol excess, hepatotoxic medication use and strongly positive autoantibodies 








Table 5-29 Multivariable association of risk factors with FIB4.  Values are standardised beta coefficients (95% CI) 
  Model 1 p R
2
  Model 2 p R
2
 
Any OAHA use  -0.170 (-0.240,-0.103) <0.001 0.029  -0.154 (-0.221,-0.090) <0.001 0.124 
Diet controlled  0.141 (0.073,0.209) <0.001 0.020  0.119 (0.053,0.184) <0.001 0.114 
HbA1c, % or mmol/mol  -0.111 (-0.183,-0.043) 0.002 0.012  -0.067 (-0.135,0.000) 0.050 0.107 
Hepatic steatosis  -0.061 (-0.132,0.009) 0.085 0.004  -0.040 (-0.108,0.027) 0.236 0.102 
Fasting glucose, mmol/L  0.024 (-0.047,0.096) 0.500 0.001  0.029 (-0.039,0.098) 0.393 0.100 
Total cholesterol, mmol/L  -0.048 (-0.126,0.031) 0.232 0.002  -0.028 (-0.105,0.049) 0.477 0.093 
Waist circumference, cm  -0.041 (-0.113,0.028) 0.240 0.002  -0.015 (-0.084,0.054) 0.666 0.101 
Triglycerides
a
, mmol/L  -0.029 (-0.109,0.050) 0.467 0.001  0.011 (-0.066,0.088) 0.786 0.092 
Duration of diabetes
a
, years  -0.001 (-0.071,0.070) 0.988 -  -0.006 (-0.074,0.061) 0.850 0.104 
Insulin therapy  -0.020 (-0.092,0.050) 0.564 -  0.002 (-0.066,0.070) 0.960 0.100 
Body mass index, kg/m
2
  -0.074 (-0.148,-0.005) 0.035 0.005  0.000 (-0.070,0.071) 0.991 0.102 
a
 Analysed on the Log10 scale 
Model 1 - Unadjusted model, individual variables with no adjustment 
Model 2 - Individual variables adjusted for age, sex, alcohol excess, hepatotoxic medication use and strongly positive autoantibodies 








Table 5-30 Multivariable association of risk factors with HA.  Values are standardised beta coefficients (95% CI) 
  Model 1 p R
2
  Model 2 p R
2
 
Body mass index, kg/m
2
  0.057 (-0.022,0.137) 0.156 0.003  0.115 (0.039,0.195) 0.003 0.118 
Waist circumference, cm  0.029 (-0.050,0.110) 0.462 0.001  0.098 (0.022,0.178) 0.012 0.115 
Duration of diabetes
a
, years  0.091 (0.013,0.170) 0.023 0.008  0.071 (-0.004,0.146) 0.065 0.112 
Insulin therapy  0.060 (-0.019,0.144) 0.132 0.004  0.069 (-0.006,0.150) 0.070 0.110 
Diet controlled  -0.054 (-0.131,0.024) 0.176 0.003  -0.068 (-0.141,0.007) 0.076 0.109 
Any OAHA use  0.045 (-0.034,0.125) 0.257 0.002  0.055 (-0.019,0.132) 0.145 0.099 
HbA1c, % or mmol/mol  0.019 (-0.059,0.097) 0.631 -  0.052 (-0.023,0.127) 0.173 0.109 
Total cholesterol, mmol/L  -0.026 (-0.119,0.066) 0.576 0.001  -0.048 (-0.138,0.042) 0.296 0.115 
Triglycerides
a
, mmol/L  -0.079 (-0.163,0.013) 0.096 0.006  -0.046 (-0.129,0.041) 0.315 0.114 
Fasting glucose, mmol/L  -0.049 (-0.127,0.029) 0.221 0.002  -0.028 (-0.103,0.047) 0.461 0.107 
Hepatic steatosis  -0.036 (-0.115,0.043) 0.370 0.001  -0.003 (-0.079,0.073) 0.938 0.105 
a
 Analysed on the Log10 scale 
Model 1 - Unadjusted model, individual variables with no adjustment 
Model 2 - Individual variables adjusted for age, sex, alcohol excess, hepatotoxic medication use and strongly positive autoantibodies 








Table 5-31 Multivariable association of risk factors with NFS.  Values are standardised beta coefficients (95% CI) 
  Model 1 p R
2
  Model 2 p R
2
 
Body mass index, kg/m
2
  0.422 (0.366,0.494) <0.001 0.178  0.504 (0.453,0.577) <0.001 0.284 
Waist circumference, cm  0.394 (0.332,0.461) <0.001 0.155  0.433 (0.373,0.500) <0.001 0.225 
Total cholesterol, mmol/L  -0.148 (-0.226,-0.069) <0.001 0.022  -0.142 (-0.221,-0.062) <0.001 0.063 
Any OAHA use  -0.088 (-0.157,-0.019) 0.013 0.008  -0.078 (-0.146,-0.010) 0.025 0.052 
Diet controlled  0.060 (-0.009,0.128) 0.089 0.004  0.045 (-0.023,0.113) 0.196 0.048 
Triglycerides
a
, mmol/L  0.018 (-0.062,0.099) 0.651 -  0.044 (-0.035,0.125) 0.271 0.046 
Fasting glucose, mmol/L  0.031 (-0.040,0.103) 0.384 0.001  0.034 (-0.036,0.105) 0.334 0.047 
HbA1c, % or mmol/mol  -0.059 (-0.130,0.010) 0.092 0.004  -0.028 (-0.097,0.041) 0.431 0.040 
Duration of diabetes
a
, years  0.020 (-0.050,0.090) 0.577 -  0.015 (-0.053,0.085) 0.656 0.047 
Hepatic steatosis  -0.015 (-0.085,0.055) 0.669 -  -0.001 (-0.070,0.068) 0.979 0.046 
Insulin therapy  -0.016 (-0.088,0.055) 0.651 -  -0.001 (-0.071,0.069) 0.983 0.046 
a
 Analysed on the Log10 scale 
Model 1 - Unadjusted model, individual variables with no adjustment 
Model 2 - Individual variables adjusted for age, sex, alcohol excess, hepatotoxic medication use and strongly positive autoantibodies 








Table 5-32 Multivariable association of risk factors with LSM.  Values are standardised beta coefficients (95% CI) 
  Model 1 p R
2
  Model 2 p R
2
 
Body mass index, kg/m
2
  0.221 (0.164,0.345) <0.001 0.049  0.235 (0.177,0.364) <0.001 0.066 
Waist circumference, cm  0.219 (0.162,0.344) <0.001 0.048  0.220 (0.162,0.344) <0.001 0.061 
Hepatic steatosis  0.196 (0.122,0.288) <0.001 0.038  0.195 (0.121,0.288) <0.001 0.052 
HbA1c, % or mmol/mol  0.127 (0.047,0.211) 0.002 0.016  0.132 (0.051,0.217) 0.002 0.032 
Triglycerides
a
, mmol/L  0.099 (0.004,0.157) 0.038 0.010  0.105 (0.009,0.162) 0.029 0.040 
Total cholesterol, mmol/L  -0.077 (-0.144,0.014) 0.109 0.006  -0.084 (-0.152,0.010) 0.085 0.034 
Fasting glucose, mmol/L  0.083 (0.001,0.170) 0.046 0.007  0.076 (-0.006,0.163) 0.069 0.021 
Duration of diabetes
a
, years  0.033 (-0.050,0.118) 0.426 0.001  0.039 (-0.044,0.125) 0.348 0.017 
Diet controlled  -0.025 (-0.104,0.055) 0.545 0.001  -0.034 (-0.114,0.046) 0.408 0.016 
Any OAHA use  0.022 (-0.059,0.104) 0.590 -  0.029 (-0.052,0.111) 0.480 0.015 
Insulin therapy  0.016 (-0.070,0.105) 0.696 -  0.017 (-0.069,0.106) 0.676 0.015 
a
 Analysed on the Log10 scale 
Model 1 - Unadjusted model, individual variables with no adjustment 
Model 2 - Individual variables adjusted for age, sex, alcohol excess, hepatotoxic medication use and strongly positive autoantibodies 




5.7 Sensitivity analysis using imputed data 
Due to the relatively large number of subjects in whom ELF (and to a lesser extent, 
CK18) data were unavailable (i.e. ‘missing’ at random) (see section 5.1.2), a 
sensitivity analysis was undertaken using multiple imputation (imputation dataset 
included all 888 subjects eligible for inclusion in the analyses, Figure 5-3).   
Standard procedures were followed with multiple imputation using chained equations 
performed on the liver sub-study data set using variables associated with missingness 
(CK18 and sex) and variables highly correlated with the missing variables.  Options 
available included using all anticipated analysis and outcome variables in a single 
imputation model or developing individual imputed datasets specific to the analysis 
of interest.  It was decided to run an exploratory imputation model to allow 
sensitivity analyses of the descriptive analyses of liver injury markers (section 5.8) 
compared with the original dataset and then to proceed with individualised imputed 
datasets as needed for analysis. 
For the initial imputation model the following variables measured at the liver sub-
study were included: alcohol excess, ALP, ALT, AST, bilirubin, BMI (at baseline), 
CK18, diabetes treatment type, diastolic and systolic blood pressures, duration of 
diabetes, ELF, fasting glucose, ferritin, GGT, HA (at BL), HbA1c, HDL-cholesterol, 
hepatic steatosis, hepatotoxic medication use, LDL-cholesterol, platelets (at 
baseline), prevalent liver disease, sex, smoking status, strongly positive 
autoantibodies, total cholesterol, triglycerides, and waist circumference.  Ten 
iterations and 100 datasets were permitted.  Conditional limits were applied to the 
imputed values: CK18 – minimum 0 and maximum 1000 (assay upper acceptable 
value), ELF minimum 0 and maximum unrestricted.   
Prior to imputation the median CK18 score (n=860) was 102.8 (IQR 76.9-138.3) and 
after imputation the pooled mean of median values (n-939) was 107.9 (sd 0.9).  For 




(n=939) was 8.96.  Given that following imputation the summary values were 
preserved it was felt the imputed dataset was suitable for further use in the thesis.   
The results confirmed those in the original dataset with only minimal differences 
found in effect sizes and significance levels (Table 5-33 and Table 5-34). 
Table 5-33 Imputed data CK18 (U/L) associations. Values are correlation coefficients or mean 
(SEM). 
 All p Steatosis p NAFL/D p 
















Duration of diabetes 0.003 0.939 0.026 0.591 0.023 0.675 
Fasting glucose 0.102 0.005 0.125 0.010 0.084 0.118 
HbA1c 0.075 0.045 0.080 0.098 0.068 0.207 






















Body mass index 0.118 0.001 0.035 0.462 0.078 0.142 
Waist circumference 0.145 <0.001 0.084 0.082 0.128 0.016 
Total cholesterol -0.064 0.154 -0.050 0.375 -0.077 0.222 
Triglycerides
a
































Analysed on the Log10 scale; 
b
 Defined as females >14 units/week, males >21 unis/week or patient 
disclosed history of a current or prior alcohol problem; 
c 
Defined as alcohol excess or ASmA titer 
>1:160 or AMA titer >1:40; 
d 
Defined as the use of (non-topical) glucocorticoids for >1 week, 
isoniazid, methotrexate, amiodarone or tamoxifen within the 6 months prior to the year 1 clinic 




Table 5-34 Imputed data ELF associations. Values are correlation coefficients or mean (SEM) 
 All p 
Hepatic 
steatosis 
p NAFL/D p 













Duration of diabetes 0.137 <0.001 0.152 0.002 0.157 0.005 
Fasting glucose 0.015 0.691 -0.009 0.861 -0.029 0.612 
























BMI 0.136 <0.001 0.183 <0.001 0.204 <0.001 
Waist circumference 0.094 0.013 0.133 0.007 0.159 0.003 
Total cholesterol -0.028 0.551 -0.058 0.331 -0.057 0.388 
Triglycerides
a



































Analysed on the Log10 scale; 
b
 Defined as females >14 units/week, males >21 unis/week or patient 
disclosed history of a current or prior alcohol problem; 
c 
Defined as alcohol excess or ASmA titer 
>1:160 or AMA titer >1:40; 
d 
Defined as the use of (non-topical) glucocorticoids for >1 week, 
isoniazid, methotrexate, amiodarone or tamoxifen within the 6 months prior to the year 1 clinic 
ELF Enhanced Liver Fibrosis pamel; NAFL/D non-alcoholic fatty liver /disease 
5.8 Liver fibrosis marker agreement 
On the assumption that all liver fibrosis markers are trying to diagnose the same 
underlying pathology and in order to try and identify a group of participants with 
probable liver fibrosis I analysed the agreement between five markers of liver 
fibrosis (APRI, AST:ALT ratio, ELF, FIB4 and LSM).  These markers were chosen 
because they were developed based on a range differing biological plausibilities and 
accessibility in clinical practice: AST:ALT ratio – non-specific liver injury; APRI 
and FIB4 – combining non-specific liver injury and portal hypertension; ELF -  




For this analysis, I used the follow up ET2DS study population, since one of the key 
markers (LSM) was not available from earlier phases of the study.  The 831 subjects 
attending the 4 year follow up clinic therefore formed the study population for the 
analysis presented in this section.  As noted previously, differences between 
attenders at baseline and at the follow-up clinic were minimal. In addition, eleven 
patients were excluded from the analysis due to pre-diagnosed liver disease.  767 
subjects had a complete dataset for APRI, AST:ALT ratio, ELF and FIB4 
(proportion missing data, APRI 2.9%, AST/ALT ratio 1.8%, ELF 3.1% and FIB4 
4.2%, all missing at random), and of these LSM was reported for 648 subjects.   
A total of 282 subjects (248 for LSM) fulfilled the criteria for NAFL/D and had a 
complete fibrosis marker dataset. 
LSM was missing in 119 subjects (15.3%) due to a) inability to obtain readings as 
described in Section 5.1.2.  In brief, participants with missing LSM were 
significantly more obese, with poorer glucose control and had higher measres of all 
non-specific liver injury markers (ALT, AST and GGT). 
5.8.1 Correlations 
Correlations between the markers are shown in Table 5-35 (associated scatter plots in 
Appendix L).  After adjustment for age and sex, correlation was strong between 
APRI and FIB4 (r=0.92) but all others were ≤0.5.  The inter-item correlation for all 
five markers was just below acceptable (α=0.67) with minimal improvement with the 






Table 5-35 Correlation between markers.  Values are correlation coefficients, adjusted for age and 
sex 
A. Full cohort  B. NAFL/D cohort 
APRI r=0.30     APRI r=0.32    
ELF r=0.24 r=0.31    ELF r=0.18 r=0.32   
FIB4 r=0.53 r=0.92 r=0.30   FIB4 r=0.53 r=0.93 r=0.29  
LSM r=0.15 r=0.20 r=0.25 r=0.16  LSM r=0.15 r=0.29 r=0.26 r=0.29 
 AST/ALT APRI ELF FIB4   AST/ALT APRI ELF FIB4 
APRI aspartate aminotransferase-platelet ratio index; AST/ALT aspartate aminotransferase-alanine 
aminotransferase ratio; ELF European Liver Fibrosis panel; FIB4 Fibrosis-4 Score; LSM liver stiffness 
measure. 
All p<0.001 
5.8.2 ‘Validated’ cut-offs 
Literature based cut-offs yielded marked differences in the proportions of the cohort 
with probable liver fibrosis in the full cohort: APRI 0.8%, AST/ALT ratio 22.4%, 
ELF 7.0%, FIB4 68.3%, and LSM 4.5%.  And in the NAFL/D subgroup: APRI 
0.4%, AST/ALT ratio 16.7%, ELF 4.3%, FIB4 63.8%, and LSM 4.8%.   
5.8.3 Highest/lowest percentile agreement 
Agreement between the top 5% of the distribution for each marker pair was poor 
(Table 5-36).  APRI and FIB4 had the best positive agreement at 76.4%, but 
agreement for all of the other marker pairs was between 9% and 32%.  When the 
comparison groups were altered to reflect the top 3% and 7% of the marker 
distributions, then with the exception of APRI and FIB4, the agreement did not alter 
greatly (agreement 9-26% and 11-38% respectively).  When analyses were restricted 
to the study population with NAFL/D, agreement between the top 10% of the 
distribution for each marker pair remained generally poor (agreement for APRI and 
FIB4 was 68%, all other pairs between 14% and 36%), as did agreement for the top 
5% and 15% of the distributions (agreements from 0% to 36% and from 21% to 36% 






Table 5-36 Agreement between marker pairs for the top 5% or 10% of values, in the full cohort and 
non-alcoholic fatty liver /disease subgroup. 
A.  Positive agreement (presence of fibrosis) in the top 5% of the full cohort. 
APRI 18.4%     
ELF 18.4% 31.6%    
FIB4 34.2% 76.3% 34.2%   
LSM 9.5% 12.7% 15.9% 12.7%  
 AST:ALT ratio APRI ELF FIB4  
      
B.  Negative agreement (absence of fibrosis) in the bottom 95% of the full cohort. 
APRI 95.7%     
ELF 95.7% 96.4%    
FIB4 96.6% 98.8% 91.8%   
LSM 95.4% 95.5% 95.7% 95.5%  
 AST:ALT ratio APRI ELF FIB4  
 
C.  Positive agreement (presence of fibrosis) in the top 10% of the non-alcoholic fatty liver 
/disease subgroup. 
APRI 28.6%     
ELF 14.3% 28.6%    
FIB4 35.7% 67.9% 32.1%   
LSM 29.2% 20.8% 25.0% 25.0%  
 AST:ALT ratio APRI ELF FIB4  
      
D.  Negative agreement (absence of fibrosis) in the bottom 90% of the non-alcoholic fatty 
liver /disease subgroup. 
APRI 92.1%     
ELF 90.6% 92.1%    
FIB4 92.9% 96.5% 92.5%   
LSM 92.4% 91.5% 9.9% 91.9%  
 AST:ALT ratio APRI ELF FIB4  
APRI aspartate aminotransferase-platelet ratio index; AST:ALT ratio aspartate aminotransferase-







The top viginile (decile in NAFL/D) was suggestive of patients with advanced liver 
fibrosis with clinical data implicating advanced fibrosis/cirrhosis with platelet counts 
being significantly lower and spleen size being significantly larger in the majority of 
cases (Appendix L). 
Negative agreement (agreement on the absence of fibrosis) was more consistent for 
both the full cohort analysis and the NAFL/D subgroup (90-99%) with minimal 
change with the alternative cut-offs described.  2x2 tables are available in the 
supplementary material (Appendix L). 
5.9 Summary 
In this chapter, I found that potential markers of steatohepatitis and liver fibrosis had 
varied relationships with diabetes history. AST:ALT ratio, ELF, FIB4, and LSM 
were statistically associated with hyperglycaemia, and ELF and HA with increasing 
duration of diabetes. Elevated ELF was associated with OAHA and insulin use and 
APRI, FIB4 and NFS with diet control.  Most commonly, elevated markers of 
steatohepatitis and liver fibrosis were associated with older age and higher body fat 
measures (BMI and waist circumference).  However, most of these relationships 
between liver markers and body fat measures lost statistical significance when 
limiting the population to only those with hepatic steatosis and/or NAFL/D.  The 
presumption that poorer diabetes control (indicated by higher HbA1c) would be 








Several studies have found type 2 diabetes to be an independent risk factor for the 
progression of NAFL/D
109,345
.  However, data on the progression to cirrhosis and 
HCC in community-based patients with diabetes is limited.  The ability to identify 
patients with and at risk of developing such clinically significant chronic liver 
disease would promote early intervention strategies and guide clinical follow-up, 
ensuring timely detection of cirrhosis where assimilation into surveillance 
programmes for HCC and varices as well as screening for cardiovascular disease has 
been shown to improve patient outcomes
113,171-173
.  Given the high prevalence of 
abnormal liver enzyme tests and of hepatic steatosis within the type 2 diabetic 
population
165,324
 there is a pressing clinical need to identify those who are most likely 
to progress, as well as those who are not, in order to reduce the costs and anxiety 
resulting from unnecessary investigations or monitoring.   
Within the diabetic population annual liver enzyme checks are commonly performed, 
but there are no clear and consistent national guidelines on their application and 
interpretation, particularly in the community setting.   
Given that I was unable to identify an accurate and reliable non-invasive measure of 
sub-clinical CLD in the pre-ceding chapter, the current chapter focuses on CLD 
identified clinically through standard clinical investigations as the outcome of 
interest.  Moreover, I aimed to investigate whether any of the non-invasive markers 
of sub-clinical CLD presented in the preceding chapter were able to discriminate 







In this chapter I have: 
(i) described the outcome of extensive liver related investigations amongst a 
population at high risk of CLD (older people with type 2 diabetes)  
(ii) described the prevalence (known and unknown) and incidence of clinically 
significant CLD amongst older people with type 2 diabetes. 
(iii) determined the association of metabolic and CLD related risk factors with 
prevalent and incident clinically significant CLD in type 2 diabetes.   
6.1 Follow-up data for clinical chronic liver disease 
In order to investigate clinically significant CLD, clinical CLD follow-up data was 
available in some form for all 939 liver sub-study clinic attenders, including non-
attenders at the follow-up clinic.  All 831 attenders at follow-up completed a patient 
self-report questionnaire.  Of the non-attenders, 147 were still alive, of which 43 had 
a GP questionnaire returned.  All 939 participants had data linkage information on 
hospital discharges related to CLD available.  Subject flow is shown in Figure 6-1A 
6.2 Outcomes of liver related investigations 
Prior to the initial liver sub-study research clinic eight patients had known prevalent 
clinically significant CLD (ALD n=5, NAFLD cirrhosis n=2, primary biliary 
cirrhosis n=1), and were therefore excluded from the investigation of unknown 





Figure 6-1 Subject flow in the investigation and diagnosis of clinically significant CLD 
(a) Research clinic investigation outcomes  (b) Development of clinically significant CLD 
     
CLD chronic liver disease; NHS National Health Service 
 
Following the liver sub-study research clinic investigations 13.4% (125/931) subjects 
met the study protocol criteria as high-risk for the presence of liver disease (section 
4.4.7) and were referred to see a consultant Hepatologist (referral reasons: positive 
autoantibodies n=84, abnormal liver enzymes n=46, elevated HA or AST:ALT n=44, 
enlarged spleen n=11, low platelets n=7, elevated ferritin, alpha-feto protein or 
positive viral serology n=6, cirrhosis on USS n=1).  Subjects meeting the criteria for 
referral were significantly more likely to be female (59.2 vs 46.3 %, p=0.009), have 
poorer diabetes control (mean fasting glucose 7.60 mmol/L (sd 3.0) vs 6.76 mmol/L 
(2.2) p=0.003, mean HbA1c 7.37 % (sd 1.2) vs 7.17 % (1.1) p=0.047), higher total 
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n=125 
Offered a NHS 
Hepatology 
appointment n=52 






































likely to have a known risk factor for CLD (alcohol excess 20.8 % vs 11.6% 
p=0.006, positive autoantibodies 3.2 % vs 0.4% p=0.010) (Table 6-1). 
Of those subjects who met the specialist Hepatology referral criteria, 52 (41.6%) 
were offered an appointment at an NHS Hepatology clinic and the remainder 
returned to standard care after triage by a consultant Hepatologist.  The referrals 
were split between two consultant Hepatologists who reviewed the triggering 
result(s) and considered it/them within the clinical context.  The majority of those not 
seen had low level titres of positive autoantibodies or isolated mildly elevated liver 
enzymes only.  Similarly to those referred, those actually seen had significantly 
poorer diabetes control (mean fasting glucose 7.93 mmol/L (sd 3.3) vs 6.81 mmol/L 
(2.2) p=0.021, mean HbA1c 7.69 % (sd 1.3) vs 7.17 % (1.0) p=0.008) and were more 
likely to have a known risk factor for CLD (34.6% vs 20.4% p=0.022) (Table 6-1). 
Of those referrals seen, 31 (59.6%) were immediately discharged following initial 
assessment on the basis of having either simple fatty liver with low risk for the 
presence of significant liver fibrosis and/or false positive indicators of clinically 
significant CLD.  Twenty-one subjects (40.4%; NAFL/D n=16, mixed 
ALD/NAFL/D n=2, ALD n=1, primary biliary cirrhosis n=1, hepatitis B viruS n=1) 






















         
Age, years  68.9 (4.2)  69.3 (4.3) 0.224  69.3 (4.6) 0.423 
Sex, % male  
52.3% 
(483) 
 40.8 (51) 0.007  40.4 (21) 0.087 
















         
Random glucose, mmol/L  6.89 (2.3)  7.60 (3.0) 0.003  7.93 (3.3) 0.021 
HbA1c, %  7.20 (1.1)  7.37 (1.2) 0.046  7.69 (1.3) 0.008 
Duration of diabetes, % <5 
years 
























         
BMI, kg/m
2
  31.3 (5.7)  31.7 (6.1) 0.411  32.0 (6.6) 0.414 
Total cholesterol, mmol/L  4.4 (0.8)  4.3 (0.8) 0.021  4.1 (0.8) 0.690 
Triglycerides, mmol/L  1.66 (0.9)  1.74 (1.0) 0.305  1.50 (0.6) 0.073 
sBP, mmHg  
138.2 
(18.5) 
 140.6 (18.6) 0.115  138.7 (17.1) 0.845 
         




 20.9 (193)  31.2 (39) 0.004  34.6 (18) 0.021 
Alcohol excess
b
, %  12.8 (118)  20.8 (26) 0.006  21.2 (11) 0.084 
Hepatotoxic medication
c
, %  9.2 (6)  10.4 (13) 0.618  11.5 (6) 0.467 
Positive autoantibodies
d
, %  0.7 (6)  3.2 (4) 0.005  3.8 (2) 0.046 
BMI body mass index; IQR inter-quartile range; OAHA oral anti-hyperglycaemic agent; sBP systolic 
blood pressure; sd standard deviation; SIMD Scottish Index of Multiple Deprivation 
a
 Defined as any of b-d below; 
b
 Defined as females >14 units/week, males >21 unis/week or patient 
disclosed history of a current or prior alcohol problem; 
c 
Defined as the use of (non-topical) 
glucocorticoids for >1 week, isoniazid, methotrexate, amiodarone or tamoxifen within the 6 months 
prior to the liver assessment; 
d 




6.3 Association of potential risk factors with unknown prevalent 
clinically significant chronic liver disease 
In addition to the known eight prevalent clinically significant CLD cases, as a 
consequence of the liver sub-study investigations, 13 (1.4%) patients were diagnosed 
with previously unknown prevalent clinically significant CLD (including one HCC, 
the remainder cirrhosis).  The reasons for their initial referral were wide-ranging and 
are shown in Table 6-2. All patients with unknown prevalent clinically significant 
CLD had abnormal liver enzymes, and each had between 2 and 6 of the referral 
criteria. 
Whilst a the presence of abnormal LFTs or an elevated HA had a high specificity for 
detecting unknown clinically significant CLD they were associated with a low 
(<10%) PPV, meaning large numbers of false positives were detected. The best 
combination of the most sensitive of the routinely measured markers only improved 
the PPV to 48%.  
Risk factors with a statistically significant association with unknown prevalent cases 
were: elevated liver enzymes (but not ALT), inflammatory markers (CRP, IL6, 
TNFα), steatohepatitis markers (CK18) and liver fibrosis markers (APRI, AST:ALT 
ratio, ELF, FIB4, HA, NFS) (all p <0.01, Table 6-3 and Table 6-4).  Given these 
associations the ‘validated’ cut-offs for NAFLD, as described in previous chapters, 
were trialled as diagnostic tests (Table 6-5). As previously the PPV of the tests 
remain poor resulting in large numbers of false positive results. 






Table 6-2 Diagnostic accuracy of referral criteria, and combinations, for unknown prevalent 









Abnormal ALT  
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 defined as ALT >50U/L, AST >45 U/L, or GGT >55U/L; 
b
total n=696 
ALT alanine aminotransferase; AST aspartate aminotransferase; GGT gamma glutamyltransferase; 
HA hyaluronic acid; LFT liver function test; NPV negative predictive value; PPV positive predictive 





Table 6-3 Potential risk factors (CONTINUOUS) for unknown prevalent CS-CLD.  Values are mean 









OR (95% CI) p 
     
Age, years 68.9 (4.2) 69.5 (4.9) 1.04 (0.91,1.18) 0.600 
     
Glucose, mmol/L 6.87 (2.3) 7.53 (3.2) 1.11 (0.91,1.35) 0.301 
HbA1c, % 7.19 (1.1) 7.34 (0.8) 1.13 (0.70,1.84) 0.615 
     
BMI, kg/m
2
 31.2 (5.6) 33.4 (6.7) 1.06 (0.98,1.16) 0.161 
Cholesterol, mmol/L 4.2 (0.8) 3.9 (0.5) 0.68 (0.32,1.43) 0.310 
Triglycerides, mmol/L 1.67 (0.9) 1.25 (0.3) 0.39 (0.14,1.11) 0.078 
sBP, mmHg 138.2 (18.4) 136.9 (16.7) 1.00 (0.97,1.03) 0.805 
     
CRP
b
, mg/L 1.69 (0.8-3.9) 2.72 (1.4-11.6) 1.83 (1.14,2.94) 0.013 
IL6
b
, pg/ml 2.70 (1.9-4.2) 6.03 (3.1-9.6) 3.13 (1.53,6.40) 0.002 
TNF
b
, pg/ml 1.03 (0.6-1.5) 1.04 (0.9-2.5) 2.11 (1.05,4.22) 0.035 
     
ALT, U/L 33.3 (12.7) 39.0 (12.6) 1.03 (1.00-1.06) 0.108 
AST, U/L 30.0 (9.5) 49.7 (12.6) 1.09 (1.06-1.13) <0.001 
GGT
b
, U/L 16.0 (10.0-26.0) 55.0 (34.0-103.0) 5.35 (2.91,9.83) <0.001 
CK18
b
, U/L 100.6 (76.2-135.5) 152.7 (143.1-207.9) 3.42 (1.59,7.34) 0.002 
APRI
b
 0.24 (0.19-0.32) 0.67 (0.35-0.92) 87.7 (20.8,369.6) <0.001 
AST:ALT 0.95 (0.3) 1.33 (0.3) 2.55 (1.22,5.34) 0.013 
ELF score 8.9 (0.8) 10.9 (1.0) 4.38 (2.20,8.70) <0.001 
FIB4 score 1.50 (0.6) 3.96 (2.0) 7.81 (3.93,15.5) <0.001 
HA
b
, micrg/L 50.6 (34.8-81.4) 220.3 (177.9-318.9) 16.4 (5.35,50.1) <0.001 
NFS -0.40 (1.1) 1.38 (1.5) 3.99 (2.36,6.73) <0.001 
a 
CS-CLD defined as cirrhosis, hepatocellular carcinoma or gastro-oesophageal varices;  
b
 Analysed on 
the Ln scale: odds ratios for a one unit increase in the ln of the risk factor 
ALT alanine aminotransferase; APRI Aspartate to Platelet Ratio Index; AST aspartate 
aminotransferase; CK18 cytokeratin-18; CRP C-reactive protein; CS-CLD clinically significant chronic 
liver disease; ELF Enhanced Liver Fibrosis; FIB4 Fibrosis-4; GGT gamma glutamyltransferase; HA 
hyaluronic acid; HR hazard ratio; IL6 interleukin-6; IQR inter-quartile range; NFS NAFLD Fibrosis 





Table 6-4 Potential risk factors (CATEGORICAL) for unknown prevalent clinically significant CLD.  














OR (95% CI) p 
       














       
Duration of diabetes >5 
years, % 




















       




 20.7 (187)  30.8 (4) 1.70 (0.52,5.59) 0.488 
Alcohol excess
c
, %  12.6 (113)  23.1 (3) 2.09 (0.57,7.71) 0.268 
       
ALT >50 U/L, %  7.8 (70)  23.1 (3) 3.56 (0.96,13.2) 0.058 
AST >45 U/L, %  6.8 (61)  69.2 (9) 30.8 (9.22,102.9) <0.001 
GGT >55 U/L, %  7.9 (71)  69.2 (9) 26.2 (7.87,87.1) <0.001 
AST:ALT ratio >1, %  35.7 (320)  76.9 (10) 6.00 (1.64,22.0) 0.007 
Hepatic steatosis, %  56.8 (513)  46.2 (6) 0.65 (0.22,1.95) 0.445 
Spleen >13 cm, %  4.1 (37)  69.2 (9) 52.5 (15.5,178.5) <0.001 
Platelets <150x10
9
/L, %  3.0 (27)  46.2 (6) 27.3 (8.59,86.6) <0.001 
a
 clinically significant CLD defined as cirrhosis, hepatocellular carcinoma or gastro-oesophageal 
varices; 
b 
Defined as any of: alcohol excess, hepatotoxic medication use (use of (non-topical) 
glucocorticoids for >1 week, isoniazid, methotrexate, amiodarone or tamoxifen within the 6 months 
prior to the liver assessment) or positive autoantibodies (ASMA titre >1:160 or AMA titre >1:40); 
c
 
Defined as females >14 units/week, males >21 unis/week or patient disclosed history of a current or 
prior alcohol problem 
ALT alanine aminotransferase; AST aspartate aminotransferase; CLD chronic liver disease; GGT 





Table 6-5 Diagnostic test accuracy of pre-determined cut-offs of biomarkers for the detection of 













Sens., % Spec., % PPV, % NPV, % 
























































APRI Aspartate to Platelet Ratio Index; CK18 cytokeratin-18; CS-CLD clinically significant chronic liver 
disease; ELF Enhanced Liver Fibrosis; FIB4 Fibrosis-4; NFS NAFLD Fibrosis Score; NPV negative 
predictive value; PPV positive predictive value; sens. sensitivity; spec. specificity. 
6.4 Association of potential risk factors with incident clinically 
significant chronic liver disease 
Following the initial liver sub-study research clinic 918 patients (Figure 6-1B) did 
not have prevalent clinically significant CLD.   
Over a mean follow-up period of 5.6 years (sd 1.0, total 5156 person-years) there 
were 15 incident cases of clinically significant CLD, IR 2.9 /1000 person-years.  
These comprised cirrhosis n=14 (2.7 /1000 person-years), HCC n=4 (0.8 /1000 
person-years), and gastro-oesophageal varices n=5 (1.0 /1000 person-years), with 
some patients having more than one complication. The underlying causes were 
attributed to: NAFLD n=12, mixed ALD/NAFLD n-1, ALD n=1 and HBV n=1.   
Patients identified as potentially high risk after the liver sub-study investigations 




liver disease (IR 10.9 vs 1.8 /1000 person-years, p=0.001).  However, of the 15 
patients that developed incident clinically significant CLD less than half (n=7, 
46.7%) were identified as high-risk by the extensive liver-related investigations at 
the year 1 clinic. Of the incident HCC, only 1 (25.0%) occurred in a subject 
identified through the year 1 investigations.  The majority of cases of varices (n=3, 
60.0%) were identified through entry into an endoscopic surveillance programme 
after being reviewed in an NHS Hepatology clinic following the research clinic. 
Rates of incident clinically significant CLD were significantly higher in those: seen 
in the NHS Hepatology clinic (IRR 18.7, 95%CI 6.5-54.0, p<0.001), with abnormal 
liver enzymes (IRR 5.7, 95%CI 2.0-16.0, p=0.001) and with very abnormal liver 
enzymes (IRR 16.3, 95%CI 5.2-50.9, p<0.001).  Individuals with hepatic steatosis or 
elevated liver enzymes as defined by the lower revised laboratory reference ranges 
had incidence rates of clinically significant CLD not significantly different to those 
without (IRR 2.9, p=0.096 and IRR 1.2, p=0.800 respectively) (Table 6-6).  
Patients with abnormal liver enzymes at the liver sub-study research clinic were 
more likely to develop incident clinically significant CLD, (normal 7/776, 0.9%; 
abnormal 3/113, 2.7%; very abnormal 5/26, 19.2%; p<0.001).  In those developing 
incident clinically significant CLD, mean/median levels of liver enzymes were 
higher, however they remained broadly within normal laboratory limits for 
transaminases (ALT 44.4 U/L, AST 46.0 U/L), with median GGT levels above the 
upper limit of normal (median 62 vs 16 U/L, p<0.001), overall 47% of those with 





Table 6-6 Incidence of developing clinically significant CLD by potential risk factors.  Values are 
incidence rates per 1000 person-years and incidence rate ratios. 
 
Had potential risk 
factor 
n            IR
a
 
Did NOT have 
potential risk factor 
n            IR
a
 
IRR 95% CI p 
Seen by Hepatology 
services 
42 30.4 876 1.6 18.  7 (6.45,54.01) <0.001 




28 32.9 881 2.0 16.3 (5.21,50.93) <0.001 
Met high risk criteria 
following liver 
assessment 
115 10.9 803 1.8 6.1 (2.18,17.23) 0.001 




151 9.4 761 1.6 5.7 (2.04,16.01) 0.001 
Hepatic steatosis 525 4.0 393 1.4 2.9 (0.82,10.50) 0.096 





701 3.0 212 2.6 1.2 (0.33,4.23) 0.800 
a 
Incidence rate /1000 person-years; 
b
 Defined as any of alanine aminotransferase (ALT) >50U/L, 
aspartate aminotransferase (AST) >45 U/L, gamma glutamyltransferase (GGT) >55U/L; 
c
 Defined as 
any of ALT >100U/L, AST >90 U/L, GGT >110U/L; 
d
 Defined as any of ALT >30U/L (male), ALT>19U/L 
(female), AST >45 U/L, GGT >55U/L 
CLD chronic liver disease; IR incidence rate; IRR incidence rate ratio. 
 
Table 6-7 and Table 6-8 show the associations between potential risk factors and 
incident clinically significant CLD.  There were no statistically significant 
differences in the age, sex or diabetes history of individuals developing clinically 
significant CLD compared to those who did not.  The only metabolic risk factor 
statistically significantly associated with incident clinically significant CLD was 
increasing BMI (HR 1.09 p=0.016).  Established hepatotoxic causes of liver disease 
were similar in both groups (p=0.123).  Higher levels of markers of systemic 
inflammation were statistically significantly associated with an increased incidence 
of clinically significant CLD (ln CRP HR 1.66 p=0.026, ln IL-6 HR 2.86 p=0.002, ln 
TNF-  HR 2.12 p=0.017). 
Nearly all patients (80.0%) with incident clinically significant CLD had hepatic 




the continuous markers of steatohepatitis and liver fibrosis (except AST:ALT ratio) 
were higher in those with incident clinically significant CLD than in those without 
(Table 6-7).   
Given these associations the ‘validated’ cut-offs for NAFLD biomarkers, as 
described in previous chapters, were trialled as diagnostic tests alongside more 
commonly used clinical markers (Table 6-9). As previously the PPV of the tests 





Table 6-7 Potential risk factors (CONTINUOUS) for incident clinically significant CLD.  Values are 










HR (95% CI) p 
     
Age, years 68.9 (4.2) 69.8 (4.1) 1.07 (0.94,1.21) 0.306 
     
Fasting glucose, mmol/L 6.87 (2.3) 6.98 (2.8) 1.21 (0.78,1.88) 0.405 
HbA1c, % 7.19 (1.1) 7.53 (1.5) 1.02 (0.98,1.06) 0.405 
     
BMI, kg/m
2
 31.2 (5.6) 34.8 (7.4) 1.09 (1.02,1.17) 0.016 
Cholesterol, mmol/L 4.2 (0.8) 3.9 (0.8) 0.66 (0.33,1.34) 0.248 
Triglycerides, mmol/L 1.67 (0.9) 1.46 (0.4) 0.70 (0.32,1.54) 0.371 
sBP, mmHg 138.2 (18.4) 135.6 (21.6) 0.99 (0.96,1.02) 0.522 
     
CRP
b
, mg/L 1.69 (0.8-3.9) 3.98 (1.9-13.6) 1.66 (1.06,2.60) 0.026 
IL6
b
, pg/ml 2.70 (1.9-4.2) 5.31 (3.4-8.6) 2.86 (1.49,5.49) 0.002 
TNF
b
, pg/ml 1.03 (0.6-1.5) 1.45 (1.1-2.9) 2.12 (1.14,3.92) 0.017 
     
ALT, U/L 33.3 (12.7) 44.4 (23.6) 1.04 (1.01,1.06) 0.002 
AST, U/L 30.0 (9.5) 46.0 (23.7) 1.07 (1.04,1.09) <0.001 
GGT
b
, U/L 16.0 (10.0-26.0) 62.0 (21.5-185.0) 3.56 (2.17,5.83) <0.001 
CK18
b
, U/L 100.6 (76.2-135.5) 127.6 (83.4-586.5) 4.10 (2.08,8.06) <0.001 
APRI
b
 0.24 (0.19-0.32) 0.39 (0.29-0.88) 20.4 (6.81,61.0) <0.001 
AST:ALT 0.95 (0.3) 1.10 (0.3) 1.56 (0.93,2.64) 0.094 
ELF score 8.9 (0.8) 10.2 (1.0) 1.64 (1.30,2.06) <0.001 
FIB4 score 1.50 (0.6) 2.56 (1.3) 4.08 (2.71,6.15) <0.001 
HA
b
, micrg/L 50.6 (34.8-81.4) 183.2 (78.9-230.6) 5.80 (2.60,13.0) <0.001 
NFS -0.40 (1.1) 0.74 (1.0) 2.18 (1.54,3.09) <0.001 
a 
clinically significant CLD defined as cirrhosis, hepatocellular carcinoma or gastro-oesophageal 
varices;  
b
 Analysed on the Ln scale: hazard ratios for a one unit increase in the ln of the risk factor. 
ALT alanine aminotransferase; APRI Aspartate to Platelet Ratio Index; AST aspartate 
aminotransferase; CK18 cytokeratin-18; CLD chronic liver disease; CRP C-reactive protein; ELF 
Enhanced Liver Fibrosis; FIB4 Fibrosis-4; GGT gamma glutamyltransferase; HA hyaluronic acid; HR 
hazard ratio; IL6 interleukin-6; IQR inter-quartile range; NFS NAFLD Fibrosis Score; OR odds ratio; sd 





Table 6-8 Potential risk factors (CATEGORICAL) for incident clinically significant CLD.  Values are % 














HR (95% CI) p 
       















       
Duration of diabetes >5 
years, % 

























 20.7 (187)  40.0 (6) 2.44 (0.87,6.85) 0.091 
Alcohol excess
c
, %  12.6 (113)  20.0 (3) 1.63 (0.46,5.77) 0.451 
       
ALT >50 U/L, %  7.8 (70)  40.0 (6) 6.69 (2.38,18.8) <0.001 
AST >45 U/L, %  6.8 (61)  40.0 (6) 8.30 (2.94,23.43) <0.001 
GGT >55 U/L, %  7.9 (71)  53.3 (8) 13.2 (4.79,36.6) <0.001 
AST:ALT ratio >1, %  35.7 (320)  60.0 (9) 3.67 (1.29,10.44) 0.015 
Hepatic steatosis, %  56.8 (513)  80.0 (12) 2.93 (0.83,10.38) 0.096 
Spleen >13 cm, %  4.1 (37)  0 - - 
Platelets <150x10
9
/L, %  3.0 (27)  14.3 (2) 4.36 (0.97,19.6) 0.055 
a
 clinically significant CLD defined as cirrhosis, hepatocellular carcinoma or gastro-oesophageal 
varices; 
b 
Defined as any of: alcohol excess, hepatotoxic medication use (use of (non-topical) 
glucocorticoids for >1 week, isoniazid, methotrexate, amiodarone or tamoxifen within the 6 months 
prior to the liver assessment) or positive autoantibodies (ASMA titre >1:160 or AMA titre >1:40); 
c
 
Defined as females >14 units/week, males >21 unis/week or patient disclosed history of a current or 
prior alcohol problem 
ALT alanine aminotransferase; AST aspartate aminotransferase; CLD chronic liver disease; GGT 






Table 6-9 Diagnostic test accuracy of pre-determined cut-offs of biomarkers for the detection of 






































































































 Defined as ALT >50U/L, AST >45 U/L, or GGT >55U/L 
ALT alanine aminotransferase; APRI Aspartate to Platelet Ratio Index; AST aspartate 
aminotransferase; CK18 cytokeratin-18; ELF Enhanced Liver Fibrosis; FIB4 Fibrosis-4; HA hyaluronic 





6.5 Overall burden of clinically significant chronic liver disease 
By the end of the follow-up period, 36 patients were identified as having either new 
or existing clinically significant CLD.  This included eight known prevalent cases 
(all cirrhosis), 13 unknown prevalent cases diagnosed as a result of the liver sub-
study investigations (12 cirrhosis only and 1 cirrhosis and HCC) and 15 incident 
cases during the follow-up period (7 with cirrhosis only, 2 cirrhosis and HCC, 4 
cirrhosis and varices, 1 cirrhosis, HCC and varices and 1 HCC only).  Of the 36 
patients, in total there were 35 (3.7%) cases of cirrhosis, 9 (1.0%) HCC cases, and 11 
(1.2%) cases of gastro-oesophageal varices.  Of note there was 1 HCC occurring in a 
patient without cirrhosis.   
Potential risk factor associations with the total burden of clinically significant CLD 
are shown in Table 6-7 and Table 6-8.  Findings were similar to those for incident 
clinically significant CLD, with the addition of statistical association with surrogate 
markers of portal hypertension (platelet count <150x10
9






Table 6-10 Potential risk factors (CONTINUOUS) for ever developing clinically significant CLD.  
Values are odds ratios (95%CI).   
  OR (95% CI)  p 
    
Age, years  1.06(0.98,1.15) 0.133 
    
Fasting glucose, mmol/L  1.04 (0.91,1.20) 0.545 
HbA1c, %  1.00 (0.73,1.37) 0.984 
    
BMI, kg/m
2
  1.06 (1.01,1.11) 0.020 
Cholesterol, mmol/L  0.66 (0.42,1.04) 0.073 
Triglycerides, mmol/L  0.57 (0.33,1.00) 0.051 
sBP, mmHg  0.99 (0.97,1.01) 0.254 
    
CRP
a
, mg/L  1.75 (1.32,2.32) <0.001 
IL6
a
, pg/ml  2.64 (1.72,4.04) <0.001 
TNF
a
, pg/ml  2.30 (1.55,3.41) <0.001 
    
ALT, U/L  1.03 (1.01,1.05) 0.001 
AST, U/L  1.07 (1.05,1.08) <0.001 
GGT
a
, U/L  3.84 (2.84,5.20) <0.001 
CK18
a
, U/L  3.50 (2.25,5.45) <0.001 
APRI
a
  19.44 (10.83,34.88) <0.001 
AST:ALT  1.75 (1.34,2.28) <0.001 
ELF score  1.66 (1.45,1.91) <0.001 
FIB4 score  2.30 (1.98,2.68) <0.001 
HA
a
, micrg/L  6.11 (3.67,10.15) <0.001 
NFS  2.43 (1.97,2.99) <0.001 
a
 Analysed on the Ln scale: odds ratios for a one unit increase in the ln of the risk factor 
ALT alanine aminotransferase; APRI Aspartate to Platelet Ratio Index; AST aspartate 
aminotransferase; CK18 cytokeratin-18; CRP C-reactive protein; ELF Enhanced Liver Fibrosis; FIB4 
Fibrosis-4; GGT gamma glutamyltransferase; HA hyaluronic acid; IL6 interleukin-6; IQR inter-quartile 






Table 6-11 Potential risk factors (CATEGORICAL) for ever developing clinically significant CLD.  
Values are odds ratios (95% CI).   
  OR (95% CI) p 
    









    












    
Established hepatotoxic cause
a
, %  2.85 (1.48,5.51) 0.002 
Alcohol excess
b
, %  2.16 (1.01,4.59) 0.046 
    
ALT >50 U/L, %  4.29 (2.11,8.73) <0.001 
AST >45 U/L, %  12.49 (6.48,24.08) <0.001 
GGT >55 U/L, %  16.11 (8.23,31.51) <0.001 
AST:ALT ratio >1, %  4.57 (2.27,9.21) <0.001 
Hepatic steatosis, %  0.93 (0.48,1.79) 0.819 
Spleen >13 cm, %  7.83 (3.76,16.31) <0.001 
Platelets <150x10
9
/L, %  10.61 (5.19,21.72) <0.001 
a
Defined as any of: alcohol excess, hepatotoxic medication use (use of (non-topical) glucocorticoids 
for >1 week, isoniazid, methotrexate, amiodarone or tamoxifen within the 6 months prior to the liver 
assessment) or positive autoantibodies (ASMA titre >1:160 or AMA titre >1:40); 
b
Defined as females 
>14 units/week, males >21 unis/week or patient disclosed history of a current or prior alcohol 
problem. 
ALT alanine aminotransferase; AST aspartate aminotransferase; GGT gamma glutamyltransferase; 






In this chapter, I found that the prevalence of clinically significant CLD (defined as 
cirrhosis, HCC or gastro-oesophageal varices) was 2.2% - 0.8% diagnosed prior to 
enrolment with an additional 1.4% identified by study investigations.  Over nearly 6 
years of follow-up, only 1.4% of the cohort developed incident clinically significant 
CLD. 
Higher levels of systemic inflammation, steatohepatitis and hepatic fibrosis markers 
were associated with both unknown prevalent and incident clinically significant 
chronic liver disease (all p<0.001).  Less than half of participants developing incident 
significant disease were identified as high risk by the study investigations.  Abnormal 
liver enzymes were associated with incident cases (IRR 5.7, p=0.001), the presence 
of hepatic steatosis was not.  Several markers had good sensitivity for the 
identification of CS-CLD but poor PPV (<10%) meant high numbers of false 






Patients with chronic liver disease, and in particular NAFL/D, are known to have 
both higher all-cause mortality
171,172
 and CV mortality rates than the general 
population
113,173
.  Although links between liver disease and CVD have frequently 
been attributed to the inter-relationships between NAFL/D, obesity and the metabolic 
syndrome, it has emerged that there is an increased risk of CV events in subjects with 
NAFLD, independent of these traditional risk factors
188,189,346,347
.   
To date, the most commonly cited hepatic marker of CV mortality
193,198
 and incident 
CVD
186,187
 is plasma GGT.  However, reports are conflicting with some refuting the 
association
173,192
 and others finding attenuation with increasing age
200
.  It is not clear 
if the relationship relates to a specific hepatic influence on CVD or whether GGT is a 
surrogate marker for systemic inflammation.   
Despite extensive studies of GGT there has been little investigation of the 
relationship between CVD and other markers of liver injury (non-specific liver 
injury, steatosis, steatohepatitis, liver fibrosis or portal hypertension).   
In this chapter I have: 
(i) described the association of a range of liver markers with both prevalent and 
incident CV events and mortality.  Liver markers include: non-specific liver 
injury (ALT, AST and GGT), steatosis, steatohepatitis (CK18), liver fibrosis 
(APRI, ELF, FIB4, NFS), and surrogates of portal hypertension (platelet 
count)  
7.1 Study population 
In order to maximise the follow-up time available for incident CVD events to occur 
where possible baseline liver markers were used (ALT, APRI, AST, AST:ALT ratio, 




was unavailable (steatosis, CK18 and ELF).  Figure 7-1 shows the subject flow and 
data availability for the analyses in this chapter.  ELF data was available on a limited 
random subgroup of n=679 subjects (missing data discussed previously Section 
5.1.2).   
Figure 7-1 Flowchart of cardiovascular outcomes in the Edinburgh Type 2 Diabetes Study 
 
ALT alanine aminotransferase; AST aspartate aminotransferase; baseline baseline; CK18 cytokeratin-
18; CV cardiovascular; ECG electro-cardio graph; GGT gamma glutamyltransferase; liver sub-study 
liver study; 
7.2 Association of liver markers with cardiovascular events 
There were 372/1033 (36.0%) patients with prevalent CVD and 319/1033 (30.9%) 
with prevalent CAD at baseline.  A significantly higher proportion of those with 
CVD and CAD were male (both 61.8%, p<0.001).  Those with CVD and CAD were 
older (mean 68.4 vs 67.6 years, p=0.004, and 68.6 vs 67.6 years, p<0.001, 
respectively) than those without.  Full results of the associations between established 
risk factors for CVD and prevalent CVD are shown in Table 7-1. Results were 
similar for the 1 year assessment with 303/858 (35.3%) patients with prevalent CVD 
and 260/858 (30.3%) with prevalent CAD at baseline.  Again those with CVD and 





Data linkage for CV events 
n=1066 
ALT, APRI, AST, AST:ALT ratio, FIB4, GGT and 
platelet count measured n=1033 
CV assessment (questionnaire/ECG/data 
linkage) 
CK18 and steatosis measured n858 
ELF measured n=679 





Table 7-1 Association of established cardiovascular risk factors with prevalent clinical 













Age, years 68.4 (4.4) 67.8 (4.1) 0.005 68.6 (4.4) 67.6 (4.1) 0.001 


















































  31.6 (5.4) 31.1 (5.7) 0.190 31.6 (5.4) 31.2 (5.7) 0.253 









dBP, mmHg  68.1 (9.5) 69.7 (8.7) 0.008 67.9 (9.6) 69.6 (8.7) 0.003 
Lipid lowering 
therapy, % yes 
92.4 (342) 81.8 (541) <0.001 93.4 (296) 82.2 (587) <0.001 
BP lowering  
therapy, %yes 
90.8 (335) 77.6 (510) <0.001 91.8 (290) 78.2 (555) <0.001 
HDL cholesterol,  1.20 (0.3) 1.35 (0.4) <0.001 1.20 (0.3) 1.34 (0.4) <0.001 
Total cholesterol,  4.21 (0.9) 4.35 (0.9) 0.013 4.18 (0.9) 4.35 (0.9) 0.004 
Smoking: % ever 68.2 (202) 56.8 (325) 0.001 67.9 (169) 57.8 (358) 0.007 
Alcohol excess, % 
yes  
9.5 (35) 7.4 (49) 0.285 9.1 (29) 7.7 (55) 0.459 
eGFR, 62.1 (16.0) 65.7 (13.9) <0.001 61.5 (15.9) 65.7 (14.0) <0.001 
BMI body mass index; BP blood pressure; CAD coronary artery disease; CVD cardiovascular disease; 
dBP diastolic BP; eGFR estimated glomerular filtration rate; HDL high density lipoprotein; OAHA oral 




Table 7-2 shows the mean/median values of each of the markers of liver injury in 
those with and without prevalent CV events.  Mean ALT was marginally lower in 
those with prevalent CVD (41.9 vs 43.7 U/L, p=0.048).  GGT values were 
statistically significantly higher than in those with both prevalent CVD and CAD 
(median 20.0 vs 17.0 U/L, p<0.001, for both) (p<0.001) – although all median levels 
were within the normal range.  Surprisingly, whilst just missing statistical 
significance, the presence of hepatic steatosis was more frequently found in the 
absence of CV events (CVD 54.1 vs 57.5% and CAD 51.2 vs 58.5%). 
Multivariable analysis adjusting for age, sex, duration of diabetes, treatment of 
diabetes, lipid lowering drugs, blood pressure lowering drugs, deprivation, smoking 
status, excess alcohol consumption, BMI, systolic blood pressure, HbA1c, HDL 
cholesterol, total cholesterol and eGFR is shown in Table 7 3 and Table 7 4.  GGT 
was the only liver marker independently statistically associated with prevalent CVD 







Table 7-1 Association of markers of liver injury with prevalent clinical cardiovascular events in all patients, values are mean (sd), median (IQR) or % (n). 
  CVD, yes CVD, no p  CAD, yes CAD, no p 
ALT, U/L  41.9 (12.6) 43.7 (14.2) 0.048  42.1 (13.0) 43.5 (14.0) 0.164 
AST, U/L  30.4 (10.5) 31.3 (10.0) 0.178  30.5 (11.0) 31.2 (9.8) 0.282 
GGT, U/L   20.0 (13-37) 17.0 (10-29) <0.001  20.0 (13-37) 17.0 (11-29) <0.001 
         
Steatosis, % yes  54.1 (164) 57.5 (319) 0.350  51.2 (133) 58.5 (350) 0.051 
         
CK18, U/L  100.7 (79-141) 104.8 (77-137) 0.911  99.1 (74-138) 105.8 (78-138) 0.589 
         
APRI  0.25 (0.19-0.35) 0.25 (0.20-0.33) 0.848  0.25 (0.19-0.36) 0.25 (0.20-0.33) 0.860 
AST/ALT ratio  0.74 (0.2) 0.73 (0.2) 0.759  0.74 (0.2) 0.74 (0.2) 0.869 
ELF score  8.9 (0.8) 8.9 (0.9) 0.930  8.9 (0.8) 8.9 (0.9) 0.950 
FIB4  1.39 (0.7) 1.34 (0.6) 0.164  1.42 (0.7) 1.33 (0.6) 0.060 
NFS  -27.0 (2.5) -27.4(2.6) 0.018  -26.9 (2.5) -27.4 (2.6) 0.010 
         
Platelets, x10
9
/L  254.5 (72.9) 260.1 (67.8) 0.240  252.4 (74.3) 260.8 (67.4) 0.094 
ALT alanine aminotransferase; APRI aspartate aminotransferase to platelet ratio index; AST aspartate aminotransferase, CAD coronary artery disease; CK18 








Table 7-2 Multivariable association between liver markers and all prevalent cardiovascular events.  Values are odds ratios (95%CI) 
  Model 1 p  Model 2 p Model 3 p 
ALT, U/L  0.990 (0.979,1.001) 0.079  0.987 (0.976,0.999) 0.028 0.989 (0.977,1.002) 0.088 
AST, U/L  0.993 (0.979,1.007) 0.341  0.990 (0.975,1.005) 0.174 0.993 (0.977,1.009) 0.385 
GGT, U/L
1
  1.211 (1.073,1.366) 0.002  1.195 (1.057,1.352) 0.005 1.178 (1.025,1.355) 0.021 
         
Steatosis, % yes  0.907 (0.676,1.218) 0.518  0.957 (0.708,1.298) 0.774 0.837 (0.599,1.169) 0.296 
         
CK18, U/L
1
  1.080 (0.895,1.304) 0.421  1.085 (0.896,1.313) 0.405 0.990 (0.805,1.218) 0.926 
         
APRI
1
  0.976 (0.778,1.225) 0.833  0.852 (0.670,1.082) 0.189 0.904 (0.701,1.67) 0.439 
AST:ALT ratio  1.342 (0.561,3.212) 0.509  1.392 (0.564,3.435) 0.473 1.507 (0.558,4.074) 0.419 
ELF score  1.002 (0.828,1.213) 0.984  1.005 (0.818,1.234) 0.964 0.940 (0.744,1.188) 0.604 
FIB4  1.128 (0.903,1.410) 0.289  1.012 (0.799,1.282) 0.921 1.033 (0.801,1.332) 0.801 
NFS  1.043 (0.986,1.103) 0.144  1.063 (1.003,1.127) 0.038 1.043 (0.971,1.120) 0.248 
         
Platelets, x10
9
/L  0.999 (0.997,1.001) 0.569  1.001 (0.998,1.003) 0.499 1.000 (0.998,1.002) 0.734 
1
 APRI, CK18 and GGT analysed on the Log2 scale for linearization, therefore odds ratios relate to a doubling of the marker. 
Model 1 - Unadjusted 
Model 2 - Adjusted for age and sex  
Model 3 - Adjusted for age, sex, duration of diabetes, treatment of diabetes, lipid lowering drugs, blood pressure lowering drugs, deprivation (Scottish Index of 
Multiple Deprivation quintile), smoking status, excess alcohol consumption, body mass index, systolic blood pressure, diastolic blood pressure, HbA1c, HDL 
cholesterol, total cholesterol and estimated glomerular filtration rate.   
ALT alanine aminotransferase; APRI aspartate aminotransferase to platelet ratio index; AST aspartate aminotransferase; CK18 cytokeratin-18; ELF Enhanced Liver 








Table 7-3 Multivariable association between liver markers and prevalent coronary artery events.  Values are odds ratios (95%CI) 
  Model 1 p  Model 2 p Model 3 p 
ALT, U/L  0.993 (0.981,1.004) 0.200  0.991 (0.976,1.003) 0.124 0.994 (0.982,1.007) 0.390 
AST, U/L  0.993 (0.978,1.008) 0.383  0.991 (0.975,1.006) 0.230 0.995 (0.979,1.012) 0.588 
GGT, U/L
1
  1.223 (1.080,1.385) 0.002  1.218 (1.073,1.384) 0.002 1.213 (1.051,1.401) 0.008 
         
Steatosis, % yes  0.747 (0.549,1.017) 0.064  0.789 (0.577,1.080) 0.140 0.661 (0.462,0.935) 0.019 
         
CK18, U/L
1
  1.047 (0.860,1.274) 0.650  1.053 (0.864,1.282) 0.610 0.959 (0.777,1.184) 0.707 
         
APRI
1
  0.998 (0.788,1.265) 0.987  0.881 (0.687,1.131) 0.320 0.953 (0.733,1.239) 0.720 
AST:ALT ratio  1.011 (0.404,2.532) 0.981  0.933 (0.360,2.416) 0.887 0.943 (0.334,2.661) 0.912 
ELF score  0.980 (0.801,1.200) 0.848  0.961 (0.772,1.194) 0.726 0.881 (0.685,1.133) 0.324 
FIB4  1.197 (0.952,1.504) 0.123  1.067 (0.838,1.359) 0.599 1.107 (0.854,1.434) 0.441 
NFS  1.044 (0.985,1.107) 0.146  1.061 (0.999,1.127) 0.055 1.045 (0.971,1.125) 0.237 
         
Platelets, x10
9
/L  0.999 (0.997,1.001) 0.386  1.000 (0.998,1.002) 0.788 1.000 (0.997,1.002) 0.967 
1
 APRI, CK18 and GGT analysed on the Log2 scale for linearization, therefore odds ratios relate to a doubling of the marker. 
Model 1 - Unadjusted 
Model 2 - Adjusted for age and sex  
Model 3 - Adjusted for age, sex, duration of diabetes, treatment of diabetes, lipid lowering drugs, blood pressure lowering drugs, deprivation (Scottish Index of 
Multiple Deprivation quintile), smoking status, excess alcohol consumption, body mass index, systolic blood pressure, diastolic blood pressure, HbA1c, HDL 
cholesterol, total cholesterol and estimated glomerular filtration rate.  Incident analysis additionally adjusted for prevalence cardiovascular disease at baseline. 
ALT alanine aminotransferase; APRI aspartate aminotransferase to platelet ratio index; AST aspartate aminotransferase; CK18 cytokeratin-18; ELF Enhanced Liver 





7.3 Association of liver markers with incident cardiovascular 
events 
There were 663 participants without CVD. After a mean follow-up of 4.4 years from 
baseline attendance there were 44/663 (6.6%) patients with incident CVD and 27/663 
(4.1%) with incident CAD events. A significantly higher proportion of those with 
incident CVD were male (59.1% vs 44.3%, p=0.061) and they were significantly 
older (68.9 vs 67.5 years, p=0.024), with no differences in those with incident CAD 
compared with those without incident CAD. Similar results were obtained for those 
patients followed up from the 1 year assessment (mean follow-up 3.5 years), with 
35/561 (6.2%) incident CVD and 19/561 (3.4%) incident CAD events and with a 
similar age/sex distribution. Full results of the associations between established CV 
risk factors and incident CV events are shown in Table 7-4. 
There were 82/1,033 (7.9%) deaths in the follow-up period from baseline, with 30/82 
(36.6%) attributable to CVD, of which 20 were attributable to CAD.  
Mean (or median) liver injury marker levels were largely similar between 
participants with and without incident CVD (Table 7-5) and after multivariable 
adjustment (Table 7-6 and Table 7-7). Only GGT appeared to have some 
independent association with either incident CVD (HR for a doubling of GGT 1.24; 
95% CI 0.97, 1.59; p=0.086) or incident CAD (HR 1.33; 95% CI 1.00, 1.78; 
p=0.053). None of the individual co-variables added to the multivariable model had a 
major attenuating effect on the HR estimating the GGT–outcome association. The 
addition of inflammatory variables to the model did result in attenuation of the HR 
point estimate (Table 7-8) for the GGT-outcome association. With regards to 
different oral anti-hyperglycaemic agents only the use of TZDs attenuated the GGT-








Table 7-4 Association of established cardiovascular risk factors with incident cardiovascular events in all patients, values are mean (sd), median (IQR) or % (n). 
  Incident CVD, n=44 
No incident CVD, 
n=619 
p  Incident CAD, n=27 No CAD, n=636 p 
Age, years  68.9 (3.7) 67.5 (4.1) 0.024  68.8 (4.1) 67.5 (4.1) 0.121 
















Duration of diabetes, years  7.0 (4.0-12.8) 6.0 (3.0-10.0) 0.088  7.0 (4.0-12.0) 6.0 (3.0-10.0) 0.248 






















   31.1 (4.8) 31.1 (5.7) 0.981  31.0 (5.1) 31.1 (5.7) 0.899 
sBP, mmHg  137.6 (14.1) 133.2 (15.9) 0.069  135.8 (13.2) 133.3 (15.9) 0.436 
dBP, mmHg   70.5 (7.2) 69.6 (8.8) 0.523  68.6 (6.6) 69.7 (8.8) 0.505 
Lipid lowering therapy, % yes  86.4 (38) 81.5 (503) 0.545  81.5 (22) 81.9 (519) 1.000 
BP lowering  therapy, %yes  81.8 (36) 77.3 (474) 0.577  85.2 (23) 77.3 (487) 0.479 
HDL cholesterol,   1.26 (0.3) 1.35 (0.4) 0.092  1.30 (0.4) 1.35 (0.4) 0.534 
Total cholesterol,   4.33 (1.0) 4.35 (0.9) 0.889  4.50 (1.1) 4.35 (0.9) 0.354 
Smoking: % ever smoked  34.2 (13) 43.8 (234) 0.310  52.0 (13) 57.0 (312) 0.682 
Alcohol excess, % yes   11.4 (5) 7.1 (44) 0.363  7..4 (2) 7.4 (47) 1.000 
eGFR, ml/L  63.0 (14.3) 65.9 (13.8) 0.196  66.1 (14.0) 65.7 (13.9) 0.867 
BMI body mass index; BP blood pressure; CAD coronary artery disease; CK18 cytokeratin-18; CVD cardiovascular disease; dBP diastolic BP; eGFR estimated 







Table 7-5 Association of markers of liver injury with incident clinical cardiovascular events in patients without pre-existing cardiovascular disease, values are 












ALT, U/L  46.0 (16.7) 43.5 (14.1) 0.266  48.2 (19.1) 43.5 (13.5) 0.218 
AST, U/L  34.2 (13.0) 31.1 (9.7) 0.047  35.6 (14.6) 31.1 (9.7) 0.125 
GGT, U/L   21.0 (10-37) 16.0 (10-27) 0.102  19.0 (9-56) 17.0 (10-28) 0.504 
Steatosis, % yes
1
  50.0 (15) 57.8 (307) 0.450  43.8 (7) 57.8 (315) 0.309 
CK18, U/L
1
  108.9 (85-146) 103.6 (76-137) 0.356  102.1 (84-176) 104.8 (77-137) 0.724 
APRI  0.26 (0.21-0.34) 0.25 (0.20-0.33) 0.669  0.26 (0.20-0.40) 0.25 (0.20-0.33) 0.782 
AST/ALT ratio  0.75 (0.2) 0.73 (0.2) 0.357  0.75 (0.1) 0.73 (0.2) 0.640 
ELF score
2
  9.3 (0.8) 8.9 (0.9) 0.066  9.1 (0.7) 8.9 (0.9) 0.416 
FIB4  1.39 (0.6) 1.33 (0.6) 0.494  1.42 (0.6) 1.33 (0.6) 0.417 
NFS  -0.81 (1.1) -0.72 (1.1) 0.600  -0.90 (1.0) -0.72 (1.1) 0.440 
Platelets, x10
9
/L  266.9 (65.6) 259.8 (69.7) 0.502  269.7 (68.4) 259.9 (67.8) 0.460 
Mean follow-up 4.4 years, except for CK18, ELF and steatosis where mean follow-up was 3.5 years. 
1 Incident CVD n=30/561 incident CAD n=16/561; 2 incident CVD n=24/444 incident CAD n=13/444. 
ALT alanine aminotransferase; APRI aspartate aminotransferase to platelet ratio index; AST aspartate aminotransferase, CAD coronary artery disease; CK18 







Table 7-6 Multivariable association between liver markers and any incident cardiovascular disease events.  Values are hazard ratios (95%CI) 
Liver marker Model 1 p value Model 2 p value Model 3 p value 
  ALT, U/l 1.00 (0.97, 1.02) 0.754 1.00 (0.97, 1.02) 0.836 0.99 (0.97, 1.02) 0.669 
  AST, U/l 1.01 (0.98, 1.04) 0.526 1.01 (0.98, 1.04) 0.544 1.01 (0.97, 1.04) 0.700 
  GGT, log2
1
 1.25 (0.99, 1.59) 0.062 1.26 (0.99, 1.60) 0.059 1.24 (0.97, 1.59) 0.086 
  Steatosis, % yes 0.78 (0.36, 1.67) 0.525 0.84 (0.39, 1.80) 0.654 0.90 (0.40, 2.00) 0.787 
  CK18, log2
1
 1.05 (0.64, 1.70) 0.857 1.13 (0.68, 1.85) 0.643 1.02 (0.60, 1.75) 0.931 
  APRI, log2
1
 0.88 (0.505, 1.525) 0.644 0.79 (0.43, 1.46) 0.448 0.76 (0.40, 1.45) 0.408 
  AST:ALT ratio 3.63 (0.61, 21.61) 0.156 2.85 (0.475, 17.06) 0.252 3.58 (0.53, 28.12) 0.183 
  ELF score 1.220 (0.91, 1.64) 0.185 1.19 (0.85, 1.66) 0.312 1.15 (0.81, 1.64) 0.443 
  FIB4 1.01 (0.54, 1.91) 0.966 0.82 (0.40, 1.68) 0.586 0.83 (0.39, 1.76) 0.625 
  NFS 0.81 (0.58, 1.14) 0.226 0.76 (0.54, 1.06) 0.109 0.78 (0.57, 1.09) 0.143 
  Platelets, ×10
9
/l 1.00 (1.00, 1.01) 0.162 1.01 (1.00, 1.01) 0.061 1.00 (1.00, 1.01) 0.110 
1
 APRI, CK18 and GGT analysed on the Log2 scale for linearization, therefore odds ratios relate to a doubling of the marker. 
Model 1 - Unadjusted  
Model 2 -  Adjusted for age and sex  
Model 3 - Adjusted for age, sex, duration of diabetes, treatment of diabetes, lipid lowering drugs, blood pressure lowering drugs, deprivation (Scottish Index of 
Multiple Deprivation quintile), smoking status, excess alcohol consumption, body mass index, systolic blood pressure, diastolic blood pressure, HbA1c, HDL 
cholesterol, total cholesterol and estimated glomerular filtration rate.  Incident analysis additionally adjusted for prevalence cardiovascular disease at baseline. 
ALT alanine aminotransferase; APRI aspartate aminotransferase to platelet ratio index; AST aspartate aminotransferase; CK18 cytokeratin-18; ELF Enhanced Liver 








Table 7-7 Multivariable association between liver markers and incident coronary artery disease events.  Values are hazard ratios (95%CI) 
Liver marker Model 1 p value Model 2 p value Model 3 p value 
  ALT, U/l 1.00 (0.98, 1.03) 0.771 1.01 (0.98, 1.04) 0.497 1.01 (0.98, 1.04) 0.611 
  AST, U/l 1.02 (0.99, 1.05) 0.213 1.03 (0.99, 1.06) 0.135 1.02 (0.99, 1.06) 0.220 
  GGT, log2
a
 1.27 (0..95, 1.69) 0.103 1.31 (9.88, 1.75) 0.060 1.33 (1.00, 1.78) 0.053 
  Steatosis, % yes 0.82 (0.32, 2.14) 0.688 0.87 (0.33, 2.27) 0.774 0.91 (0.33, 2.53) 0.858 
  CK18, log2
a
 1.07 (0.58, 1.99) 0.822 1.10 (0.60, 2.01) 0.748 0.96 (0.49, 1.90) 0.908 
  APRI, log2
a
 1.07 (0.56, 2.06) 0.839 1.15 (0.56, 2.34) 0.709 1.10 (0.52, 2.32) 0.804 
  AST:ALT ratio 4.36 (0.51, 37.18) 0.178 3.40 (0.37, 31.13) 0.278 4.25 (0.39, 46.73) 0.237 
  ELF score 1.24 (0.85, 1.80) 0.269 1.15 (0.76, 1.74) 0.508 1.12 (0.69, 1.82) 0.642 
  FIB4 1.28 (0.64, 2.60) 0.486 1.22 (0.57, 2.64) 0.611 1.25 (0.56, 2.79) 0.583 
  NFS 0.84 (0.55, 1.28) 0.416 0.81 (0.53, 1.23) 0.323 0.76 (0.51, 1.17) 0.225 
  Platelets, ×10
9
/l 1.00 (1.00, 1.01) 0.301 1.00 (1.00, 1.01) 0.286 1.00 (1.00, 1.01) 0.297 
1
 APRI, CK18 and GGT analysed on the Log2 scale for linearization, therefore odds ratios relate to a doubling of the marker. 
Model 1 - Unadjusted 
Model 2 - Adjusted for age and sex  
Model 3 - Adjusted for age, sex, duration of diabetes, treatment of diabetes, lipid lowering drugs, blood pressure lowering drugs, deprivation (Scottish Index of 
Multiple Deprivation quintile), smoking status, excess alcohol consumption, body mass index, systolic blood pressure, diastolic blood pressure, HbA1c, HDL 
cholesterol, total cholesterol and estimated glomerular filtration rate.  Incident analysis additionally adjusted for prevalence cardiovascular disease at baseline. 
ALT alanine aminotransferase; APRI aspartate aminotransferase to platelet ratio index; AST aspartate aminotransferase; CK18 cytokeratin-18; ELF Enhanced Liver 






Table 7-8 Multivariable association between liver markers and incident cardiovascular disease 
events, effects of inflammatory markers.  Values are hazard ratios (95%CI) 
Liver marker CVD p value CAD p value 
GGT, log2 1.26 (1.03, 1.55) 0.027 1.27 (0.95, 1.69) 0.103 
   + age and sex 1.27 (1.03, 1.56) 0.027 1.30 (1.00, 1.69) 0.050 
   + cardiovascular risk factors
1
 1.21 (0.94, 1.55) 0.134 1.26 (0.94, 1.67) 0.118 
   + inflammatory markers
2
 1.23 (1.00, 1.52) 0.054 1.28 (0.98, 1.66) 0.066 
+age and sex and 
cardiovascular risk factors 
1.24 (0.97, 1.59) 0.086 1.33 (1.00, 1.78) 0.053 
+ all of above 1.16 (0.89, 1.52) 0.275 1.34 (0.98, 1.85) 0.071 
1 defined as duration of diabetes, treatment of diabetes, lipid lowering drugs, blood pressure 
lowering drugs, deprivation (Scottish Index of Multiple Deprivation quintile), smoking status, excess 
alcohol consumption, BMI, systolic blood pressure (sBP), diastolic blood pressure (dBP), HbA1c, HDL 
cholesterol, total cholesterol and eGFR.  ; 2 defined as c-reactive protein, interleukin-6 and tumour 
necrosis factor alpha 
CAD coronary artery disease; CVD cardiovascular disease; GGT gamma-glutamyltransferase 
 
Table 7-9 Multivariable association between liver markers and incident cardiovascular disease 
events, effects of different oral anti-hyperglcaemic agents.  Values are hazard ratios (95%CI) 
Liver marker CVD p value CAD p value 
GGT, log2 1.26 (1.03, 1.55) 0.027 1.27 (0.95, 1.69) 0.103 
   + metformin 1.26 (1.00, 1.60) 0.054 1.25 (0.91,1.70) 0.163 
   + sulphonylurea 1.26 (1.00, 1.60) 0.054 1.25 (0.91, 1.70) 0.164 
   + glitazone 1.21 (0.96, 1.53) 0.109 1.20 (0.88, 1.64) 0.250 
CAD coronary artery disease; CVD cardiovascular disease; GGT gamma-glutamyltransferase 
 
In further analyses performed on all participants with either a first or subsequent CV 
event occurring after baseline (i.e. including those with prevalent CVD at baseline, 
but with adjustment for prevalent cases), an association between GGT and events 
was confirmed (Appendix M). HRs with similar magnitudes were observed with 
increased statistical significance (p<0.05), likely due to the increase in sample size.  
When restricted to patients with NAFLD (n=319) there were 38 incident 




investigated, GGT alone showed an independent association with incident CVD in 
this subgroup (fully adjusted HR for a doubling of GGT 1.56; 95% CI 1.08, 2.28; 
p=0.019) (Appendix M)  
7.4 Summary 
In this chapter, I found that at baseline there were 372/1035 patients with prevalent 
CVD, including 319/1035 with CAD. After mean follow-up of 4.4 years there were 
44/663 incident CVD events, including 27/663 CAD events.  There were 30/82 CVD 
related deaths.  
I was able to replicate existing knowledge of the relationship between GGT and 
CVD and in addition I was able to add that this finding persisted into older age and 
that other liver markers (steatosis, steatohepatitis, liver fibrosis and surrogates of 






CHAPTER 8  
8.1 Overview 
This thesis aimed to investigate the epidemiology of CLD in older people with type 2 
diabetes.  In this chapter I discuss the main findings of this work in the context of 
previous literature.  Additionally, I discuss key strengths and weakness of the thesis 
and finish with potential directions for future research. 
8.2 Key findings of thesis 
8.2.1 Non-invasive markers of steatohepatitis and liver fibrosis in older 
people with type 2 diabetes  
In this community based cohort of older people with type 2 diabetes, examination of 
a wide range of potential markers of steatohepatitis and liver fibrosis found varied 
relationships with diabetes history. AST:ALT ratio, ELF, FIB4, and LSM were 
statistically associated with hyperglycaemia, and ELF and HA with increasing 
duration of diabetes. Elevated ELF was associated with OAHA and insulin use and 
APRI, FIB4 and NFS with diet control.  Most commonly, elevated markers of 
steatohepatitis and liver fibrosis were associated with older age and higher body fat 
measures (BMI and waist circumference).  However, most of these relationships 
between liver markers and body fat measures lost statistical significance when 
limiting the population to only those with hepatic steatosis and/or NAFL/D.  The 
presumption that poorer diabetes control (indicated by higher HbA1c) would be 
related to elevated steatohepatitis and fibrosis markers was not proven.   
As noted above, there were differences in the associations between different liver 
fibrosis markers and potential diabetes and metabolic risk factors, suggesting that 
these markers are not actually measuring the same underlying “fibrosis” condition. 




the top vigintile (5%) of each marker resulted in excellent agreement on the absence 
of advanced liver disease but poor agreement on the presence of advanced liver 
disease. 
8.2.2 Clinically significant chronic liver disease in older people with type 2 
diabetes – prevalence, incidence and associated risk factors  
The prevalence of clinically significant CLD (defined as cirrhosis, HCC or gastro-
oesophageal varices) was 2.2% - 0.9% diagnosed prior to enrolment with an 
additional 1.4% identified by study investigations.  Over nearly 6 years of follow-up, 
only 1.4% of the cohort developed incident clinically significant CLD. 
Higher levels of systemic inflammation, steatohepatitis and hepatic fibrosis markers 
were associated with both unknown prevalent and incident clinically significant 
chronic liver disease (all p<0.001).  Less than half of participants developing incident 
significant disease were identified as high risk by the study investigations.  Abnormal 
liver enzymes were associated with incident cases (IRR 5.7, p=0.001), the presence 
of hepatic steatosis was not.   
8.2.3 Association between liver markers and cardiovascular events 
At baseline there were 372/1035 patients with prevalent CVD, including 319/1035 
with CAD. After mean follow-up of 4.4 years there were 121/1035 incident CVD 
events, including 76/1035 CAD events.  There were 30/82 CVD related deaths.  
However, risk of dying from or developing CVD was no higher in subjects with 
steatosis than without (OR 0.84, p>0.05).  There was also no statistically significant 
relationship between CVD and steatohepatitis or liver fibrosis. The only statistically 
significant relationship between CVD and any liver markers was with GGT 
(prevalent CVD, OR 1.28, p=0.007; incident CAD, OR 2.35, p=0.042), suggesting 
that in our study population, CLD may have little effect on the development of, or 




8.3 Study strengths and limitations 
8.3.1 Study population 
A major strength of this thesis is that it provides a comprehensive assessment of a 
wide range of markers of steatohepatitis and liver fibrosis in a population-based 
cohort of all older people with type 2 diabetes, and not just subjects selected 
primarily on the diagnosis of hepatosteatosis using recruitment from diabetes clinics 
at tertiary referral centres as in previous studies
161,162,167,348
.  I have provided 
diabetes-specific information on the distribution of these markers, which is essential 
to inform further research on the clinical relevance of possible subclinical liver 
dysfunction in this high risk group.   
The sample was drawn from the whole of the Lothian region, and included the full 
spectrum of people with type 2 diabetes.  Whilst in general the study population was 
largely representative of the target population of older people with type 2 diabetes 
there were some differences.  These differences (e.g. sex) were small at baseline, but 
sometimes statistically significant most likely because of the large sample size.  I 
also only examined representativeness in a limited number of variables chosen 
because of a) their availability, and b) their presumed influence on outcomes of 
interest.  It may be that there were other variables not measured which differed and 
had an influence on the results.  This would in turn influence the generalisability of 
the results.  However, overall the ET2DS can be considered generalisable to the 
target population (high external validity).   
Retention of nearly 80% (831/1066) of the cohort between the baseline and follow-
up clinics is good.  Differences in attenders and non-attenders at the year 1 liver sub-
study clinic and year 4 follow-up are probably in the expected direction: non-
attenders were slightly older with higher systolic BP and from more deprived areas, 
which likely reflects higher morbidity and mortality.  These differences are 
inevitable when relying on clinic attendance in an elderly population.  Again the 
differences are small, but could have reached statistical significance if sample size 




other means of follow-up such as GP questionnaires and data linkage with hospital 
discharge data.   
At both baseline and follow-up the power calculations were undertaken with respect 
to cognitive function outcomes.  For example, a follow-up sample size of 800 
(allowing for a combined 20% death and drop-out rate), was deemed to be powered 
at 90% to detect a correlation coefficient of 0.12 and above between change in 
cognitive test scores and each of the risk factors.  There were no a priori liver sub-
study power calculations undertaken as the ET2DS cohort had already been recruited 
prior to its commencement.  Given that the sample is large, it is likely that the 
analyses undertaken were powered sufficiently to detect similar differences in the 
cross-sectional analyses of liver markers.  However, the analyses of both prevalent 
and incident clinically significant CLD may be underpowered.   
Given that there were lower prevalences of high levels of non-invasive markers 
(Chapter 5) and less cases of clinically significant CLD than perhaps anticipated 
(Chapter 6)  it has to be questioned whether the ET2DS study population is perhaps 
unusual.  It is evident from the representativeness analysis that the study subjects are 
representative of all older people with type 2 diabetes in Scotland, however it may be 
that older people with type 2 diabetes show some sort of healthy survivor bias i.e. 
they are biologically different to those not surviving to age 60 years.  A brief 
comparison of mortality in the ET2DS compared to the age-sex matched Lothian and 
Scottish figures (Appendix N) suggests that this is not the case with the mortality rate 
in the ET2DS exceeding that of Lothian and Scotland (25 vs 16 vs 17 per 1000 
population/year respectively). 
8.3.2 Missing data  
Some variables (e.g.  BMI, platelets) were only measured at the baseline clinic and 
not at the initial liver sub-study visit.  As a result, for some analyses these measures 
are used interchangeably.  This is a reasonable decision to take as these are all 





Another noteable limitation is the volume of missing data relating to LSM (15%).  
The XL probe is believed to increase the success rates of obtaining ≥10 valid TE 
readings  from 56% to 75%
292
 in obese populations.  This is consistent with the 85% 
success in a mixed overweight and obese cohort.  Despite the use of the XL probe, 
TE still appears to be limited by body habitus.  Those patients with missing LSM had 
more severe diabetes profiles and higher alternative markers of liver fibrosis.  Hence, 
it was felt necessary to expand the majority of analysis to those patients with a full 
set of markers excluding LSM in order to reduce biasing the sample.  However, 
interpretation of the results of any analyses relating to LSM need to be undertaken 
with the recognition that it is not generalizable to all older people with diabetes. 
8.3.3 Study design 
This thesis is subject to the inherent disadvantages of an observational cohort study.  
Many of the analyses relate to cross-sectional studies where it is not possible to 
determine the order of events ie which came first the elevated liver marker or the 
elevated metabolic risk factor? Cross-sectional design also relies on CLD having a 
long natural history, as any sort duration illnesses would be under represented by 
such a design.   
The prospective design of the ET2DS allowed the investigation of the relationship 
between baseline risk factors and subsequent clinical outcomes (clinically significant 
CLD and CVD).  The natural history of CLD is long.  By collating cases of clinically 
significant CLD beyond the follow-up research clinic we were able to extend the 
follow-up period for incident cases to nearly six years (Chapter 6).  Despite this, six 
years is not long in the liver disease pathway.   
8.3.4 Immortal time bias 
Immortal person-time arises in an observational study when follow-up time is 
included in person-time at risk for the study outcome, even though that time precedes 
the exposure definition
349
. An exposure category that includes immortal person-time 




This bias occurs because the accumulated person-time exceeds person-time actually 
at risk. Particular consideration was given to this issue when analysing incident CVD 
events in Chapter 7. Here, some exposures were measured at the baseline research 
clinic and others at the year 1 liver sub-study visit, allowing for the potential for 
immortal time to arise. The two most widely advocated ways to deal with the issue of 
immortal person-time is a) to only compare this patients surviving the immortal time 
period or b) allow for time varying covariates in the analyses. Because the different 
exposure variables were treated as different analyses in Chapter 7, immortal time was 
excluded from the analyses (see Figure 8-1). The exposure (e.g. CK18 testing) 
occurred to all individuals at the same time and there was therefore no difference 
between the ‘exposed’ and ‘unexposed’ groups. A consequence of this action is 
potential selection and survival bias, as discussed previously. If in analysis 2 of the 
example below (Figure 8-1) patient time had been in included prior to the exposure 
and all of these attributed to the ‘non-exposure’ group, immortal time 
misclassification would have occurred.  
Figure 8-1 Immortal time bias example 
 



























8.3.5 Data quality 
All research staff were appropriately trained in the collection of data and standard 
operating procedures were followed to reduce observer bias.  Training in the use of 
TUE (Fibroscan, Echosens) was undertaken by the external company and the single 
assessor had to reach an acceptable standard set by Echosens prior to commencement 
of the study.   
All Edinburgh based laboratory assays were measured in the same laboratory at all 
study phases, reducing any risk of biases from changes in measurement protocols on 
the results.   
Both CK18 and ELF were measured at external laboratories in Nottingham and 
London respectively.  All CK18 samples were assayed as a minimum in duplicate 
and where sample volumes allowed they were measured up to four times with the 
median result taken as the final value.  The coefficient of variation for the high 
control sample was 3.3% (mean 694u/l) and for the low control 7.1% (mean 104u/l).  
The iQur laboratory in London reported for the ELF measurements that “the results 
have been validated and passed quality assurance”. 
All analysed measurements of LSM met the quality guidance issued by the developer 
(at least 60% of 10 LSM successful, and the inter-quartile range <30% of the final, 
median, result).  A number of measures did not meet this criteria so were not used.  
Use of a single TUE operative eliminated the risk of any inter-observer variability, 
however, I was unable to arrange for any repeated measures of LSM on individuals 
to be undertaken to allow the intra-observer variation to be assessed.   
8.3.6 Number of analyses 
The number of analyses undertaken and p values reported in this thesis is large 
(approximately 1500). As discussed in section 4.7.4 one potential approach to the 
resulting high risk of Type I statistical error is to apply Bonferroni adjustment to p-
values. As described this type of adjustment beings its own difficulties so was not used 




p-value indicating statistical significance would be p<0.00003, and (presumably) few or 
none of the analyses would survive this adjustment. However, the overall pattern of 
results suggests that a majority of findings with p<0.05 reflect more than chance results, 
so that the findings presented here likely to be relatively accurate reflections of the 
described associations. Furthermore, where-ever possible confidence intervals around 
point estimates have been included so that context specific decisions about the statistical 
versus clinical significance can be made.  
As noted previously as significant proportion of this thesis involved the generation of 
hypotheses as opposed to targeted hypothesis testing. Significant marker findings could 
now be taken forward and for example validated in a new cohort. 
8.3.7 Agreement statistics 
There are a number of ways of assessing agreement between markers and to assess 
the (inter-observer) agreement of liver fibrosis markers I reported proportions of 
positive and negative agreement (sections 4.7.3 and 5.8). A common alternative 
approach would be to use the Kappa statistic. The Kappa statistic assesses the 
difference between how much agreement is actually present (“observed” agreement) 
compared to how much agreement would be expected to be present by chance alone 
(“expected” agreement)
350
.  A problem with the Kappa statistic is that it is affected 
by the prevalence of the disease under consideration - for uncommon findings, very 
low values of kappa can result which may not reflect actual high rates of overall 
agreement
342,343,350
. To avoid this issue the alternative approach of separating positive 
and negative agreement was used. 
8.4 Non-invasive markers of steatohepatitis and liver fibrosis in 
older people with type 2 diabetes  
8.4.1 Distributions of markers of steatohepatitis and liver fibrosis 
In Chapter 5, I demonstrated the distributions of CK18, AST:ALT ratio, APRI, ELF, 




distributions of potential steatohepatitis and fibrosis markers, in both populations 
with diabetes and community based cohorts, there is limited evidence available in 
individuals unselected for liver disease.   
My findings for the distribution of CK18 in people with type 2 diabetes were 
consistent with the ‘general population’ assay literature
351
.  In developing the normal 
ranges for the serum CK18 assay, 200 healthy Swedish blood donors were tested; as 
in my study, the results showed similar levels in males and females with little change 
in levels with increasing age and an overall marker distribution similar to the one I 
found.  In a second study 
351
,  a normal cut-point of the 80
th
 percentile, or 145U/L, 
was suggested, and this is also consistent with our finding (146U/L).   
For ELF, Yoo et al suggest a normal range of 5.95-8.73 in apparently healthy South 
Korean subjects
352
.  I found that ELF scores were very slightly lower in men and 
increased with age.  In the absence of a  biologically plausible reason to expect any 
difference in any of the components of ELF by sex, it is possible that the higher ELF 
scores in females may truly represent more advanced liver fibrosis.  The components 
of ELF (HA, TIMP-1 and P3NP) are all related to extra-cellular matrix turnover and 
are not exclusive to the liver.  As a result, one might expect an increase in ELF with 
age, both due to the greater time in which liver fibrosis has had to develop
107
 and due 
to increasing prevalence of unrelated causes of raised analytes; indeed, consistent 
with my own findings, an early study examining HA and P3NP found higher levels 
in ‘healthy’ elderly people compared with younger subjects 
353
 . 
I found LSM ranged from 0.37-33.30 kPa (mean 5.07 kPa), with similar levels in 
males and females.  There have been several ‘community-based’ studies of TUE. In 
France, Roulot et al
354
 offered all individuals aged >45 years who attended for a 
scheduled medical check-up (no additional selection information provided) the 
opportunity to be screening for CLD with TUE. 1190 individuals participated and the 
range of LSM was 1.8-35kPa, median 5.3kPa. These results were similar to my own, 
however, they found significantly higher levels in males than females (5.7 versus 








8.4.2 Associations with potential risk factors 
I determined a number of relationships between potential risk factors (diabetes 
history and metabolic factors) and non-invasive markers of steatohepatitis and 
hepatic fibrosis.  However, these relationships were typically small with correlation 
coefficients <0.2.  A challenge in interpreting these results clinically is the lack of 
validated marker cut-points to diagnose hepatic inflammation and/or fibrosis in 
population-based cohorts.  Despite this, these results suggest that at least a number of 
metabolic risk factors (including fasting glycaemia, BMI and waist circumference) 
are likely to be associated with liver fibrosis and/or inflammation in people with type 
2 diabetes.   
In terms of diabetic populations, it is not known whether the measures and scores of 
non-invasive markers of steatohepatitis (CK18) and liver fibrosis (APRI, AST:ALT 
ratio, ELF, FIB4, NFS and LSM) investigated differ, on average, from non-diabetic 
populations, although there is also no known biological reason why this should be 
the case.  For this reason, alongside concerns over the use of validated cut-offs, I 
chose the top quintile of the marker distribution as the highest risk groups.  Whilst 
the imprecision of such an approach in terms of diagnosing disease must be 
acknowledged, I have shown that the highest quintiles of each of the markers 
contained higher surrogate markers of portal hypertension, providing some 
confirmatory evidence that this group included a particularly high risk group of 
patients in terms of clinically significant CLD.  In addition I was able to confirm that 
the presence of other conditions known to influence levels of the markers (such as 
chronic kidney disease and arthritis) do not appear to have a major effect on the 
results (i.e. unlikely to confound the results).   
The finding of associations of hepatic steatosis, increased body fat, hyperglycaemia 
and more intensive diabetes treatment with steatohepatitis and liver fibrosis markers 




metabolic profile are involved in increasing the risk of developing CLD.  However, 
these findings were not consistent across markers.  In a recent liver biopsy study 
348
 
in people with type 2 diabetes, in which high rates of both NASH (78%) and 
moderate fibrosis (34-60%) were detected, no statistical associations between 
diabetes related/metabolic factors and NASH or liver fibrosis were found.  However, 
this biopsy study was small (n=98) and focused on patients at the severe end of the 
diabetes spectrum attending a tertiary referral hospital. 
The cross-sectional nature of these analyses associating liver markers of 
steatohepatitis and liver fibrosis with diabetes and metabolic risk factors limits any 
temporal inference; it is not possible to determine whether metabolic factors might 
be a risk factor for liver disease or vice versa.  However, if causal relationships were 
to be confirmed, this would have important implications for strategies aimed at CLD 
risk reduction e.g.  losing or redistributing fat and reducing insulin resistance.  
Although associations between the markers and metabolic factors appeared relatively 
weak, addressing even weak risk factors for disease could be beneficial at a 
population level, especially if those risk factors are highly prevalent. 
In addition to the association of steatohepatitis and fibrosis markers with metabolic 
risk factors, I was also interested in their association with steatosis and established 
hepatotoxic causes (alcohol excess, hepatotoxic medication use and strongly positive 
autoantibodies) of CLD.  I found that subjects with hepatic steatosis had higher 
CK18 and LSM measures and lower AST:ALT ratios and HA measures compared 
with non-steatotic individuals, but not APRI, ELF FIB4 or NFS.  This is perhaps 
unsurprising given that CK18 levels rise with increasing hepatic inflammation as a 
by-product of hepatocellular apoptosis and that according to established models of 
NAFL/D progression
62,356
, initial development of hepatic steatosis is followed by 
NASH and then hepatic scarring with steatosis typically receding as fibrosis 
progresses.   
I again found varied associations between established hepatotoxic causes and any 
steatohepatitis or liver fibrosis markers, with some markers being higher in those 




(CK18, ELF and HA), and AST:ALT ratio showing no association.  These varied 
results may be explained, at least in part, by the small numbers of study subjects with 
high levels of the established hepatotoxic causes (alcohol excess 11.8%, hepatotoxic 
medication use 3.6%, strongly positive autoantibodies 0.6%) and by lack of 
consensus around the precise level of risk factor which should be used to establish 
increased risk.  I defined alcohol excess using cut-points which are consistent with 
the published literature in the UK and I was unable to find any consensus in the 
literature on how best to define hepatotoxic medications in terms of what types, 
duration and dosage are required to have a significant effect on the liver
61
.   
One of the most consistent findings in the current study was the association of all the 
investigated markers of steatohepatitis and liver fibrosis with measures of increasing 
body fat (except HA).  Previous studies have shown a direct association between 
liver fat and  hepatic inflammation, with the latter increasing proportionately 
according to liver fat volume
357
.  It has been proposed that this effect is  mediated 
though the direct release of toxic free fatty acid by hepatic fat and through altered 
lipid partitioning within hepatocytes, mitochondrial dysregulation, generation of 
reactive oxygen species, lipid peroxidation and endoplasmic reticulum stress
358
.  
Given the relationship between visceral fat and inflammation, the finding of 
increased body fat in patients in the highest CK18 quintile is consistent with 
proposed underlying mechanisms of hepatic inflammation
63,359
.  In addition to 
increased body fat, subjects in the top CK18 quintile also had higher fasting glucose 
and plasma HbA1c levels, as well as more intensive diabetes treatment modalities.  
These factors may  be considered  as surrogates of beta cell failure and worsening 
insulin resistance, which is in turn related to hepatic inflammation through increased 
lipolysis, increased free fatty acid presence in the liver and ultimately oxidative 
stress
360
.  As in other studies 
361,362
, I found higher triglyceride levels with increased 
CK18 levels, which would be consistent with  the theory of free fatty acids driving 




8.4.3 Marker agreement 
Overall there was poor correlation between the fibrosis markers measured and 
compared in this study.  The only exception was APRI and FIB4 (r=0.92 in full 
cohort and 0.93 in NAFL/D subgroup, p<0.001), which is unsurprising given they 
have a number of components in common (AST level and platelets).  Assessment of 
inter-item correlation (α=0.67) determined that the five markers were not consistent 
with each other in what they were measuring, with a score of α=0.70 being the 
minimum score usually accepted.  However, a minimum of 0.90 is often suggested 
for clinical practice
363
.  This suggests some discrepancy in what the markers are 
measuring.  This seems plausible as AST/ALT, APRI and FIB4 are all similar in 
their composition, including markers of hepatocellular damage.  Conversely, ELF is 
measuring markers related to extracellular matrix turnover in fibrosis, and LSM is 
examining structural properties of the liver through shear wave transmission.   
A higher prevalence of fibrosis in the NAFL/D cohort compared to the full cohort 
was expected.  However, using validated cut-offs, my results showed the opposite.  
This probably reflects the natural history of NAFL/D in which fibrotic progression is 
often associated with steatosis regression and hence this group of advanced liver 
disease patients might not be captured by my definition of NAFL/D.  ELF scores and 
LSM values for the top vigintile were most in keeping with the values one would 
expect to find from previous published studies
159,161,163
, however, with no reference 
standard (biopsy) it is impossible to establish which of the five markers is the most 
accurate and to comment on the true prevalence of liver fibrosis using non-invasive 
markers.   
In addition, using validated cut-offs for advanced fibrosis, I found a wide range of 
fibrosis prevalence results for the different markers (0.8-68.3%).  The reasons for the 
wide discrepancies are probably two-fold.  Firstly, as demonstrated by the lack of 
inter-correlation, there is an inconsistency in what the different markers/panels are 
measuring.  Secondly, published fibrosis cut-offs from clinical validation studies do 
not appear to translate readily into research or clinical practice.  The difficulty with 




influenced by the prevalence of underlying disease.  Most validation cohorts have 
typically comprised a high proportion of patients with advanced liver disease 
selected from tertiary referral centres.  The study population used in this thesis has a 
presumed lower prevalence of advanced liver disease and consequently the 
predictive values are likely to be different.  This resulting lower positive predictive 
value and higher negative predictive value would mean that literature based cut-offs 
are neither reliable nor directly comparable with one another in different patient 
cohorts.  Without liver biopsy (the current reference standard) it is not possible to 
decide which marker is ‘best suited’ for diagnosing significant liver fibrosis in a 
lower prevalence population. 
There are numerous other markers of liver fibrosis available as discussed in Chapter 
2 e.g.  BARD, BAAT, NFS.  These are typically simple scoring systems using easily 
available plasma results and patient data.  Previous work from the ET2DS 
investigators has found that these scores are likely to overestimate the prevalence of 
liver fibrosis in populations similar to mine as they rely heavily on the incorporation 
of impaired glucose tolerance, age and body mass index.  For example the prevalence 
of fibrosis using the BARD and BAAT scores was 92.6% and 79.3% respectively, 
with the NFS predicting 16.4% fibrosis and 66.8% indeterminate
364
.  It is therefore 
necessary to concentrate on the development of liver fibrosis markers that are 
independent of the underlying characteristics of the population under study.   
A further area which requires clarification is the most appropriate use of hepatic 
markers in the general/healthy population.  Without this information, it is hard to 
predict whether expected values are likely to differ in discrete populations, such as 
the elderly or people with diabetes.  Normal routine liver function tests vary with 
age, sex and ethnicity
329,365
, and therefore any fibrosis marker panel including these 





8.5 Clinically significant chronic liver disease in older people with 
type 2 diabetes – prevalence, incidence and associated risk factors  
In Chapter 6, I reported that the prevalence of clinically significant CLD was 2.2% - 
0.9% diagnosed prior to study enrolment with an additional 1.4% identified by study 
investigations.  Over nearly 6 years of follow-up, only 1.4% of the cohort developed 
incident clinically significant CLD. 
The existing literature on prevalence and incidence of clinically significant CLD is 
limited by its heavy reliance on confirmatory liver biopsy in secondary care 





).  Single ‘disease’ classifiers each bring 
their own limitations, for example liver enzymes have low diagnostic accuracy, non-
invasive fibrosis markers (e.g.  ELF, NFS) have poor positive predictive values for 
later stages of CLD
236,243
, ICD codes only identify hospitalised cases with 
decompensation, and biopsy has marked ascertainment bias.  A study by Wong et al  
highlighted the challenge of applying such markers in a general population, finding 
the prevalence of advanced fibrosis in NAFL/D to range from 0-12% depending on 
the markers used
355
.  This methodological variation, coupled with the high 
‘unknown’ prevalence of clinically significant CLD, provides an important 
explanation for discordance in the literature regarding prevalence rates of clinically 
significant CLD.  Another issue to note with identifying CLD is that it is 
predominantly an out-patient treated condition, therefore not easily identified from 
hospital discharge (SMR01) records. Therefore, I used a combination of methods to 
comprehensively phenotype our cases including radiology, clinical codes, non-
invasive markers and clinician verification.  Each of these methods has their own 
limitations, and reviewing all medical records is highly time consuming and not 
feasible for larger studies,  but together they provide a detailed phenotype within the 
current limitations of diagnostic tools and lends confidence in the ascertainment of 
clinically significant CLD given the multimodal approach.  It would have been 
preferable to have been able to include some level of advanced fibrosis in the 




rarely coded or referred to in medical records, most likely due to the need for liver 
biopsy to confidently diagnose it.  
My findings support the suggestion that NAFL/D is an under-diagnosed chronic 
disease
366
 despite patients with type 2 diabetes having, as a minimum, annual clinical 
reviews including liver enzyme tests.  The extensive study investigations increased 
the prevalence by more than 150% through the diagnosis of unknown clinically 
significant CLD, of which almost 70% was attributable to NAFL/D.  However, it 
was a labour intensive process with 14% of the study subjects referred to a 
Consultant Hepatologist.  In the majority of these patients, simple laboratory tests 
were abnormal (e.g.  liver enzymes above the upper limit of normal, low platelet 
count) although, typically, values were only marginally elevated.   
Reassuringly, despite a relatively high prevalence of uncomplicated NAFL/D at year 
1 of the study, there were only a small number of patients who went on to develop 
incident clinically significant CLD after 6 years of follow-up (2.9 /1000 person-
years).  Adams et al
109
 followed 103 NAFL/D patients over a mean period of 3.2 
years and found a fibrosis progression rate of 0.35 stages/year in those with diabetes.  
This is high compared with the ET2DS cohort as it equates to a 2-stage advancement 
over the 6 year follow-up of the cohort in those with NAFL/D.  Whilst difficult to 
quantify, given a NAFL/D prevalence in the cohort of 43%
165
 with 60% of incident 
clinically significant CLD being attributable to NAFL/D, this would indicate that 
around 2% of the non-cirrhotic NAFL/D subjects had F2-3 disease at the start of the 
study, with nearly 98% having F0-1.  In NASH populations, Harrison et al
116
 found 
that 32% of their cohort progressed fibrosis score over 3 years and, similarly, Fassio 
et al
115
 showed that 31% of subjects had progressive fibrosis although no subject 
developed cirrhosis during 4 years of follow-up.   
A further difficulty in the interpretation of NAFL/D prevalence/incidence is the 
diagnostic criteria for NAFL/D. In this thesis a criteria in line with many others was 
taken – presence of steatosis on USS, absence of secondary cause including, positive 
autoantibodies, hepatotoxic medication use and excess alcohol consumption. 




opposed t using well phenotyped cohorts as in this study. As a result diagnoses are a) 
often limited to secondary care only, and b) the exclusion criteria are often poorly 
recorded. Further to that, what exclusion criteria so use can vary by study. The 
majority of incident cases in my work were attributed to NAFL/D. The measurement 
of exclusion criteria was robust – perhaps with the exception of alcohol. This is 
related to two issues: the difficulties there are measuring alcohol intake and knowing 
at what level to determine NAFL/D from ALD.   
Various methodological issues influence the measurement of alcohol consumption in 
research. Firstly, the period of time information is recalled for – a short recent period 
vs a longer time to allow for a recognition that there may be variation in drinking 
patterns, but issues of actual recall. Two commonly used measurement approaches 
are the usual quantity/frequency and graduated frequency approaches, both of which 
allow researchers to estimate the volume of alcohol intake. Other issues include 
whether to ask drink type specific questions and estimation of drink sizes. Finally the 
mode of collection, face-to-face vs “anonymous” influences the responders 
behaviour
367-369
. In this thesis I used a quantity/frequency approach, asking face-to-
face over the past year. This may have resulted in under reporting of alcohol 
consumption. The cut-off criteria then applied were the ‘safe-drinking’ limits advised 
by the Royal College of Physicians
70
. Some argue that they should be higher
61
, 
however, this stricter criteria helps to offset any patient under reporting. 
I did not find any aspect of diabetes history to be associated with the development of 
clinically significant CLD.  However, it is notable that my incidence rate was 3.6 
times higher than that found by Porepa et al 
370
 in a large population-based study in 
Canada using similar non-biopsy related outcomes to our own, where those with 
newly diagnosed diabetes had an incidence rate of 0.82 /1000 person-years (twice 
that of those without diabetes) and I had over 90% of my incident cases occurring in 
subjects with a diabetes duration of >5 years.  A recent systematic review of cross-
sectional studies found the presence of diabetes to significantly increase the risk of 
HCC in both case-control and cohort studies with a pooled OR 2.5 (95% CI 1.8-3.5) 
and a pooled RR 2.5 (95% CI 1.9-3.2)
371




shows that within the whole Scottish population aged 60-75 the IR for liver-related 
cancer (including biliary) in 2012 was 0.3/1000 person-years
20
.  This is substantially 
lower than the rate for HCC alone in the ET2DS cohort (0.8/1000 person-years).  In a 
prospective study, El-Serag et al found the incidence of HCC in patients with 
diabetes to be 0.2/1000 person-years, 2.7 times the rate of their control group
372
.  
This indicates that the presence of diabetes is associated with increased cirrhosis and 
HCC risk.   
I found that incident clinically significant CLD was associated with higher measures 
of body fat, markers of systemic inflammation and a wide range of markers of liver 
disease.  Indeed, all three markers of systemic inflammation were associated with the 
development of clinically significant CLD.  The role of inflammatory mediators in 
the development of cirrhosis and HCC due to virtually any underlying CLD has been 
noted previously
373
.   
Critically, the majority of people with incident clinically significant CLD had normal 
liver function tests with no steatosis and so were not identified by the extensive 
research clinic assessment.  Whilst those with abnormal liver enzymes per se were 
more likely to develop clinically significant CLD, the mean levels of liver enzymes 
in those that did were still within the normal laboratory reference range.  The lack of 
statistical significance between hepatic steatosis and the development of clinically 
significant CLD may be due to the small number of outcomes or it may be a true. If 
true, it could reflect that steatosis and NAFL confers little additional risk over that 
already present in people with type 2 diabetes due to their shared background of 
insulin resistance. 
It is not surprising that markers of liver fibrosis were associated with the future 
development of clinically significant CLD given they have been developed to 
diagnose that disease process.  Previously work from the ET2DS group found the 
NFS to be problematic for diagnosing liver fibrosis in a population with type 2 
diabetes due to its composition leading to an over estimation of prevalence
364
.  
However, the NFS may be of benefit in the prediction of future liver related events.  
In a large general population cohort, McLernon at al
374




for incident CLD using routinely collected data, although this had a PPV of just 40% 
and only examined short term incidence (up to 2 years). 
Given the associations found between the various markers of liver injury with both 
prevalent and incident clinically significant CLD I trialled the use of pre-determined 
cut-offs to diagnose clinically significant CLD. Whilst Chapter 5 determined that 
‘validated’ cut-offs of markers for hepatic fibrosis could not be used for the diagnosis 
of fibrosis, it may have been that they could be used for this alternative purpose – 
prediction of future disease. Despite good sensitivity of some tests (>85%) all of the 
corresponding PPVs were below 10% meaning that in clinical practice large numbers 
of patients would have false positive results. This would mean a large burden of 
work for clinical services and also subjecting a lot of patients unnecessarily to further 
investigation. Combining the most sensitive of the routine markers (AST. ALT, 
GGT, platelet count, spleen size) still did not produce a test with sufficient positive 
predictive power to result in a clinically acceptable test for screening for liver 
disease. 
Receiver operator curves were not constructed to determine the optimal cut-off point 
for markers of liver injury in the diagnosis of clinically significant CLD as the 
number of outcomes (n=15) was too small to have the power to provide accurate 
results with confidence. 
Despite the findings of this work, it is still not clear how ‘screening’ programmes for 
clinically significant CLD could be structured. Beyond trying to identify subsets of 
the population who might benefit most from further investigation the practical 
aspects of the process require consideration. 
Because the different non-invasive markers of liver disease are all potential useful, in 
addition to their clinical utility factors such as access and cost need to be considered.  
For example, routine liver enzymes (ALT, AST and GGT) can be measured within 
all existing hospital laboratory services at an approximate cost of £0.50, £1.00 and 
£0.50. Serum HA is a more specialist test, available in most hospital laboratories, at a 




processed UK at the iQur Laborarotory in London at a standard cost of 
approximately £80 per test.   
8.6 Association between liver markers and cardiovascular events 
In Chapter 7, I found a statistically significant association between GGT and both 
prevalent and incident CV events, but no association between other liver markers 
investigated (AST, ALT, steatosis, CK18, APRI, AST:ALT ratio, ELF, FIB4, NFS 
and platelet count) and CVD. 
My findings are consistent with previous reports that GGT is independently 
associated with both prevalent and incident CV events and that this association is not 
attenuated by increased age.  In addition, my work supports CAD as the main 
element of association within the spectrum of CVD.  Perhaps surprisingly, no other 
markers of liver injury - hepatic steatosis, inflammation or fibrosis - were associated 
with CV events. 
This work consolidates previous findings of an association between GGT and both 
prevalent and incident CVD, with the largest effect on CAD
162,375-379
.  There is 
biological plausibility for this relationship.  GGT degrades glutathione to glutamate, 
which via cysteinylglycine is involved in iron reduction, allowing lipoprotein 
oxidation within atheromatous plaques.  What is unclear is whether GGT is a 
pathogenic factor in atherogenesis or simply a surrogate marker of the micro-
inflammatory plaque-associated inflammatory response. 
The relationship between transaminases and CVD is controversial, with reports of 
significant associations in both directions
347,380,381
.  A number of centres have 
previously investigated the relationship between NAFL/D (presence of hepatic 
steatosis on USS) and CV events
184,382
, with sample populations comprised 
exclusively of patients with type 2 diabetes
162,189,346,376
.  In this study, there was no 




CK18 is an apoptosis marker released by injured hepatocytes.  It has been 
demonstrated that in patients with NAFLD, relative concentrations can differentiate 
between steatosis and NASH
84
.  There are no previous studies examining the 
relationship between CK18 and CV events.  Several prior studies diagnosing NASH 
using different methods (biopsy, elevated ALT levels) showed mixed results for the 
association of CV risk (e.g.  risk scores, lipid levels)
383-385





 found associations between all-cause and CV mortality with the presence 
of biopsy proven NASH, but no association with steatosis.  Conversely Lazo
386
 
found no association NASH and CV mortality in patients diagnosed by USS and 
elevated hepatic enzymes – suggesting that the criteria and methodology for 
NAFL/D and NASH classification may have a significant impact in determining 
prognostic value.   
Data on the relationship between liver fibrosis and CVD is also limited.  Kim et al 
found significant associations between the NAFLD Fibrosis Score, aspartate to 
platelet ratio index and the FIB-4 Score with CV mortality
387
.  Our study used the 
ELF score, an extracellular matrix related multi-component panel (HA, P3NP and 
TIMP-1), validated for use in patients with NAFL/D
236
 as a non-invasive marker test 
for liver fibrosis, and found no relationship.   
The lack of a relationship of markers of hepatic steatosis, inflammation and fibrosis 
with CV events in my study may be due to a number of reasons.  Firstly, it may be 
that there is truly no relationship in the population under study.  This cohort differs 
from many of those studied previously, mainly in its broad spectrum of patients with 
type 2 diabetes.  Targher et al used populations for NAFL/D study derived 
exclusively from secondary care diabetes settings (spectrum bias), where the 
influence of hepatic steatosis would be expected to be stronger in more severe 
diabetes, consistent with other studies looking at more general populations and CV 
mortality
184
.  Secondly, it may relate to specific cohort effects within my study, 
although the size and follow-up time are comparable with several other similar 
studies
189,200
.  The association between the presence of steatosis and the absence of 




with advancing liver disease
388
 or it may  reflect survival bias, in that those with the 
most severe NAFL/D had already died prior to enrolment into the ET2DS.  I note 
that my analysis takes into account all patients, not only those with USS diagnosed 
NAFL/D, however, other aetiologies of liver disease were excluded and few people 
drank alcohol to excess.  Thirdly, it may reflect issues with the markers of liver 
injury under study in that they are not the most appropriate measures of advanced 
liver disease in a community cohort.  Fourthly, there may truly be no relationship.   
Given that no markers of liver injury were independently associated with CVD, this 
strengthens the argument for the GGT association being driven by systemic 
inflammation through the shared ectopic fat hypothesis, as opposed to a direct 
consequence of chronic liver disease (the atherogenic liver hypothesis).   
The utility of different liver injury markers may be determined by the precise 
question being asked.  For example, there is a body of evidence validating non-
invasive liver markers for the cross-sectional stratification of liver disease in 
secondary care and predicting future liver-related clinical outcomes
389,390
.  In this 
study, these markers do not appear to add prognostic benefit in determining 
cardiovascular end-points.  However, GGT which is generally not considered useful 
for stratifying active liver disease does appear to be beneficial in determining 
prognostic CVD.  Thus, one marker test or panel may not provide a diagnostic or 
prognostic panacea.   
8.7 Future work 
Given the wide variety of liver fibrosis markers identified (Chapter 2) and 
investigated (Chapters 5 and 6) is would have been most useful to determine the 
most accurate marker for identifying advanced fibrosis/cirrhosis in a community-
based cohort.  Without existing biopsy validation studies in a comparable cohort, or 
liver biopsy in this study, it is not possible to do this. 
It has become increasingly evident during the time period that this work has been 




steatosis, predominantly due to NAFL/D and/or ALD, for the majority it will be a 
benign condition.  The clinical questions that need to be answered are: i) who has 
clinically significant CLD and ii) who is going to get clinically significant CLD.  
This thesis contributes to answering these questions but there are several obstacles to 
answering them fully: 
Using non-invasive markers to diagnose and/or predict the stages of non-alcoholic 
fatty liver disease or chronic liver disease 
Currently this cannot be done.  Markers are validated against an imperfect gold 
standard in select populations with poor PPVs.  Moving forward, the most value is 
likely to come from the use of imaging modalities allowing the whole liver to be 
assessed for a number of different purposes. 
Redefining the stages of ‘advanced’ chronic liver disease 
The current histological grading systems are limited in their usefulness not only by 
the need for liver biopsy but also in their clinical utility.  The move for example from 
Metavir F2 to the more severe Metavir F3, is not equal in magnitude to the move 
from Metavir F3 to F4, nor does a move in stage indicate useful clinical 
interpretation for developing hepatic failure and complications.   
A more useful system would be to be able to provide a composite tool, most likely 
incorporating imaging alongside alternative markers allowing the categorisation of 
patients into those with: i) early disease at low risk of progression, ii) early disease at 
high risk of progression, iii) advanced disease amenable to treatment, iv) advanced 
disease not amenable to treatment, and v) end-stage disease (cirrhosis). 
Defining chronic liver disease and robust clinical end-points in order to allow fair 
comparisons 
Definitive diagnoses are needed to allow fair comparisons. What ICD-10 codes 
should be included in CLD? – as these current differ in many studies.   
A more robust NAFLD diagnosis would be beneficial including formalising the 




medication use, what drugs, at what dose, over what time period? Also, what cut-off 
(and how should we measure) of alcohol consumption is clinically relevant i.e. does 
it matter if someone has ALD, NAFL/D or more commonly mixed ALD/NAFL/D?  
Finally, what is the best way of defining progression to clinically significant chronic 
liver disease? For large scale population based studies, neither liver biopsy or 
reliance on hospital discharge coding is feasible or accurate. 
Models for predicting CVD in people with type 2 diabetes 
There are already both general population (Framingham Heart Study
391
) and diabetes 
specific (UK Pospective Diabetes Study
392
) risk prediction tools available for the 
prediction of CVD. However, the findings of this thesis suggest it may be useful to 
consider the addition of GGT into ascoring system for people with type 2 diabetes. 
Such a score would need to be tested in a large cohort with sufficient outcomes to see 
if the addition of GGT was beneficial, prior to further validation. 
8.8 Conclusion 
In conclusion, this thesis provides the first ever information on the ‘normal’ 
distribution of non-invasive markers of CLD in a diabetic population unselected for 
liver disease.  Also, I have provided evidence that CK18 and ELF are increased in 
those people with type 2 diabetes who have a more adverse metabolic profile, 
including higher levels of body fat, whilst established risk factors for CLD were not 
found to have a major influence of levels of the markers.  At present, choice of and 
use of these non-invasive markers is limited within low disease prevalence settings to 
excluding significant liver fibrosis.  The practical and ethical challenges of large 
scale liver biopsy in ‘normal’ patients persist, but emerging techniques, such as 
magnetic resonance elastography
251
, have the potential to become a more acceptable 
reference standard. 
This investigation represents the only large prospective population-based study of 
clinically significant CLD in people with type 2 diabetes.  Here for the first time, I 




tests in order to identify those at high risk of both immediate and future clinically 
significant CLD and finding a large burden of undiagnosed clinically significant 
CLD. 
Ultimately these findings could help identify particularly high risk groups within the 
diabetic population who may benefit from increased surveillance in relation to 
development of CLD and/or from targeting of specific metabolic risk factors.   
Prospective studies are now required to determine the extent to which non-invasive 
markers predict the development of clinically relevant liver-related endpoints, such 
as hepatocellular carcinoma, oesophageal varices and cardiovascular outcomes, in a 
range of different low and high risk population groups, most notably community 
settings and to identify additional risk factors responsible for the development of 
advanced liver disease in people with type 2 diabetes. 
For maximal clinical impact future work needs to include continued longer term 
follow-up of the ET2DS cohort to capture future incident liver related events.  Of 
particular interest will be how the rate of change of potential markers in earlier stages 
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Appendix A Classification of diabetes 
Classification of diabetes mellitus according to the American Diabetes Association.  Diabetes 






Appendix B Histological fibrosis staging systems 
Table B-1 Histological staging systems for liver fibrosis 








Enlarged, fibrotic portal tracts  
Periportal or portal-portal septa but intact architecture  
Fibrosis with architectural distortion but no obvious cirrhosis 









No fibrosis  
Fibrous expansion of some portal areas, with or without short fibrous septa  
Fibrous expansion of most portal areas, with or without short fibrous septa  
Fibrous expansion of most portal areas with occasional P-P bridging  
Fibrous expansion of portal areas with marked bridging (P-P and P-C)  
Marked bridging (P-P and/or P-C) with occasional nodules  








Stellate enlargement of portal tract but without septa formation 
Enlargement of portal tract with rare septa formation 










Zone 3 perisinusoidal/pericellular fibrosis; focally or extensively present. 
Zone 3 perisinusoidal/pericellular fibrosis with focal or extensive periportal fibrosis 
Zone 3 perisinusoidal/pericellular fibrosis and portal fibrosis with focal or extensive 
bridging fibrosis 
Cirrhosis 
P-C portal-central; P-P portal to portal  
 
Scheuer, P.  J.  (1991).  "Classification of chronic viral hepatitis: a need for reassessment." Journal of 
Hepatology 13(3): 372-374. 
Ishak, K., A.  Baptista, et al.  (1995).  "Histological grading and staging of chronic hepatitis." Journal of 
Hepatology 22(6): 696-699. 
Bedossa, P.  and T.  Poynard (1996).  "An algorithm for the grading of activity in chronic hepatitis C.  
The METAVIR Cooperative Study Group." Hepatology 24: 289 - 293. 
Brunt, E.  M., C.  G.  Janney, et al.  (1999).  "Nonalcoholic steatohepatitis: a proposal for grading and 




Appendix C Systematic review – protocol 
Background 
Non-alcoholic fatty liver disease (NAFLD) is an increasingly recognised chronic 
liver disease characterised by fat deposition within the liver parenchyma. It requires 
the absence of significant alcohol consumption at levels thought to be harmful to the 
liver. It involves a wide spectrum of disease with histological findings ranging from 
fat deposition only, through inflammatory changes to fibrosis and cirrhosis
204
. 
Clinical difficulties arise as most patients with NAFLD have no clinical signs or 
symptoms until the disease has progressed to significant fibrosis, with a proportion 
progressing to end-stage liver disease and there is also an association with the 
development of hepatocellular carcinoma
205,206
. 
The true prevalence of NAFLD is unknown, however it is estimated to be between 6 
and 14% in the general population
393
, rising to up to 74% in obese individuals
394
 . 
There are strong associations between NAFLD and the metabolic syndrome and 
experts in the field continue to argue the exact relationship with divided opinion as to 




Confirmation of hepatic fibrosis in NAFLD is currently only possible using liver 
biopsy 
204
. This is an invasive investigation requiring a 6 hour inpatient observation 
period post procedure. Common minor complications include pain, nausea, and 
vomiting. Potential significant complications include haemorrhage, billiary leakage 
and transient jaundice, with a small but acknowledged mortality rate of <0.5%
150,207
. 
It is therefore not feasible to use liver biopsy recurrently for follow-up investigation 






The search objective is to identify all published original research studies examining 
the use of non-invasive methods for the diagnosis of hepatic fibrosis in patients with 
non-alcoholic fatty liver disease.  
Search sources: 
 An electronic database search will be conducted from inception to present date; 
MEDLINE, EMBASE. Global Health, Web of Science, SCIRUS and Cochrane.  
 Additional studies will be identified via manual review of the reference lists of 
identified studies, review articles and citation searching using Web of Science 
Citation Index.  
 From relevant websites: American Association for the Study of the Liver, 
European Association for the Study of the Liver. 
Search terms employed are detailed below. MESH terms were used where available. 
Criteria for inclusion  
Non-invasive methods of diagnosing hepatic fibrosis 
 Individual serum markers; or 
 Marker panels must include ≥2 components; or 
 Any imaging modality 
Study characteristics 
 Data on NAFLD extractable 
 They are systematic reviews, meta-analyses, or primary studies of one or more 
non-invasive markers 
 Written in English 
 Liver biopsy as the reference standard 
 >30 participants 
NAFLD defined as a biopsy diagnosis with a statement regarding the attempt to 
exclude other causes of liver disease (e.g. alcoholic liver disease, viral hepatitis, 
autoimmune disorders, metabolic disorders). Studies where patients consumed 




Primary outcome of grade hepatic fibrosis as defined using any recognised 
histological classification. 
Those studies with data reported as sensitivity, specificity, predictive values, 
likelihood ratios (LR), or ROC curves or included sufficient data to calculate these 
parameters will be included. 
Data presented as to allow the construction of diagnostic 2x2 tables with the 4 cells; 
true positives, false negatives, false positives and true negatives for a defined 
diagnostic threshold. 
Data collection  
Data extraction will be undertaken by one reviewer (JM) and checked by a second 
reviewer (JP) with any disagreements being resolved through discussion. 
Methodological quality assessment of the identified studies will be undertaken using 
the Quality Assessment of Diagnostic Accuracy Studies (QUADAS) score
255,256,396
.  
1. *Hyperlipidemia/ or *Hypertriglyceridemia/ or *Metabolic Syndrome X/ or 
*Obesity/ or *Insulin Resistance/ or *Diabetes Mellitus, Type 2/ or metabolic 
syndrome.mp.  










12. steatosis.mp. [mp=title, original title, abstract, name of substance word, subject 
heading word] 
13. inflammation.mp. 
14. 9 or 10 or 11 or 12 or 13 




16. diagnosis/ or "diagnostic techniques and procedures"/ or "laboratory techniques 
and procedures"/ 
17. $invasive.mp. 
18. exp Liver Function Tests/ 





24. 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 OR 23 
25. 8 and 14 and 24 
26. limit 25 to (humans and english language) 

















Appendix D Systematic review data extraction forms 
 
Study Selection, Quality Assessment & Data Extraction Form 


















Yes / No / Unclear 
 
Yes / No / Unclear 
 
Yes / No / Unclear 
 
Yes / No / Unclear 
 
 














References to study 
 
Check other references identified in searches. If there are further references to 
this trial link the papers now & list below. All references to a single study 
should be linked. 
 
Code  Author(s) Journal/Conference 
Proceedings etc 
Year 
A The paper 
listed above 
  
B Further papers   
    
 
 
Participants and trial characteristics 
Participant characteristics 
Age (mean, median, range, etc) 
 




Single centre / multicentre 
 
Country / Countries 
 






NAFLD exclusions (alcohol, hep B/C etc) 
 
How many people were included?  
 
Number of participants in each fibrosis 
group 
 
Number of participants who were 
analysed 
 
Histology system used (e.g. Brunt) 
 
Fibrosis cut-offs reported 
 
Single serum marker (name and manufacturer) 
 
Marker panel (name and manufacturer, algorithm) 
 





F0 vs F1-4 
Yes / No 
F0-1 vs F2-4 
Yes / No 
F0-2 vs F3-4 
Yes / No 
F0-3 vs F4 




Diagnostic test accuracy 
Code Fibrosis level Cut-off Sensitivity Specificity PPV NPV AUROC Notes 
         
         
         
         
         
         
         

















References to other studies 
 
Did this report include any references to published reports of potentially eligible 
studies not already identified for this review? 
First author Journal / Conference Year of publication 
   
   
   
Did this report include any references to unpublished data from potentially eligible 










Appendix E PRISMA Checklist for systematic literature review: non-
invasive markers of liver fibrosis in NAFL/D 
Section/topic  # Checklist item  
Reported 
on page #  
TITLE   
Title  1 Identify the report as a systematic review, meta-analysis, or 
both.  
 
ABSTRACT   
Structured 
summary  
2 Provide a structured summary including, as applicable: 
background; objectives; data sources; study eligibility criteria, 
participants, and interventions; study appraisal and synthesis 
methods; results; limitations; conclusions and implications of 
key findings; systematic review registration number.  
 
INTRODUCTION   
Rationale  3 Describe the rationale for the review in the context of what is 
already known.  
 
Objectives  4 Provide an explicit statement of questions being addressed 
with reference to participants, interventions, comparisons, 
outcomes, and study design (PICOS).  
 
METHODS   
Protocol and 
registration  
5 Indicate if a review protocol exists, if and where it can be 
accessed (e.g., Web address), and, if available, provide 




6 Specify study characteristics (e.g., PICOS, length of follow-up) 
and report characteristics (e.g., years considered, language, 





7 Describe all information sources (e.g., databases with dates 
of coverage, contact with study authors to identify additional 
studies) in the search and date last searched.  
 
Search  8 Present full electronic search strategy for at least one 
database, including any limits used, such that it could be 
repeated.  
 
Study selection  9 State the process for selecting studies (i.e., screening, 
eligibility, included in systematic review, and, if applicable, 




10 Describe method of data extraction from reports (e.g., 
piloted forms, independently, in duplicate) and any processes 
for obtaining and confirming data from investigators.  
 
Data items  11 List and define all variables for which data were sought (e.g., 
PICOS, funding sources) and any assumptions and 





Risk of bias in 
individual 
studies  
12 Describe methods used for assessing risk of bias of individual 
studies (including specification of whether this was done at 
the study or outcome level), and how this information is to be 




13 State the principal summary measures (e.g., risk ratio, 




14 Describe the methods of handling data and combining results 
of studies, if done, including measures of consistency (e.g., I
2
) 
for each meta-analysis.  
N/A 
Risk of bias 
across studies  
15 Specify any assessment of risk of bias that may affect the 
cumulative evidence (e.g., publication bias, selective 




16 Describe methods of additional analyses (e.g., sensitivity or 
subgroup analyses, meta-regression), if done, indicating 
which were pre-specified.  
N/A 
RESULTS   
Study selection  17 Give numbers of studies screened, assessed for eligibility, and 
included in the review, with reasons for exclusions at each 




18 For each study, present characteristics for which data were 
extracted (e.g., study size, PICOS, follow-up period) and 
provide the citations.  
 
Risk of bias 
within studies  
19 Present data on risk of bias of each study and, if available, 





20 For all outcomes considered (benefits or harms), present, for 
each study: (a) simple summary data for each intervention 
group (b) effect estimates and confidence intervals, ideally 




21 Present results of each meta-analysis done, including 
confidence intervals and measures of consistency.  
N/A 
Risk of bias 
across studies  
22 Present results of any assessment of risk of bias across 




23 Give results of additional analyses, if done (e.g., sensitivity or 
subgroup analyses, meta-regression [see Item 16]).  
 
DISCUSSION   
Summary of 
evidence  
24 Summarize the main findings including the strength of 
evidence for each main outcome; consider their relevance to 
key groups (e.g., healthcare providers, users, and policy 
makers).  
 
Limitations  25 Discuss limitations at study and outcome level (e.g., risk of 
bias), and at review-level (e.g., incomplete retrieval of 
identified research, reporting bias).  
 
Conclusions  26 Provide a general interpretation of the results in the context 
of other evidence, and implications for future research.  
 




Funding  27 Describe sources of funding for the systematic review and 
other support (e.g., supply of data); role of funders for the 
systematic review.  
 
 
From:  Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(6): e1000097. 
doi:10.1371/journal.pmed1000097  






Appendix F Systematic review of non-invasive markers of liver 
fibrosis: additional tables 
Table F-1 Excluded studies n=16 


















performed in a 
subgroup 





De Ledinghen 2010 France 2008 No liver biopsy 
Fujii 2009 Japan 
1998-
2007 
Only report AUROC 
for cirrhosis (F4) 







 2007 USA 2007* 
No AUROC 
presented 







2008 Ukraine 2008* 
No AUROC 
presented 
Laine 2004 France 
2000-
2003 
Unable to separate 
NAFLD and ALD 
Pimentel 2010 Brazil 2010* 
No AUROC 
presented 





Schmilovitz-Weiss 2008 Israel 2008* N<30 




















Table E-2 Publication years of included studies 
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012* 
1 0 0 0 3 6 6 6 9 9 6 5 1 





Appendix G Systematic review of non-invasive markers of liver 
fibrosis: quality assessment of included studies 
Table G-1 Quality scoring of included studies: QUADAS-2 









































g  Overall Reason for risk of bias 
Angulo
243
       None    
Cales
272
       None    
Guha
236
       None    
Park
296
       None  
Petta
297
       None  
Ruffillo
301
       None  
Suzuki
305
       None  
Wong
246





      Risk 
Interval between index and reference 
test 18 months 
Gaia
276
       Risk 
Interval between index and reference 
test 6 months 
Gholam
277





    ?  Risk 
All gastric bypass surgery participants 




     ?  Risk All gastric bypass surgery participants 
Kelleher
282 $
     ?  Risk All NASH participants 
Lassailly
284
     ?  Risk All gastric bypass surgery participants 
Lupsor
285
       Risk All NASH participants 
Lydatakis
286
     ?  Risk All NASH participants 
McPherson
228
       Risk 
Interval between index and reference 
test 6 months 
Miao
288$
     ?  Risk All participants morbidly obese 
Myers
291
  ?     Risk 
Interval between index and reference 
test 6 months 
Myers
292
       Risk 
All participants morbidly obese 
Interval between index and reference 
test 6 months 
Tetri
293




Study  Risk of bias   
PIVENs clinical trial – multiple 
exclusion criteria. 
Interval between index and reference 
test 6 months 
Ratziu
119
       Risk All participants obese 
Ratziu
241
     ?  Risk Hospitalised patients only 
Rodriguez
299
       Risk All gastric bypass surgery participants 
Rosenberg
235
       Risk 
Interval between index and reference 
test 6 months 
Shah
303
  ?     Risk 
Interval between index and reference 
test 12 months 
Talwalker
306$
  ? ? ?   Risk 
Interval between index and reference 
test 12 months 
Wong
309
       Risk Chinese population 
Yoneda
311
     ?  Risk All NASH participants 
Yu
314
     ?  Risk Included a group of liver donors 
Adams
271$
  ?     Unclear    
de Ledinghen
273
      ?  Unclear    
Dos Santos
274
  ?   ?  Unclear    
Fujii
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EDINBURGH TYPE 2 DIABETES STUDY 
BASELINE 
QUESTIONNAIRE 
PLEASE NOTE:  ONE OF OUR RESEARCH NURSES WILL GO OVER THE 
QUESTIONNAIRE WITH YOU AT THE CLINIC AND MAY ASK A FEW 
ADDITIIONAL QUESTIONS 
THE INFORMATION IN THIS QUESTIONNAIRE IS HIGHLY CONFIDENTIAL 
AND IS PART OF A MEDICAL RESEARCH STUDY 
The information you give in this questionnaire will be treated as strictly 
confidential and will be available only to your own doctor and the study team.  
The results of the research will appear only in the form of general statistics from 
which it will be impossible to identify you as an individual. 
 
Please complete the following: 
SURNAME:  ……………………………………………………………….. 
FORENAMES: ……………………………………………………………….. 
DATE:            ……………………………………………………………….. 
If you have any difficulties in answering some of the questions, you will have a 
chance to discuss these with a member of the study team.   
 
THANK YOU FOR YOUR CO-OPERATION IN THIS STUDY 
 












1. Please tick one box:            Male    Female      
                                
                  
                  Day    Month          Year 
2. Enter your date of birth:         
 
 
3.  Please tick the box showing your present marital status: 
 
  Married and/or living with long-term partner   
  Single        
  Widowed         
Divorced or separated     
 
 
4. Please enter your address (including postcode) and telephone no.   
 
  Address:   …………………………………………………………………. 
 
    …………………………………………………………………. 
 
  Postcode: ……………………………….. 
 
Telephone no: ………………………………… 
 
                        
5. Please enter the details of your GP       
 




  …………………………………………………………………. 
 
EDUCATION 
6. What is the HIGHEST level of education you and your spouse/ex-spouse or long-term 
partner  have completed? 
 Please tick appropriate boxes: 
         You Spouse/ex-
spouse            /partner
  University/college degree course      
   
 Other professional/technical qualification after leaving school      
 Secondary school           







7. What is your ethnic group? 
 
 Please choose ONE section from 1 to 5, then tick the appropriate box to indicate your ethnic 
Group 
 
 (i)  White  
 
  
      British 
     
    Any Other White background, please write in _____________________________ 
 
 (ii)  Mixed 
 
     
    White and Black Caribbean 
     
    White and Black African 
     
    White and Asian 
     
   Any Other Mixed background, please write in _____________________________ 
 
 (iii)  Asian or Asian British 
 
     
    Indian 
     
    Pakistani 
     
    Bangladeshi 
     
    Any Other Asian background, please write in _____________________________ 
 
 (iv)  Black or Black British 
 
     
    Caribbean 
     
    African 
     
    Any Other Black background, please write in _____________________________ 
 
 (v)  Chinese or other ethnic group 
 
     
    Chinese 
     
    Any Other, please write in  __________________________________ 
 
CURRENT EMPOYMENT STATUS 
8. At the moment, what is the employment status of you and your spouse/ex-spouse or 
long-term  partner? 
 You                 Spouse/ex-spouse/partner 
 Employed, full-time           Employed, full-time      
 Employed, part-time    
        
Employed, part-time      
 Unemployed     
        
Unemployed       
 
 Retired      
          
Retired        
 A Housewife (full-time)    
          
A Housewife (full-time)      
 Other     
          
Other       
 
















9. When was your diabetes diagnosed (if known)?    Year ……..…… 
 
10. What treatment do you receive currently for your diabetes? 
 
Yes No 
(i) Tablets        
 
If ‘yes’, please give name(s)  ……………………................................................. 
 
  Yes No 
(ii) Insulin injections    
 
If ‘yes’,  
 
(a) give total number of units per day                            
……………….…units/day 
(b) give date (year) when you started insulin       year   ………………… 
 
Yes  No  Don’t know 
11. Have you ever had an episode of low blood glucose (hypoglycaemia)  
     
  
 when you have needed someone else to treat you eg. give sugary  
drink or glucagon?    
 
 If ‘yes’, how many times has this ever happened? 
 
  1-2    
3-4    
5 or over  
 
 
 How many times has this happened over the past year? 
 
  1-2    
  3-4    
             5 or over  
 
 
            
12.  Are you on any regular medical treatment from a doctor as follows:  
        Yes No  Don’t Know 
   Aspirin?        
  
  
   Drugs for angina (including spray)?   
     
  
   Drugs to lower blood pressure?     
               
  
   Drugs to lower cholesterol?     
               
  
   
(If you have answered YES to any of these, please include details below) 
13. Give names of all current medication if possible (including regular skin creams, eye 
drops, inhalers, tablets and injections which may or may not be repeat prescriptions): 
  
……………………………………………  ………………………………………….... 
……………………………………………  ………………………………………….... 




……………………………………………  ………………………………………….... 
 
              Yes  No Don’t Know 
14. Have you taken any oral steroids, used steroid inhalers or used       
  
   
       
  





15. Have you ever been told by a doctor that you have or have had any of the following? 
 
  
Yes No  Don’t Know 
(i) Heart attack (coronary thrombosis, myocardial infarction)?       
(ii) Angina?            
(iii) Stroke?            
(iv) Hardening of the arteries in the legs?        
(v)    High blood pressure?           
 
If you have answered ‘yes’ to any of the above, please give the year in which the event 
occurred and/or condition was diagnosed (as near as you can remember) and the name 
of the hospital/GP surgery where you were/are treated for the condition 
 
Event/condition   Year of event/diagnosis  Hospital/GP surgery  
where treated 
 
 …………………………… ……………………….  …………………………. 
 




16. Have you ever undergone any of the following procedures/operations? 
                Don’t 
          Yes No Know 
(i) An operation or balloon treatment to relieve a blockage in         
the arteries of your heart (coronary by-pass or angioplasty)?     
 
(ii) An operation or balloon treatment to relieve a blockage in        
the arteries of your leg(s) , other than for varicose veins?  
 
(iii) Surgery to remove toes or leg (above or below the knee)?      
 
(iv)   An operation or balloon treatment to relieve a blockage in       
the arteries of your neck (carotid surgery/angioplasty/stenting)? 
 
 
If you have answered ‘yes’ to any of the above, please give the year in which the 
procedure was performed and the name of the hospital you attended 
 
Procedure/operation  Year performed   Hospital attended  
 
 …………………………… ……………………….  …………………………. 
 












17. Have you ever been told by a doctor that you have or have had any of the following? 
  
Yes  No Don’t Know 
(i) Hepatitis?             
(ii) Cirrhosis of the liver?            
(iii) Any other disease/medical condition affecting the liver? 
 
     
            
 
If you have answered ‘yes’ to any of the above, please give the name of the condition, 
the year in which it was diagnosed (as near as you can remember) and the name of the 
hospital where you were/are treated for the condition 
 
Name of condition  Year of diagnosis  Hospital where treated 
 
 …………………………… ……………………….  …………………………. 
 
 …………………………… ………………………..  …………………………. 
 
 
18. Have you ever had any of the following investigations of your liver 
   
Yes  No Don’t Know 
(i)          Abnormal blood tests of liver function?        
 
(ii)          Liver biopsy?           
 
(iii)         Scan (ultrasound or CT etc.) of the liver?       
 
  (iv)         Other investigation of the liver?         
 
 
If you have answered ‘yes’ to any of the above, please give the name of the 
investigation, the year in which it was done (as near as you can remember) and the 
name of the hospital where the test/investigation was performed 
 
Name of investigation  Year done   Hospital where  
performed 
 
 …………………………… ……………………….  …………………………. 
 
 …………………………… ………………………..  …………………………. 
      
 
Other Medical Conditions         
Yes No Don’t Know 
19. Do you suffer from disease of the thyroid gland?       
   
20. Do you have any other medical conditions not mentioned above?      
 





    







21. Current alcohol intake 
 
(i)  Think back carefully over the last seven days.  Please write in each column the exact 
number  of alcoholic drinks you consumed on each day during the past week.  If none 
consumed write ‘0’  in the boxes. 
 
 Try to remember where and who you were with on each day.  This may help you 
remember what  you had to drink. 
 
            Pints of beer,       Single glasses of        Single glasses of 
           lager, cider etc      whisky, vodka, gin etc       martini, wine, sherry, etc 
 
        
Monday                          
Tuesday                          
Wednesday                       
Thursday                        
Friday                        
Saturday                        
Sunday                         
 
          Yes No 
(ii) Would you say that last week was fairly typical of what you usually 
have to drink in a week? 
          More Less 
(iii) If last week was not typical, would you normally drink more or 
less in a week?  
 
  
22.   Alcohol intake over past year 
 
(i)   How often did you have a drink containing alcohol in the past year?  
 Consider a “drink” to be a can or bottle of beer, a glass of wine, or one cocktail or a 
measure of  spirits (like scotch, gin, or vodka).  
 
never        
monthly or less     
2 to 4 times a month    
2 to 3 times a week     
4 to 5 times a week     
6 or more times a week    
 
 (ii)  How many drinks did you have on a typical day when you were drinking in the past year?  
 
0 drinks      
1 to 2 drinks     
3 to 4 drinks     
5 to 6 drinks        




10 or more drinks     
(iii)  How often did you have 6 or more drinks on one occasion in the past year?  
 
never      
less than monthly     
monthly      
weekly      
daily or almost daily    
 
23.   Have you or your doctor ever considered that you suffer/have   Yes No 





Smoking has been linked with many health problems.  It is important that you answer the 
following section as accurately as possible. 
         Yes No 
24. Do you smoke at present?          
        
 
If no, proceed to Question 29 
 
25. What do you usually smoke now? 
Yes No 
 Cigarettes          
        
Pipe           
  
Cigars           
          
 
26. How many do you usually smoke now? 
 
Cigarettes per day      …… cigarettes 
 
Ozs. tobacco per week      ……… ozs. 
 
Cigars per week      ……… cigars 
 
27. For how many years during your life have you smoked cigarettes? ……… years
           
 
28. How many cigarettes have you smoked on average per day during  
 the period you have smoked?     ………cigarettes
        
 Now proceed to Question 34     
       Yes No 
29. Have you ever smoked regularly?         
     
   If no, proceed to Question 34 
           
30. What did you usually smoke?       Yes No 




Pipe            
Cigars            
 
 
31. How much did you smoke on average while you were a smoker? 
 
Cigarettes per day      ……… 
cigarettes 
 
Ozs. tobacco per week      ……… oz. 
 
Cigars per week      ……… cigars 
 
32. For how many years did you smoke cigarettes?    ……… years 
 
33.     If you smoked cigarettes, how long is it since you finally  
 gave up?   








34. Do you ever get pain or discomfort in your chest?        
                     
 
IF NO, PROCEED TO QUESTION 40 
         Yes No 
35. Do you get this pain or discomfort when you walk uphill or hurry?      
         
  
  IF NO, PROCEED TO QUESTION 40 
           
          Yes No 
36. Do you get it when you walk at an ordinary pace on the level?     
  
         
          
37. When you get any pain or discomfort in your chest what do you do?  
                      Tick one 
Stop           
 
Slow down         
 
Continue at the same pace        
   
        Yes No 
38. Does it go away when you stand still or sit down?       
  
 
How soon?                       Tick one 
10 minutes or less         
 
More than 10 minutes         
 
 
39. Where do you get this pain or discomfort?  Mark the place(s) 
with an ‘X’ on the diagram 
 
 
         Yes No 
40. (i) Have you ever had a severe pain across the front of your     
  chest lasting for half an hour? 
 






Yes No I am unable 
  to walk 
 41.  Do you get a pain or discomfort in your leg(s) when you walk?       
   
 
If you answered ‘yes’ to question 41, please answer the following questions.   
 
          Yes No 
 (i) Does this pain ever begin when you are standing still or sitting?     
 (ii) Do you get it if you walk uphill or hurry?       
 (iii) Do you get it when you walk at an ordinary pace on the level?    
 
 (iv) Does the pain ever disappear while you are still walking?      
 (v) What do you do if you get it when you are walking?       
 
         Tick one 
   Stop          
Slow down         
  Continue at same pace        
 
(vi) What happens to it if you stand still? 
        Tick one 
 Usually continues for more than 10 minutes     
 Usually disappears in 10 minutes or less     
  
(vii) Where do you get this pain or discomfort? 
          Yes No 
  (i) Do you get this pain in your calf (or calves)?      
    








THANK YOU FOR COMPLETING THIS QUESTIONNAIRE – PLEASE BRING IT WITH YOU 







EDINBURGH TYPE 2 DIABETES STUDY 
 
YEAR 1  QUESTIONNAIRE 
 
 
(LIVER FUNCTION & DIABETES COMPLICATIONS) 
 
 
THE INFORMATION IN THIS QUESTIONNAIRE IS HIGHLY CONFIDENTIAL AND IS PART OF 
A MEDICAL RESEARCH STUDY. 
 
 
The information you give in this questionnaire will be treated as strictly confidential and will be 
available only to your own doctor and the study team.  The results of the research will appear 





Please complete the following : 
 
 
SURNAME :  ……………………………………………………………….. 
 
FORENAMES : ……………………………………………………………….. 
 




If you have any difficulties in answering some of the questions, you will have a chance to discuss 




Thank you for your continued participation in the  




      PART 1 
       1. Medications 
(a) What medications are you taking at present?   












(b) Have you, to your knowledge, used any of the following medications over the last six months? 
                Yes      No   Not sure  
Amiodarone        
Isoniazid         
Methotrexate        
 Steroids (e.g. prednisolone, dexamethasone)    
 Allopurinol        
 Tamoxifen         
 
If so, please indicate when it was started and how long you were on it. 
 
Medication   When started?  How long on it?  
 





 2. Alcohol Intake 
 
(a)  Current alcohol intake 
 
Think back carefully over the last seven days.  Please write in each column exactly the 
number of alcoholic drinks you consumed on each day during the past week.  If none 
consumed write ‘0’ in the boxes. 
 
Try to remember where and who you were with on each day.  This may help you remember 
what you had to drink. 
 
             Pints of beer,        Single glasses of Single glasses of 
    lager, cider etc       whisky, vodka, etc.  martini, wine, sherry, etc 
Monday                  
Tuesday         
Wednesday        
Thursday         
Friday         
Saturday         
Sunday         
    
    (b)  Alcohol intake over past year 
 
    (i)  How often did you have a drink containing alcohol in the past year?  
Consider a “drink” to be a can or bottle of beer, a glass of wine, or one cocktail or a measure 
of spirits (like scotch, gin, or vodka).  
never      
monthly or less   
2 to 4 times a month  
2 to 3 times a week   
4 to 5 times a week   
6 or more times a week  
 
(ii) How many drinks did you have on a typical day when you were drinking  in the past year?  
 
0 drinks    
1 to 2 drinks   
3 to 4 drinks   
5 to 6 drinks      
7 to 9 drinks   
10 or more drinks   
 
(iii) How often did you have 6 or more drinks on one occasion in the past year?  
never    
less than monthly   
monthly    
weekly    







(c) Have you or your doctor ever considered that you suffer/ have suffered in the past from an 
alcohol problem/excessive drinking?        
                Yes            No  
  
3.  Liver condition/disease 
 
(a) In the past year (i.e. since we first saw you at the research clinic), have you been told by 
a doctor that you have any of the following? 
 
          Yes     No     Not sure 
(i) Fatty liver?         
(ii) Hepatitis?         
(iii) Cirrhosis of the liver?        
(iv) Any other medical condition affecting the liver?     
            
If you have answered ‘yes’ to any of the above, please give the name of the condition, 
when it was diagnosed and the name of the hospital where you were/are treated for the 
condition 
 
Name of condition  When diagnosed Hospital where treated 
 
 ……………………… …………………        …………………… 
 





(b) Have you had any of the following investigations of your liver within the last year? 
 
Yes    No      Not sure  
 
(v) Abnormal blood tests of liver function?     
(vi) Liver biopsy?        
(vii) Scan (ultrasound or CT etc.) of the liver?    
(viii) Other investigation of the liver?      
 
 
If you have answered ‘yes’ to any of the above, please give the name of the 
investigation, when it was done and the name of the hospital where the test/investigation 
was performed 
 
Name of investigation When done          Hospital where performed 
 
 
 …………………………              …………………                    ………………………… 
 
 
      ………………………….            …………………                      ………………………..









4.  Joint condition/disease? 
 
Have you ever been told by a doctor that you have any of the following? 
 
        Yes No   Not sure 
    
(i) Osteoarthritis          
(ii) Rheumatoid arthritis        
(iii) Scleroderma        
(iv) Any other disease affecting the joints     
 
 
If you have answered ‘yes’ to any of the above, please give the name of the condition, when it 
was diagnosed and the name of the hospital where you were/are treated for the condition 
 
 
Name of condition  When diagnosed Hospital where treated 
 
 
 ……………………… …………………        …………………… 
 






Some people find that they have altered breathing when they are asleep, sometimes leading to 
snoring. It has been suggested that this may affect their thinking skills, such as those which we 
measured when you first attended our research clinic. We are interested in finding out more 
about this condition and would therefore be grateful if you would answer the following questions. 
Do you snore? 
  Yes 
 No          (If NO, go to Question 5) 
 Don’t know 
 
        If you snore: 
 
Your snoring is: 
 Slightly louder than breathing 
 As loud as talking 
 Louder than talking 
 Very loud – can be heard in adjacent rooms     
How often do you snore? 
 
 Nearly every day 
 3-4 times per week 
 1-2 times per week 
 1-2 times per month 
 Never or nearly never 
 
Has your snoring ever bothered other people? 
 
  Yes 
 No 
 Don’t know 
 
Has anyone noticed that you stop breathing during your sleep? 
 
  Nearly every day 
 3-4 times per week 
 1-2 times per week 
 1-2 times per month 
 Never or nearly never   
 
How often do you feel tired or fatigued after your sleep? 
 
 Nearly every day 
 3-4 times per week 
 1-2 times per week 
 1-2 times per month 









During your waking time, do you feel tired, fatigued or not up to par? 
 
 Nearly every day 
 3-4 times per week 
 1-2 times per week 
 1-2 times per month 
 Never or nearly never  
 





How often does this occur? 
 
 Nearly every day 
 3-4 times per week 
 1-2 times per week 
 1-2 times per month 
 Never or nearly never 
 




 Don’t know 
 
 11.  Sleepiness Score 
 
How likely are you to doze off or fall asleep in the following situations, in contrast to feeling just 
tired? This refers to your usual way of life in recent times. Even if you have not done some of 
these things recently try to work out how they would have affected you. Use the following scale to 
choose the most appropriate number for each situation. 
 
0 = would never dose 
1 = slight chance of dozing 
2 = moderate chance of dozing 
3 = high chance of dozing 
 
                                 
                                           SITUATION                                                                              
CHANCE OF 
DOZING
Sitting and reading  
Watching television  
Sitting inactive in a public place (e.g. a theatre or meeting)  
As a passenger in the car for an hour without a break  
Lying down to rest in the afternoon when circumstances permit  
Sitting and talking to someone  
Sitting quietly after a lunch without alcohol  










PART 3: DIABETES SERVICES 
 
We would like to ask you some questions about the care that you receive for your diabetes.  This 
part of the questionnaire has been developed by the research team and clinicians involved in the 
care of people with diabetes in Lothian.  The aim is to provide feedback and information which 
will help improve the quality of care provided for people with diabetes.  Please answer the 
questions as carefully as possible.  Your responses will remain confidential and will not be 
disclosed to anyone involved in the care of your diabetes at an individual level. 
 
A. Visits to the doctor or nurse 
 
Q1. Where do you usually go for your diabetes check-up, where your test results and treatment 
are reviewed?  This check-up is sometimes known as an ‘annual review’ though some people 
have more or less than one every year (please tick one box only) 
 
 My doctor’s surgery 










 It varies 
 I have recently changed where I go for my check ups (please specify) 
 
 I have never had a diabetes check-up 
 Don’t know 
 
Q2. How often do you usually have a diabetes check-up? 
 
 Approximately once a year 
 Approximately once every 6 months 
 Approximately once every 3 months 
 More than once every 3 months 
 Less than once a year 
 I have never had a check-up 






Q3. Where do you go if you need help or advice from healthcare staff to  manage your diabetes 
in between your scheduled check-ups (please tick all that apply)? 
 
 My general practitioner  
 The practice nurse 
 The diabetes specialist nurse 
 The hospital clinic 
 NHS 24 
 A community pharmacist  
 I never contact healthcare staff between check-ups 








Q4. Overall, who have you seen for diabetes care in the last year (please tick all that apply)? 
 
 The hospital consultant  
 A hospital registrar  
 My general practitioner 
 The practice nurse  
 The diabetes specialist nurse 
 A podiatrist 
 A dietician  








Q5. Who do you see most often about your diabetes (please tick one box only)? 
 
 The hospital consultant  
 A hospital registrar  
 My general practitioner 
 The practice nurse  
 The diabetes specialist nurse  










Q6. Who is your lead healthcare professional; the person that you perceive to be in overall 
charge of your diabetes care (please tick one box only)? 
 
 The hospital consultant  
 My general practitioner 
 The practice nurse  
 The diabetes specialist nurse  






 I don’t know which healthcare professional is in overall charge of my care  
 
Q7. At your doctor’s surgery, which of the doctors or nurses have a special interest in diabetes 
(please tick all that apply)? 
 
 My general practitioner  
 One of the other general practitioners 
 One of the nurses 
 None of the doctors or nurses  
 Don’t know 
 
Q8. How do you feel about where you currently go for your diabetes check-ups, where your test 
results and treatment are reviewed (please tick the box which applies most to you)? 
 
 I am happy having my check-ups where I go at the moment (  Go To Q10) 
 I would prefer to have my check-ups at a hospital clinic 
 I would prefer to have my check-ups at my doctor’s surgery 






Q9. If you would prefer to have your diabetes check-ups somewhere other than where you go at 
present, why is this (please tick all that apply)? 
 
 I would find my check-ups easier to get to 
 I would be more likely to see the same doctor or nurse each time 
 I would be able to get all my checks and tests done at the same time 
 I would be able to see an expert in diabetes care 









B. Information and communication 
 
Q10  Thinking about the last 12 months, when you received care for your diabetes…. 
 
(a)   How would you describe the overall amount of information you received about your 
diabetes from your healthcare professional(s)? 
 
 I didn’t receive any information 
 I received about the right amount of information 
 I received too much information 
 I didn’t want any information  
 
(b)   How do you feel about the amount of written information that you received? 
 
 I received about the right amount of written information  
 I would like more written information 
 I would like less written information 
 I didn’t want any written information  
 
(c)   Were you given personal advice about the kinds of food to eat? 
 
 Rarely or not at all 
 Some of the time 
 Almost always 
 
(d)   Were you given personal advice about your levels of physical activity? 
 
 Rarely or not at all 
 Some of the time 
 Almost always 
 
(e)   In the last 12 months, which of the following, if any, would you have liked to receive more 




 Physical activity 
 Blood glucose monitoring 
 Sources of support 
 Footcare  
 Illnesses associated with diabetes, such as eye disease  
 What is likely to happen to me because of my diabetes in the future 
 What kind of services I should receive for my diabetes 










Q11. In addition to any information you receive from your doctor, nurse or other healthcare 
professional about your diabetes, where else do you get information and/or discuss your diabetes 
(Please tick all that apply)? 
 
 Diabetes UK or other helpline 
 Internet 
 Magazine or newspaper articles 
 Friends or work colleagues 
 Relatives 
 I don’t receive any other information or discuss diabetes with anyone else 




Q12. Thinking about your diabetes check-up or annual review (where your test results and 
treatment are reviewed) …………  
 
(a) Do you feel that the doctor/nurse you see for your diabetes check-up has the right type of 
expertise and experience to manage your diabetes? 
 
 Yes or almost certainly yes 
 Possibly 
 No or probably not 
 Don’t know 
 
(b)  Do you usually see the same doctor/nurse each time for your diabetes check up? 
 
 Always or almost always 
 Sometimes 
 Rarely or never 
 Don’t know 
  
(c) How important is it to you that you should see the same doctor or nurse each time? 
 
 Very important 
 Quite important 
 Not very important 
 Don’t know 
 
(d)  Is it easy and convenient for you to get to your diabetes check-ups? 
 
 Always or almost always 
 Sometimes 
 Rarely or never 










(e)  Do you feel that you have sufficient time with the doctor or nurse when you see them for 
your diabetes check up? 
 
 Always or almost always 
 Sometimes 
 Rarely or never 
 Don’t know 
 
(f)   Do you understand what is said at your diabetes check up?  
 
 Always or almost always 
 Sometimes 
 Rarely or never 
 Don’t know 
 
(g)  Would you like to have a written copy of what is discussed and of any decisions that are 
made at your diabetes check-up? 
 
 I would definitely like a written copy of all check-ups 
 I could be interested in a written copy but do not feel strongly about it 
 I do not want a written copy of my check-ups 
 Don’t know 
 
(h)  Do you feel that the doctor/nurse takes your concerns into account at your diabetes 
check-up? 
 
 Always or almost always 
 Sometimes 
 Rarely or never 
 Don’t know 
 
(i)  Do you feel that the advice given at your diabetes check-up is tailored to your needs and 
to your ability to act on that advice? 
 
 Always or almost always 
 Sometimes 
 Rarely or never 
 Don’t know 
 
(j)  Do you feel that you are involved in the decision making process around your diabetes 
care during your diabetes check up? 
 
 Always or almost always 
 Sometimes 
 Rarely or never 










(k)   Do you have a management plan? 
 
 Yes, verbal and written 
 Yes, verbal only 
 No 
 Don’t know 
 
Q13. In general, do you feel that the health professionals looking after you have enough 
information about you eg. do they have your up-to-date records to refer to? 
 
 Always or almost always 
 Sometimes 
 Rarely or never 




Q14. It is likely that from time to time you will have a special blood test taken to look at your long-
term or ‘average’ blood glucose level. This test is called HbA1c.  Thinking about the last time you 
had this blood test: 
 




 I don’t want to know my HbA1c test value 
 I have not had an HbA1c test     (  Go To Q15) 
 




 I did not want the result in writing 
 Don’t know 
 




 Don’t know 
 
Q15. Thinking about the last time you had your blood pressure measured: 
 
















 I did not want the result in writing 
 Don’t know 
 








Q16. Thinking about the last time you had a blood test to measure your cholesterol level: 
 




 I don’t want to know the result 
 I have not had my cholesterol measured (  Go to end of Questionnaire) 
 




 I did not want the result in writing 
 Don’t know 
 









THANK YOU FOR COMPLETING THIS QUESTIONNAIRE - 
PLEASE BRING IT WITH YOU TO YOUR CLINIC VISIT AND HAND 









EDINBURGH TYPE 2 DIABETES STUDY 
 





Please note:  one of our research nurses will go over the questionnaire with you at the clinic and 
may ask a few additional questions 
 
The information in this questionnaire is highly CONFIDENTIAL and is part of a medical research 
study 
 
The information you give in this questionnaire will be treated as strictly confidential and will be 
available only to your own doctor and the study team.  The results of the research will appear 





Please complete the following: 
 
 








If you have any difficulties in answering some of the questions, you will have a chance to discuss 








Thank you for your co-operation in this study
  




YEAR 4 QUESTIONNAIRE 
 
Many of the questions below may be familiar to you as they are similar to those you 
answered at our previous research clinics. However this time we are concentrating on 
what has happened to you during the 4 years since you attended our first research clinic. 
If you are unsure if a change in circumstances, a new diagnosis or test occurred during 
this period or not, please include it. 
 
It is important to answer all the questions carefully.  







Have you changed your address since we first saw you i.e. in the past 4 years? 
 
Yes   No  
 
If ‘yes’,  
New address _______________________________________________ 
__________________________________________________________ 
_______________________________ Postcode ___________________ 
Telephone number ___________________________________________ 
 
 
Have you changed your G.P. since we first saw you i.e. in the past 4 years? 
 
Yes   No  
 
If ‘yes’,  






Has your marital status changed since we first saw you i.e. in the past 4 years? 
 
Yes   No  
 
 If ‘yes’, are you now: 
 
 Married and/or living with long-term partner 
 Single 
 Widowed 




Current Employment Status 
 
At the moment, what is the employment status of you and your spouse/ex-spouse or long-term 
partner? 
 
You  Spouse/ex-partner/partner 
 Employed, full-time   Employed, full-time 
 Employed, part-time   Employed, part-time 
 Unemployed   Unemployed 
 Retired   Retired 
 Housewife (full-time)   Housewife (full-time) 








What treatment do you receive currently for your diabetes? 
 
(i) Tablets   Yes   No  
 
If ‘yes’, please give name(s) _______________________________________ 
 
(ii) Insulin injections  Yes   No  
 
If ‘yes’, 
give total number of units per day  units/day 
what year did you start insulin   
 
 
In the past 4 years have you had an episode of low blood glucose (hypoglycaemia) when you 
have needed someone else to treat you eg. give sugary drink or glucagon? 
 
Yes  No   Don’t know  
 




 5 or over 
 
 
















Are you on any of the following regular medical treatments from a doctor? 
 
 Yes No Don’t know 
Aspirin    
Drugs for angina including spray    
Drugs to lower blood pressure    
Drugs to lower cholesterol    
 
 
Have you, to your knowledge, used any of the following medications over the last six months? 
 
 Yes No Don’t know 
Amiodarone    
Isoniazid    
Methotrexate    
Allopurinol    
Tamoxifen    
Steroids (e.g. prednisolone, 
dexamethasone) – this includes oral 
steroids, steroid inhalers or steroid 
containing creams or eye drops 
   
 
If yes, please indicate when it was started and how long you were on it. 
 
Medication  When started?  How long on it? 
     
     
     
 
 
Give names of all current medication if possible (including regular skin creams, eye drops, 
inhalers, tablets and injections which may or may not be repeat prescriptions): 
 



































Vascular and Liver Disease 
 
We are interested in any diagnoses of vascular disease or liver conditions which you have had 
over the past 4 years. If you have been told that you have had one or more of the events 
mentioned in the next few questions (numbers 0 to 0), but can’t remember whether the event 




Have you experienced either of the following since we first saw you in the research clinic i.e. 
during the past 4 years? 
 
  Yes No Don’t know 
(i) 
Heart attack (coronary thrombosis, myocardial 
infarction) 
   
(ii) Stroke    
 
 
If you have answered ‘yes’ to either of the above, please give the year in which the event 
occurred (as near as you can remember) and the name of the hospital/GP surgery where you 








     
     
     
 
 
Have you been told by a doctor that you have developed any of the following for the first time in 
the past 4 years? 
 
 
  Yes No Don’t know 
(i) Angina    
(ii) Hardening of the arteries in the legs    
(iii) High blood pressure    
 
If you have answered ‘yes’ to any of the above, please give the year in which the condition was 
diagnosed (as near as you can remember) and the name of the hospital/GP surgery where you 








     
     





During the past 4 years have you undergone any of the following procedures/operations? 
 
  Yes No Don’t know 
(i) 
An operation or balloon treatment to relieve a 
blockage in the arteries of your heart (coronary-by-
pass or angioplasty) 
   
(ii) 
An operation or balloon treatment to relieve a 
blockage in the arteries of your leg(s), other than 
for varicose veins 
   
(iii) 
Surgery to remove toes or leg (above or below the 
knee) 
   
(iv) 
An operation or balloon treatment to relieve a 
blockage in the arteries of your neck (carotid 
surgery, angioplasty or stenting) 
   
 
 
If you have answered ‘yes’ to any of the above, please give the year in which the procedure was 
performed and the name of the hospital you attended 
 
 
Procedure/operation  Year performed  Hospital attended 
     
     
     
 
 
Have you been told by a doctor that you have developed any of the following for the first time in 
the past 4 years? 
 
 
  Yes No Don’t know 
(i) Hepatitis    
(ii) Cirrhosis of the liver    
(iii) 
Any other disease/medical condition affecting 
the liver 
   
 
If you have answered ‘yes’ to any of the above, please give the name of the condition, the year in 
which it was diagnosed (as near as you can remember) and the name of the hospital where you 
were/are treated for the condition 
 
 
Name of condition  Year of diagnosis  
Hospital where 
treated 
     
     







Although we are mainly interested in vascular diseases and liver disease, we also need to know 
about any other conditions which you may have developed over the past 4 years as this may 
affect some of the tests we do. 
 
Have you been told by a doctor that you may have developed any of the following for the first 
time over the past 4 years? 
 
  Yes No Don’t know 
(i) Disease affecting the joints    
(ii) Disease of the thyroid gland    
(iii) 
Any other medical condition not mentioned 
elsewhere in the questionnaire 
   
 
If you have answered ‘yes’ to any of the above, please give the name of the condition and the 
year in which it was diagnosed (as near as you can remember). 
 




Name of condition  
Year of 
diagnosis 
1.   
 5.   
2.   
 6.   
3.   
 7.   
4.   
 8.   
 
 
Birth weight and menstrual history 
 
We are interested in looking at the role of birth weight and reproductive history in the subsequent 
development of disease. Please answer the following questions as far as you can remember. 
 
Do you know roughly what your birth weight was? 
 
Yes  No    
 
If ‘yes’, what was it? 
 
 lbs  oz 
 
 





WOMEN only (MEN please go to Question 0)  
 
How old were you when you started your periods? 
 
 years  Don’t know  
 
 
How old were you when your periods stopped? 
 
 years  Don’t know  
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The remaining questions in this questionnaire are the same as those we asked you in previous 
questionnaires. Although you may find that you are giving very similar answers to those you gave 
previously, please complete all of these as accurately as possible, as they will enable us to work 




Current alcohol intake 
 
Think back carefully over the last seven days.  Please write in each column the exact number of 
alcoholic drinks you consumed on each day during the past week.  If none consumed write ‘0’ in 
the boxes. 
 
Try to remember where and who you were with on each day.  This may help you remember what 
you had to drink. 
 
 
Pints of beer, 
lager, cider etc 
Single glasses of 
whisky, vodka, gin 
etc 
Single glasses of 
martini, wine, 
sherry etc 
Monday    
Tuesday    
Wednesday    
Thursday    
Friday    
Saturday    
Sunday    
 
Would you say that last week was fairly typical of what you usually have to drink in a week? 
 
Yes  No  
 
 
If last week was not typical, would you normally drink more or less in a week? 
 
More  Less  
 
Alcohol intake over the past year 
 
How often did you have a drink containing alcohol in the past year?  
 
Consider a “drink” to be a can or bottle of beer, a glass of wine, or one cocktail or a measure of 
spirits (like scotch, gin, or vodka).  
 
 Never 
 Monthly or less 
 2 to 4 times a month 
 2 to 3 times a week 
 4 to 5 times a week 





How many drinks did you have on a typical day when you were drinking in the past year? 
 
 0 drinks 
 1 to 2 drinks 
 3 to 4 drinks 
 5 to 6 drinks 
 7 to 9 drinks 
 10 or more drinks 
 
 
How often did you have 6 or more drinks on one occasion in the past year?  
 
 Never 
 Less than monthly 
 Monthly 
 Weekly 
 Daily or almost daily 
 
 
Have you or your doctor ever considered that you suffer/have in the past suffered from an alcohol 
problem/excessive drinking? 
 







Do you smoke cigarettes at present? 
 
Yes  No  
 
 
If no, please go to Question 0 
 
 
If ‘yes’, how many cigarettes do you usually smoke now? 
 
 per day 
 
 





How many cigarettes have you smoked on average per day during the period you have smoked 
 
 cigarettes per day 
 
 
Now please go to Question 0 
 
 
Have you ever smoked cigarettes regularly? 
 
Yes  No  
 
 
If no, please go to Question 0 
 
 
If ‘yes’, how many cigarettes did you smoke on average when you were a smoker? 
 
 per day 
 
 





How long is it since you finally gave up? 
 






Do you ever get pain or discomfort in your chest? 
 
Yes  No  
 
 
If no, please go to Question 0 
 
 
Do you get this pain or discomfort when you walk uphill or hurry? 
 
Yes  No  
 
 
If no, please go to question 0 
 
 
Do you get it when you walk at an ordinary pace on the level? 
 
Yes  No  
 
 
When you get any pain or discomfort in your chest what do you do? (Tick one only) 
 
Stop  Slow down  Continue at the same pace  
 
 
Does it go away when you stand still or sit down? 
 
Yes  No  
 
 
If yes, how soon? (Tick one only) 
 
10 minutes or less   More than 10 minutes  
 
 




 Have you ever had a severe pain across the front of your chest lasting for half an hour? 
 
Yes  No  
 
 





Do you get a pain or discomfort in your leg(s) when you walk? 
 
Yes  No  I am unable to walk  
 
If no, you do not need to complete anymore of the questionnaire 
 
 
Please answer the following questions about your leg pain 
 
  Yes No 
(i) Does this pain ever begin when you are standing still or sitting?   
(ii) Do you get it if you walk uphill or hurry?   
(iii) Do you get it when you walk at an ordinary pace on the level?   
(iv) Does the pain ever disappear while you are still walking?   
 
(v) What do you do if you get it when you are walking? 
 
Stop  Slow down  Continue at the same pace  
 
(vi) What happens to it if you stand still? 
 
 Usually continues for more than 10 minutes  
 Usually disappears in 10 minutes or less  
 
(vii) Where do you get this pain or discomfort? 
 
Do you get this pain in your calf (or calves)?  
 
Yes  No  
 
 






Thank you for completing this questionnaire – please bring it with you to your appointment at the 




Appendix I Variables measured in the ET2DS 
TableI-1 Variables measured in the ET2DS 
Variable Baseline Year 1 Year 4 
Demographics 
Age x - - 
Sex x - - 
Marital status x - - 
Occupation x - - 
SIMD x - - 
Ethnicity x - - 
Education x - -  
Employment x - - 
Diabetes history 
Year of diagnosis x - - 
Current treatment x x x 
Hypo episodes x 
x (up to 6 months 
prior) 
x 
Fasting BG x x x 
HBA1c x x x 
Miscellaneous 
Medications x x x 
History of joint conditions - x  
Sleep apnoea Q’s - x - 
Use of HC services - x - 
Intra-abdominal pathology - x  
Cognitive and mood tests 
MHVS x - x 
DST x - x 
LNS x - x 
MR x - x 
Faces x - x 
Logical Memory x - x 
TMT-B x - x 
Verbal fluency x - x 
MMSE x - x 
HAD x - x 
Reaction time - - x 
 
A63 
Variable Baseline Year 1 Year 4 
Retinopathy 
ETDRS grading x   
Retinal vessel Mx x   
Cardiovascular disease/risk factors 
CV events 
  IHD 
  Cerebrovascular disease 













ECG x - x 
% body fat x - - 
BMI x - x 
WHR x - x 
sBP, dBP x x x 
ABI x - x 
Smoking history x - x 
Alcohol intake x x x 
Neurothesiometry x - - 
cIMT/plaque - x x 
Pulse wave analysis - x - 
Pulse wave velocity - x - 
Clot structure 
  Final turbidity (clot density) 
  Clot formation time 











Stress  x - - 
Personality etc. x - - 
Markers 
tChol x x x 
HDL  x x x 
TGs - x x 
Apolipoprotein AI - x x 
Apolipoprotein B - x x 
Free fatty acids - x x 
LFTs x x x 
FBC x x x 
HA x - - 
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Variable Baseline Year 1 Year 4 
Fibrinogen x - - 
TNF alpha x - - 
IL-6 x - - 
CRP x - - 
PV x - - 
Leptin x   
ELF panel x (stored plasma) x (stored plasma) 
Creatinine x - x 
Urinary albumin x -  
Urinary creatinine x -  
ACR x -  
Cortisol x (fasting am) - x (timed) 
Uric acid - x  
TFTs 
  Free T3 
  Free T4 
  TSH 
  Total T3 















  Total testosterone 
  Free testosterone 
  Bioavailable testosterone 












Complement C3 - x  
Asymmetric dimethylarginine - x  
Symmetric dimethylarginine - x  
L-arginine - x  
NT proBNP x   
Oxidative stress  (x)  
Glycans x (if funded)  
Liver disease 
History of liver 
disease/investigations 
x x x 
Steatosis (USS) - x x 
MRS (subgroup) - x  
TE (Fibroscan) - - x 
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Variable Baseline Year 1 Year 4 
MRE (subgroup) - - (x) 
Stored samples 
Plasma/serum x x x 
Urine x - x 
DNA x - - 





Appendix J Distributions of variables in the ET2DS 




Duration of diabetes at baseline






















































































































































































































Alcohol intake at year1




















































































































































































































Appendix K Liver injury marker distributions (histograms) 
Figure K-1 Histograms showing the distributions of markers of liver injury in the whole study 
population, those with hepatic steatosis and those with NAFLD. 
 











































































































































































































































































































































































































































































































Appendix L Liver injury marker agreement (scatter plots and 2x2 
tables) 
Figure L-1 Scatter plots of markers correlations 
 
Lower panel (black) = all patients 
Upper panel (red) = NAFLD patients  
 
A75 
Figure L-2 Scatter plots of change in marker correlations 
 
Lower panel (black) = all patients 




Table L-1 Comparison of surrogate markers of advanced portal hypertension between the top 5% 
and lower 95% of all subjects. Values are mean (sd). 
















































ALT alanine aminotransferase; APRI aspartate to platelet ratio index; AST aspartate 
aminotransferase; ELF Enhanced Liver Fibrosis panel; FIB4 Fibrosis-4 Index; LSM liver stiffness 
measure. 
Table L-2 Comparison of surrogate markers of advanced portal hypertension between the top 10% 
and lower 90% of subjects with non-alcoholic fatty liver. Values are mean (sd). 
















































ALT alanine aminotransferase; APRI aspartate to platelet ratio index; AST aspartate 





Figure L-3 2x2 tables for all markers, top 5% 
  APRI     ELF  
  Fibrosis No fib Total    Fibrosis No fib Total 
AST/ALT 
ratio 
Fibrosis 7 31 38  AST/ALT 
ratio 
Fibrosis 7 31 38 
No fib 31 698 729  No fib 31 698 729 
 Total 38 729 767   Total 38 729 767 
           
  FIB4     LSM  
  Fibrosis No fib Total    Fibrosis No fib Total 
AST/ALT 
ratio 
Fibrosis 13 25 38  AST/ALT 
ratio 
Fibrosis 3 29 32 
No fib 25 704 729  No fib 28 588 616 
 Total 38 729 767   Total 31 617 648 
           
  ELF     FIB4  
  Fibrosis No fib Total    Fibrosis No fib Total 
APRI 
Fibrosis 12 26 38  
APRI 
Fibrosis 29 9 38 
No fib 26 703 729  No fib 9 720 729 
 Total 38 729 767   Total 38 729 767 
           
  LSM     FIB4  
  Fibrosis No fib Total    Fibrosis No fib Total 
APRI 
Fibrosis 4 28 32  
ELF 
Fibrosis 13 25 38 
No fib 27 589 616  No fib 25 704 729 
 Total 31 617 648   Total 38 729 767 
           
  LSM     LSM  
  Fibrosis No fib Total    Fibrosis No fib Total 
ELF 
Fibrosis 5 27 32  
FIB4 
Fibrosis 4 28 32 
No fib 26 590 616  
No 
fibrosis 
27 589 616 
 Total 31 617 648   Total 31 617 648 
         
  APRI     ELF  
  Fibrosis No fib Total    Fibrosis No fib Total 
AST/ALT 
ratio 
Fibrosis 8 20 28  AST/ALT 
ratio 
Fibrosis 4 24 28 
No fib 20 234 254  No fib 24 230 254 
 Total 28 254 282   Total 28 254 282 
           
  FIB4     LSM  
  Fibrosis No fib Total    Fibrosis No fib Total 
AST/ALT 
ratio 
Fibrosis 10 18 28  AST/ALT 
ratio 
Fibrosis 7 17 24 
No fib 18 236 254  No fib 17 206 223 
 Total 28 254 282   Total 24 223 247 
           
           
  ELF     FIB4  
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  Fibrosis No fib Total    Fibrosis No fib Total 
APRI 
Fibrosis 8 20 28  
APRI 
Fibrosis 19 9 28 
No fib 20 234 254  No fib 9 245 254 
 Total 28 254 282   Total 28 254 282 
           
  LSM     FIB4  
  Fibrosis 
No 
fibrosis 
Total    Fibrosis No fib Total 
APRI 
Fibrosis 5 19 24  
ELF 
Fibrosis 9 19 28 
No fib 19 204 223  No fib 19 235 254 
 Total 24 223 247   Total 28 254 282 
           
  LSM     LSM  
  Fibrosis No fib Total    Fibrosis No fib Total 
ELF 
Fibrosis 6 18 24  
FIB4 
Fibrosis 6 18 24 
No fib 18 205 223  No fib 18 205 223 




Appendix M Markers of chronic liver disease and cardiovascular 
disease 
Table M-1  Multivariable association between liver markers and incident cardiovascular disease 
events (all subjects).  Values are hazard ratios (95%CI) 
  Model 1 p Model 2 p Model 3 p 
ALT, U/L  0.99 (0.98,1.01) 0.379 0.99 (0.98,1.01) 0.262 0.99 (0.97,1.00) 0.140 
AST, U/L  1.00 (0.99,1.02) 0.674 1.00 (0.98,1.02) 0.888 1.00 (0.98,1.02) 0.794 
GGT, log2
a
  1.28 (1.10,1.49) 0.001 1.26 (1.08,1.47) 0.003 1.18 (1.00,1.39) 0.045 
        
Steatosis, % yes
b
  1.24 (0.75,2.04) 0.399 1.32 (0.80,2.17) 0.282 1.31 (0.78,2.20) 0.307 
        
CK18, log2
a, b
  1.15 (0.84,1.56) 0.380 1.20 (0.88,1.64) 0.254 1.07 (0.78,1.46) 0.687 
        
APRI, log2
a
  0.97 (0.69,1.36) 0.873 0.81 (0.56,1.17) 0.263 0.78 (0.54,1.13) 0.193 
AST:ALT ratio  2.90 (0.92,9.16) 0.069 2.67 (0.86,8.33) 0.090 2.85 (0.90,8.98) 0.074 
ELF score
c
  1.20 (0.98,1.48) 0.082 1.23 (0.97,1.56) 0.095 1.15 (0.88,1.50) 0.304 
FIB4  1.15 (0.82,1.62) 0.421 0.94 (0.63,1.39) 0.747 0.91 (0.61,1.34) 0.621 
NFS  0.97 (0.90, 1.06) 0.542 0.98 (0.90,1.07) 0.642 0.96 (0.88,1.04) 0.320 
        
Platelets, x10
9
/L  1.00 (1.00,1.00) 0.596 1.00 (1.00,1.01) 0.071 1.00 (1.00,1.01) 0.101 
a
 APRI, CK18 and GGT analysed on the Log2 scale for linearization, therefore odds ratios relate to a 
doubling of the marker; 
b
 Incident CVD n=30/561; 
c
 incident CVD n=24/444. 
Model 1 – Unadjusted; Model 2 -  Adjusted for age and sex; Model 3 - Adjusted for age, sex, duration 
of diabetes, treatment of diabetes, lipid lowering drugs, blood pressure lowering drugs, deprivation 
(Scottish Index of Multiple Deprivation quintile), smoking status, excess alcohol consumption, body 
mass index, systolic blood pressure, diastolic blood pressure, HbA1c, HDL cholesterol, total 
cholesterol and estimated glomerular filtration rate.  Incident analysis additionally adjusted for 
prevalence cardiovascular disease at baseline. 
ALT alanine aminotransferase; APRI aspartate aminotransferase to platelet ratio index; AST 
aspartate aminotransferase; CK18 cytokeratin-18; ELF Enhanced Liver Fibrosis; FIB4 Fibrosis-4 score; 




Table M-2  Multivariable association between liver markers and incident coronary artery disease 
events (all subjects).  Values are hazard ratios (95%CI) 
  Model 1 p Model 2 p Model 3 p 
ALT, U/L  1.00 (0.98,1.02) 0.976 1.00 (0.98,1.02) 0.911 1.00 (0.98,1.02) 0.742 
AST, U/L  1.02 (1.00,1.04) 0.148 1.02 (0.99,1.04) 0.151 1.01 (0.99,1.03) 0.316 
GGT, log2
a
  1.31 (1.10,1.58) 0.003 1.33 (1.11,1.59) 0.002 1.24 (1.02,1.51) 0.032 





 1.62 (0.86,3.05) 0.133 1.70 (0.90,3.20) 0.103 1.12 (0.82,3.04) 0.175 
        
CK18, log2
a, b
  1.15 (0.81,1.65) 0.440 1.20 (0.83,1.73) 0.328 1.08 (0.74,1.57) 0.687 
        
APRI, log2
a
  1.06 (0.70,1.60) 0.775 0.98 (0.63,1.53) 0.932 0.93 (0.60,1.45) 0.751 
















FIB4  1.31 (0.89,1.92) 0.167 1.16 (0.75,1.79) 0.504 1.11 (0.72,1.71) 0.628 
NFS  1.00 (0.90,1.10) 0.934 0.99 (0.89,1.10) 0.859 0.97 (0.87,1.07) 0.535 





 1.00 (1.00,1.0) 0.359 1.00 (1.00,1.01) 0.114 1.00 (1.00,1.01) 0.132 
a
 APRI, CK18 and GGT analysed on the Log2 scale for linearization, therefore odds ratios relate to a 
doubling of the marker; 
b
 incident CAD n=16/561; 
c
 incident CAD n=13/444. 
Model 1 – Unadjusted; Model 2 -  Adjusted for age and sex; Model 3 - Adjusted for age, sex, duration 
of diabetes, treatment of diabetes, lipid lowering drugs, blood pressure lowering drugs, deprivation 
(Scottish Index of Multiple Deprivation quintile), smoking status, excess alcohol consumption, body 
mass index, systolic blood pressure, diastolic blood pressure, HbA1c, HDL cholesterol, total 
cholesterol and estimated glomerular filtration rate.  Incident analysis additionally adjusted for 
prevalence cardiovascular disease at baseline. 
ALT alanine aminotransferase; APRI aspartate aminotransferase to platelet ratio index; AST 
aspartate aminotransferase; CK18 cytokeratin-18; ELF Enhanced Liver Fibrosis; FIB4 Fibrosis-4 score; 




Table M-3  Multivariable association between liver markers and any incident cardiovascular 
disease events (subjects with NAFL).  Values are hazard ratios (95%CI) 
 Model 1 p Model 2 p Model 3 p 
ALT, U/L 0.99 (0.97,1.02) 0.446 0.98 (0.968,1.01) 0.236 0.98 (0.96,1.01) 0.219 
AST, U/L 1.01 (0.97,1.04) 0.800 1.00 (0.97,1.04) 0.851 1.00 (0.96,1.04) 0.860 
GGT, log2
a
 1.58 (1.15,2.17) 0.005 1.57 (1.13,2.18) 0.007 1.56 (1.08,2.28) 0.019 
       
CK18, log2
a
 0.91 (0.54,1.52) 0.711 0.91 (0.55,1.52) 0.718 0.98 (0.58,1.66) 0.944 
       
APRI, log2
a











ELF score 1.10 (0.80,1.50) 0.567 1.19 (0.86,1.66) 0.294 1.20 (0.84,1. 07) 0.317 
FIB4 1.06 (0.47,2.35) 0.895 0.92 (0.39,2.19) 0.854 0.70 (0.28,1.73) 0.436 
NFS 0.96 (0.83,1.11) 0.564 0.98 (0.84,1.14) 0.784 0.97 (0.84,1.12) 0.682 





1.00 (1.00,1.01) 0.479 1.00 (1.00,1.01) 0.145 1.01 (1.00,1.01) 0.068 
ALT, AST, GGT, APRI, AST:ALT ratio, FIB4, NFS and platelets total n=319 incident CVD n=38; CK18 total 
n=295 incident CVD n=29; ELF total n=231 incident CVD n=26. 
a
 APRI, CK18 and GGT analysed on the Log2 scale for linearization, therefore odds ratios relate to a 
doubling of the marker. 
Model 1 – Unadjusted; Model 2 -  Adjusted for age and sex; Model 3 - Adjusted for age, sex, duration 
of diabetes, treatment of diabetes, lipid lowering drugs, blood pressure lowering drugs, deprivation 
(Scottish Index of Multiple Deprivation quintile), smoking status, excess alcohol consumption, body 
mass index, systolic blood pressure, diastolic blood pressure, HbA1c, HDL cholesterol, total 
cholesterol and estimated glomerular filtration rate.  Incident analysis additionally adjusted for 
prevalence cardiovascular disease at baseline. 
ALT alanine aminotransferase; APRI aspartate aminotransferase to platelet ratio index; AST 
aspartate aminotransferase; CK18 cytokeratin-18; ELF Enhanced Liver Fibrosis; FIB4 Fibrosis-4 score; 





Table M-4  Multivariable association between liver markers and incident coronary artery disease 
events (subjects with NAFL).  Values are hazard ratios (95%CI) 
 Model 1 p Model 2 p Model 3 p 
ALT, U/L 0.98 (0.94,1.01) 0.188 0.97 (0.94,1.01) 0.127 0.96 (0.92,1.00) 0.065 
       
AST, U/L 0.99 (0.94,1.04) 0.748 0.99 (0.94,1.04) 0.709 0.98 (0.93,1.03) 0.367 
GGT, log2
a
 1.47 (0.98,2.22) 0.063 1.46 (0.97,2.21) 0.072 1.36 (0.84,2.22) 0.212 
       
CK18, log2
a
 0.68 (0.35,1.32) 0.258 0.67 (0.35,1.28) 0.228 0.75 (0.38,1.50) 0.422 
       
APRI, log2
a











ELF score 0.80(0.39,1.63) 0.538 0.80 (0.38,1.68) 0.553 0.76 (0.29,1.98) 0.574 
FIB4 0.48 (0.14,1.63) 0.241 0.51 (0.14,1.81) 0.299 0.31 (0.08,1.22) 0.093 
NFS 1.04 (0.86,1.25) 0.692 1.05 (0.87,1.27) 0.632 0.99 (0.81,1.20) 0.883 





1.01(1.00,1.01) 0.076 1.01 (1.00,1.01) 0.060 1.01 (1.00,1.02) 0.015 
ALT, AST, GGT, APRI, AST:ALT ratio, FIB4, NFS and platelets total n=319 incident CAD n=23; CK18 total 
n=295 incident CAD n=18; ELF total n=231 incident CAD n=15. 
a
 APRI, CK18 and GGT analysed on the Log2 scale for linearization, therefore odds ratios relate to a 
doubling of the marker. 
Model 1 – Unadjusted; Model 2 - Adjusted for age and sex; Model 3 - Adjusted for age, sex, duration 
of diabetes, treatment of diabetes, lipid lowering drugs, blood pressure lowering drugs, deprivation 
(Scottish Index of Multiple Deprivation quintile), smoking status, excess alcohol consumption, body 
mass index, systolic blood pressure, diastolic blood pressure, HbA1c, HDL cholesterol, total 
cholesterol and estimated glomerular filtration rate.  Incident analysis additionally adjusted for 
prevalence cardiovascular disease at baseline. 
ALT alanine aminotransferase; APRI aspartate aminotransferase to platelet ratio index; AST 
aspartate aminotransferase; CK18 cytokeratin-18; ELF Enhanced Liver Fibrosis; FIB4 Fibrosis-4 score; 






Appendix N  Mortality in the ET2DS vs general population 
Table N-1 Numbers of deaths in the age group 60-74 years 
 Scotland Lothian ET2DS 
2008 14,060 1,794 26* 
2009 13,623 1,724 22
#
 
2010 13,563 1,808 29
$
 
Total 41,246 5,326 51 
Table N-2 Population at risk in the age group 60-74 years 
 Scotland Lothian ET2DS 
2008 781,273 107,516 1,063* 
2009 796,971 109,939 1,037
#
 
2010 809,394 109,939 1,015
$
 
Total 2,387,638 327,394 2,052 
Table N-3 Death rate per 1000 population/year in the age group 60-74 years 
 Scotland Lothian ET2DS 
2008 18.0 16.7 24.5* 
2009 17.1 15.7 21.2
#
 
2010 16.8 16.4 28.6
$
 
Total 17.3 16.3 24.7 
* In 2008 the ET2DS population were aged 62-76 years 
#
 In 2009 the ET2DS population were aged 63-77 years 
$




Figure N-1 Death rates in Scotland, Lothian and the ET2DS in people aged 60-74 years, 2008-2010.  
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